

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 16/28, G01N 33/577, A61K 39/395, C07K 14/705		A2	(11) International Publication Number: WO 99/45031
			(43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: PCT/US99/04583 (22) International Filing Date: 3 March 1999 (03.03.99) (30) Priority Data: 09/034,607 3 March 1998 (03.03.98) US 09/244,253 3 February 1999 (03.02.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 09/034,607 (CIP) Filed on 3 March 1998 (03.03.98) US 09/244,253 (CIP) Filed on 3 February 1999 (03.02.99) (71) Applicant (for all designated States except US): ABGENIX, INC. [US/US]; 7601 Dumbarton Circle, Fremont, CA 94555 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVIS, C., Geoffrey [US/US]; 1132 Vancouver Avenue, Burlingame, CA 94010 (US). BLACHER, Russell, W. [US/US]; 16800 Columbia Drive, Castro Valley, CA 94552 (US). CORVALAN, Jose, R. [US/US]; 125 Williams lane, Foster City, CA		94404 (US). CULWELL, Alan, R. [US/US]; 290A Hemlock Avenue, Carlsbad, CA 92008 (US). GREEN, Larry, L. [US/US]; Apartment 12, 70 Crestline Drive, San Francisco, CA 94131 (US). HALES, Joanna [GB/US]; 5180 Selma Avenue, Fremont, CA 94536 (US). HAVRILLA, Nancy [US/US]; 6 Martin Cove, Oakland, CA 94618 (US). IVANOV, Vladimir, E. [RU/US]; 4275 Tanager Common, Fremont, CA 94555 (US). LIPANI, John, A. [US/US]; 2263 Latour Avenue, Livermore, CA 94550 (US). LIU, Qiang [CN/US]; 55 Williams Lane, Foster City, CA 94404 (US). WEBER, Richard, F. [US/US]; 2537 Pacheco Street, San Francisco, CA 94116 (US). YANG, Xiao-Dong [CN/US]; 2833 Bryant Street, Palo Alto, CA 94306 (US). (74) Agents: HALEY, James, F. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: CD147 BINDING MOLECULES AS THERAPEUTICS			
(57) Abstract			
<p>In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CD147 BINDING MOLECULES AS THERAPEUTICS

5

BACKGROUND OF THE INVENTION

1. Summary of the Invention

In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized as a target for the treatment of a variety of diseases. In particular, we have demonstrated that an antibody that binds to CD147 and that results in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas) and pancreatic), autoimmune diseases (including, without limitation, lupus), inflammatory diseases (including, without limitation, arthritis), and others.

2. Background of the Technology

In about 1982, a group from UCLA reported the generation of antibodies cytotoxic to human leukemia cells in mice through immunization with acute leukemia cells followed by formation of hybridomas and screening of the hybridomas in a microcytotoxicity assay in which toxicity of the antibody against the immunizing cells and normal lymphocytes was assayed. See U.S. Patent Nos. 5,330,896 and 5,643,740, the disclosures of which are hereby incorporated by reference in their entirety. One hybridoma was recovered that was cytotoxic to tumor cells but non-toxic to normal cells (except activated T-cells, activated B-cells, and monocytes were also killed). Such hybridoma was cloned and isolated and deposited with the ATCC as HB 8214. The monoclonal antibody expressed by this hybridoma was designated CBL1, and is a murine IgM. The group further demonstrated that the antibody was reactive with an

antigenic determinant that appeared to be present in the cytoplasm of both activated and nonactivated cells. However, the antigenic determinant appeared to be present on the extracellular membrane of only certain circulating cells, including, activated T-cells, activated B-cells, and resting and activated monocytes, but not present
5 extracellularly on other circulating nonactivated cells.

The group also endeavored to isolate the antigen responsible for the observations. The patents characterize the antigenic determinant recognized by the CBL-1 antibody as being a molecule that:

- 10 (i) is present on the cell membrane and within the cytoplasm of tumor cells and activated lymphocytes;
- (ii) is present in the cytoplasm of unstimulated normal peripheral blood lymphocytes but when these cells are stimulated by antigens or by mitogens, said antigen appears also on the cell membrane;
- (iii) is present on lymphocytes activated in vitro by mitogens;
- 15 (iv) is capable of binding to CBL1 monoclonal antibody which is produced by the hybridoma cell line having the ATCC number HB8214;
- (v) functions as an autocrine growth factor produced by tumor cells and activated lymphocytes;
- (vi) binds to the surface membrane of tumor cells and stimulates the
20 growth of these cells and cells of the lymphoid series;
- (vii) is present in the medium from growing cancer cells and in the serum of patients with cancer and diseases in which activated lymphocytes are present; and
- (viii) has a molecular weight of approximately 15,000 daltons.

25

No improved identification of the antigen to which the CBL1 antibody binds has been accomplished with respect to the UCLA group's papers and patents. Nevertheless, the CBL1 antibody has been effective in patients in the treatment of a variety of diseases including: graft versus host disease (GVHD) and kidney transplant
30 rejection. See e.g., Heslop et al. *The Lancet* 346:805-806 (1995) (GVHD); Benamin *Clinical Trial Monitor* Abstract No. 13385 (1995); Takahashi et al. *The Lancet* 2:1155-1158 (1983) (kidney allograft rejection); Takahashi *Transplantation*

Proceedings 17:10-12 (1985) (kidney allograft rejection); Oei et al. *Transplantation Proceedings* 17:13-16 (1985) (kidney allograft rejection). In connection with such studies, there has been no evidence of safety concerns or cross-reactivity. The following papers relate to additional characterization of the CBL1 antibody: Billing et al. *Hybridoma* 1:303-311 (1982); Billing et al. *Clin. Exp. Immunol.* 49:142-148 (1982); Chatterjee et al. *Hybridoma* 1:369-377 (1982); Billing R. and Chatterjee S. *Transplantation Proceedings* 15:649-650 (1983); Kinukawa T. and Terasaki P.I. *Transplantation Proceedings* 1:993-998 (1985); Billing in *Monoclonal Antibodies: Diagnostic and Therapeutic Use in Tumor and Transplantation* Ch. 9, 85-90 (Chatterjee ed., PSG Publ. Co., Inc. (1985)); Billing et al. in *Monoclonal Antibodies: Diagnostic and Therapeutic Use in Tumor and Transplantation* Ch. 2, 11-19 (Chatterjee ed., PSG Publ. Co., Inc. (1985)).

Human Graft Versus Host Disease (GVHD) was first described by Mathe et al. in 1960 (Mathe et al. "Nouveaux essais de greffe de moelle osseuse homologue apres irradiation totale chez des enfants atteints de leucemie aigue en remission. Le probleme du syndrome secondaire chez l'homme" *Rev Fr Etud Clin Biol* 15:115-161 (1960)). Essentially GVHD is the clinical manifestation of an immunological reaction between donor cells and host tissue. The clinical syndrome consists of skin rash, gastro-intestinal symptoms, and hepatic dysfunction seen usually within two weeks of allogeneic bone marrow transplant. The immunopathogenesis requires recognition of host antigens by immunocompetent donor cells; immunosuppressed host (recipient); and alloantigenic differences to exist between donor and recipient. The immunocompetent donor cells are mature T-cells (Ferrara JL and Deeg HJ "Graft versus Host Disease" *NEJM* 324:667 (1991) and the clinical severity of the disease correlates with the number of T-cells transferred to the patient (Ferrara JL and Deeg HJ "Graft versus Host Disease" *NEJM* 324:667 (1991)).

The clinical features of acute GvHD include dermatitis, jaundice and gastro-intestinal involvement. These symptoms may occur alone or in any combination and can range from mild to life-threatening. Skin involvement is the most common manifestation. The most severe manifestation of skin involvement includes bullous lesions similar to third degree burns. Jaundice is brought about from an elevated bilirubin with and without alteration of other liver enzymes. Gastro-intestinal

involvement includes watery diarrhea. This diarrhea can be voluminous and bloody, causing life-threatening fluid and electrolyte losses as well as a portal of entry for infections. Other patients may experience severe ileus. Upper GI involvement is less common. This presents as anorexia, dyspepsia, food intolerance and nausea/vomiting.

5 Most patients with GI involvement require total parenteral nutrition (TPN) support.

Strategies for prevention and possibly treatment should be and sometimes are, directed towards removal of T-cells from the donor marrow or toward blocking their activation. However, the T- depleted marrow results in a higher rate of graft failure that is usually fatal. An additional concern associated with T-depleted marrow is the
10 increased relapse rate in marrow recipients with a primary diagnosis of leukemia. A graft versus leukemia effect, mediated by donor T-cells, also mitigates against using a T-depleted marrow in allogeneic bone marrow transplantation.

Clinically significant acute GVHD (Grades II – IV) occurs in up to 50% of patients who receive a marrow from a HLA genotypically identical sibling. If
15 unrelated matched donors are used, the incident increases to 80% in some studies. The greater the HLA incompatibility, the greater the incidence and severity of GVHD.

The primary treatment for acute GvHD is prevention. Prevention regimens include the use of immunosuppression therapy and T-cell depletion of the donor cells. “Standard” first-line therapy consists of glucocorticoids. Approximately 20-25% of
20 patients achieve a complete response and patients who do not respond have a poor outcome. Those patients who continue to require treatment with steroids are susceptible to all of the untoward effects of steroid use. These untoward effects include increased susceptibility to infections, GI bleed, altered metabolic states, hypertension, etc.

25 Glucocorticoids, cyclosporine, methotrexate, cyclophosphamide have all been used in prevention as well as treatment of GVHD. Anti-thymocyte globulin (ATG) has been used for many years. All of these agents are potentially quite toxic. Monoclonal antibodies such as anti-Interleukin-2 and immunotoxins like anti-CD5-ricin have been used and found to be of limited success. A humanized anti-TAC was
30 used for prophylaxis of GVHD but failed in the treatment protocols.

Because of the indication that CBL1 was effective in treating GVHD, we undertook additional investigations of the CBL1 antibody. In connection with such

additional work, we have now demonstrated that the CBL1 antibody, in fact, appears to bind to and be efficacious with respect to the CD147 antigen as expressed on certain cells, such as T-cells, B-cells, and/or monocytes through the process of complement dependent cytotoxicity (killing).

5 CD147 is a member of the immunoglobulin (Ig) superfamily that is expressed on a large number of different cells in a variety of tissues. It was originally named human Basigin (for basic immunogloblin superfamily) and was first cloned in about 1991. (Miyauchi et al. *J Biochem (Tokyo)* 110:770-774 (1991); Kanekura et al. *Cell Struct Funct* 16:23-30 (1991); Miyauchi et al. *J Biochem (Tokyo)* 110:770-774
10 (1991)). The molecule is composed of approximately 269 amino acids (Miyauchi et al. *J Biochem (Tokyo)* 110:770-774 (1991)) and is a glycoprotein with about 40% of its molecular weight made up of carbohydrate, having a predicted deglycosylated molecular weight of approximately 27 KD and a fully glycosylated molecular weight of between 43-66 KD (Kanekura et al. *Cell Struct Funct* 16:23-30 (1991)). The
15 Basigin gene was mapped to Chromosome 19p13.3 (Kaname et al. *Cytogenet Cell Genet* 64:195-197 (1993)).

The molecule has been identified to possess homology with, or identity to, a number of other molecules, including:

Mouse Basigin (Miyauchi et al. *J Biochem (Tokyo)* 107:316-323 (1990);
20 Joseph et al. *Adv Exp Med Biol* 342:389-391 (1993); Kaname et al. *J Biochem (Tokyo)* 118:717-724 (1995));

Rabbit Basigin (Schuster et al. *Biochim Biophys Acta* 1311:13-19 (1996));

Mouse gp42 (Altruda et al. *Gene* 85:445-451 (1989); Imboden et al. *J Immunol* 143:3100-3103 (1989); Cheng et al. *Biochim Biophys Acta* 1217:307-311
25 (1994));

Chicken HT7 or 5A11 (Albrecht et al. *Brain Res* 535:49-61 (1990);
Seulberger et al. *EMBO J* 9:2151-2158 (1990); Miyauchi et al. *J Biochem (Tokyo)* 110:770-774 (1991); Janzer et al. *Adv Exp Med Biol* 331:217-221 (1993); Lobrinus et al. *Brain Res Dev Brain Res* 70:207-211 (1992); Seulberger et al. *Neurosci Lett*
30 140:93-97 (1992); Fadool JM & Linser PJ *J Neurochem* 60:1354-136 (1993); Fadool JM & Linser PJ *Dev Dyn* 196:252-262 (1993); Unger et al. *Adv Exp Med Biol* 331:211-215 (1993); Rizzolo LJ & Zhou S *J Cell Sci* 108:3623-3633 (1995); Ikeda et

al. *Neurosci Lett* **209**:149-152 (1996) ; Fadool JM & Linser PJ *Biochem Biophys Res Commun* **229**:280-286 (1996));

Neurothelin (Schlosshauer B & Herzog KH *J Cell Biol* **110**:1261-1274 (1990); Schlosshauer B *Development* **113**:129-140 (1991); Schlosshauer B *BioEssays* **15**:341-346 (1993); Schlosshauer et al. *Eur J Cell Biol* **68**:159-166 (1995));

M6 leukocyte activation antigen (Felzmann et al. *J Clin Immunol* **11**:205-212 (1991); Gadd et al. *Rheumatol Int* **12**:153-157 (1992); Kasinrerker et al. *J Immunol* **149**:847-854 (1992));

OX-47 (Fossum et al. *Eur J Immunol* **21**:671-679 (1991); Fossum et al. *Eur J Immunol* **21**:671-679 (1991); Cassella et al. *J Anat* **189**:407-415 (1996));

Mo3 (Mizukami et al. *J Immunol* **147**:1331-1337 (1991));

CE9 (Petruszak et al. *J Cell Biol* **114**:917-927 (1991); Scott LJ & Hubbard AL *J Biol Chem* **267**:6099-6106 (1992); Nehme et al. *J Cell Biol* **120**:687-694 (1993); Cesario MM & Bartles JR *J Cell Sci* **107**:561-570 (1994); Cesario et al. *Dev Biol* **169**:473-486 (1995); Nehme et al. *Biochem J* **310**:693-698 (1995));

EMMPRIN (Biswas et al. *Cancer Res* **55**:434 (1995); DeCastro et al. *J Invest Dermatol* **106**:1260-1265 (1996));

RET-PE2 (Finnemann et al. *Invest Ophthalmol Vis Sci* **38**:2366-2374 (1997));

OK^a Blood Group Antigen (Spring et al. *Eur J Immunol* **27**:891-897 (1997));

and

1W5 (Seulberger et al. *EMBO J* **9**:2151-2158 (1990)).

Indeed, Seulberger et al. *Neurosci Lett* **140**:93-97 (1992) demonstrated that HT7, Neurothelin, Basigin, gp42 and OX-47 were each names for one molecule which is a developmentally regulated immunoglobulin-like surface glycoprotein which is present on blood-brain barrier endothelium, epithelial tissue barriers, and neurons. Further, Kasinrerker et al. *J Immunol* **149**:847-854 (1992) demonstrated that the human leukocyte activation antigen M6 is a member of the Ig superfamily and is the species homologue of rat OX47, mouse Basigin, and chicken HT7 antigens. EMMPRIN was demonstrated to be identical to the M6 antigen and human Basigin (Biswas et al. *Cancer Res* **55**:434 (1995)). See also Guo et al. "Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix

metalloproteinases" *Gene* 220:99-108 (1998) conducted additional characterization of the gene for human EMMPRIN;

Through its homology with the related molecules, CD147 has been shown or postulated to have a role in a number of physiological processes, diseases, and/or conditions. For example, an early role postulated for the molecule was activity in the blood-brain barrier. Such relationship was first demonstrated with respect to the chick HT7 antigen (Risau et al. *EMBO J* 5:3179-3183 (1986); Albrecht et al. *Brain Res* 535:49-61 (1990); Seulberger et al. *EMBO J* 9:2151-2158 (1990); Janzer et al. *Adv Exp Med Biol* 331:217-221 (1993); Lobrinus et al. *Brain Res Dev* 70:207-211 (1992); Unger et al. *Adv Exp Med Biol* 331:211-215 (1993)). A similar relationship was observed in connection with Neurothelin (Schlosshauer B & Herzog KH *J Cell Biol* 110:1261-1274 (1990); Schlosshauer B *Development* 113:129-140 (1991); Schlosshauer B *BioEssays* 15:341-346 (1993); Schlosshauer et al. *Eur J Cell Biol* 68:159-166 (1995)). The molecule has also been postulated to be involved in development and activation of various cells, for example: lymphocyte activated killer (LAK) cell activation (Imboden et al. *J Immunol* 143:3100-3103 (1989)), T-cell activation (Paterson et al. *Mol Immunol* 24:1281-1290 (1987); Kirsch et al. *Tissue Antigens* 50:147-152 (1997)), leukocyte activation (Fossum et al. *Eur J Immunol* 21:671-679 (1991); Fossum et al. *Eur J Immunol* 21:671-679 (1991)), and mononuclear phagocyte activation (Mizukami et al. *J Immunol* 147:1331-1337 (1991)). Other regulatory, signaling, and recognition functions have also been postulated, for instance: MHC function (Miyauchi et al. *J Biochem (Tokyo)* 107:316-323 (1990)), signal transduction and membrane transport (Kasinrerk et al. *J Immunol* 149:847-854 (1992); Berditchevski et al. *J Biol Chem* 272:29174-29180 (1997)), cellular recognition (Fadool JM & Linser PJ *Dev Dyn* 196:252-262 (1993); Kaname et al. *Cytogenet Cell Genet* 64:195-197 (1993)), cellular adhesion (Miyauchi et al. *J Biochem (Tokyo)* 110:770-774 (1991); Seulberger et al. *Neurosci Lett* 140:93-97 (1992); Joseph et al. *Adv Exp Med Biol* 342:389-391 (1993); Sudou et al. *J Biochem (Tokyo)* 117:271-275 (1995)), intercellular stimulation and matrix metalloproteinase synthesis (Biswas et al. *Cancer Res* 55:434 (1995)), tissue remodeling (Guo et al. *J Biol Chem* 272:24-27 (1997)), metabolism, and sperm development and maturation (Petruszak et al. *J Cell Biol* 114:917-927 (1991); Nehme et al. *J Cell Biol* 120:687-

694 (1993); Cesario MM & Bartles JR *J Cell Sci* **107**:561-570 (1994); Cesario et al. *Dev Biol* **169**:473-486 (1995)). CD147 also appears to have a role in retinal development and disease, see Marmorstein et al. "Morphogenesis of the retinal pigment epithelium: toward understanding retinal degenerative diseases" *Ann N Y Acad Sci* **857**:1-12 (1998) (suggested that N-CAM and EMMPRIN are potentially important molecules in other RPE functions necessary for photoreceptor survival). See also Marmorstein et al. "Apical polarity of N-CAM and EMMPRIN in retinal pigment epithelium resulting from suppression of basolateral signal recognition" *J Cell Biol* **142**:697-710 (1998).

10 The molecule has also been investigated for a potential association in both rheumatoid and reactive arthritis (Felzmann et al. *J Clin Immunol* **11**:205-212 (1991); Gadd et al. *Rheumatol Int* **12**:153-157 (1992)) and renal disease (Schuster et al. *Biochim Biophys Acta* **1311**:13-19 (1996)). Moreover, certain clear associations between the molecule and cancer have also been indicated (Biswas *Biochem Biophys Res Commun* **109**:1026 (1982); Miyauchi et al. *J Biochem (Tokyo)* **110**:770-774 (1991); Biswas et al. *Cancer Res* **55**:434 (1995); Guo et al. *J Biol Chem* **272**:24-27 (1997); Guo et al. *J Biol Chem* **272**:24-27 (1997)). See also Lim et al. "Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38" *FEBS Lett* **441**:88-92 (1998); van den Oord et al. "Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin" *Am J Pathol* **151**:665-70 (1997); Polette et al. "Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers" *J Histochem Cytochem* **45**:703-9 (1997).

25 A mouse model in which the Basigin gene was knocked-out has been examined (Igakura et al. *Biochem Biophys Res Commun* **224**:33-36 (1996)). The work indicated that the molecule was not necessarily active in the blood-brain barrier. However, the work indicated that there was enhanced interaction in connection with lymphocyte activation as well as an abnormal response to irritating odors. Later work indicated certain abnormalities in sensory and memory functions in such model
30 Naruhashi et al. *Biochem Biophys Res Commun* **236**:733-737 (1997)).

In connection with the expression of CD147, *see* Woodhead et al. "From sentinel to messenger: an extended phenotypic analysis of the monocyte to dendritic cell transition" *Immunology* **94**:552-9 (1998) demonstrated that CD147 was expressed on dendritic cells, Ghannadan et al. "Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies" *J Invest Dermatol* **111**:689-95 (1998) demonstrated that clustered CD antigens (including CD147) were detectable foreskin mast cells, Mutin et al. "Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules" *Tissue Antigens* **50**:449-58 (1997) discussed quantitative analysis of cell surface molecules on cultured endothelial cells (HUVEC).

In view of the foregoing, CD147 has been implicated as a potentially useful target for the treatment of diseases. However, at the same time, CD147 is expressed in and on many cells that are widely distributed amongst many tissues. For example, the Ok^a blood group antigen is expressed on virtually all cells (Williams et al. *Immunogenetics* **27**:322-329 (1988)). OX-47 has been disclosed to be on most immature cells, endothelial cells, and cells with excitable membranes (Fossum et al. *Eur J Immunol* **21**:671-679 (1991)). Similarly, Basigin was demonstrated to be expressed not only in endothelial cells but was also found in a variety of tissues, including, the spleen, small intestine, kidney, and liver in relatively high levels and in small quantities in the testes (Kanekura et al. *Cell Struct Funct* **16**:23-30 (1991)). CE9 was disclosed to be widely expressed on rat hepatocytes (Scott LJ & Hubbard *AL J Biol Chem* **267**:6099-6106 (1992)). Seulberger et al. *Neurosci Lett* **140**:93-97 (1992) demonstrated that the HT7 molecule (which is identical to Neurothelin, Basigin, gp42, and OX-47) was expressed on the blood-brain barrier, choroid plexus (blood-CNS fluid barrier), retinal epithelium (blood-eye barrier), neurons, kidney tubules, some endothelium, epithelium, and epithelial tissue barriers. The CE9 antigen (which was demonstrated to possess identity to the OX-47 antigen) is expressed, to some extent, in virtually all rat tissues (Nehme et al. *Biochem J* **310**:693-698 (1995)). Because of the broad tissue distribution, there would be a number of concerns related to the safety of any therapy that inhibited or killed cells expressing it.

There is some evidence that there may be different forms of CD147, stemming from, for example, differential glycosylation or alternative splicing of the molecule (Kanekura et al. *Cell Struct Funct* 16:23-30 (1991) (Basigin); Schlosshauer B *Development* 113:129-140 (1991) (Neurothelin); Fadool JM & Linser PJ *J Neurochem* 60:1354-136 (1993) (5A11/HT7); Nehme et al. *J Cell Biol* 120:687-694 (1993) (CE9); DeCastro et al. *J Invest Dermatol* 106:1260-1265 (1996) (EMMPRIN); Spring et al. *Eur J Immunol* 27:891-897 (1997) (Ok⁸)).

BRIEF DESCRIPTION OF THE DRAWING FIGURES

Figure 1 is a 12% SDS-PAGE/Western Blot showing the binding of particular antibodies to CEM cell membrane extracts lysates. Lane A: rabbit-anti-mouse-hn-RNP-K protein antibody; Lane B: ABX-CBL antibody; Lane C: 2.6.1 antibody (also referred to herein as cem2.6 and ABX-Rb2); Lane D: anti-CD147 antibody (Pharmingen); and Lane E: anti-CD147 antibody (RDI). Sample: 5 microliters CEM Cell Extract.

Figures 2A-2B is an analysis of the components obtained from the CBL1 antibody produced by the hybridoma cell line having ATCC Deposit No. HB 8214. The data demonstrate that the CBL1 IgM antibody produced by the HB 8214 hybridoma is the active component that inhibits MLR in the presence of complement.

Figure 3 is a graph comparing the inhibition of MLR using antibodies from various CBL1 subclones in comparison to CBL1.

Figure 4 is a graph comparing MLR inhibition utilizing ABX-CBL in the presence of rabbit and human complement.

Figure 5 is a graph comparing the activity of the ABX-CBL antibody and the 2.6.1 antibody (also referred to as cem 2.6) in inhibiting the MLR assay. The data demonstrate that the 2.6.1 antibody is not an effective inhibitor.

Figures 6A-6B: FACS analyses of activated lymphocytes demonstrating co-expression of CD147 and CD25.

Figures 7A-7D: FACS analyses of PBMC demonstrating the selective upregulation of CD25 upon stimulation, and the specific depletion of the same cells after treatment with ABX-CBL and complement. Fig. 7A: untreated PBMC. Figs. 7B and

7D: PBMC stimulated with ConA. **Figure 7C:** PBMC stimulated with ConA, then treated with ABX-CBL plus complement.

Figures 8A-8D compare FACS analyses of PBMC demonstrating the selective upregulation of CD25 upon stimulation, and the specific depletion of the same cells after treatment with ABX-CBL and complement. **Fig. 8A:** PBMC + ConA; **Fig. 8B:** CBL-1 only/Medium; **Fig. 8C:** Complement only/Medium; **Fig. 8D:** CBL-1 + complement/Medium. M1: CD25 high (depleted); M2: CD25 low (undepleted); M3: CD25 null (undepleted).

Figures 9A-9D show another series of FACS analyses of PBMC demonstrating the selective upregulation of CD25 and CD147 upon stimulation.

Figures 10A-10F show a comparison of activated T-cells (**Figs. 10A-10B**), activated monocytes, (**Figs. 10C-10-D**) and activated B-cells (**Figs. 10E-10F**) before and after treatment with ABX-CBL and complement and demonstrating the specific depletion of the same cells upon treatment with ABX-CBL and complement.

Figures 11A-11F shows a similar comparison of subpopulations of activated T-cells (**Figures 11A-11B**), activated B-cells (**Figures 11C-11D**), and activated monocytes (**Figures 11E-11F**) before and after treatment with ABX-CBL and complement. The data demonstrate the specific depletion of the same cells upon treatment with ABX-CBL and complement.

Figure 12 illustrates that the mode of action of ABX-CBL is by depleting leukocyte subpopulations. The table compares cell type, surface markers, and Complement-Dependent Cytotoxicity (CDC) depletion of leukocyte subpopulations.

Figure 13 is a table comparing cell, cell type, CD147 expression, and CDC after treatment of the cells with ABX-CBL and complement. The data demonstrate that not all cells that express CD147 are killed upon such treatment.

Figure 14 is a table summarizing the expression of CDC resistant molecules on CBL-1⁺ cells. The chart compares cell, cell type, CD147 expression, CDC after treatment of the cells with ABX-CBL and complement, and expression of the complement inhibitory molecules CD55 and CD59. The data demonstrate that of these cells, only cells that do not express both CD55 and CD59 are killed upon such treatment.

Figures 15A-15C present FACS analyses showing the expression of CD147 on the human endothelial cell line ECV-304.

Figures 16A-16C present FACS analyses showing the expression of CD147 on the human endothelial cell line HUVEC-C.

Figure 17 is a graph showing the effects of ABX-CBL and complement on the human endothelial cell line ECV-304 in comparison to the effects of the same on CEM cells.

Figure 18 is a graph showing the effect of ABX-CBL on human endothelial cell line HUVEC-C in comparison to the effects of the same on CEM cells.

Figures 19A-19C present FACS analyses showing the expression of the complement inhibitory molecules CD46, CD55, and CD59 on the human endothelial cell line ECV-304.

Figures 20A-20C present FACS analyses showing the expression of the complement inhibitory molecules CD46, CD55, and CD59 on the human endothelial cell line HUVEC-C.

Figure 21 is a schematic diagram of the vector utilized for cloning and expression of CD147 cDNA in COS cells.

Figure 22 is a schematic diagram of the pBK-CMV phagemid vector utilized for cloning and expression of CD147 cDNA in COS and *E. coli* cells.

Figure 23 is a SDS-PAGE/Western Blot of CD147 expressed in COS cells (Figure 23A) and *E. coli* (Figure 23B). **Figs. 23A-23B:** Antibodies: Pharmingen (panel A), 2.6.1 (panel B), and ABX-CBL (panel C). **Fig. 23A:** 5 μ L CEM cell membrane extract (Lane 1); 7.5 μ L control vector transfected COS cell extract (Lane 2); 7.5 μ L CD147 transfected COS cell extract (Lane 3). **Fig. 23B:** Clone 1: CD147-Transfected, uninduced (Lane 1); Clone 1: CD147-Transfected, induced (Lane 2); Clone 5: Control Vector Transfected, uninduced (Lane 3); Clone 5: Control Vector Transfected, induced (Lane 4).

Figures 24-33 are heavy chain and kappa chain cDNA and protein sequences of or for the antibodies: CEM 10.1 C3 (Fig. 24), CEM 10.1 G10 (Fig. 25), CEM 10.12 F3 (Fig. 26), CEM 10.12 G5 (Fig. 27), CEM 13.12 (Fig. 28), CEM 13.5 (Fig. 29), 2.4.4 (Fig. 30), 2.1.1 (Fig. 31), 2.3.2 (Fig. 32), and 2.6.1 (Fig. 33).

Figures 34-43 are heavy chain and kappa chain protein sequences of or for the antibodies: CEM 10.1 C3 (Fig. 34), CEM 10.1 G10 (Fig. 35), CEM 10.12 F3 (Fig. 36), CEM 10.12 G5 (Fig. 37), CEM 13.12 (Fig. 38), CEM 13.5 (Fig. 39), 2.4.4 (Fig. 40), 2.1.1 (Fig. 41), 2.3.2 (Fig. 42), and 2.6.1 (Fig. 43) showing CDR positions.

Figures 44A-44B show the amino acid sequences and structure of human heavy chains derived from CBL-1 specific hybridomas showing alignment against the germline V-segment genes.

Figures 45A-45C and Figure 46 show amino acid sequences and structure of human kappa chains derived from CBL-1 specific hybridomas, showing alignment against the germline V-segment genes.

Figure 47 is a restriction map of the vector pWBFNP MCS that was utilized for the construction and cloning of certain constructs in accordance with the invention.

Figure 48 is a schematic restriction map of the vector pIK6.1+Puro that was utilized for the construction and cloning of certain constructs in accordance with the invention.

Figure 49 shows a comparison of the activity of the ABX-CBL antibody and the 2.6.1 multimeric IgM antibody (also known as ABX-Rb2) in inhibiting the MLR assay, demonstrating that the 2.6.1 multimeric IgM antibody is effective in inhibition of MLR. C: Rabbit complement.

Figures 50A-50F provide additional detail of the cloning strategy utilized in connection with the generation of CD147-IgG2 and gp42-IgG2 fusion proteins for use in connection with the generation of surrogate antibodies for use in animal models.

and is substantially non-toxic to cells expressing CD55 and CD59, with and without the presence of complement, with the proviso that the antibody is not CBL1.

In accordance with a fourth aspect of the present invention, there is provided a method to select an anti-CD147 antibodies for the treatment of disease, comprising:
5 generating antibodies that bind to CD147 and that are capable of binding complement; assaying the antibodies for one or more of the following properties: competition with ABX-CBL for binding to CD147; capability to selectively kill activated T-cells, activated B-cells, and monocytes in a MLR assay only in the presence of complement; and being substantially non-toxic to cells expressing CD55 and CD59, with and
10 without the presence of complement, with the proviso that the antibody is not CBL1. In a preferred embodiment, the method comprises assaying the antibodies for binding to CEM cell lysates on Western blot in a manner similar to that provided in Figure 1. In another preferred embodiment, the method comprises assaying the antibodies for binding to a consensus sequence in a peptide of RXRS. In another preferred
15 embodiment, the method comprises assaying the antibodies for cross reaction with hn-RNP-k protein. In another preferred embodiment, the method comprises assaying the antibodies for binding to a form of CD147 expressed by COS cells and *E. coli* cells.

In accordance with a fifth aspect of the present invention, there is provided a method for preventing or lessening the severity of disease, comprising providing to a
20 subject in need of such treatment an antibody that has an isotype that fixes complement and a variable region that binds to CD147 on populations of activated T-cells, activated B-cells, and resting or activated monocytes, that, in the presence of complement, selectively depletes such populations through complement mediated killing while being substantially nontoxic to other cells, with the proviso that the
25 antibody is not CBL1. In a preferred embodiment, the antibody is a human antibody. In another preferred embodiment, the antibody has an isotype is selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

In accordance with a sixth aspect of the present invention, there is provided a
30 method to prevent or lessen the severity of GVHD, comprising providing to a subject in need of such treatment an antibody that has an isotype that fixes complement and a variable region that binds to CD147 on populations of activated T-cells, activated B-

cells, and resting or activated monocytes, that, in the presence of complement, selectively depletes such populations through complement mediated killing while being substantially nontoxic to other cells, with the proviso that the antibody is not CBL1. In a preferred embodiment, the antibody is a human antibody. In another
5 preferred embodiment, the antibody has an isotype is selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

In accordance with a seventh aspect of the present invention, there is provided a monoclonal antibody that binds to an epitope on CD147 comprising the consensus
10 sequence RVRSH, wherein the antibody is not CBL1. In a preferred embodiment, the antibody is a human antibody.

In accordance with an eighth aspect of the present invention, there is provided an isolated peptide comprising the sequence selected from the group consisting of RXRS, RXRSH, RVRS, and RVRSH. In a preferred embodiment, the peptide is used
15 for the generation of antibodies.

In accordance with a ninth aspect of the present invention, there is provided a human monoclonal antibody that binds to CD147.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

20

Discussion of the Present Invention

The pharmaceutical agent ABX-CBL was derived from the hybridoma cell line expressing the CBL1 antibody. CBL1 is a murine IgM, anti-human
25 lymphoblastoid monoclonal antibody that was raised in Balb/c mice immunized with the T cell acute lymphoblastic leukemia cell line (T-ALL) CEM (Billing et al. "Monoclonal and heteroantibody reacting with different common antigens common to human blast cells and monocytes" *Hybridoma* 1:303-311 (1982)). Following fusion of the splenocytes and selection in HAT medium, supernatants from hybridoma-
30 containing wells were screened by microcytotoxicity assay for reactivity with CEM cells. Hybridomas that tested positive in this assay were further screened for their ability to discriminate between resting lymphocytes and blast cells. CBL1 was selected for further study because it showed selectivity for blast cells (Billing et al.

"Monoclonal and heteroantibody reacting with different common antigens common to human blast cells and monocytes" *Hybridoma* 1:303-311 (1982)). The CBL1 antibody was deposited with the ATCC as HB 8214.

The assignee of the present application, Abgenix, Inc., Fremont, CA, acquired
5 CBL1 in 1997 and determined that the hybridoma line deposited with the ATCC as
HB 8214 was not entirely pure. Rather, it was actually a mix of two distinct
hybridoma lines, one producing an IgG and one producing an IgM. Following
subcloning, a pure IgM producer as well as a pure IgG producer were derived.
Through a series of *in vitro* experiments described herein, it was demonstrated that the
10 IgM antibody mediated the activities previously attributed to the CBL1 hybridoma.
Only the IgM is biologically active in inhibition of complement mediated lysis of
cells in a mixed lymphocyte reaction assay (MLR). The mechanism of inhibition is
via antibody mediated complement-dependent cytotoxicity (CDC) because the
inhibition is specific and complement-dependent, as discussed herein. Therefore, in
15 connection with our work described herein, using conventional techniques, we
subcloned the line to produce a cell line producing solely the IgM. Further, the HB
8214 cell line expressing the CBL1 antibody possessed a second kappa light chain
(MOPC-21) which appears to have been derived from the myeloma fusion partner, a
P3 myeloma cell line, that was used to prepared the original hybridoma cell line. Our
20 subcloned hybridoma cell line possesses and expresses both light chains and the
ABX-CBL antibody appears to contain both light chains. IgM antibodies generally
possess a pentameric structure, where five heavy and light chain dimers are
associated. With the two light chains in the ABX-CBL antibody, we expect that the
IgM pentameric structure of the ABX-CBL antibody contains both light chains in
25 various ratios of light chains to form pentamers with homodimeric, heterodimeric, and
homo- and heterodimeric combinations.

In order to manufacture the ABX-CBL antibody for use in preclinical and
clinical development, we utilized hollow fiber cell culture technology through
contract manufacturing with Goodwin Biotechnology, Plantation, Florida. The
30 growth medium is a serum free formulation HYBRIDOMA-SFM supplied by Gibco
Life Technologies.

The stability of the Master Cell Bank (MCB) of ABX-CBL was determined by single cell subcloning. Cells were subcloned showing >95% stability for the single cell colony producers. The ABX-CBL MCB also showed stable antibody production for more than 130 generations in culture. The manufacturing process in hollow fiber
5 bioreactors is an approximately 40 day growth process that is equivalent to approximately 130 generations.

Primary purification of the monoclonal antibody from the cell culture supernatant is performed using Protein A affinity chromatography. Incubation at low pH following elution is performed as a viral inactivation step. The material is further
10 purified by anion exchange chromatography. This provides for residual protein A and DNA removal. The final step in the purification process is a filtration of the material to provide additional viral removal.

The formulated bulk drug substance is stored at 2-8°C prior to vialing. Using aseptic techniques, the antibody is filled in liquid form from the bulk containers into 5
15 mL glass vials. The vials are stored and shipped at 2-8°C. ABX-CBL is a murine IgM, anti-human lymphoblastoid monoclonal antibody raised to a T-ALL (Acute Lymphoblastic Leukemia) cell line (CEM). ABX-CBL is formulated in 20 mM sodium citrate and 120 mM sodium chloride at a pH of 6.0.

As used herein, the term "ABX-CBL" is used to refer to the purified and
20 reactive IgM antibody derived from the original cell line deposited with the ATCC as HB 8214. The sequence of the ABX-CBL heavy and light chains are discussed above and presented as SEQ ID NO.: 18 and SEQ ID NO.: 19, respectively.

We have now demonstrated that the active agent of the CBL1 antibody and ABX-CBL binds to the CD147 antigen as expressed on certain cells, such as T-cells,
25 B-cells, and/or monocytes. Accordingly, it is expected that the CD147 antigen, can be utilized as a target for the treatment of a variety of diseases. Since the CBL1 antibody has been effective in patients in the treatment of the diseases mentioned above, and based upon the results discussed herein, it is expected that additional CD147 based therapeutics will be similarly effective. Thus, in accordance with the
30 present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies

that bind to CD147 and that result in the killing of such cells, for example, through the activation of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without
5 limitation, renal transplant, corneal transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), and pancreatic), autoimmune diseases, inflammatory diseases, and others.

As was mentioned above, CBL1 had not previously been indicated to bind to CD147. Further, the particular epitope or antigen to which the CBL1 antibody bound
10 was unknown or at least relatively uncharacterized. Thus, because of the apparent safety and therapeutic efficacy of the CBL1 antibody, we were interested in determining the precise antigen or epitope to which the CBL1 and our ABX-CBL antibody bound. Further, we were interested in further understanding the manner in which the CBL1 antibody was efficacious, particularly in connection with the
15 treatment of GVHD.

By way of reference, the hybridoma line deposited with the ATCC as HB 8214 was not entirely pure. The line produced an IgG antibody and an IgM antibody. Only the IgM is biologically active in inhibition of complement mediated lysis of cells in a mixed lymphocyte reaction assay (MLR). The mechanism of inhibition is
20 via antibody mediated complement-dependent cytotoxicity (CDC) because the inhibition is specific and complement-dependent, as discussed herein. Therefore, in connection with our work described herein, we subcloned the line to produce a cell line producing solely the IgM. Further, the HB 8214 cell line expressing the CBL1 antibody possessed a second kappa light chain (MOPC-21) which appears to have
25 been derived from the myeloma fusion partner, a P3 myeloma cell line, that was used to prepare the original hybridoma cell line. Our subcloned hybridoma cell line possesses and expresses both light chains and the ABX-CBL antibody appears to contain both light chains. IgM antibodies generally possess a pentameric structure, where five heavy and light chain dimers are associated. With the two light chains in
30 the ABX-CBL antibody, we expect that the IgM pentameric structure of the ABX-CBL antibody contains both light chains in various ratios of light chains to form pentamers with homodimeric, heterodimeric, and homo- and heterodimeric

combinations.

The role of the MOPC-21 light chain in CBL1 and ABX-CBL binding was unknown. In connection with our work, we endeavored to clarify the role of the MOPC-21 light chain through, for example, preparation of hybridoma subclones that
5 express only the ABX-CBL light chain or the MOPC-21 light chain. One approach that we utilized was to fuse the ABX-CBL hybridoma with a mouse myeloma cell line to achieve light chain shuffling. Upon generation of hybridomas expressing only the MOPC-21 light chain or the ABX-CBL light chain, we were able to conduct certain characterizations to distinguish the role of the two light chains in ABX-CBL binding.

10

Definitions

Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by
15 those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well known and commonly used in the
20 art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection, etc.). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures are generally performed according
25 to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. *See e.g.*, Sambrook et al. *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference. The nomenclatures utilized in connection with,
30 and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for

chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

As utilized in accordance with the present disclosure, the following terms,
5 unless otherwise indicated, shall be understood to have the following meanings:

The term "isolated polynucleotide" as used herein shall mean a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which by virtue of its origin the "isolated polynucleotide" (1) is not associated with all or a portion of
10 a polynucleotide in which the "isolated polynucleotide" is found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence.

The term "isolated protein" referred to herein means a protein of cDNA,
15 recombinant RNA, or synthetic origin or some combination thereof, which by virtue of its origin, or source of derivation, the "isolated protein" (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g. free of murine proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.

20

The term "polypeptide" is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein, fragments, and analogs are species of the polypeptide genus.

25 The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally-occurring.

30

The term "operably linked" as used herein refers to positions of components so described are in a relationship permitting them to function in their intended manner.

A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

5 The term "control sequence" as used herein refers to polynucleotide sequences that are necessary to effect the expression and processing of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes,
10 generally, such control sequences include promoters and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

15

 The term "polynucleotide" as referred to herein means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double stranded forms of DNA.

20

 The term "oligonucleotide" referred to herein includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring oligonucleotide linkages. Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer. Preferably oligonucleotides are
25 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g. for probes; although oligonucleotides may be double stranded, e.g. for use in the construction of a gene mutant. Oligonucleotides of the invention can be either sense or antisense oligonucleotides.

30

 The term "naturally occurring nucleotides" referred to herein includes deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred

to herein includes nucleotides with modified or substituted sugar groups and the like. The term "oligonucleotide linkages" referred to herein includes oligonucleotide linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. See e.g., LaPlanche et al. *Nucl. Acids Res.* 14:9081 (1986); Stec et al. *J. Am. Chem. Soc.* 106:6077 (1984); Stein et al. *Nucl. Acids Res.* 16:3209 (1988); Zon et al. *Anti-Cancer Drug Design* 6:539 (1991); Zon et al. *Oligonucleotides and Analogues: A Practical Approach*, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)); Stec et al. U.S. Patent No. 5,151,510; Uhlmann and Peyman *Chemical Reviews* 90:543 (1990), the disclosures of which are hereby incorporated by reference. An oligonucleotide can include a label for detection, if desired.

The term "selectively hybridize" referred to herein means to detectably and specifically bind. Polynucleotides, oligonucleotides and fragments thereof in accordance with the invention selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments of the invention and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%. Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff,

M.O., in *Atlas of Protein Sequence and Structure*, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 to this volume, pp. 1-10. The two sequences or parts thereof are more preferably homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the
5 ALIGN program. The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. In contradistinction, the term "complementary to" is used herein to mean that the
10 complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA".

15 The following terms are used to describe the sequence relationships between two or more polynucleotide or amino acid sequences: "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger
20 sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing or may comprise a complete cDNA or gene sequence. Generally, a reference sequence is at least 18 nucleotides or 6 amino acids in length, frequently at least 24 nucleotides or 8 amino acids in length, and often at least 48 nucleotides or 16 amino acids in length. Since two polynucleotides or amino acid sequences may each
25 (1) comprise a sequence (i.e., a portion of the complete polynucleotide or amino acid sequence) that is similar between the two molecules, and (2) may further comprise a sequence that is divergent between the two polynucleotides or amino acid sequences, sequence comparisons between two (or more) molecules are typically performed by comparing sequences of the two molecules over a "comparison window" to identify
30 and compare local regions of sequence similarity. A "comparison window", as used herein, refers to a conceptual segment of at least 18 contiguous nucleotide positions or 6 amino acids wherein a polynucleotide sequence or amino acid sequence may be

compared to a reference sequence of at least 18 contiguous nucleotides or 6 amino acid sequences and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions, deletions, substitutions, and the like (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson and Lipman *Proc. Natl. Acad. Sci. (U.S.A.)* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, (Genetics Computer Group, 575 Science Dr., Madison, Wis.), Geneworks, or MacVector software packages), or by inspection, and the best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by the various methods is selected.

The term "sequence identity" means that two polynucleotide or amino acid sequences are identical (i.e., on a nucleotide-by-nucleotide or residue-by-residue basis) over the comparison window. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) or residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the

reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence.

5 As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. *See Immunology - A Synthesis* (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino
10 acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ -N-methylarginine, and
15 other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the righthand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

20 Similarly, unless specified otherwise, the lefthand end of single-stranded polynucleotide sequences is the 5' end; the lefthand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and
25 which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences".

30 As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity,

preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity, and most preferably at least 99 percent sequence identity. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic-aspartic, and asparagine-glutamine.

15

As discussed herein, minor variations in the amino acid sequences of antibodies or immunoglobulin molecules are contemplated as being encompassed by the present invention, providing that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99%. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. More preferred families are: serine and threonine are aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a

30

major effect on the binding or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site. Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Assays are described in detail herein. Fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains. Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-dimensional structure are known. Bowie et al. *Science* 253:164 (1991). Thus, the foregoing examples demonstrate that those of skill in the art can recognize sequence motifs and structural conformations that may be used to define structural and functional domains in accordance with the invention.

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and (5) confer or modify other physicochemical or functional properties of such analogs. Analogs can include various muteins of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in *Proteins, Structures and Molecular Principles* (Creighton, Ed., W. H. Freeman and Company, New York (1984)); *Introduction to Protein Structure* (C.

Branden and J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); and Thornton et al. *Nature* 354:105 (1991), which are each incorporated herein by reference.

5 The term "polypeptide fragment" as used herein refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence deduced, for example, from a full-length cDNA sequence. Fragments typically are at least 5, 6, 8 or 10 amino acids long, preferably at least 14
10 amino acids long, more preferably at least 20 amino acids long, usually at least 50 amino acids long, and even more preferably at least 70 amino acids long. The term "analog" as used herein refers to polypeptides which are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of a deduced amino acid sequence and which has at least one of the following properties: (1) specific binding
15 to a CD147, under suitable binding conditions, (2) ability to modify CD147's binding to its ligand or receptor, or (3) ability to kill or inhibit growth of CD147 expressing cells *in vitro* or *in vivo*. Typically, polypeptide analogs comprise a conservative amino acid substitution (or addition or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at
20 least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types
25 of non-peptide compound are termed "peptide mimetics" or "peptidomimetics". Fauchere, *J. Adv. Drug Res.* 15:29 (1986); Veber and Freidinger *TINS* p.392 (1985); and Evans et al. *J. Med. Chem.* 30:1229 (1987), which are incorporated herein by reference. Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically
30 useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biochemical property or pharmacological activity), such

as human antibody, but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH₂NH--, --CH₂S--, --CH₂-CH₂--, --CH=CH--(cis and trans), --COCH₂--, --CH(OH)CH₂--, and --CH₂SO--, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) may be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo and Gierasch *Ann. Rev. Biochem.* 61:387 (1992), incorporated herein by reference); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

"Antibody" or "antibody peptide(s)" refer to an intact antibody, or a binding fragment thereof that competes with the intact antibody for specific binding. Binding fragments are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab', F(ab')₂, Fv, and single-chain antibodies. An antibody other than a "bispecific" or "bifunctional" antibody is understood to have each of its binding sites identical. An antibody substantially inhibits adhesion of a receptor to a counterreceptor when an excess of antibody reduces the quantity of receptor bound to counterreceptor by at least about 20%, 40%, 60% or 80%, and more usually greater than about 85% (as measured in an *in vitro* competitive binding assay).

The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids, sugar, or other carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is $\leq 1 \mu\text{M}$, preferably $\leq 100 \text{ nM}$ and most preferably $\leq 10 \text{ nM}$.

The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.

5 As used herein, the terms "label" or "labeled" refers to incorporation of a detectable marker, e.g., by incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinylated moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). In certain situations, the label or marker can also
10 be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., ^3H , ^{14}C , ^{15}N , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, β -galactosidase, luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups, predetermined
15 polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

20

The term "pharmaceutical agent or drug" as used herein refers to a chemical compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient. Other chemistry terms herein are used according to conventional usage in the art, as exemplified by *The McGraw-Hill Dictionary of*
25 *Chemical Terms* (Parker, S., Ed., McGraw-Hill, San Francisco (1985)), incorporated herein by reference).

The term "substantially non-toxic to resting T-cells and resting B-cells" as used herein means, preferably, that the antibody in the presence of complement at at
30 least a 2-fold lower level of depletion of resting cells occurs than the level of depletion of activated T- and B-cells. More preferably, there is at least a 5-fold lower

level of cell depletion of resting cells compared to the level of depletion of activated cells. And, most preferably, there would be no detectable depletion of resting cells.

ABX-CBL Antigen Identification and Characterization

5

We undertook two primary approaches to the identification and characterization of the antigen to which the ABX-CBL antibody bound (i) an immunoaffinity purification approach and (ii) a classical protein purification approach.

10

Immunoaffinity Purification

We investigated immunoaffinity purification of the antigen to which the CBL1 antibody bound. The antigen to which the CBL1 antibody bound appeared to be highly expressed on CEM cells which is a T lymphoblastoid cell line derived by Foley et al. *Cancer* 18:522-529 (1965) and available from the ATCC, Rockville, MD (ATCC No. CCL-119). Immunoaffinity purification using the native ABX-CBL antibody was frustrated by the fact that the ABX-CBL antibody is an IgM antibody having a pentameric structure and prone to nonspecific interactions *in vitro*. Therefore, we prepared human IgG2 antibodies against CEM cells and tested for competition with the ABX-CBL antibody in binding assays with CEM cells. Such human antibodies were prepared in accordance with Mendez et al. *Nature Genetics* 15:146-156 (1997) and U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996, the disclosures of which are hereby incorporated by reference herein in their entirety, through the immunization of XenoMouseTM animals with CEM cells, followed by fusions, and screening of the resulting hybridoma supernatants against CEM cells and in FACS competition assays with the ABX-CBL antibody. In the FACS competition assays, inhibition of the binding of ABX-CBL antibodies, labeled with FITC, to CEM cells was analyzed, both alone and in the presence of hybridoma supernatants containing human antibodies reactive with the CEM cells.

25
30

Four hybridoma clones were isolated and determined, in this manner, to be that were highly competitive with the ABX-CBL antibody in binding to the CEM

cells. One hybridoma clone, designated 2.6.1, was selected for further analysis. We generated ascites to each of the hybridomas, including the 2.6.1 hybridoma, in SCID mice and purified the 2.6.1 antibody using a Protein A affinity purification process using standard conditions. From the purified 2.6.1 antibody, we prepared an immunoaffinity column. To prepare the column, the purified 2.6.1 antibody was conjugated to CNBr activated Sepharose-4B, according to the manufacturer's specifications. Approximately 8.4 mg of the antibody was conjugated to about 2.0 g of the activated Sepharose. We passed cell lysates of CEM cells through the column and eluted the components that bound. The elution product was analyzed by Western blotting and probing with both the ABX-CBL antibody and the 2.6.1 antibody. Based upon preliminary data, the 2.6.1 antibody bound most intensely to a molecule or molecules contained within a diffuse band from about 45-55 KD, while the ABX-CBL antibody showed binding with a low intensity to a similar diffuse band from about 45-55 KD. Through use of preparative gel electrophoresis and electroblotting techniques, we isolated a portion of the 45-55 KD band and obtained a partial amino acid sequence of the molecule (35/40 residues). The resulting sequence information was analyzed through a protein database search (Protein Identification Resource (PIR) R47.0, December 1995) and the sequence comparison data indicated that the molecule was CD147.

20

Protein Purification and Sequencing

In connection with our work related to the characterization of the antigen to which the ABX-CBL antibody bound, we saw significant ABX-CBL binding on Western blots to molecules localized in relatively sharp bands at 35 KD and 62 KD. The intensity of this 35 KD band appeared to vary from prep to prep, depending on culture age and other conditions not completely understood. Therefore, we initially purified the 62 KD material. Because the N-terminus was blocked, we cleaved the protein with CNBr and sequenced two of the peptides that resulted from the cleavage. The resulting sequence information was analyzed through a protein database search (Protein Identification Resource (PIR) R47.0, December 1995) and the sequence comparison data indicated that the molecule was heterogeneous ribonuclear protein k (hnRNP-k). Such molecule is an intracellular component, and, accordingly, does not

30

conform to the observations that the ABX-CBL antibody appeared to recognize an extracellular component. Nevertheless, the identification of this molecule may be useful in connection with further understanding of the binding of ABX-CBL to CD147, for example in connection with epitope elucidation.

- 5 Characterization of the 35 KD band can also be undertaken for similar reasons. In such an approach, the 35 KD molecule can be purified in a similar manner to that utilized in connection with the 62 KD band mentioned above. The purified material from the 35 KD band can be characterized to further understand any potential structural differences between material contained in the 45-55 KD CD147 band. The
- 10 material contained in the 35 KD band can be sequenced to either demonstrate that the material is CD147 or to determine epitopic information related to ABX-CBL's binding to CD147.

Further Elucidation of CD147 Binding and Epitopic Analysis of ABX-CBL

- 15 As was discussed above, another area of exploration is in connection with the elucidation of the binding of the ABX-CBL antibody to the CD147 molecule. Because of the safety and efficacy of the ABX-CBL antibody, we expect that molecules, particularly antibodies, that mimic the binding of the ABX-CBL antibody to CD147 should possess a similar safety profile. Thus, in order to further understand
- 20 the binding of the ABX-CBL antibody to CD147, we have undertaken, or designed, experiments in order to elucidate the same. Our experiments include (i) cloning of CD147 and expression in eukaryotic (COS) cells, (ii) expression in prokaryotic (*E. coli*) cells, and (iii) screening of random peptide libraries utilizing phage display techniques.

25

Cloning of CD147 and Expression in COS Cells

- We cloned CD147 cDNA from a Jurkat library (Stratagene), prepared constructs for transfection, and transfected COS cells with the CD147 cDNA. Transfected cells were analyzed for expression of CD147 utilizing FACS analysis and
- 30 Western blotting in connection with the ABX-CBL antibody, the 2.6.1 antibody, and the Pharmingen antibody mentioned above. COS cells transfected with CD147 cDNA showed binding to each of the antibodies in each of the FACS and Western blot

analyses. In contrast, COS cells transfected with control vectors were negative for binding with each of the 2.6.1 and ABX-CBL antibodies. With respect to the Pharmingen antibody, certain background staining was observed in cells transfected with control vectors on FACS and no binding on Western blot analysis. The transfected cells showed significant binding over background on FACS and were positive on Western blot analysis. Our results confirm that the ABX-CBL and the 2.6.1 antibodies bind to CD147.

Expression of CD147 in *E. Coli* Cells

Utilizing a slightly modified vector, we also transfected *E. coli* cells with the CD147 cDNA. The *E. coli* cells so transfected were capable of expression of the CD147 molecule as evidenced by Western blotting analysis of each of the ABX-CBL, 2.6.1, and Pharmingen antibodies. Since the prokaryotic *E. coli* cells should not glycosylate the expressed CD147, it was expected that the molecular weight of the CD147 expressed by the *E. coli* should closely approximate the predicted, unglycosylated molecular weight of CD147 of about 27 KD. Indeed, in each case, binding of the three antibodies on Western blot analysis was observed to a band between about 27 and 30 KD.

This data further confirms that the ABX-CBL and the 2.6.1 antibodies bind to CD147. Further, the evidence indicates that ABX-CBL binding to CD147 is not directly based on carbohydrate binding, i.e., that ABX-CBL does not bind directly to a carbohydrate epitope on CD147. Such data, however, does not eliminate the possibility that binding to CD147 is influenced by the presence of carbohydrate or glycosylation.

Screening Utilizing Phage Display

In order to further elucidate the binding of the ABX-CBL antibody to CD147, we undertook phage display experiment. Such experiments were conducted through panning a phage library expressing random peptides for binding with the ABX-CBL and 2.6.1 antibodies to determine if we could isolate peptides that bound. If successful, certain epitope information can be gleaned from the peptides that bind.

In general, the phage libraries expressing random peptides were purchased from New England Biolabs (7-mer and 12-mer libraries, Ph.D.-7 Peptide 7-mer

Library Kit and Ph.D.-12 Peptide 12-mer Library Kit, respectively) based on a bacteriophage M13 system. The 7-mer library represents a diversity of approximately 2.0×10^9 independent clones, which represents most, if not all, of the $20^7 = 1.28 \times 10^9$ possible 7-mer sequences. The 12-mer library contains approximately 1.9×10^9 independent clones and represents only a very small sampling of the potential sequence space of $20^{12} = 4.1 \times 10^{15}$ 12-mer sequences. Each of 7-mer and 12-mer libraries were panned or screened in accordance with the manufacturer's recommendations in which plates were coated with an antibody to capture the appropriate antibody (goat anti-human IgG Fc for the 2.6.1 antibody and goat anti-mouse μ chain for the ABX-CBL antibody) followed by washing. Bound phage were eluted with 0.2 M glycine-HCl, pH 2.2. After 3 rounds of selection/amplification at constant stringency (0.5% Tween), through use of DNA sequencing, we characterized a total of 5 clones from the 7-mer library and 6 clones from the 12-mer library reactive with the ABX-CBL antibody and a total of 6 clones from each of the 7-mer and 12-mer libraries reactive with the 2.6.1 antibody. Reactivity of the peptides was determined by ELISA. For an additional discussion of epitope analysis of peptides see also Scott, J.K. and Smith, G.P. *Science* 249:386-390 (1990); Cwirla et al. *PNAS USA* 87:6378-6382 (1990); Felici et al. *J. Mol. Biol.* 222:301-310 (1991), and Kuwabara et al. *Nature Biotechnology* 15:74-78 (1997).

No consensus sequence was readily apparent for reactivity of the 2.6.1 antibody with CD147. However, sequence alignment of the characterized 7-mer and 12-mer sequences against the amino acid sequence of CD147 yielded a number of matches for a single sequence within CD147 from residue number 177 through residue number 188 (ITLRVRSR (SEQ ID NO:1)). In particular, each of the 7-mers contained sequence matches (represented by *) to 3 or more residues within this sequence of CD147:

7-mer sequences

- | | | | | | | | |
|----|----|----|-----|---|---|---------------|--|
| 30 | | | | * | * | * | |
| | 1. | EE | RLR | S | Y | (SEQ ID NO:2) | |
| | | | | * | * | * | |
| | 2. | YE | RVR | W | Y | (SEQ ID NO:3) | |

3. EE RLR S Y (* * *) (SEQ ID NO:4)

5 4. AE RIR S I (SEQ ID NO:5)

5. EE RLR S Y (SEQ ID NO:6)

Further, 4 of the 12-mers contained sequence matches (represented by *) to 3 or more residues within this sequence of CD147, with 4 matches for 12-mer peptide number 1 and for 6 matches of 12-mer peptide number 2:

12-mer sequences

15

* * *

1. TVHGD L RLR S LP (SEQ ID NO:7)

20 2. TNDIGL RQR S HS (SEQ ID NO:8)

3. SPLLDGQ RER S Y (SEQ ID NO:9)

25 * * *

4. YDLPM RSR S YPG (SEQ ID NO:10)

These results indicate a consensus sequence of RXRS (SEQ ID NO:11) that is present in 10 of the sequenced clones. Accordingly, we had a synthetic peptide prepared (AnaSpec Incorporated, San Jose, CA) which spanned residues 169-183 of CD147 with the following sequence (with -OH representing carboxy terminus):

KGSDQAIITLRVRSH-OH (SEQ ID NO:12)

35 169 184

Below, the amino acid sequence of CD147 is provided with the 15-mer peptide's sequence indicated by double underlining and the RXRSH (SEQ ID NO:13) consensus sequence indicated in bold. In addition, putative N-linked glycosylation sites of CD147 are shown as underlined and italics:

CD147 Sequence

MAAALFVLLGFALLGTHGASGAAGTVFTTVEDLGSKILLTCSLNDSATEVTG
 HRWLKGGVVLKEDALPGQKTEFKVDSDDQWGEYSCVFLPEPMGTANIQLHG
 PPRVKAVKSSEHINEGETAMLVCKSESVPPVTDWAWYKITDSEDKALMNGSE
 5 SRFFVSSSQGRSELHIENLNMEADPGQYRCNGTSSKGSDOAITLRVRSHLAAL
 WPFLGIVAEVLVLVTIIFIYEKRRKPEDVLDDDDAGSAPLKSSGQHQNCKGKN
 VRQRNSS (SEQ ID NO:14)

The 15-mer peptide was assayed using ELISA and it was determined that the
 10 ABX-CBL antibody specifically bound to the peptide. Further, neither the 2.6.1
 antibody nor a control murine IgM antibody bound to the peptide. However, based on
 a competition study between the CD147 antigen and the 15-mer peptide, the ABX-
 CBL antibody's binding to the 15-mer peptide can only be measured when the 15-mer
 peptide is coated on plates and not when the peptide is in solution. Indeed, in
 15 competition experiments in which the ABX-CBL antibody is bound to either the
 peptide or the CD147 antigen coated to plates, the ABX-CBL antibody is not removed
 or replaced by the peptide in solution even at high concentrations. Nevertheless, the
 binding of the ABX-CBL antibody to the 15-mer peptide can be specifically
 competed by the CD147 antigen and positive phage preparations mentioned above but
 20 not with non-specific antigen (i.e., L-Selectin isolated from cell membrane or human
 plasma) or the negative phage preparations mentioned above. Similarly, the binding
 of the ABX-CBL antibody to the CD147 antigen can be specifically competed by
 positive phage preparations as compared to negative phage preparation in competition
 assays using preincubation.

25 These results indicate that while the sequence within CD147 that contains the
 consensus sequence RXRSH is important to the binding of the ABX-CBL antibody to
 CD147, it does not fully explain ABX-CBL's binding to CD147. Indeed, the data
 also suggests that the consensus sequence contained either in the 15-mer peptide when
 bound to the plate or the reactive phage materials when tethered to the phage coat
 30 protein binds more tightly to the ABX-CBL antibody than does the free peptide in
 solution. Taken together, while not wishing to bound to any particular theory or mode
 of operation, it is possible that CD147 possesses certain conformations that are not

well mimicked in the 15-mer peptide in solution. Nevertheless, the above epitopic information is important to understanding the manner in which the ABX-CBL antibody binds to CD147 and to producing other candidate molecules against CD147 as a therapeutic target.

5 It is interesting to note that in addition to the results above in connection with the presence of the RXRSH consensus sequence within CD147, we also looked for the presence of the consensus sequence within the hn-RNP-k protein to which ABX-CBL also appears to bind. Such analyses were conducted by sequence alignment against the phage derived peptides discussed above. Two sequences were found
10 which possessed statistically interesting matches:

First, there was a match (indicated by *) of 5 amino acids with the 7-mer peptide number 4:

15 * ** **
 PE RIL SI (SEQ ID NO:15)
 |
 84

20 Second, there was a match (indicated by *) of 5 amino acids with the 12-mer peptide number 1:

 * * * **
 GGS RAR NLP (SEQ ID NO:16)
25 | |
 300 306

 The amino acid sequence of the hn-RNP-k protein is provided below with such sequences indicated by double underlining. In addition, a number of RXR
30 sequence motifs are present in the hn-RNP-k protein's sequence which are also indicated by underlining:

hn-RNP-k Protein Sequence

METEQPEETFPNTETNGEFGKRPAEDMEEEQAFKRSRNTDEMVELRILLQSKN
35 AGAVIGKGGKNIKALRTDYNASVSPDSSGPERILSISADIETIGEILKKIPTLE
EGLQLPSPTATSQLPLESDAVECLNYQHYKGSDFDCELRLLIHQSLAGGIIGVK

GAKIKELRENTQTTIKLFQECCPHSTDRVVLIGGKPDRVVECIKILDLISESPIK
 GRAQPYDPNFYDETYDYGFTMMFDDRRGRPVGFPMRGRGGFDRMPPGRG
 GRPMPPSRDYDDMSPRRGPPPPPPGRGGGRGGSRRARNLPLPPPPPPRGDDLMA
 YDRRGRPGDRYDGMVGFSADETWDSAIDTWSPSEWQMA YEPQGGSGYDYS
 5 YAGGRGSYGDLGGPIITTQVTIPKDLAGSIIGKGGQRIKQIRHESGASIKIDEPLE
 GSEDRIITITGTQDQIQNAQYLLQNSVKQYSGKFF (SEQ ID NO:17)

Without wishing to be bound to any particular theory or mode of operation, it is possible that the binding of the ABX-CBL antibody to the hn-RNP-k protein is
 10 partially explained by the presence of these motifs within the protein.

Discussion of Results of Antigen Identification and Analysis

It is interesting to note that the ABX-CBL antibody appears to bind to the 45-55 KD band with less intensity than it does the 35 KD band in CEM cell lysates.
 15 However, without wishing to be bound to any particular theory or mode of operation of the ABX-CBL antibody, the 35 KD band could either represent another epitope or could be an alternative form of CD147. Indeed, as discussed above, there is evidence in the literature for alternative splicings of CD147 or differential glycosylation. See e.g., Kanekura et al. *Cell Struct Funct* 16:23-30 (1991) (Basigin); Schlosshauer B
 20 *Development* 113:129-140 (1991) (Neurothelin); Fadool JM & Linser PJ *J Neurochem* 60:1354-136 (1993) (5A11/HT7); Nehme et al. *J Cell Biol* 120:687-694 (1993) (CE9); DeCastro et al. *J Invest Dermatol* 106:1260-1265 (1996) (EMMPRIN); Spring et al. *Eur J Immunol* 27:891-897 (1997) (Ok^a). Anecdotal evidence indicates that a 35 KD band could correspond to a singly-glycosylated form of CD147. See
 25 Kanekura et al. *Cell Struct Funct* 16:23-30 (1991). Further, it is also interesting to note that in comparisons of Western blots produced by two commercially available anti-CD147 antibodies (RDI-CBL535 (an anti-CD147 IgG2 antibody), available from RDI, Flanders, NJ, and 36901A (an anti-CD147 IgG1 antibody), available from Pharmingen, San Diego, CA) to the ABX-CBL and 2.6.1 antibodies indicates that
 30 each of the commercially available antibodies recognize a molecule that has a molecular weight around 35 KD and appearing similar to the 35 KD band recognized

by the ABX-CBL antibody. However, the 45-55 KD diffuse band is more intense. See Figure 1.

Based upon preliminary data, another interesting observation is that in the immunoaffinity purification mentioned above, when the effluent product from the 2.6.1 antibody was probed with the ABX-CBL antibody, the 35 KD band was no longer visible by Western blot. Rather, the ABX-CBL antibody appeared to bind to the diffuse band from 45-55 KD with relatively low intensity.

Further, our results in phage display experiments indicates that the ABX-CBL antibody and the 2.6.1 antibody bind to different epitopes. However, from our work related to the expression of CD147 in *E. coli* cells and based on the phage display work, the ABX-CBL antibody appears to recognize a protein epitope of CD147 and glycosylation, alone, does not appear responsible for ABX-CBL binding to CD147.

Nevertheless, in light of all of the foregoing, taken together, our results and data indicate that the ABX-CBL antibody does bind to the CD147 antigen. However, the ABX-CBL antibody appears to preferentially recognize a different epitope than recognized by the 2.6.1 or commercially available antibodies. Our finding that the ABX-CBL antibody binds to the CD147 antigen is indicative that a form of CD147 as expressed on particular cells is a viable therapeutic target for the treatment of disease.

Functional Understanding of the Mode of CD147 Therapy

As mentioned above, the CBL1 antibody has been used extensively in the treatment of GVHD in patients. Indeed, about a number of GVHD patients have been treated using the CBL1 antibody with a high percent success rate. Corneal and renal transplant studies have shown similar efficacy. Further, no signs of safety concerns or adverse effects have been observed. This is striking, given that, as discussed above, CD147 is so widely expressed in various tissues and cells of man. One would be concerned that an antibody to CD147 could cause a variety of adverse effects. Accordingly, we also endeavored to study the mechanism through which the CBL1 antibody operated to result in the treatment of disease, focused on models relevant to the reversal of GVHD. Understanding the mechanism could assist in elucidating why the CBL1 antibody is efficacious in patients and could also provide an understanding

of how to use the antigen to which the CBL1 antibody binds, CD147, in the treatment of disease.

There are several possible explanations related to the safety and specificity of the CBL1 antibody in the treatment of disease. Without limitation, these include (i) that there is a unique role of complement mediated cell killing (complement dependent cytotoxicity, CDC), (ii) that certain cells in becoming activated become sensitive to CBL1 binding and cell killing, (iii) that there are particular protective elements in certain cellular populations that render the cells resistant to CBL1 induced CDC, (iv) that CD147 expression levels are higher in given populations of cells (which could also be relevant to CDC); and (v) that the CBL1 antibody binds to a particular form of CD147 expressed on certain cellular populations (as discussed above). Each of these roles will be discussed in additional detail below.

Complement Mediated Killing of Cells

The role of complement mediated cell killing (complement dependent cytotoxicity, CDC) in connection with the CBL1 antibody has been studied previously and we have additionally studied its role extensively.

Past Work with CBL1

The UCLA group mentioned above (*see e.g.*, U.S. Patent Nos. 5,330,896 and 5,643,740) provided certain evidence that the CBL1 antibody operated through killing of certain activated cell populations while the antibody did not react with non-activated cells. For example, in microcytotoxicity assays, the CBL1 antibody was disclosed to kill activated lymphocytic cells but not non-activated lymphocytic or other normal cells. Further, the patents disclose that the cell killing operated through complement mediated killing of the cells.

Further Demonstration of the Role of CDC

Indeed, in our work, we have further demonstrated that CBL1 and ABX-CBL operates through complement mediated cell killing. We have utilized a mixed lymphocyte reaction (MLR) assay or a modified MLR assay in our work. The MLR assay provides an *in vitro* system for assaying proliferation of alloreactive T-

lymphocytes. In this manner, the MLR assay is an excellent model of GVHD in patients receiving bone marrow transplant (BMT). In the MLR assay, MHC mismatch lymphocytes from two individuals are co-cultured. Typically the assays are set up so that the lymphocytes from one patient are inactivated by, for example, radiation (the "stimulators") and the lymphocytes from the other patient are able to act as "Responders" and proliferate and undergo extensive blast transformation. After a suitable period of co-culture, the extent of proliferation of the cells can be quantified by adding tritium-labeled thymidine ($[^3\text{H}]$ thymidine) to the culture medium and monitoring uptake of the label into the DNA of the Responder lymphocytes.

In our work, use of the CBL1 antibody by itself, the isotype-matched control mouse IgM antibody by itself (Figure 2), or complement (either human or rabbit) by itself in an MLR or ConA induced lymphocyte proliferation assay is ineffective in inhibiting T-cell proliferation. See Figures 2-5. However, when both complement and the CBL1 and/or ABX-CBL antibody are present, T-cell proliferation is inhibited in a dose dependent manner. See Figures 2-5. The human IgG2 antibody 2.6.1 is ineffective in inhibiting T-cell proliferation in the same assay, either by itself, or in combination with complement. See Figure 5. This is expected, since the 2.6.1 antibody as a gamma-2 isotype is notoriously less efficient in complement mediated lysis than is an IgM antibody, such as the CBL1 or ABX-CBL antibody.

Role of Cellular Activation Levels

We have also studied whether certain cells in becoming activated become sensitive to ABX-CBL binding and cell killing.

Indeed, we have demonstrated in our work that the T-cell activation marker, CD25 (the alpha-2 subunit of the IL-2 receptor), appears to be expressed in high levels in the same cellular populations as those expressing the antigen to which the ABX-CBL antibody binds. See Figure 6. This finding provided a useful marker to detect whether activated cells were depleted in connection with the MLR assay. Where the MLR assay is conducted utilizing ABX-CBL alone, complement alone, or ABX-CBL and complement in combination, it is only in those experiments where ABX-CBL and complement are used in combination that CD25 expressing cell populations are depleted. See Figures 7-11. In particular, Figure 8 shows cells

expressing low levels of CD25. The selective killing of different cell populations are shown in Figures 10-12.

Role of Density or Expression Levels of CD147 in CDC

5 We have also considered whether CD147 expression levels are higher in given populations of cells (which could also be relevant to CDC).

In flow cytometry studies with peripheral blood mononuclear cells (PBMC) with the ABX-CBL antibody, we have noticed that, prior to the addition of complement, there are populations of cells that appear to express high and low levels of CD147. After complement is added, there are populations of cells that appear to correspond to the low level expressers mentioned above. It appears that these results could be indicative of density of CD147 expression levels on the cell surface. Density can play a role in CDC through providing additional antigen binding sites to allow for distortion of the antibody which is the first step in triggering the complement cascade.
10 Upon distortion of the antibody, the factor $C1q$ binds first and the cascade proceeds.

Whether the expression level (or, density) of CD147 in cellular populations plays a role in the therapeutic efficacy of the ABX-CBL antibody can be assayed through analyzing the expression levels of the CD147 molecule in various cellular populations. Generally, the experiments are conducted where beads having various known quantities of the CD147 antigen on their surface are prepared and analyzed on FACS (i.e., utilizing a FITC-labeled anti-CD147 IgG antibody) in order to generate approximately 10-20 data points of different quantities of antigen on the beads. A linear regression curve is prepared from such data. Thereafter, cells expressing the CD147 antigen can be run through FACS and the relative quantities of antigen on the surface of the cells can be calculated from the linear regression curve.
20
25

Presence and Role of Protective Elements in Cellular Populations

We have also studied whether there is a correlation between certain cellular protective elements in particular cellular populations that inhibit CDC induced by ABX-CBL binding and fixing of complement.
30

In connection with this work, we have investigated various cells to which the ABX-CBL antibody binds and considered whether such cells were (i) killed and (ii) if

so, was the mechanism similar to complement mediated lysis. In the experiment, we looked for ABX-CBL antibody binding to a number of cells (and, thus, the antigen to which the ABX-CBL antibody binds is expressed upon such cells). Those cells to which ABX-CBL would bind were then tested for complement mediated lysis through treatment with the ABX-CBL antibody and complement. Two T-cell lines (CEM and Jurkat cells), a monocyte line (U937 cells), and three tumor cell lines (A431 (epidermal), SW948 (colon), and MDA468 (breast)), each of which bound the ABX-CBL antibody were examined. Despite the expression on such cells lines, the ABX-CBL antibody is very specific about which cells are killed, being restricted to the CEM T-cell line and U937 monocyte line. See Figure 13. We also analyzed two endothelial cell lines (i) ECV-304 (ATCC CRL-1998) is a spontaneously transformed immortal EC established from the vein of an apparently normal human umbilical cord and carrying EC characteristics and (ii) HUVEC-C (ATCC CRL-1730) is an EC line derived from the vein of a normal human umbilical cord. Using FACS, we found that the ECV-304 and HUVEC-C lines each stained positive against the 2.6.1, Pharmingen, and ABX-CBL antibodies suggesting that these ECs do express CD147 on the surface. Figures 15 and 16, respectively. We then carried out in vitro Alamar-blue based CDC assay and demonstrated that both EC lines were resistant to ABX-CBL mediated CDC in the presence of human complement. See Figures 17 and 18, respectively.

In order to further understand why cells that all appear to express CD147 would not be killed by the ABX-CBL antibody in the presence of complement, we looked into CD46, CD55, and CD59 expression in such cells. Each of CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, DAF), and CD59 (membrane attack complex inhibitor, MACI) have been implicated as complement inhibitory molecules. See e.g., Liszewski et al. *Annu. Rev. Immunol.* 9:431 (1991) and Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59" *Transpl. Proc.* 26:1070 (1994) related to CD46, Kinoshita et al. "Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria" *J. Exp. Med.* 162:75 (1985) and Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59"

Transpl. Proc. 26:1070 (1994) related to CD55, and Whitlow et al. "H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement" *Cell. Immunol.* 126: 176 (1990), Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59" *Transpl. Proc.* 26:1070 (1994), and Davies, A. and Lachmann, P.J. "Membrane defense against complement lysis: the structure and biological properties of CD59" *Immunol. Res.* 12: 258 (1993) related to CD59. Accordingly, we considered whether there was differential expression of either, or both, of these molecules on the cell lines tested above. Indeed, all of the cells, except the CEM line and the U937 line, expressed both of the molecules. And, indeed, the endothelial cell line ECV-304 expressed all three, CD46, CD55, and CD59. Figures 19 and 20, respectively. In contrast, the CEM line expressed only CD59 and the U937 line expressed only CD55. See Figure 14. This data is useful in connection with the prediction of cells that could be selectively eradicated by ABX-CBL and consequently targeted in connection with anti-CD147 in accordance with the present invention.

Discussion of Function of ABX-CBL/CD147 Based Therapy

From the foregoing, it is clear that CBL1 and ABX-CBL operates to kill cells through the activation of complement. The combination of ABX-CBL and complement only kill activated T-cells (both CD4⁺ and CD8⁺), activated B-cells, and monocytes, but does not effect resting T-cells and B-cells because such cells do not appear to express CD147 at the same level as the activated cells. It is important, to note that monocytes are also killed by ABX-CBL and complement. This data provides an explanation for the operation of ABX-CBL therapy in diseases, such as GVHD, because, ABX-CBL selectively depletes those effector cells (activated T- and B-cells) and the antigen presenting cells (monocytes and B-cells) which ordinarily would lead to further T-cell activation.

The mode of operation of the ABX-CBL antibody, and future therapeutic molecules directed against CD147, in this regard appears to be at least partially related to, or dependent upon, each of the above-discussed functional characteristics: (i) complement mediated lysis, (ii) cellular activation, (iii) expression levels of CD147 and/or density of CD147 on the cell surface, and (iv) the absence of

expression of one or more of the complement inhibitory molecules on the cell surface. Accordingly, through use of this information, it is possible to design functional assays for the prediction of efficacy of a CD147 based therapeutic.

Indeed, the desirability of mimicking ABX-CBL binding and efficacy is highlighted based upon a preliminary tissue distribution study of the ABX-CBL antibody. In the study, ABX-CBL is widely distributed throughout a variety of tissues. However, the majority of the distribution is likely to be due to nonspecific binding. Nevertheless, there appears to be specific binding in endothelial cells (venules, arterioles, but not capillary beds), smooth muscle, and some mesothelium. Also, the lymphoreticular tissues appear to be bound, although, the staining seems to be restricted to large lymphocytes, presumably activated blasts. From the study conducted, it was difficult to distinguish intracellular from extracellular staining. A certain amount of cytoplasmic staining was clearly evident and could have been related to hn-RNP-k binding.

15

Discussion of Results; Utilization of the ABX-CBL Antibody for the Design of Therapeutics

The above *in vitro* work with the ABX-CBL antibody, in combination with the association of the ABX-CBL antibody with the CD147 antigen herein, provide the first evidence that antibodies to CD147 that are capable of complement mediated killing could provide an efficacious approach to the treatment of disease. Moreover, because of CD147's wide distribution and expression in the body and the tissue binding information that indicates that the CBL1 and ABX-CBL antibody associates with many tissues, the excellent prior clinical experience with the CBL1 antibody was difficult to reconcile unless CBL1 and ABX-CBL are, for example, specific to forms of CD147 expressed on certain cells or that other factors associated with complement mediated cell killing limit the CBL1 and ABX-CBL antibody's effects to particular tissues or perhaps a combination thereof.

30

Criteria for Generation of CD147 Based Therapeutics

From the foregoing, it is clear that the ABX-CBL antibody provides a powerful tool for the development of other CD147 based therapeutics. First, because

of the extreme safety demonstrated to date with the CBL1 and ABX-CBL antibody, it is desirable to mimic the binding of the ABX-CBL antibody as closely as possible. Second, because of the apparent efficacy of the CBL1 antibody it is desirable, at least initially, that any new therapeutic mediate complement fixation and lysis. Accordingly, in connection with the design of other CD147 based therapeutics, it is expected that through simulating the binding (or structural aspects) and mode of operation (or functional aspects) of ABX-CBL in the therapeutic candidates, safety and efficacy can be expected.

Structural Considerations

In connection with simulating or mimicking the structural aspects of ABX-CBL binding, we expect to be able readily generate antibodies that bind to CD147 in a similar manner as ABX-CBL. With the information discussed above, we know at least three levels of detail related to ABX-CBL's binding to CD147: (i) ABX-CBL appears to bind, if not preferentially, to a form of CD147 expressed on the population of cells selected from the group consisting of activated T-cells, activated B-cells, and monocytes, (ii) ABX-CBL shows clear and specific binding to 62 KD and 35 KD molecular species on Western blot analysis, and (iii) ABX-CBL appears very specific to an epitope on CD147 (and potentially a similar epitope on hn-RNP-k protein) defined by the consensus sequence RXRSH. In addition, ABX-CBL can be utilized to "structurally" compare, screen, or act as a functional assay for additional antibody candidates to CD147 through competition studies.

As will be appreciated, the above information provides highly useful information to the generation of additional antibody candidates. Put another way, antibody candidates that are generated that possess one or more of the above-characteristics are more likely to possess similar activity to the ABX-CBL antibody. An antibody candidate that possesses greater numbers of similar characteristics is likely to be a very close mimic to the ABX-CBL antibody and, accordingly, would likely exhibit similar safety and efficacy data as the ABX-CBL antibody.

In addition, as was discussed above, we expect to be able to generate additional information related to the binding of the ABX-CBL antibody to CD147

through certain experiments designed to elucidate ABX-CBL binding, for example, through:

- Additional mapping experiments related to the binding of CD147 to the ABX-CBL antibody. One such set of experiments relate to depletion experiments in which the ABX-CBL antibody bound to CD147 is cleaved with protease and the resulting products scanned with mass spectroscopy and the process repeated as necessary. Another such set of experiments relate to the isolation, purification, and understanding of the 35 KD species recognized by the ABX-CBL antibody. One method of accomplishing this is through the classical purification of the 35 KD molecule as discussed above in connection with the 62 KD species (hn-RNP-k protein). Another approach is the immunoaffinity purification of the 35 KD band through the generation of, for example, Fab fragments of the ABX-CBL antibody and binding the same to a column as discussed above in connection with the immunoaffinity purification conducted with the 2.6.1 antibody.
- Experiments directed to understanding CD147 cellular development. For example, the development of CD147 on the cell surface can be gleaned through conducting "pulse-chase" experiments. In such experiments, cells (such as CEM cells) growing in culture (Met⁽⁺⁾ media) are "pulsed" with S³⁵-Met for a sufficient time periods (and varied time periods) for the label to be enrolled into the cellular protein synthesis. Thereafter, cells are washed with "cold" medium and CD147 on the cell surface can be immunoprecipitated and subjected to autoradiography. Information can be gained related to potential alternative splicings, glycosylation levels, and other developmental differences of the expressed CD147 molecules.
- Experiments related to the role of glycosylation levels to ABX-CBL binding to CD147 can also be queried through reaction of CD147 with various glycosidases (*see e.g.*, Mizukami et al. *J. Immunol.* **147**:1331-1337 (1991), Schlosshauer *Development* **113**:129-140 (1991), Fadool and Linser *J. Neurochemistry* **60**:1354-1364 (1993)) and considering ABX-CBL binding to the various forms.

Functional Considerations

Once, or, concurrently with determining whether, one is satisfied with the "structure" of an antibody candidate (i.e., in connection with the antibody's binding to CD147), in accordance with the present invention, we have provided detailed functional criteria that appear important to the ABX-CBL antibody's *in vivo* efficacy that can be utilized to determine whether an antibody candidate is likely to operate in a similar manner to the ABX-CBL antibody. Such features include (i) cell killing through CDC, (ii) apparent effect of density or expression of the CD147 molecule on cellular populations, and (iii) the role of protective factors (for example, CD46, CD55, and CD59) on cellular populations.

As will be appreciated, the above information provides highly useful information to the generation of additional antibody candidates. Put another way, antibody candidates that are generated that possess one or more of the above-characteristics are more likely to possess similar activity to the ABX-CBL antibody. An antibody candidate that possesses greater numbers of similar characteristics is likely to be a very close mimic to the ABX-CBL antibody and, accordingly, would likely exhibit similar safety and efficacy data as the ABX-CBL antibody.

In Vivo Models

Each of the foregoing features, whether structural or functional, can essentially be carried out *in vitro*. Of course, however, prior to proceeding into man with therapeutic candidates it is desirable to generate *in vivo* data to ensure that operation of the antibody candidate will be safe and efficacious *in vivo*. In connection with GVHD, there are several animal models that have been shown to be highly predictive of the operation of therapeutic candidates in man. Such models include:

- Murine model (Hakim FT & Mackall CL "The Immune System: Effector and Target of Graft-Versus-Host Disease" in *Graft-vs.Host Disease* (Ferrara et al. eds, 2d edition, Marcel Dekker, Inc., NY (1997)).
- Canine Model (Storb et al. *Blood* 89:3048-3054 (1997); Yu et al. *Bone Marrow Transplantation* 17:649-653 (1996); Raff et al.

Transplantation 54:813-820 (1992); and Deeg et al. *Transplantation* 37:62-65 (1984))

- Primate Skin Graft Model (Chatterjee et al. *Hybridoma* 1:369-377 (1982) and Billing R. and Chatterjee S. *Transplantation Proceedings* 15:649-650 (1983))

As will be appreciated, in order such models to predictive, it is necessary that the antibody candidate is reactive with the endogenous form of CD147 in the animal.

10 *Construction of Antibodies*

An excellent model in which to generate therapeutic molecules targeting CD147 is in connection with the generation of antibodies. Antibodies can be generated with relative ease and are also capable of ready screening. In recent years, it has become possible to generate different "types" of antibodies; from conventional
15 murine antibodies through human antibodies generated from transgenic animals. Within that spectrum, antibodies can also be generated through display techniques (i.e, phage), murine or other antibodies can be humanized, and the like. Some of these techniques are discussed below.

In connection with the generation of antibodies through immunization
20 techniques, both classical and advanced immunization techniques can be used. By classical, we mean that animals can simply be immunized with the antigen, lymphocytic cells fused with myeloma cells, and hybridomas screened therefrom. By advanced, we mean that either immunization schemes can be biased or, instead of simply forming hybridomas, lymphocytic cells can be used directly to form display
25 libraries and screened using, for example, phage or other display technologies. Such techniques are conventional in the art and are discussed in additional detail below. In connection with biasing immunizations, one can immunize with CD147, followed by immunization with peptides, such as the 15-mer peptide mentioned above. In this manner, there is a higher probability of generating antibodies that possess specificity
30 and affinity for selected epitopes for example. Thus, it is expected that antibodies having specificity for the RXRSH consensus sequence in CD147, as discussed above, can be more readily generated. It will be appreciated that such immunization

techniques can be utilized in connection with standard fusions and screening procedures or advanced screening procedures. Another set of advanced immunization techniques are related to techniques of antigen presentation (i.e., DEC systems) and techniques to augment the immune response (i.e., CD140 systems) in the animal in which the immunization is being undertaken.

Generation of Human Antibodies from Transgenic Animals

The generation of fully human antibodies, for example, from transgenic animals, is very attractive. Fully human antibodies are expected to minimize the immunogenic and allergic responses intrinsic to mouse or mouse-derived Mabs and thus to increase the efficacy and safety of the administered antibodies. The use of fully human antibodies can be expected to provide a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation, autoimmunity, and cancer, which often require repeated antibody administrations.

One approach that has been utilized in connection with the generation of human antibodies is the construction of mouse strains that are deficient in mouse antibody production but that possess large fragments of the human Ig loci so that such mice would produce a large repertoire of human antibodies in the absence of mouse antibodies. Large human Ig fragments preserve the large variable gene diversity as well as the proper regulation of antibody production and expression. By exploiting the mouse machinery for antibody diversification and selection and the lack of immunological tolerance to human proteins, the reproduced human antibody repertoire in these mouse strains yields high affinity antibodies against any antigen of interest, including human antigens. Using hybridoma technology, antigen-specific human Mabs with the desired specificity can be readily produced and selected.

This general strategy was demonstrated in connection with the generation of the first XenoMouse strains as published in 1994. See Green et al. *Nature Genetics* 7:13-21 (1994). The XenoMouse strains were engineered with 245 kb and 190 kb-sized germline configuration fragments of the human heavy chain loci and kappa light chain loci, respectively, which contained core variable and constant region sequences. *Id.* The human Ig containing yeast artificial chromosomes (YACs) proved to be compatible with the mouse system for both rearrangement and

expression of antibodies, and were capable of substituting for the inactivated mouse Ig genes. This was demonstrated by their ability to induce B-cell development and to produce an adult-like human repertoire of fully human antibodies and to generate antigen-specific human Mabs. These results also suggested that introduction of larger portions of the human Ig loci containing greater numbers of V genes, additional regulatory elements, and human Ig constant regions might recapitulate substantially the full repertoire that is characteristic of the human humoral response to infection and immunization.

Such approach is further discussed and delineated in U.S. Patent Application Serial Nos. 07/466,008, filed January 12, 1990, 07/610,515, filed November 8, 1990, 07/919,297, filed July 24, 1992, 07/922,649, filed July 30, 1992, filed 08/031,801, filed March 15, 1993, 08/112,848, filed August 27, 1993, 08/234,145, filed April 28, 1994, 08/376,279, filed January 20, 1995, 08/430, 938, April 27, 1995, 08/464,584, filed June 5, 1995, 08/464,582, filed June 5, 1995, 08/463,191, filed June 5, 1995, 08/462,837, filed June 5, 1995, 08/486,853, filed June 5, 1995, 08/486,857, filed June 5, 1995, 08/486,859, filed June 5, 1995, 08/462,513, filed June 5, 1995, 08/724,752, filed October 2, 1996, and 08/759,620, filed December 3, 1996. *See also* European Patent No., EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published February 3, 1994, International Patent Application No., WO 96/34096, published October 31, 1996, and PCT Application No. PCT/US96/05928, filed April 29, 1996. The disclosures of each of the above-cited patents and applications are hereby incorporated by reference in their entirety.

In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" strategy. In the minilocus strategy, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H genes, one or more J_H genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Patent No. 5,545,807 to Surani et al., U.S. Patent Nos. 5,545,806, 5,625,825, 5,661,016, 5,633,425, and 5,625,126, each to Lonberg and Kay, U.S. Patent No. 5,643,763 to Dunn and Choi, U.S. Patent No. 5,612,205 to Kay et al., U.S. Patent No. 5,591,669 to Krimpenfort and Berns, and GenPharm International U.S. Patent

Application Serial Nos. 07/574,748, filed August 29, 1990, 07/575,962, filed August 31, 1990, 07/810,279, filed December 17, 1991, 07/853,408, filed March 18, 1992, 07/904,068, filed June 23, 1992, 07/990,860, filed December 16, 1992, 08/053,131, filed April 26, 1993, 08/096,762, filed July 22, 1993, 08/155,301, filed November 18, 1993, 08/161,739, filed December 3, 1993, 08/165,699, filed December 10, 1993, 08/209,741, filed March 9, 1994, 08/544,404, filed October 10, 1995, the disclosures of which are hereby incorporated by reference. *See also* International Patent Application Nos. WO 97/13852, published April 17, 1997, WO 94/25585, published November 10, 1994, WO 93/12227, published June 24, 1993, WO 92/22645, published December 23, 1992, WO 92/03918, published March 19, 1992, the disclosures of which are hereby incorporated by reference in their entirety. *See further* Taylor et al., 1992, Chen et al., 1993, Tuailon et al., 1993, Choi et al., 1993, Lonberg et al., (1994), Taylor et al., (1994), and Tuailon et al., (1995), the disclosures of which are hereby incorporated by reference in their entirety.

The inventors of Surani et al., cited above, and assigned to the Medical Research Counsel (the "MRC"), produced a transgenic mouse possessing an Ig locus through use of the minilocus approach. The inventors on the GenPharm International work, cited above, Lonberg and Kay, following the lead of the present inventors, proposed inactivation of the endogenous mouse Ig locus coupled with substantial duplication of the Surani et al. work.

An advantage of the minilocus approach is the rapidity with which constructs including portions of the Ig locus can be generated and introduced into animals. Commensurately, however, a significant disadvantage of the minilocus approach is that, in theory, insufficient diversity is introduced through the inclusion of small numbers of V, D, and J genes. Indeed, the published work appears to support this concern. B-cell development and antibody production of animals produced through use of the minilocus approach appear stunted. Therefore, the present inventors have consistently urged introduction of large portions of the Ig locus in order to achieve greater diversity and in an effort to reconstitute the immune repertoire of the animals.

It will be appreciated that through use of the above-technology, human antibodies can be generated to, for example, CD147 expressing cells, CD147 itself, forms of CD147, epitopes or peptides thereof, and expression libraries thereto (*see*

e.g. U.S. Patent No. 5,703,057) through immunization of a transgenic mouse therewith, forming hybridomas, and screening the resulting hybridomas as described above for the activities described above.

Indeed, through use of the above-discussed technology, we prepared a panel of
5 human monoclonal antibodies that bind CD147 through immunization of
XenoMouseTM strains of transgenic mice (*see* Mendez et al., (1997), *supra.* and U.S.
Patent Application, No. 08/759,620, filed December 3, 1996), available from
Abgenix, Inc., Fremont, CA. Such antibodies were further screened for their ability to
10 compete with ABX-CBL for binding with CD147. In such panel, both human IgG2
and human IgM antibodies were detected that bound to CD147 and were capable of
competition with ABX-CBL for binding to CD147. The hybridomas expressing such
antibodies were designated as follows:

IgMs: CEM 10.1 C3, CEM 10.1 G10, CEM 10.12 F3, CEM 10.12 G5 CEM
15 13.12, CEM 13.5; and

IgG2s: 2.4.4, 2.1.1, 2.3.2, 2.6.1.

Each of the above antibodies were sequenced through isolating cDNAs
20 encoding them from the corresponding hybridomas through RT-PCR. Germline gene
identifications were made and the sequences of the antibodies compared to the
germline sequences. Germline gene identifications are provided in the following
Table:

25

30

TABLE 1

Antibody	Heavy/Light	V _H or V _K	D	J _H or J _K
CEM 10-1 C3	Heavy	V4-34	D2/D2-15	JH6b
	Light	A3/A19/DPK 15		JK1
CEM 10.1 G10	Heavy	DP71 (V4-59)	D1-26	JH6b
	Light	A30		JK1 (not identical seq)
CEM 10.12 F3	Heavy	DP15 (V1-8)	D1-26	JH6b
	Light	B3/DPK24		JK1
CEM 10.12 G5	Heavy	DP15 (V1-8)	D6-19	JH6b
	Light	A30		JK1
CEM 13.12	Heavy	V4-34	D2-2/D4	JH6b
	Light	A3/A19/DPK 15		JK3
CEM 13.5	Heavy	DP77-WH16 (3-21)	D6-19	JH4b
	Light	B3/DPK24		JK1 (not identical seq)
2.4.4	Heavy	VII-5	D21-9/D3-22	JH4b
	Light	A2 DPK12		JK4
2.1.1	Heavy	DP77	D6-19	JH4b
	Light	LFVK431		JK3
2.3.2	Heavy	VII-5	D21-9/D3-22	JH4b
	Light	A2 DPK12		JK4
2.6.1	Heavy	DP47	DXP4	JH4b
	Light	LFVK431		JK3

5

Germline sequences of the V_H, D, J_H, V_K, and J_K genes are available on GenBank. The sequences of certain of the antibodies were compared to transcripts of the germline V-gene segments to observe somatic mutations in the amino acid sequences. Such sequence comparisons are shown in Figures 44 through 46. cDNA sequences and protein transcripts of and for each of the antibodies are shown in Figures 24 through 33. In addition, CDRs, according to Kabat numbering scheme, of the heavy chains and kappa light chains of the antibodies are shown in Figures 34 through 43.

10

It will be appreciated that CDRs of the above antibodies are generally very important in connection with antibody binding to an antigen. Accordingly, it will be understood that a variety of FR and other modifications can be made in and to antibodies that do not modify an antibodies binding the epitope on an antigen. Thus, an important factor in an antibody's activity is the epitope on an antigen to which an antibody binds. So long as the epitope binding is conserved, in many ways it may matter little if the primary sequence of the antibody is modified. Therefore, where sequences are discussed herein, it is submitted that the sequence of an antibody may initially define an efficacious epitope on the antigen, however, once the epitope is identified by the antigen, any antibody that binds to the same epitope on the is contemplated herein.

In view of a number of tests that were conducted, the 2.6.1 IgM antibody was chosen for additional development. As will be appreciated, all of the IgMs that were generated were monovalent. Accordingly, in order to prepare a fully human multimeric IgM antibody, we cloned the human J-chain gene from human buffy coat cells, prepared a first expression vector containing the 2.6.1 kappa light chain cDNA and the J-chain cDNA and a second expression vector containing the 2.6.1 heavy chain cDNA, cotransfected DHFR⁻ Chinese hamster ovary cells with the two vectors, and selected clones expressing the multimeric IgM.

The 2.6.1 IgM + J-Chain antibody was capable of acting in ADCC as shown in Figure 50.

Humanization and Display Technologies

As was discussed above in connection with human antibody generation, there are advantages to producing antibodies with reduced immunogenicity. To a degree, this can be accomplished in connection with techniques of humanization and display techniques using appropriate libraries. It will be appreciated that murine antibodies or antibodies from other species can be humanized or primatized using techniques well known in the art. See e.g., Winter and Harris *Immunol Today* 14:43-46 (1993) and Wright et al. *Crit, Reviews in Immunol.* 12:125-168 (1992). Further, human antibodies or antibodies from other species can be generated through display-type technologies, including, without limitation, phage display, retroviral display, ribosomal display, and

other techniques, using techniques well known in the art and the resulting molecules can be subjected to additional maturation, such as affinity maturation, as such techniques are well known in the art. Wright and Harris, *supra.*, Hanes and Plutchau *PNAS USA* 94:4937-4942 (1997) (ribosomal display), Parmley and Smith *Gene* 73:305-318 (1988) (phage display), Scott *TIBS* 17:241-245 (1992), Cwirla et al. *PNAS USA* 87:6378-6382 (1990), Russel et al. *Nucl. Acids Research* 21:1081-1085 (1993), Hoganboom et al. *Immunol. Reviews* 130:43-68 (1992), and Chiswell and McCafferty *TIBTECH* 10:80-84 (1992). If display technologies are utilized to produce antibodies that are not human, such antibodies can be humanized as described above.

Using these techniques, antibodies can be generated to CD147 expressing cells, CD147 itself, forms of CD147, epitopes or peptides thereof, and expression libraries thereto (*see e.g.* U.S. Patent No. 5,703,057) which can thereafter be screened as described above for the activities described above.

Further, the sequence for the active antibody from the deposited hybridoma cell line expressing the ABX-CBL antibody was previously unknown. In view of our findings discussed above that the IgM antibody was the entity responsible for the activity of the CBL1 antibody and the fact that neither the presence nor the absence of the MOPC21 light chain appeared to be advantageous nor detrimental to the activity of the antibody, we cloned the heavy chain and the kappa light chains from the IgM (ABX-CBL) producing hybridoma through RT-PCR and sequenced the cDNAs. The results of such sequencing studies, including the cDNA sequences of the heavy chain and kappa light chain and the protein transcripts thereof are shown below:

ABX-CBL Heavy Chain Nucleotide Sequence

25	ATGTA	CTTGG	GACTGA	ACTA	TGTATT	CATA	GTTTT	TCTCT	TAAAT	GGTGT	50
	CCAGAG	TGAA	GTGAAG	CTTG	AGGAGT	CTGG	AGGAGG	CTTG	GTGCA	ACCTG	100
	GAGGAT	CCAT	GAAACT	TCTCC	TGTGTT	GCCT	CTGGAT	TAC	TTTCA	GTAAC	150
	TACTGG	ATGA	ACTGGG	TCCG	CCAGT	CTCCA	GAGAAG	GGGC	TTGAG	TGGGT	200
	TGCTGAA	ATT	AGATTGAA	AT	CTAATA	ATTA	TGCAAC	ACAT	TATGC	GGAGT	250
30	CTGTGAA	AGG	GAGGTT	CACC	ATCTCA	AGAG	ATGATT	CCAA	AAGTAG	TGTC	300
	TACCTG	CAAA	TGAACA	ACTT	AAGAG	CTGAA	GACACT	GGCA	TTTATT	ACTG	350
	TACGGAT	TAC	GATGCT	TACT	GGGGCC	AAGG	GACTCT	GGTC	ACTGT	CTCTG	400
	CAGAGAG	TCA	GTCCTT	CCCA	AATGT	CTTCC	CCCTCG	TCTC	CTGCG	AGAGC	450
	CCCCTG	CTG	ATAAGA	ATCT	GGTGG	CCATG	GGCTGC	CTTG	CCCGG	GA	500
35	CCTGCCC	AGC	ACCATT	TCT	TCACCT	GGA	CTACCA	GAAC	AACACT	GAAG	550
	TCATCC	AGGG	TATCAG	AACC	TTCCCA	ACAC	TGAGGA	CAGG	GGGCA	AGTAC	600
	CTAGCC	ACCT	CGCAGG	TGT	GCTGT	CTCCC	AAGAGC	ATCC	TTGAAG	GTTC	650
	AGATGA	ATAC	CTGGTA	TGCA	AAATCC	ACTA	CGGAGG	CAAA	AACAG	AGATC	700
	TGCATG	TGCC	CATTCC	AGCT	GTCGCA	GAGA	TGAACCC	CAA	TGTAA	TGTG	750

58

	TTCGTCCAC	CACGGGATGG	CTTCTCTGGC	CCTGCACCAC	GCAAGTCTAA	800
	ACTCATCTGC	GAGGCCACGA	ACTTCACTCC	AAAACCGATC	ACAGTATCCT	850
	GGCTAAAGGA	TGGGAAGCTC	GTGGAATCTG	GCTTCAACCAC	AGATCCGGTG	900
	ACCATCGAGA	ACAAAGGATC	CACACCCCAA	ACCTACAAGG	TCATAAGCAC	950
5	ACTTACCATC	TCTGAAATCG	ACTGGCTGAA	CCTGAATGTG	TACACCTGCC	1000
	GTGTGGATCA	CAGGGGTCTC	ACCTTCTTGA	AGAACGTGTC	CTCCACATGT	1050
	GCTGCCAGTC	CCTCCACAGA	CATCCTAACC	TTCACCATCC	CCCCCTCCTT	1100
	TGCCGACATC	TTCTCAGCA	AGTCCGCTAA	CCTGACCTGT	CTGGTCTCAA	1150
	ACCTGGCAAC	CTATGAAACC	CTGAATATCT	CCTGGGCTTC	TCAAAGTGGT	1200
10	GAACCACTGG	AAACCAAAAT	TAAAATCATG	GAAAGCCATC	CCAATGGCAC	1250
	CTTCAGTGCT	AAGGGTGTGG	CTAGTGTTTG	TGTGGAAGAC	TGGAATAACA	1300
	GGAAGGAATT	TGTGTGTACT	GTGACTCACA	GGGATCTGCC	TTCACCACAG	1350
	AAGAAATTCA	TCTCAAAACC	CAATGAGGTG	CACAAACATC	CACCTGCTGT	1400
	GTACCTGCTG	CCACCAGCTC	GTGAGCAACT	GAACCTGAGG	GAGTCAGCCA	1450
15	CAGTCACCTG	CCTGGTGAAG	GGCTTCTCTC	CTGCAGACAT	CAGTGTGCAG	1500
	TGGCTTCAGA	GAGGGCAACT	CTTGCCCCAA	GAGAAGTATG	TGACCAAGTGC	1550
	CCCGATGCCA	GAGCCTGGGG	CCCCAGGCTT	CTACTTTACC	CACAGCATCC	1600
	TGACTGTGAC	AGAGGAGGAA	TGGAACTCCG	GAGAGACCTA	TACCTGTGTT	1650
	GTAGGCCACG	AGGCCCTGCC	ACACCTGGTG	ACCGAGAGGA	CCGTGGACAA	1700
20	GTCCACTGGT	AAACCCACAC	TGTACAATGT	CTCCCTGATC	ATGTCTGACA	1750
	CAGGCGGCAC	CTGCTATTGA	CCAT			1774

(SEQ ID NO: 81)

ABX-CBL Heavy Chain Protein Sequence

25	EVKLEESGGG	LVQPGGSMKL	SCVASGFTFS	NYWMNWVRQS	PEKGLEWVAE	50
	IRLKSNNYAT	HYAESVKGRF	TISRDDSKSS	VYLQMNNLRA	EDTGIYYCTD	100
	YDAYWQGQTL	VTVSAESQSF	PNVFPLVSCE	SPLSDKNLVA	MGCLARDFLP	150
	STISFTWNYQ	NNTEVIQIR	TFPTLRTGGK	YLATSQVLLS	PKSILEGSDE	200
30	YLVCKIHYGG	KNRDLHVPI	AVAEMNPVN	VFVPPRDGFS	GPAPRKSCLI	250
	CEATNFTPKP	ITVSWLKDGK	LVESGFTTDP	VTIENKGSTP	QTYKVISTLT	300
	ISEIDLNLNL	VYTCRVDHRG	LTFLKNVSST	CAASPSTDIL	TFTIPPSFAD	350
	IFLSKSANLT	CLVSNLATYE	TLNISWASQS	GEPLETKIKI	MESHPNGTFS	400
	AKGVASVCVE	DWNNRKEFVC	TVTHRDLPSP	QKKFISKPNE	VHKHPPAVYL	450
35	LPPAREQLNL	RESATVTCLV	KGFSPADISV	QWLQRGQLLP	QEKYVTSAPM	500
	PEPGAPGFYF	THSILTVTEE	EWNSGETYTC	VVGHEALPHL	VTERTVDKST	550
	GKPTLYNVSL	IMSDTGGTCY				570

(SEQ ID NO:18)

ABX-CBL Light Chain Protein Sequence

40	KELLVSAGDR	VTITCKASQS	VSNDVAWYQQ	KPGQSPKLLI	YYASNRYTGV	50
	PDRFTGSGYG	TDFTFITSTV	QAEDLAVYFC	QQDYSSPYTF	GGGTKLEIKR	100
	ADAAPTIVSIF	PPSSEQLTSG	GASVVCFLNN	FYPKDINVKW	KIDGSRQNG	150
45	VLNSWTDQDS	KDSTYSMSST	LTITKDEYER	HNSYTCEATH	KTSTSPIVKS	200
	FNRNEC					206

(SEQ ID NO:19)

As will be appreciated, through utilization of the sequence, it is possible to
 50 prepare a humanized version of the ABX-CBL antibody. In general, the nucleotide
 sequences encoding the CDRs are grafted into human framework (FR) sequences
 using conventional techniques. Alternatively, amino acid residues in the framework

regions surrounding the CDRs (i.e., residues in FR1 and FR2, surrounding CDR1, FR2 and FR3, surrounding CDR2, and/or FR3 and FR4, surrounding CDR3) are modified through mutagenesis of cDNAs encoding the same also using conventional techniques. In either case, the modified cDNAs encoding the humanized kappa light chain and the heavy chain are generally then introduced into a cell line for expression (i.e., NSO, CHO, or the like) either directly, through cotransfection, or through use of the cell-cell fusion techniques described in U.S. Patent Application, Serial No. 08/730,639, filed October 11, 1996 or International Patent Application No. WO 98/16654, published April 23, 1998. Thereafter, the humanized antibodies are expressed and assayed for binding and other functional attributes. The molecules can be iteratively modified at the DNA level as desired or necessary to achieve improved binding or other functional attributes of the antibodies. For example, in certain cases, it is necessary to reintroduce murine sequences within the human FRs to improve binding. A good step-by-step introduction to humanization and demonstrating how conventional humanization has become in the art is provided on the internet <http://www.cryst.bbk.ac.uk/~ubcg07s/>.

In general, at the same time, or during the process, the constant region would be switched from the murine IgM to another human constant region (such as a human IgM constant region, without or without the J-chain, as discussed above) to prepare a humanized chimeric antibody.

Additional Criteria for Antibody Therapeutics

As discussed herein, the function of the ABX-CBL antibody appears important to at least a portion of its mode of operation. By function, we mean, by way of example, the activity of the ABX-CBL antibody is CDC. Accordingly, it is desirable in connection with the generation of antibodies as therapeutic candidates against CD147 that the antibodies be capable of fixing complement and participating in CDC. There are a number of isotypes of antibodies that are capable of the same, including, without limitation, the following: murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3. It will be appreciated that antibodies that are generated need not initially possess such an isotype but, rather, the antibody as generated can possess any isotype and the antibody

can be isotype switched thereafter using conventional techniques that are well known in the art. Such techniques include the use of direct recombinant techniques (*see e.g.*, U.S. Patent No. 4,816,397), cell-cell fusion techniques (*see e.g.*, U.S. Patent Application No. 08/730,639, filed October 11, 1996), among others.

5 In the cell-cell fusion technique, a myeloma or other cell line is prepared that possesses a heavy chain with any desired isotype and another myeloma or other cell line is prepared that possesses the light chain. Such cells can, thereafter, be fused and a cell line expressing an intact antibody can be isolated.

By way of example, the 2.6.1 antibody discussed herein is a human anti-
10 CD147 IgG2 antibody. If such antibody possessed desired binding to the CD147 molecule, it could be readily isotype switched to generate an human IgM, human IgG1, or human IgG3 isotype, while still possessing the same variable region (which defines the antibody's specificity and some of its affinity). Such molecule would then be capable of fixing complement and participating in CDC, in a similar manner to the
15 ABX-CBL antibody.

Accordingly, as antibody candidates are generated that meet desired "structural" attributes as discussed above, they can generally be provided with at least certain of the desired "functional" attributes through isotype switching.

20 *Design and Generation of Other Therapeutics*

In accordance with the present invention and based on the activity of the ABX-CBL antibody with respect to CD147, it is now also possible to design other therapeutic modalities beyond ordinary antibody moieties, including, without limitation, advanced antibody therapeutics, such as bispecific antibodies,
25 immunotoxins, and radiolabeled therapeutics, generation of peptide therapeutics, gene therapies, particularly intrabodies, antisense therapeutics, and small molecules.

In connection with the generation of advanced antibody therapeutics, it may be possible to sidestep the dependence on complement for cell killing that we have demonstrated is necessary for the function of the ABX-CBL antibody through the use
30 of bispecifics, immunotoxins, or radiolabels, for example.

For example, in connection with bispecific antibodies, bispecific antibodies can be generated that comprise (i) two antibodies one with a specificity to CD147 and

another to a second molecule that are conjugated together, (ii) a single antibody that has one chain specific to CD147 and a second chain specific to a second molecule, or (iii) a single chain antibody that has specificity to CD147 and the other molecule. Such bispecific antibodies can be generated using techniques that are well known for example, in connection with (i) and (ii) *see e.g.*, Fanger et al. *Immunol Methods* 4:72-81 (1994) and Wright and Harris, *supra.* and in connection with (iii) *see e.g.*, Traunecker et al. *Int. J. Cancer (Suppl.)* 7:51-52 (1992). In each case, the second specificity can be made to the heavy chain activation receptors, including, without limitation, CD16 or CD64 (*see e.g.*, Deo et al. 18:127 (1997)) or CD89 (*see e.g.*, Valerius et al. *Blood* 90:4485-4492 (1997)). Bispecific antibodies prepared in accordance with the foregoing would be likely to kill cells expressing CD147, and particularly those cells in which the ABX-CBL antibody is effective.

In connection with immunotoxins, antibodies can be modified to act as immunotoxins utilizing techniques that are well known in the art. *See e.g.*, Vitetta *Immunol Today* 14:252 (1993). *See also* U.S. Patent No. 5,194,594. In connection with the preparation of radiolabeled antibodies, such modified antibodies can also be readily prepared utilizing techniques that are well known in the art. *See e.g.*, Junghans et al. in *Cancer Chemotherapy and Biotherapy* 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996)). *See also* U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (RE 35,500), 5,648,471, and 5,697,902. Each of immunotoxins and radiolabeled molecules would be likely to kill cells expressing CD147, and particularly those cells in which the ABX-CBL antibody is effective.

In connection with the generation of therapeutic peptides, through the utilization of structural information related to CD147 and antibodies thereto, such as the ABX-CBL antibody (as discussed below in connection with small molecules) or screening of peptide libraries, therapeutic peptides can be generated that are directed against CD147. Design and screening of peptide therapeutics is discussed in connection with Houghten et al. *Biotechniques* 13:412-421 (1992), Houghten *PNAS USA* 82:5131-5135 (1985), Pinalla et al. *Biotechniques* 13:901-905 (1992), Blake and Litzi-Davis *BioConjugate Chem.* 3:510-513 (1992). Immunotoxins and radiolabeled molecules can also be prepared, and in a similar manner, in connection with peptidic moieties as discussed above in connection with antibodies.

Assuming that the CD147 molecule (or a form, such as a splice variant or alternate form) is functionally active in a disease process, it will also be possible to design gene and antisense therapeutics thereto through conventional techniques. Such modalities can be utilized for modulating the function of CD147. In connection therewith the discovery of the present invention allows design and use of functional assays related thereto. A design and strategy for antisense therapeutics is discussed in detail in International Patent Application No. WO 94/29444. Design and strategies for gene therapy are well known. However, in particular, the use of gene therapeutic techniques involving intrabodies could prove to be particularly advantageous. See e.g., Chen et al. *Human Gene Therapy* 5:595-601 (1994) and Marasco *Gene Therapy* 4:11-15 (1997). General design of and considerations related to gene therapeutics is also discussed in International Patent Application No. WO 97/38137.

Small molecule therapeutics can also be envisioned in accordance with the present invention. Drugs can be designed to modulate the activity of CD147 based upon the present invention. Knowledge gleaned from the structure of the CD147 molecule and its interactions with other molecules in accordance with the present invention, such as the ABX-CBL antibody, CD46, CD55, CD59, and others can be utilized to rationally design additional therapeutic modalities. In this regard, rational drug design techniques such as X-ray crystallography, computer-aided (or assisted) molecular modeling (CAMM), quantitative or qualitative structure-activity relationship (QSAR), and similar technologies can be utilized to focus drug discovery efforts. Rational design allows prediction of protein or synthetic structures which can interact with the molecule or specific forms thereof which can be used to modify or modulate the activity of CD147. Such structures can be synthesized chemically or expressed in biological systems. This approach has been reviewed in Capsey et al. *Genetically Engineered Human Therapeutic Drugs* (Stockton Press, NY (1988)). Further, combinatorial libraries can be designed and synthesized and used in screening programs, such as high throughput screening efforts.

Therapeutic Administration and Formulations

It will be appreciated that administration of therapeutic entities in accordance with the invention will be administered with suitable carriers, excipients, and other

agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences (15th ed, Mack Publishing Company, Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. See also Powell et al. "Compendium of excipients for parenteral formulations" *PDA J Pharm Sci Technol.* 52:238-311 (1998) and the citations therein for additional information related to excipients and carriers well known to pharmaceutical chemists.

EXAMPLES

The following examples, including the experiments conducted and results achieved, are provided for illustrative purposes only and are not to be construed as limiting upon the present invention.

EXPERIMENT 1 GENERATION OF HUMAN ANTIBODIES

Human antibodies were prepared in accordance with Mendez et al. *Nature Genetics* 15:146-156 (1997) and U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996, the disclosures of which are hereby incorporated by reference herein in their entirety, through the immunization of XenoMouseTM animals with CEM cells, followed by fusions, and screening of the resulting hybridoma supernatants against CEM cells and in competition assays with the ABX-CBL antibody (Example 2).

EXPERIMENT 2 **IMMUNO-AFFINITY PURIFICATION OF ABX-CBL ANTIGEN**

We undertook immunoaffinity purification of the antigen to which the ABX-CBL antibody bound. The antigen to which the CBL1 and ABX-CBL antibody bound appeared to be highly expressed on CEM cells. Immunoaffinity purification using the native ABX-CBL antibody was frustrated by the fact that the ABX-CBL antibody is an IgM antibody having a pentameric structure. Therefore, we prepared human IgG2 antibodies (Example 1), followed by fusions, and screening of the resulting hybridoma supernatants against CEM cells and tested for competition with the ABX-CBL antibody in binding assays with CEM cells using FACS. In the FACS competition assays, inhibition of the binding of ABX-CBL antibodies, labeled with FITC, to CEM cells was analyzed, both alone and in the presence of the anti-CEM human antibodies.

We obtained four hybridoma clones from the fusions that produced monoclonal antibodies that bound to the CEM cells and that were highly competitive with the ABX-CBL antibody in binding to the CEM cells. One hybridoma clone, designated 2.6.1 appeared most competitive.

We generated ascites to each of the four hybridoma clones, including the 2.6.1 hybridoma, in SCID mice and purified the 2.6.1 antibody using a Protein A affinity purification process using standard conditions. From the purified 2.6.1 antibody, we prepared an immunoaffinity column. To prepare the column, the purified 2.6.1 antibody was conjugated to CNBr activated Sepharose-4B, according to the manufacturer's specifications. Approximately 8.4 mg of the antibody was conjugated to about 2.0 g of the activated Sepharose. We passed cell lysates of CEM cells through the column and eluted the components that bound. The elution product was analyzed by SDS-PAGE electrophoresis, Western blotting, ELISAs, and BiaCore reactivity against CEM cell lysates.

The elution product that was purified from CEM cell lysates was demonstrated to be CD147 upon our sequencing of the diffuse band corresponding to 45-55 KD that we observed on Western Blot analysis after reaction with each of the 2.6.1 antibody and the ABX-CBL antibody. As will be observed from Figure 1, the 2.6.1 antibody bound most intensely to a molecule or molecules contained within a diffuse band

from about 45-55 KD, while the ABX-CBL antibody showed binding with a lower intensity to a similar band from about 45-55 KD.

Sequencing was accomplished upon a portion of the 45-55 KD band that was isolated through use of preparative gel electrophoresis and electroblotting techniques using a Perkin Elmer sequencer. We obtained a partial amino acid sequence of the molecule (between 35 through 40 residues). The resulting sequence information was analyzed through a protein database search (Protein Identification Resource (PIR) R47.0, December 1995) and the sequence comparison data indicated that the molecule was CD147.

Western blots on CEM lysates were generally accomplished as follows:

CEM cells were homogenized in 10mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, and protease inhibitors to generate CEM extracts at 5×10^8 cells/ml. The extract (5 μ l) were electrophoresed on 12% SDS-PAGE gels and then blotted onto PVDF. The blot was cut into 5 strips in preparation for antibody staining. All first antibody staining was done at 1 μ g/ml in 1% gelatin/PBST buffer. All AP labeled second antibody was done at a dilution of 1:1000 in the same buffer. The rabbit-anti-mouse-hnRNP-k Protein antibody was supplied to us by Dr. Karol Bomstzyk at the University of Washington. Each of the ABX-CBL, Pharmingen, and 2.6.1 antibodies are described further herein.

EXPERIMENT 3 PURIFICATION OF 62 KD BAND

In order to purify the material contained in the 62 KD band, CEM whole cell lysates were prepared from approximately 3×10^{10} cells. The lysates were extracted and concentrated to provide about 3.8 mg of protein. A portion of the recovered protein was subjected to a series of chromatography steps: size exclusion, anion exchange, hydrophobic interaction, reversed phase, and microbore reversed phase. In each step, the fraction showing binding to the ABX-CBL antibody on Western blot was carried on to the next step. Following microbore reversed phase chromatography, approximately 5×10^{-6} grams of protein was recovered and a portion of the protein subjected to gel electrophoresis and electroblotting to generate approximately 90% pure 62 KD protein.

A direct N-terminal sequence was attempted, however, the molecule possessed a blocked N-terminus. Thus, the material was digested with CNBr and preparative gel electrophoresis and electroblotting were conducted, yielding bands at approximately 12 KD and 32.5 KD. The blotted fragments were sequenced and the
5 resulting sequence results were analyzed through protein database searches (Protein Identification Resource (PIR) R47.0, December 1995). The sequence comparison data indicated that the molecule was heterogeneous ribonuclear protein k (hnRNP-k), with the 12 KD band having residues 360 and up (after Methionine; 359) and the 32.5 KD band having residues 43 and up (after Methionine; 42).

10

EXPERIMENT 4 CD147 ELISA ASSAY

We have utilized the enriched purified antigen obtained from CEM cell lysates to develop a specific ELISA assay for the detection of the expression of CD147 in a secreted or membrane bound form. In the assay, we immobilize the CD147 antigen
15 (for example, the CD147 antigen that is affinity purified from CEM cell lysates) in the wells of plates. Binding of the antigen can be accomplished using conventional techniques. Thereafter, the plates containing the antigen can be used for the detection of antibodies that are reactive with it using conventional techniques. We have demonstrated that each of the commercially available anti-CD147 antibodies (RDI-
20 CBL535 (a murine anti-CD147 IgG2b antibody), available from RDI, Flanders, NJ, and 36901A (a murine anti-CD147 IgG1 antibody), available from Pharmingen, San Diego, CA), the ABX-CBL antibody, and the human antibodies that we have generated in Example 2 react specifically in this assay.

The present ELISA assay is useful as a screening system for detecting
25 antibodies that bind to the CD147 antigen.

EXPERIMENT 5 EVIDENCE RELATED TO ROLE OF 35 KD BAND

As mentioned above, anecdotal evidence indicates that a 35 KD band could correspond to a singly-glycosylated form of CD147. See Kanekura et al. *Cell Struct*
30 *Funct* 16:23-30 (1991). Further, it is also interesting to note that in comparisons of Western blots produced by two commercially available anti-CD147 antibodies (RDI-CBL535 (a murine anti-CD147 IgG2b antibody), available from RDI, Flanders, NJ,

and 36901A (a murine anti-CD147 IgG1 antibody), available from Pharmingen, San Diego, CA) to the ABX-CBL and 2.6.1 antibodies indicates that each of the commercially available antibodies recognize a molecule that has a molecular weight around 35 KD and appearing similar to the 35 KD band recognized by the ABX-CBL antibody. See Figure 1. Another interesting observation is that in the immunoaffinity purification mentioned above, when the effluent product from the 2.6.1 antibody was probed with the ABX-CBL antibody, the 35 KD band was no longer visible by Western blot. Rather, the ABX-CBL antibody appeared to bind to the diffuse band from 45-55 KD with relatively low intensity (similar to that shown in Figure 1). This evidence indicates that the ABX-CBL antibody could bind preferentially to a different epitope on, or a different form of, CD147 than the 2.6.1 antibody and the commercially available antibodies.

EXPERIMENT 6 **COMPLEMENT MEDIATED CELL KILLING**

The UCLA group mentioned above (see e.g., U.S. Patent Nos. 5,330,896 and 5,643,740) provided certain evidence that the CBL1 antibody operated through killing of certain activated cell populations while the antibody did not react with non-activated cells. For example, in a microcytotoxicity assay, the CBL1 antibody was disclosed to kill activated lymphocytic cells but not other normal cells.

In connection with this experiment, the following materials and procedures were utilized:

Mixed lymphocyte reaction

Mixed lymphocyte reaction (MLR) is an *in vitro* system for assaying T lymphocyte proliferation in cell-mediated responses. A cell-mediated response is an *in vitro* assay of effector cytotoxic function, which can also be assayed *in vivo* by graft-versus-host reaction in experimental animals. When co-culturing allogeneic lymphocytes in MLR the cells undergo extensive blast transformation and cell proliferation. Thus, MLR can be quantified by adding tritium-labeled thymidine ($[^3\text{H}]$ thymidine) to the culture medium and monitoring uptake of label into DNA of the dividing lymphocytes.

To determine the function and quality CBL-1 and ABX-CBL antibody we used MLR to test the ability of CBL-1 and ABX-CBL to inhibit lymphocyte proliferative responses. Peripheral blood mononuclear cells were isolated from two HLA mismatched individuals by Ficoll-Paque gradient centrifugation. Allogeneic lymphocytes were mixed (1:1) and co-cultured (total of 5×10^5 cells/well in 96-well plate) *in vitro* for six days. Lymphocytes from one individual were irradiated with 3000 rads prior to the culture. CBL-1 and ABX-CBL antibody plus either 10 % rabbit or 25% human complement were added to the culture 24 h prior to the end of the culture. The culture was pulsed with [3 H]methyl-thymidine (Amersham) overnight and harvested on day 6. Lymphocyte proliferative response was determined by measuring [3 H]-thymidine incorporation. Percentage inhibition was calculated as the cpm in the absence of antibody minus the cpm in the presence of antibody divided by the cpm in the absence of antibody.

15 *ConA stimulated lymphocyte proliferation*

Human PBMC were isolated as described above and stimulated by the mitogen Concanavalin A (ConA) at 5ug/ml for 48 h. Antibodies with or without 10% complement were added to the culture 24 h prior to the end of the culture. The culture was pulsed with [3 H]-methyl-thymidine overnight and harvested next day. Lymphocyte proliferative response was determined by measuring [3 H]-thymidine incorporation. Percentage inhibition was calculated as the cpm in the absence of antibody minus the cpm in the presence of antibody divided by the cpm in the absence of antibody.

25 *FACS analysis of cell surface molecules*

For cell surface expression of different surface molecules, immunofluorescent staining and analysis on a FACSVantage (Becton Dickinson, San Jose, CA) have been described (*FACScan Manual*, Becton Dickinson, San Jose, CA). Monoclonal antibodies anti-CD3-PE, anti-CD4-PE, anti-CD8-PE, anti-CD14-PE, anti-CD20-PE, anti-CD25-FITC and anti-CD25-PE were obtained from Becton Dickinson. Anti-CD55-FITC and anti-CD59-FITC were purchased from Pharmingen (San Diego, CA).

ABX-CBL and cem2.6.1 were conjugated with FITC and PE, respectively, at Abgenix.

Complement-dependent cytotoxicity assay using Alamar blue

5 Complement-dependent cytotoxicity (CDC) assay was performed as described (Gazzano-Santoro et al. "A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody" *J. Immunol. Methods* 202:163-171 (1997)). Fifty microliters of a cell suspension of 10^6 cells/ml, 50 μ l of various concentrations of antibodies and 50 μ l of a 10% rabbit or human complement were added to flat-bottomed 96-well tissue culture plate and incubated for 2 hours at 37°C and 5% CO₂.
10 Fifty microliters of Alamar blue (Accumed International) were then added (final 10%) and the incubation continued for another 5 hours. The plates were allowed to cool to room temperature for 10 minutes on a shaker and the fluorescence was read using a 96-well fluorometer with excitation at 530 nm and emission at 590 nm. Results were
15 expressed in relative fluorescence units (RFU).

 In our work, we have demonstrated that CBL1 and ABX-CBL operate through complement mediated cell killing. Use of the CBL1 antibody by itself, the isotype-matched control mouse IgM antibody by itself (Figure 2), or complement (either human or rabbit) by itself in the MLR or modified MLR assay (ConA induced
20 lymphocyte proliferation assay) is ineffective in inhibiting T-cell proliferation. See Figures 2-5. However, when both complement and the CBL1 or ABX-CBL antibody are present, T-cell proliferation is inhibited in a dose dependent manner. See Figures 2-5. The human IgG2 antibody 2.6.1 is ineffective in inhibiting T-cell proliferation in the same assay, either by itself, or in combination with complement. See Figure 5.
25 This is expected, since the 2.6.1 antibody as a gamma-2 is notoriously less efficient in complement mediated lysis than is an IgM antibody, such as the ABX-CBL antibody.

 The combination of CBL1 or ABX-CBL and complement only kill activated T-cells (both CD4⁺ and CD8⁺), activated B-cells, and monocytes, but does not effect resting T-cells and B-cells because such cells do not express CD147. It is important,
30 to note that monocytes are also killed by ABX-CBL and complement. This data provides an explanation for the operation of ABX-CBL therapy in diseases, such as GVHD, because, ABX-CBL selectively depletes those effector cells (activated T- and

B-cells) and the antigen presenting cells (monocytes and B-cells) which ordinarily would lead to further T-cell activation.

EXPERIMENT 7 **EVIDENCE RELATED TO CELLULAR ACTIVATION**

5 Using techniques described in Experiment 6, we also demonstrated that the CD25 marker appears to be expressed in high levels in the same cellular populations as those expressing the antigen to which the ABX-CBL antibody binds. *See* Figure 6. This finding provided a useful marker to detect whether the cells expressing CD25 were depleted in connection with the MLR assay. Where the MLR assay is conducted
10 utilizing a variety of activated cell populations, CD25 expressing cell populations are depleted only in those treated with the ABX-CBL antibody plus complement. *See* Figures 7-11. The selective killing of different cell populations are shown in Figures 10-12.

15 **EXPERIMENT 8** **EVIDENCE RELATED TO THE ROLE OF EXPRESSION LEVELS OF CD147**

We have also considered whether CD147 expression levels are higher in given populations of cells (which could also be relevant to CDC).

In flow cytometry studies with peripheral blood mononuclear cells (PBMC)
20 with the ABX-CBL antibody, we have noticed that, prior to the addition of complement, there are populations of cells that appear to express high and low levels of CD147. After complement is added, there are populations of cells that appear to correspond to the low level expressers mentioned above. It appears that these results could be indicative of density of CD147 expression levels on the cell surface. Density
25 can play a role in CDC through providing additional antigen binding sites to allow for distortion of the antibody which is the first step in triggering the complement cascade. Upon distortion of the antibody, the factor *clq* binds first and the cascade proceeds.

Whether the expression level (or, density) of CD147 in cellular populations plays a role in the therapeutic efficacy of the ABX-CBL antibody can be assayed
30 through analyzing the expression levels of the CD147 molecule in various cellular populations. Generally, the experiments are conducted where beads having various known quantities of the CD147 antigen on their surface are prepared and analyzed on

FACS (i.e., utilizing a FITC-labeled anti-CD147 IgG antibody) in order to generate approximately 10-20 data points of different quantities of antigen on the beads. A linear regression curve is prepared from such data. Thereafter, cells expressing the CD147 antigen can be run through FACS and the relative quantities of antigen on the surface of the cells can be calculated from the linear regression curve.

EXPERIMENT 9 EVIDENCE RELATED TO THE ROLE OF COMPLEMENT INHIBITORY MOLECULES

Further, in order to consider the cellular specificity of the mode of operation of the ABX-CBL antibody, we investigated various cells to which the ABX-CBL antibody binds and considered whether such cells were killed in a manner similar to complement mediated lysis. In connection with this work, we have investigated various cells to which the ABX-CBL antibody binds and considered whether such cells were (i) killed and (ii) if so, was the mechanism similar to complement mediated lysis. In the experiment, we looked for ABX-CBL antibody binding to a number of cells (and, thus, the antigen to which the ABX-CBL antibody binds is expressed upon such cells). Those cells to which ABX-CBL would bind were then tested for complement mediated lysis through treatment with the ABX-CBL antibody and complement. Two T-cell lines (CEM and Jurkat cells), a monocyte line (U937 cells), and three tumor cell lines (A431 (epidermal), SW948 (colon), and MDA468 (breast)), each of which bound the ABX-CBL antibody were examined. Despite the expression on such cells lines, the ABX-CBL antibody is very specific about which cells are killed, being restricted to the CEM T-cell line and U937 monocyte line. *See* Figure 13. We also analyzed two endothelial cell lines (i) ECV-304 (ATCC CRL-1998) is a spontaneously transformed immortal EC established from the vein of an apparently normal human umbilical cord and carrying EC characteristics and (ii) HUV-EC-C (ATCC CRL-1730) is an EC line derived from the vein of a normal human umbilical cord. Using FACS, we found that each of the ECV-304 and HUVEC-C lines stained positive against the 2.6.1, Pharmingen, and ABX-CBL antibodies suggesting that these ECs do express CD147 on the surface. Figures 15 and 16, respectively. We then carried out in vitro Alamar-blue based CDC assay and demonstrated that both

EC lines were resistant to ABX-CBL mediated CDC in the presence of human complement. See Figures 17 and 18, respectively.

In order to further understand why cells that all appear to express CD147 would not be killed by the ABX-CBL antibody in the presence of complement, we
5 looked into CD46, CD55, and CD59 expression in such cells. Each of CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, DAF), and CD59 (membrane attack complex inhibitor, MACI) have been implicated as complement inhibitory molecules. See e.g., Liszewski et al. *Annu. Rev. Immunol.* 9:431 (1991) and Loveland et al. "Coordinate functions of multiple complement
10 regulating molecules, CD46, CD55 and CD59" *Transpl. Proc.* 26:1070 (1994) related to CD46, Kinoshita et al. "Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria" *J. Exp. Med.* 162:75 (1985) and Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59"
15 *Transpl. Proc.* 26:1070 (1994) related to CD55, and Whitlow et al. "H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement" *Cell. Immunol.* 126: 176 (1990), Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59" *Transpl. Proc.* 26:1070 (1994), and Davies, A. and Lachmann, P.J. "Membrane
20 defense against complement lysis: the structure and biological properties of CD59" *Immunol. Res.* 12: 258 (1993) related to CD59. Accordingly, we considered whether there was differential expression of either, or both, of these molecules on the cell lines tested above. Indeed, all of the cells, except the CEM line and the U937 line, expressed both of the molecules. And, indeed, the endothelial cell lines HUVEC-C
25 and ECV-304 expressed all three, CD46, CD55, and CD59. Figures 19 and 20, respectively. In contrast, the CEM line expressed only CD59 and the U937 line expressed only CD55. See Figure 14. This data is useful in connection with the prediction of cells that could be selectively eradicated by ABX-CBL and consequently targeted in connection with anti-CD147 in accordance with the present
30 invention.

EXPERIMENT 10 **CLONING AND EXPRESSION OF CD147 IN EUKARYOTIC CELLS**
AND BINDING OF ANTIBODIES

In the present experiment, we cloned full length CD147 cDNA through use of PCR in connection with the Jurkat Zapp Express phagemid DNA (Stratagene).

5 The following PCR primers were utilized, based on the CD147 sequence reported by Miyauchi et al. *J. Biochem.* 110:770-774 (1991) (Gene Bank Accession No. D45131):

5': 5'-GACTACGAATTCTTGTAGGACCGGCGAGGAATAGG-3'
10 (SEQ ID NO:42)

3': 5'-GACTACGGGCCCGGTGAGAACTTGGAATCTTGCAAGC-3'
 (SEQ ID NO:43)

15 A 949 base-pair PCR product was isolated whose open reading frame encoded the 269 amino acid CD147 protein. The PCR product was digested with EcoR1 and Apa1 and ligated into the EcoR1 and Apa1 sites of mammalian expression vectors pWBFNP (Figure 21) and pBKCMV (Stratagene) (Figure 22) (digested with NheI/SpeI to remove the lac promoter and the lacZ ATG between positions 1300 and
20 1098) to create the vectors CD147/pWBFNP and CD147/pBKCMV(delta-NheI/SpeI) respectively. In the constructs, eukaryotic expression of CD147 is driven from the cytomegalovirus (CMV) immediate early promoter. CD147/pWBFNP, CD147/pBKCMV(delta-NheI/SpeI) and control vectors pWBFNP and pBKCMV were transiently transfected into monkey kidney (COS-7) cells by the CAPO₄ method.
25 Cells were harvested 60 hours later, washed in PBS and stained with anti-ABX-CBL-FITC, anti-CEM2.6.1/anti-HuIgG-FITC, or anti-CD147-FITC (Pharmingen) and analyzed by FACS analysis and Western blot analysis (see Figure 23A). The blot was accomplished using procedures described in Example 3.

30 FACS analysis revealed an increase in specific cell surface staining with all three antibodies only on COS cells transfected with vectors expressing CD147 cDNA (CD147/pWBFNP and CD147/pBKCMV (delta-NheI/SpeI)). COS cells transfected with CD147 cDNA showed binding to each of the antibodies in each of the FACS and Western blot analyses. In contrast, COS cells transfected with control vectors were

negative for binding with each of the 2.6.1 and ABX-CBL antibodies. With respect to the Pharmingen antibody, certain background staining was observed in cells transfected with control vectors on FACS and no binding on Western blot analysis. The transfected cells showed significant binding over background on FACS and were positive on Western blot analysis. Our results confirm that the ABX-CBL and the 2.6.1 antibodies bind to CD147.

EXPERIMENT 11 CLONING AND EXPRESSION OF CD147 IN EUKARYOTIC CELLS AND BINDING OF ANTIBODIES

Utilizing a slightly modified vector, we also transfected *E. coli* cells with the CD147 cDNA. In the experiment, CD147 cDNA generated as above was subcloned into pBKCMV (Stratagene) (Figure 22). CD147/pBKCMV plasmid DNA was transformed into *E. coli* strain XL1-Blue MRF' (Stratagene). Cultures were grown in LB media supplemented with kanamycin at 50µg/ml to OD₆₀₀ of 0.7 then for an additional 3 hours in the presence of 1mM isopropyl-B-D-thio-galactopyranoside (IPTG). Cells were harvested by centrifugation and stored frozen at -20° C. The *E. coli* cells so transfected were capable of expression of the CD147 molecule as evidenced by Western blotting analysis of each of the ABX-CBL, 2.6.1, and Pharmingen antibodies. Since the prokaryotic *E. coli* cells should not glycosylate the expressed CD147, it was expected that the molecular weight of the CD147 expressed by the *E. coli* should closely approximate the predicted, unglycosylated molecular weight of CD147 of about 27 KD. Indeed, in each case, binding of the three antibodies on Western blot analysis was observed to a band between about 27 and 30 KD. Figure 23B. The blot was accomplished using procedures described in Example 3.

This data further confirms that the ABX-CBL and the 2.6.1 antibodies bind to CD147. Further, the evidence indicates that ABX-CBL binding to CD147 is not directly based on carbohydrate binding, i.e., that ABX-CBL does not bind directly to a carbohydrate epitope on CD147. Such data, however, does not eliminate the possibility that binding to CD147 is influenced by the presence of carbohydrate or glycosylation.

EXPERIMENT 12 EPITOPE ANALYSIS

In order to further elucidate the binding of the ABX-CBL antibody to CD147, we undertook phage display experiment. Such experiments were conducted through panning a phage library expressing random peptides for binding with the ABX-CBL and 2.6.1 antibodies to determine if we could isolate peptides that bound. If successful, certain epitope information can be gleaned from the peptides that bind.

In general, the phage libraries expressing random peptides were purchased from New England Biolabs (7-mer and 12-mer libraries, Ph.D.-7 Peptide 7-mer Library Kit and Ph.D.-12 Peptide 12-mer Library Kit, respectively) based on a bacteriophage M13 system. The 7-mer library represents a diversity of approximately 2.0×10^9 independent clones, which represents most, if not all, of the $20^7 = 1.28 \times 10^9$ possible 7-mer sequences. The 12-mer library contains approximately 1.9×10^9 independent clones and represents only a very small sampling of the potential sequence space of $20^{12} = 4.1 \times 10^{15}$ 12-mer sequences. Each of 7-mer and 12-mer libraries were panned or screened in accordance with the manufacturer's recommendations in which plates were coated with an antibody to capture the appropriate antibody (goat anti-human IgG Fc for the 2.6.1 antibody and goat anti-mouse μ chain for the ABX-CBL antibody) followed by washing. Bound phage were eluted with 0.2 M glycine-HCl, pH 2.2. After 3 rounds of selection/amplification at constant stringency (0.5% Tween), through use of DNA sequencing, we characterized a total of 5 clones from the 7-mer library and 6 clones from the 12-mer library reactive with the ABX-CBL antibody and a total of 6 clones from each of the 7-mer and 12-mer libraries reactive with the 2.6.1 antibody. Reactivity of the peptides was determined by ELISA. For an additional discussion of epitope analysis of peptides see also Scott, J.K. and Smith, G.P. *Science* 249:386-390 (1990); Cwirla et al. *PNAS USA* 87:6378-6382 (1990); Felici et al. *J. Mol. Biol.* 222:301-310 (1991), and Kuwabara et al. *Nature Biotechnology* 15:74-78 (1997).

No consensus sequence was readily apparent for reactivity of the 2.6.1 antibody with CD147. However, sequence alignment of the characterized 7-mer and 12-mer sequences against the amino acid sequence of CD147 yielded a number of matches for a single sequence within CD147 from residue number 177 through residue number 188 (ITLRVRS (SEQ ID NO:1)). In particular, each of the 7-mers

contained sequence matches (represented by *) to 3 or more residues within this sequence of CD147:

7-mer sequences

- 5
1. EE RLR S Y (SEQ ID NO:2)
- * * *
- 10 2. YE RVR W Y (SEQ ID NO:3)
- * * *
3. EE RLR S Y (SEQ ID NO:4)
- * * *
- 15 4. AE RIR S I (SEQ ID NO:5)
- * * *
5. EE RLR S Y (SEQ ID NO:6)
- 20

Further, 4 of the 12-mers contained sequence matches (represented by *) to 3 or more residues within this sequence of CD147, with 4 matches for 12-mer peptide number 1 and for 6 matches of 12-mer peptide number 2:

25 12-mer sequences

1. TVHGD RLR S LP (SEQ ID NO:7)
- * * * *
- 30 2. TNDIGL RQR S HS (SEQ ID NO:8)
- * * * *
3. SPLLDGQ RER S Y (SEQ ID NO:9)
- * * *
- 35 4. YDLPM RSR S YPG (SEQ ID NO:10)
- * * *
- 40 5. SLAPLWY YSR H G (SEQ ID NO:20)
6. HTPETAPLPATV (SEQ ID NO:21) (no binding)

These results indicate a consensus sequence of RXRS (SEQ ID NO:11) that is present in 10 of the sequenced clones. Accordingly, we had a synthetic peptide prepared (AnaSpec Incorporated, San Jose, CA) which spanned residues 169-183 of CD147 with the following sequence (with -OH representing carboxy terminus):

KGSDQAIITLRVRSH-OH (SEQ ID NO:12)

170 184

Below, the amino acid sequence of CD147 is provided with the 15-mer peptide's sequence indicated by double underlining and the RXRSH (SEQ ID NO:13) consensus sequence indicated in bold. In addition, putative N-linked glycosylation sites of CD147 are shown as underlined and italics:

CD147 Sequence

MAAALFVLLGFALLGTHGASGAAGTVFTTVEDLGSKILLTCSLNDSATEVTG
HRWLKGGVVLKEDALPGQKTEFKVDSDDQWGEYSCVFLPEPMGTANIQLHG
PPRVKAVKSSEHINEGETAMLVCKSESVPVTDWAWYKITDSEDKALMNGSE
SRFFVSSSQGRSELHIENLNMEADPGQYRCNGTSSKGSDQAITLRVRSHLAAL
WPFLGIVAEVLVLVTIIFIYEKRRKPEDVLDDDDAGSAPLKSSGQHQNDKGKN
VRQRNSS (SEQ ID NO:14)

The 15-mer peptide was assayed using ELISA and it was determined that the ABX-CBL antibody specifically bound to the peptide. Further, neither the 2.6.1 antibody nor a control murine IgM antibody bound to the peptide. However, based on a competition study between the CD147 antigen and the 15-mer peptide, the ABX-CBL antibody's binding to the 15-mer peptide can only be measured when the 15-mer peptide is coated on plates and not when the peptide is in solution. Indeed, in competition experiments in which the ABX-CBL antibody is bound to either the peptide or the CD147 antigen coated to plates, the ABX-CBL antibody is not removed or replaced by the peptide in solution even at high concentrations. Nevertheless, the binding of the ABX-CBL antibody to the 15-mer peptide can be specifically competed by the CD147 antigen and positive phage preparations mentioned above but not with non-specific antigen (i.e., L-Selectin isolated from cell membrane or human

plasma) or the negative phage preparations mentioned above. Similarly, the binding of the ABX-CBL antibody to the CD147 antigen can be specifically competed by positive phage preparations as compared to negative phage preparation in competition assays using preincubation.

5 These results indicate that while the sequence within CD147 that contains the consensus sequence RXRSH is important to the binding of the ABX-CBL antibody to CD147, it does not fully explain ABX-CBL's binding to CD147. Indeed, the data also suggests that the consensus sequence contained either in the 15-mer peptide when bound to the plate or the reactive phage materials when tethered to the phage coat
10 protein binds more tightly to the ABX-CBL antibody than does the free peptide in solution. Taken together, while not wishing to bound to any particular theory or mode of operation, it is possible that CD147 possesses certain conformations that are not well mimicked in the 15-mer peptide in solution. Nevertheless, the above epitopic information is important to understanding the manner in which the ABX-CBL
15 antibody binds to CD147 and to producing other candidate molecules against CD147 as a therapeutic target.

It is interesting to note that in addition to the results above in connection with the presence of the RXRSH consensus sequence within CD147, we also looked for the presence of the consensus sequence within the hn-RNP-k protein to which ABX-
20 CBL also appears to bind. Such analyses were conducted by sequence alignment against the phage derived peptides discussed above. Two sequences were found which possessed statistically interesting matches:

First, there was a match (indicated by *) of 5 amino acids with the 7-mer
25 peptide number 4:

	*	**	**	
	PE	RIL	SI	(SEQ ID NO:15)
30	84			

Second, there was a match (indicated by *) of 5 amino acids with the 12-mer peptide number 1:

5	* GGS 300	* * RAR 306	** NLP 306	(SEQ ID NO:16)
---	----------------------	-----------------------	-----------------------	----------------

The amino acid sequence of the hn-RNP-k protein is provided below with such sequences indicated by double underlining. In addition, a number of RXR sequence motifs are present in the hn-RNP-k protein's sequence which are also indicated by underlining:

hn-RNP-k Protein Sequence

15 METEQPEETFPNTETNGEFGKRPAEDMEEEQAFKRSRNTDEMVELRILLQSKN
 AGAVIGKGGKNIKALRTDYNASVSPDSSGPERILSISADIETIGEILKKIIPTE
 EGLQLPSPTATSQLPLESDAVECLNYQHYKGSDFDCELRLLIHQSLAGGIIGVK
 GAKIKELRENTQTTIKLFQECCPHSTDRVVLIGGKPDRVVECIKILDLISESPIK
 GRAQPYDPNFYDETYDYGGFTMMFDDRRGRPVGFPMRGRGGFDRMPGRG
 20 GRPMPPSRRDYDDMSPRRGPPPPPPGRGGGRGGSRRARNLPLPPPPPPRGGDLMA
 YDRRGRPGDRYDGMVGFSADETWDSAIDTWSPSEWQMA YEPQGGSGYDYS
 YAGGRGSYGD LGGPHTTQVTIPKDLAGSIHGKGGQRIKQIRHESGASIKIDEPLE
 GSEDRIITITGTQDQIQNAQYLLQNSVKQYSGKFF (SEQ ID NO:17)

25 Without wishing to be bound to any particular theory or mode of operation, it is possible that the binding of the ABX-CBL antibody to the hn-RNP-k protein is partially explained by the presence of these motifs within the protein.

EXPERIMENT 13 EXPRESSION OF CD147 AND BINDING OF ANTIBODIES

30 Indeed, the desirability of mimicking ABX-CBL binding and efficacy is highlighted based upon a preliminary tissue distribution study of the ABX-CBL antibody. In the study, ABX-CBL is widely distributed throughout a variety of tissues. However, the majority of the distribution is likely to be due to nonspecific binding. Nevertheless, there appears to be specific binding in endothelial cells

(venules, arterioles, but not capillary beds), smooth muscle, and some mesothelium. Also, the lymphoreticular tissues appear to be bound, although, the staining seems to be restricted to large lymphocytes, presumably activated blasts. From the study conducted, it was difficult to distinguish intracellular from extracellular staining. A
5 certain amount of cytoplasmic staining was clearly evident and could have been related to hn-RNP-k binding.

**EXPERIMENT 14 ANALYSIS OF ACTIVITY OF MOPC21 LIGHT CHAIN ACTIVITY
IN ABX-CBL ANTIBODY**

10 Two different techniques were utilized to endeavor to study the role of the MOPC21 light in ABX-CBL activity. In each technique, efforts were made to segregate the MOPC21 light chain from the cell line producing the IgM antibody. In the first technique, segregation was effected by fusion of the ABX-CBL IgM producing cell line with another cell line (NSO). In the second technique, segregation
15 by spontaneous loss variants was endeavored. The fusion technique was successful and work was stopped on the second technique.

 In the fusion technique, in general, NSO cells were transfected with a puromycin containing vector to create a puromycin⁺ NSO cell line. The ABX-CBL IgM producing cell line was grown in HAT medium was fused with the puromycin⁺
20 NSO cell line.

 In general, fusions are accomplished in accordance with the following techniques and procedures:

Preparation of cells

25

 Prior to fusion, parental cell lines for use in the fusion are grown up and maintained in medium containing DMEM high, 10% FBS, 1% non-essential amino acids, 1% pen-strep, and 1% L-glutamine.

30 On the day prior to fusion, each of the parental cell lines are prepared and split to provide a cell density of approximately 10^5 cells/ml. On the day of the fusion, cells are counted and the fusion is commenced when, and assuming, that cell count for each of the parental cell lines are within the range of about $1.5-2.5 \times 10^5$ cells/ml. Sufficient quantities of each of the parental cell lines to make up 5×10^6 cells each are

withdrawn from the cultures and added to a 50ml centrifugation tube and the cells are pelleted at 1200 rpm for approximately 5 minutes. Concurrently with the preparation of the cells, incomplete DMEM, PEG, and double selection media are prewarmed in an incubator bath. Following pelleting, cells are resuspended in 20 ml incomplete DMEM and pelleted again. Thereafter, the cells are resuspended in 5 ml incomplete DMEM and the two parental cell lines are pooled in a single tube and pelleted again to form a co-pellet containing both of the parental cell lines. The co-pellet is resuspended in 10 ml incomplete DMEM and again pelleted. All of the supernatant is then removed from the co-pellet and the cells are ready for fusion.

Fusion

Following removal of all of the supernatant, 1 ml PEG-1500 is added over the course of 1 minute to the co-pellet while stirring. After addition of the PEG is completed, either gentle stirring with a pipet is continued for 1 minute or the suspended co-pellet can be allowed to stand for 1 minute. Thereafter, 10 ml of incomplete DMEM is added to the co-pellet over the course of 5 minutes with slow stirring. The mixture is then centrifuged at about 1200 rpm for 5 minutes and following centrifugation, the supernatant is aspirated off, and 10 ml of complete double selection medium is added and gently stirred into the cells. The cells are then plated at 100 μ l/well into 10 96-well microtiter plates and placed into an incubator (37° C with 10% CO₂) where they are not disturbed for 1 week. After the passage of a week, plates are fed by adding 100 μ l of complete double selection medium to each well.

Double selection medium is prepared depending upon the marker gene utilized in connection with the parental cell lines. In the majority of our experiments, the selectable markers conferring puromycin, hygromycin, of hypoxanthine and thymidine resistance are utilized. Concentrations required to obtain complete cell killing of NS/O cells were determined through use of kill curves and resulted in our use of 6 micrograms/ml of puromycin and 350 micrograms/ml of hygromycin. In

connection with HPRT resistance, we used HAT media supplement from Sigma using standard conditions.

In the present case, cells were selected for puromycin⁺/HAT resistance. Individual clones were picked based on selection and clones were expanded in 96-well plates. Plates were split (½ for freezer stock, ½ for growth). Total RNA was isolated from the growth plates using the Qiagen 96-well RNA isolation kit according to the manufacturer's instructions. Primers were designed based on conserved sites on the MOPC21 and the ABX-CBL kappa chains that would amplify fragments of the chains which contained unique restriction sites in the respective chains, as follows:

	<u>Restriction site</u>	<u>Chain</u>	<u>Position</u>
	AgeI (BsrFI)	MOPC21	135
	BstYI	MOPC21	173
15	KpnI	ABX-CBL	85
	NsiI	ABX-CBL	130
	XcmI	MOPC21	58
20	5 prime:	5'-GCA GTC TCC TAA ACT GCT (SEQ ID NO:44) positions 99-116 allows analysis of BstYI restriction site; or	
	5 prime:	5'-ACC TGC AAG GCC AGT (SEQ ID NO:45) positions 40-54 allows analysis of NsiI or KpnI restriction sites,	
25	3 prime:	5'-CAC TCA TTC CTG TTG AAG (SEQ ID NO:46).	

Accordingly, through amplification with the above primers, followed by digestion with the appropriate restriction enzymes, presence or absence of MOPC21 or ABX-CBL could be readily detected on agarose gel electrophoresis. Through use of the above techniques, at least 6 variants were obtained that lost the MOPC21 light chain expression but retained the ABX-CBL kappa. No variants were directly obtained that lost ABX-CBL kappa chain expression and retained the MOPC21 chain

expression. However, we isolated a cell line that appeared to be a minimal producer of ABX-CBL light chain and subcloned the line. It turned out to be a mixed cell line of a heterogeneous MOPC21/ABX-CBL light chain producer and a MOPC21 light chain only producer. Accordingly, we isolated the MOPC21 only producer after
5 subcloning.

MOPC21 only light chain containing and ABX-CBL only light chain containing antibodies were compared and supported the conclusion that the presence or absence of the MOPC21 light chain did not appear to substantially impact antibody binding or properties of the antibodies. Although, it did appear that the MOPC21
10 only light chain containing antibody did not bind as intensely on Western blotting to CEM cells or CD147.

EXPERIMENT 15 GENERATION AND CHARACTERIZATION OF HUMAN ANTIBODIES TO CD147

15 In accordance with Experiment 1, we generated a panel of fully human anti-CD147 antibodies. Antibodies were screened by ELISA for binding with CD147 and FACs for ability to compete with ABX-CBL. Certain of such antibodies were sequenced. The sequences of certain of the antibodies were compared to transcripts of the germline V-gene segments to somatic mutations in the amino acid
20 sequences. Such sequence comparisons are shown in Figures 44 through 46. cDNA sequences and protein transcripts of and for each of the antibodies are shown in Figures 24 through 33. In addition, CDRs, according to Kabat numbering scheme, of the heavy chains and kappa light chains of the antibodies are shown in Figures 34 through 43.

25 In view of a number of tests that were conducted, particularly, competition studies between ABX-CBL and the certain of the antibodies, the 2.6.1 IgM antibody was chosen for additional development.

EXPERIMENT 16

GENERATION OF 2.6.1 EXPRESSION VECTORS FOR THE

GENERATION OF IGG1, IGM, AND MULTIMERIC IGM

ANTIBODIES

5 In order to investigate the ability of the 2.6.1 antibody to operate in ADCC, similar to the CBL1 and ABX-CBL antibodies, we were interested in preparing IgM and IgG1 isotypes of the 2.6.1 antibody. The isotype switching of the 2.6.1 antibody from an IgG2 to an IgG1 was relatively simple. Whereas, the switching of the 2.6.1 antibody to a multimeric IgM required certain additional steps.

As will be appreciated, all of the IgMs that were generated from XenoMouse animals were monovalent. Accordingly, in order to prepare a fully human multimeric IgM antibody, we first were required to clone the human J-chain gene from human buffy coat cells. The sequence of the human J-chain cDNA is shown below with the 5'-untranslated portion shown in bold, italics and underlining:

15	<u>TCAGAAGAAG</u>	<u>TGAAGTCAAG</u>	ATGAAGAACC	ATTTGCTTTT	CTGGGGAGTC	50
	CTGGCGGTTT	TTATTAAGGC	TGTTTCATGTG	AAAGCCCAAG	AAGATGAAAG	100
	GATTGTTCTT	GTTGACAACA	AATGTAAGTG	TGCCCCGATT	ACTTCCAGGA	150
	TCATCCGTTC	TTCCGAAGAT	CCTAATGAGG	ACATTGTGGA	GAGAAACATC	200
20	CGAATTATTG	TTCCTCTGAA	CAACAGGGAG	AATATCTCTG	ATCCCACCTC	250
	ACCATTGAGA	ACCAGATTTG	TGTACCATTT	GTCTGACCTC	TGTAaaaaaAT	300
	GTGATCCTAC	AGAAGTGGAG	CTGGATAATC	AGATAGTTAC	TGCTACCCAG	350
	AGCAATATCT	GTGATGAAGA	CAGTGCTACA	GAGACCTGCT	ACACTTATGA	400
	CAGAAACAAG	TGCTACACAG	CTGTGGTCCC	ACTCGTATAT	GGTGGTGAGA	450
25	CCAAAAATGGT	GGAAACAGCC	TTAACCCAG	ATGCCTGCTA	TCCTGACTAA	500

(SEQ ID NO:47)

The J-chain gene encodes the human J-chain with the following sequence.

30	MKNHLLFWGV	LAVFIKAVHV	KAQEDERIVL	VDNKCKCARI	TSRIIRSEED	50
	PNEDIVERNI	RIIVPLNNRE	NISDPTSPLR	TRFVYHLSDL	CKKCDPTEVE	100
	LDNQIVTATQ	SNICDEDSAT	ETCYTYDRNK	CYTAVVPLVY	GGETKMVETA	150
	LTPDACYPD					159

(SEQ ID NO:22)

The following primers, retrofitted with the indicated restriction sites for further cloning, were designed for amplifying the human J-chain cDNA out of RT-PCR prepared materials from human Buffy coat cells:

5 5'- GAA TTC AGA AGA AGT GAA GTC (SEQ ID NO:48)
 EcoRI

 3'- GTC GAC TAT GCA GTC AGC AAT GAC (SEQ ID NO:49)
 SalI

10

The J-chain cDNA and the 2.6.1 kappa gene isolated through RT-PCR were amplified using the above primers and a 500 base pair PCR product was isolated whose open reading frame encoded the 159 amino acid J-chain protein. The PCR product was cloned into the TA cloning kit (Invitrogen) and had an EcoRI restriction

15 site on each end. This vector was digested with EcoRI and the digest cloned into pWBFNP MCS (Figure 47) that was cut with EcoRI and treated with CIP. Orientation of the insert was determined through digestion with PvuII which created differently sized fragments based on orientation (PvuII sites were present in the pWBFNP MCS vector as shown in Figure 47 and at position 421 in the J-chain insert.

20 This vector was called pWBJ1

The 2.6.1 kappa chain was amplified by RT-PCR using the following primers:

5 prime: 5' TGC AGG AAT CAG ACC CAG TC (SEQ ID NO:50)

25 3 prime: 5' GTC AGG CTG GAA CTG AGG AGC A (SEQ ID NO:51)

using the TA cloning kit providing EcoRI sites on each end of the VJCK insert. The kappa chain was sequenced. The kappa cDNA was EcoRI digested and cloned into the EcoRI site in pWBFNP MCS. Orientation was determined based on

30 fragment size by NotI and PstI digestion of the NotI site in pWBFNP MCS and the PstI site contained at position 243 of the kappa insert shown in Figure 33. This vector was called pWBK1.

In order to allow insertion of the J-chain expression cassette into pWBK1 from pWBJ1, pWBK1 was cut with PacI and blunted and recut with AvrII and pWBJ1 was cut with SpeI and blunted and recut with AvrII and the blunted SpeI/AvrII fragment was cloned into pWBK1 blunt PacI/AvrII to yield pWBK1(J). pWBK1(J) contained
5 expression cassettes for both the 2.6.1 kappa chain and the J-chain.

pWBK1(J) was further modified to contain DHFR resistance through cloning DHFR through NotI digestion from a vector pWB DHFR (containing DHFR at NotI) into pWBK1(J) at the NotI site. This vector was called pWBK1(J) DHFR.

In order to make an IgG1 expression vector, the 2.6.1 heavy chain was
10 amplified through RT-PCR using the TA cloning vector (Invitrogen) using the following primers:

5 prime: 5' TCA TTT GGT GAT CAG CAC T (SEQ ID NO:52)

15 3 prime: 5' GCT AGC TGA GGA GAC GGT GAC CAG G
(SEQ ID NO:53)

3' gamma 1 NheI (introduces a NheI restriction site)

The resulting product contained only the VDJ cDNA sequences and not the constant
20 region. The sequence was confirmed by sequencing. This vector was utilized to prepare an IgG1 expression vector as described below.

pWBFNP MCS was digested with EcoRI and treated with CIP and the EcoRI digest from the TA vector, above, was cloned into the vector. Orientation was determined by size through digestion with NheI, which confirmed the insertion,
25 followed by digestion with NotI. This vector was called pWBVDJ261NheI. PWBVDJ261NheI was cut with XhoI and blunted and recut with NheI. A human gamma1 construct was cloned in from a pWBFNP vector containing the gamma1 constant region between NheI and EcoRI sites was cut with EcoRI and blunted and recut with NheI. This vector was called pWBVDJ261G1 (or pWBIgG1). A
30 puromycin cassette was cloned in from a pIK6.1+puro vector (Figure 48) which was cut with HindIII and blunted and recut with AvrII. The pWBIgG1 was cut with PacI

and blunted and recut with AvrII and the puro cassette was cloned therein. This vector was called pWBIgG1 Puro.

In order to make an IgM expression vector, the 2.6.1 heavy chain was amplified through RT-PCR using the TA cloning vector (Invitrogen) using the following primers:

5 prime: 5' TCA TTT GGT GAT CAG CAC T (SEQ ID NO:54)

3 prime: 5' GGA TCC TGA GGA GAC GGT GAC G (SEQ ID NO:55)

10 3' Mu BamHI (introduces BamHI restriction site)

The resulting product contained only the VDJ cDNA sequences and not the constant region. The sequence was confirmed by sequencing. This vector was utilized to prepare an IgM expression vector as described below.

15 pWBFNP MCS was digested with EcoRI and treated with CIP and the EcoRI digest from the TA vector, above, was cloned into the vector. Orientation was determined by size through digestion with BamHI, which confirmed the insertion, followed by digestion with NotI. This vector was called pWBVDJ261BamHI.

A human Mu construct was PCR amplified from a yeast artificial chromosome construct, YAC 2CM, described in Mendez et al., (1997), *supra*. and U.S. Patent Application, No. 08/759,620, filed December 3, 1996, through RT-PCR using the TA cloning vector (Invitrogen) using the following primers:

25 5 prime: 5' GGA TTA GCA TCC GCC CCA ACC CTT (SEQ ID NO:56)

(which introduced a BamHI restriction site on the 5' end)

3' prime: 5' GTC GAC GCA CAC ACA GAG CGG CCA (SEQ ID NO:57)

30

The vector pWBVDJ261BamI was cut with BamHI and recut with XhoI. The TA cloning vector containing the Mu insert was cut with BamHI and XhoI (which is

another site in the TA vector) and was cloned into the BamHI/XhoI sites of pWBVDJ261BamI. The resulting vector was called pWBVDJ261IgM (or pWBIGM). The vector was further equipped with a puromycin cassette in the same manner as described above in connection with the construction of pWBIGG1 Puro. The resulting
5 vector was called pWBIGM Puro.

EXPERIMENT 17 GENERATION OF CELL LINE EXPRESSING 2.6.1 IGG1 ANTIBODIES

In order to generate a cell line expressing the 2.6.1 IgG1 antibody, we
10 cotransfected DHFR⁻ CHO cells with The pWBIGG1 Puro vector and the pWBK1
DHFR vector through electroporation. This was accomplished by taking a stock of
approximately 2×10^7 DHFR⁻ CHO cells and electroporating at 290 V, 960µFD,
200µg of linearized plasmid DNA plus 200µg of carrier DNA. Cells were seeded in
 α^+ medium and allowed to grow for two days. 8×10^5 cells were seeded in 10 cm
15 dish in α^- medium with 4µg/ml puromycin selection medium. Cells were incubated
for 4-5 days and then transferred to α^- medium with 0.5µM MTX at 5×10^5 cells per
10 cm dish. Cells were incubated for approximately 14 days for selection and,
thereafter, clones were picked and expanded and assayed for ability to bind to CD147
and the presence of IgG1.

20 We recovered a number of clones expressing a 2.6.1 antibody with a gamma-1
isotype that bound specifically to CD147.

EXPERIMENT 18 GENERATION OF CELL LINE EXPRESSING 2.6.1 MULTIMERIC IGM ANTIBODIES

25 In order to generate a cell line expressing the 2.6.1 multimeric IgM antibody,
we cotransfected DHFR⁻ CHO cells with The pWBIGM Puro vector and the
pWBK1(J) DHFR vector through electroporation. The same techniques described in
Experiment 18 were utilized.

We recovered a number of clones expressing a 2.6.1 antibody with a
30 multimeric Mu isotype that bound specifically to CD147.

EXPERIMENT 19 CHARACTERIZATION OF THE 2.6.1 IgG1 AND MULTIMERIC IgM ANTIBODIES

In order to assess the function of the 2.6.1 IgG1 and multimeric IgM antibodies, we assayed the antibodies in several assays. Each of the 2.6.1 IgG1 and multimeric IgM bound to CEM cells and bound to CD25⁺ activated human peripheral blood cells in a similar manner to the CBL1 and ABX-CBL. The antibodies were assayed in a potency and a lysis assay, in the same manner described above. In connection with these experiments, the 2.6.1 multimeric IgM antibody appeared approximately as active as CBL1 and ABX-CBL. Further, the 2.6.1 multimeric IgM antibody was capable of acting in ADCC as shown in Figure 50.

EXPERIMENT 20 AFFINITY MEASUREMENT OF THE 2.6.1 MULTIMERIC IgM ANTIBODIES

We also examined the affinity of the the 2.6.1 multimeric IgM antibody in comparison to ABX-CBL and certain other forms of the 2.6.1 antibody. Affinity measurements were conducted as described in Mendez et al., (1997), *supra*. and U.S. Patent Application, No. 08/759,620, filed December 3, 1996. The results are shown in the following Table:

TABLE 2

Antibody	Ig class	On-rates ka (M ⁻¹ s ⁻¹)	Off-rates kd(s ⁻¹)	KA kd/ka (M ⁻¹)	KD ka/kd (M)	BIACore surface Hu rCD147- IgG [RU]
ABX-CBL	M IgM	7.25 x 10 ⁵	3.76 x 10 ⁻⁴	1.39 x 10 ⁹	5.18 x 10 ⁻¹⁰	791
ABX-CBL	M IgM monomer	6.34 x 10 ⁴	4.94 x 10 ⁻³	1.28 x 10 ⁷	7.84 x 10 ⁻⁸	791
CEM 2.6.1	Hu IgG2	8.20 x 10 ⁵	3.75 x 10 ⁻⁴	2.19 x 10 ⁹	4.57 x 10 ⁻¹⁰	791
CEM2.6.1	Hu IgG2	7.17 x 10 ⁵	4.03 x 10 ⁻⁴	1.78 x 10 ⁹	5.61 x 10 ⁻¹⁰	242
CEM2.6.1	Hu IgM	6.52 x 10 ⁵	2.03 x 10 ⁻⁴	3.21 x 10 ⁹	3.12 x 10 ⁻¹⁰	242
CEM2.6.1	Hu IgM monomer	2.63 x 10 ⁵	1.67 x 10 ⁻³	1.57 x 10 ⁸	6.39 x 10 ⁻⁹	242
CEM2.6.1	Hu IgG1	3.13 x 10 ⁵	2.01 x 10 ⁻⁴	1.55 x 10 ⁹	6.43 x 10 ⁻¹⁰	242

EXPERIMENT 21 HUMAN CLINICAL TRIAL WITH ABX-CBL ANTIBODY**Phase II Clinical Trial of ABX-CBL**5 A. **Background**

As we mentioned above, in view of the positive results observed with respect to the CBL1 antibody, we undertook clinical trials utilizing ABX-CBL. The first such trial was a Phase II, multicenter, open label, dose escalation clinical trial examining multiple intravenous infusions of four doses of ABX-CBL in patients with steroid resistant GVHD. The trial enrolled patients with acute GVHD who were unresponsive to at least three days of treatment with corticosteroids and who had a severity index of at least B according to a modified IBMTR Severity Index (Rowlings et al. "IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with glucksberg grade" *British Journal of Haematology* 97: 855-864 (1997)). In the trial, four different doses were administered intravenously in a dose escalation design using an induction regimen of seven days followed by a maintenance dose of twice weekly for two weeks. Patients were followed for 8 weeks after completion of the treatment course. Long-term safety follow-up has been instituted.

The study was designed with three primary objectives and four secondary objectives under review, as follows:

Primary Objectives (i) to assess the safety of multiple doses of ABX-CBL in patients with steroid resistant acute GVHD; (ii) to determine the maximum tolerated IV dose of ABX-CBL in patients with steroid resistant acute GVHD; and (iii) to determine the pharmacokinetics of multiple doses of ABX-CBL in patients with steroid resistant acute GVHD.

Secondary Objectives (i) to assess the clinical efficacy of four different doses of ABX-CBL in patients with steroid resistant acute GVHD; (ii) to assess a dose response of ABX-CBL; (iii) to assess long-term safety in patients with acute GVHD who have received multiple doses of ABX-CBL; and (iv) to assess the long-term

survival in patients with acute GVHD who have received multiple doses of ABX-CBL.

Determination of the dosing for ABX-CBL was considered essential. As discussed above, the initial clinical trials conducted with the CBL1 antibody utilized ascites fluid that was not purified. Thus, the concentration of the antibody within the materials given to patients was not known. Further, because CBL1 was generated in a cell line that was not producing solely the IgM, but also an IgG, the concentration of the IgM antibody given to patients was even less clear.

In order to assess the above objectives, a four cohort trial plan was established with the following dose cohorts of patients:

Cohort 1: 0.01mg/kg

Cohort 2: 0.1 mg/kg

Cohort 3: 0.3mg/kg

Cohort 4: 1.0 mg/kg

Patients in all cohorts were to receive, and received, up to 11 intravenous infusions of ABX-CBL. ABX-CBL was infused over 2 hours via a syringe pump. The dosing schedule was as follows: daily times 7 days, followed by twice a week for two weeks. Safety evaluations were conducted prior to advancing to the next dose cohort. 27 patients were enrolled across all 4 of the dose cohorts.

During the conduct of the study, adverse events were observed in patients in the third cohort, receiving 0.3 mg/kg of ABX-CBL. There, several of the patients experienced myalgia or myalgia-like symptoms. As a result, the third dose cohort (0.3 mg/kg) was determined as the maximum tolerated dose. Thus, the fourth dose cohort was reduced to a dosage of 0.2 mg/kg so that the actual dosing utilized in the study was as follows:

Cohort 1: 0.01mg/kg

Cohort 2: 0.1 mg/kg

Cohort 3: 0.3mg/kg

Cohort 4: 0.2 mg/kg

The eligibility requirements for patients to enter the study were as follows:

- One year old or older
- 5 • Stem Cell transplant within 100 days
- Steroid resistant acute GVHD with a severity index of B, C, or D
- No experimental drugs or devices within 30 days of enrollment unless mutually agreed upon by the investigator, the sponsor's medical monitor, and the FDA
- 10 • ANC >500/mm³ with or without GCSF or GMCSF

Patients were screened and assigned to a treatment cohort once the patient met the eligibility criteria. Standard post stem cell transplant treatment was continued.

Once dosing was initiated, patients were infused with ABX-CBL the applicable dose for their dose cohort daily for 7 days (referred to as an induction regimen) followed by infusions 2 times per week for two weeks (referred to as a maintenance regimen). Patients were followed for 8 weeks following their infusions (visits are weekly for 4 weeks followed by a visit 4 weeks later) for safety and clinical effect. Further, patients who received at least one infusion of ABX-CBL were scheduled to participate in a long term follow up program to evaluate the long term safety of ABX-CBL and long term survival.

Safety was assessed by monitoring adverse events while on study as well as vital signs during the infusion of ABX-CBL. Further, patients received frequent physical exams and underwent extensive laboratory studies. Laboratory studies included complete blood counts, T-cell subsets, serum chemistries, and urinalyses at regular intervals as outlined below. Baseline CPK with isoenzymes were obtained on all patients and patients who experienced any infusion related adverse experiences were reanalyzed with CPK and isoenzymes. In addition, patients were monitored for Human Anti Mouse Antibody (HAMA) response by ELISA. Further, five patients in each cohort were assigned to have pharmacokinetic blood samples for pK profile.

Clinical effect of ABX-CBL was assessed by evaluating changes to the overall score of acute GVHD based upon the modified IBMTR Severity Index (Rowlings et

al. "IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with glucksberg grade" *British Journal of Haematology* 97: 855-864 (1997)), time to response, duration of response, time and incidence of flare of acute GVHD, and length of hospitalization.

5

B. Protocol Procedures

In connection with the trial, the following tests, observation schedules, preparations of the study medication were utilized:

TABLE 3 -- TESTS AND OBSERVATION SCHEDULE

		ON STUDY									
PERIOD	SCREEN	TREATMENT						TREATMENT FOLLOW UP			L.T. FOLLOW UP
WEEK		0		1		2		3,4,5,6	10		Q 6 mos
DAY		0	1-6	9	13	16	20	23,30,37,44	72	100^	
Visit #	1	2	3-8	9	10	11	12	13-16	17	Oth	19+
Procedures:											
Informed Consent	X										
Elig for enrollment	X										
Medical History	X										
Serum pregnancy	X ⁴										
Hgt/Wgt ¹	X		X ⁷	X ⁷	X ⁷	X ⁷	X ⁷	X	X	X	
Phys. Exam(C/A)	C		A ⁷	A ⁷	A ⁷	A ⁷	A ⁷	C	C	A	
Vital Signs	X	X ⁶	X ⁶	X ⁶	X ⁶	X ⁶	X ⁶	X	X	X	
Mod IBMTR score	X	X ⁵	X ⁷	X ⁷	X ⁷	X ⁷	X ⁷	X	X	X	
KPS/Lansky	X		X ⁷	X ⁷	X ⁷	X ⁷	X ⁷	X	X	X	
CBC/DIFF/PLAT	X ²	X ⁵	X ⁷	X ⁷	X ⁷	X ⁷	X ⁷	X	X	X	
Serum Chem	X ²	X ⁵	X ⁷	X ⁷	X ⁷	X ⁷	X ⁷	X	X	X	
CPK-III (mm) ³	X ²		X ³	X ³	X ³	X ³	X ³	X ³	X ³		
CD 3, 4, 8, 19		X ⁷	X ⁷	X ⁷		X ⁷		X	X		
Blood for HAMA	X ¹³	X ¹³	X ⁷					X ⁹	X ¹⁰		
Blood for pK		X ⁸	X ⁸	X ⁸			X ⁸				
UA	X ²			X ⁷		X ⁷		X ⁹	X		
Study med adm		X	X	X	X	X	X				
Intercurrent Illness	X									➔	X ¹¹
AE'S		X								➔	X ¹²
Concomitant meds	X									➔	X ¹¹
ECG/CXR	X*	Data will be collected as tests completed per routine patient care									
Biopsy assessment		Data will be collected on biopsies as they occur based on pt status									

[^] This visit occurs 100 days post allogeneic stem cell transplant not post infusion of study medication

5 * Obtain if not completed within 7 days of randomization (ECG if patient is ≥ 16 years)

C/A C = Complete PE, A = Abbreviated PE

1 Obtain Height at first visit only

2 Obtain within 48 hours of randomization request

3 Obtain at baseline, obtain if patient experiences any infusion related AE's (refer to protocol)

10 4 Serum pregnancy will be obtained on females of child bearing potential (refer to protocol)

5 Obtain if results are > 8 hours from the start of the infusion of the study medication

6 Obtain vital signs (T, P, R, BP) prior to the start of the infusion (maximum of 10 mins), q 15 mins during the first hour of the infusion, followed by 90, 120, 180, 240, 300, and 360 minutes after the start of the infusion

15 7 Obtain prior to the start of the infusion (maximum of 12 hours)

8 Obtain just prior to the start of the first infusion and the following timepoints after the completion of the first infusion; 15 and 30 minutes, 1, 2, 4, 8, 12, 18, and 24 hours (before the 2nd infusion) and at 4 hours after the completion of the Days 9 and 20 infusions (assigned patients only)

20 9 Obtain at weeks 4 and 6 only

10 Obtain during long term follow up if + at end of study

11 GVHD status and current treatment(s)

12 Resolve any ongoing AEs

13 Obtain HAMA during screen if the patient previously received a murine derived product.

25 This needs to be negative in order for the patient to qualify. If the patient has never received a murine product, this is to be obtained on Day 0 prior to the start of the infusion

In connection with the trial, it was preferred that the modified IBMTR Severity Index scoring was completed by the same physician.

The following labs were to be completed by laboratory at each clinical site

5 (local lab):

HEMATOLOGY

CBC w/ differential

White blood cells count (WBC)

WBC differential (diff)

-bands/stabs

-neutrophils

-EOS

-basophils

-lymphocytes

-monocytes

Red blood cell count (RBC)

Hemoglobin (Hgb)

Hematocrit (Hct)

Platelet count (Plt)

URINALYSIS

Specific gravity

PH

Protein

Glucose

Ketones

SERUM CHEMISTRY

Sodium (Na)

Potassium (K)

Chloride (Cl)

Bicarbonate (HCO₃)

Glucose

Blood Urea Nitrogen (BUN)

Creatinine (Cr)

Uric acid

Albumin

Total protein

Total bilirubin (bili)

Alkaline Phosphatase (alk phos)

Alanine aminotransferase (ALT, SGPT)

Aspartate aminotransferase (AST, SGOT)

Calcium (Ca)

Phosphate (PO₄)

CPK-III isoenzyme* (mm) (skeletal muscle)

Females only: serum Pregnancy
(if applicable)

*Obtain CPK with isoenzymes at baseline and post infusion on any patients with infusion related AE's.

10

In addition, the following lab assessments were completed by a central testing laboratory:

- T cell subset (CD3, 4, 8) and CD19: lymphocyte count, %, and CD4:CD8 ratio)

15

Further, the following lab assessment were completed by Abgenix, Inc.:

- ELISA for HAMA

- pK (a minimum of 5 patients/cohort to include those who previously received a murine product)

The Study Medication (ABX-CBL) was prepared and administered as follows:

5

ABX-CBL is a protein so it requires gentle handling to avoid foaming. The avoidance of foaming during product handling, preparation, and administration is important because foaming can lead to denaturation of the protein product. The pharmacist prepared each dose of study medication. The dose was based upon the patient's weight prior to randomization and the patient's cohort assignment, therefore the patient will receive the same dose for all 11 infusions. The pharmacist prepared the syringe and filter (filter supplied by Abgenix) and sent this to the patient unit for patient dosing.

15 *Infusion setup:* The infusion syringe was prepared using aseptic techniques. The appropriate volume of study medication was drawn up into the syringe(s), followed by the calculated volume of the pyrogen-free 0.9% sodium chloride solution, USP (saline solution). A 0.22 micron low-protein binding filter was attached and the tubing was primed to minimize fluid loss and according to the manufacturer's instructions.

20

Infusion volume: The total infusion volume (study medication + saline solution) to be infused for each infusion (0.01, 0.1, 0.3, 0.2 mg/kg) is equal to the patient's weight in kg. Below are examples:

25

TABLE 4

Pt's Weight (kg)	Cohort Assignment	Total Infusion Volume (mL)
70 kg	0.01	70 mL
70 kg	0.1	70 mL
70 kg	0.3	70 mL
70 kg	0.2	70 mL

The formula below was used to determine the volume of study medication and saline solution for each dose.

- a. Dose required = patient's weight X mg/kg (mg/kg is based upon cohort assignment)
- b. ABX-CBL Volume required = dose/study medication concentration (1mg/mL)
- c. Number of vials required = volume of ABX-CBL required (b above)/5mL
(each vial contains 5 mL of ABX-CBL)
- d. Total volume to be administered: For all treatment cohorts the patients received a total volume which was equal to their weight in kg (a 15 kg patient will receive a total of 15 mL, a 70 kg will receive 70 mL, etc.)

TABLE 5

15	<i>Example:</i>
	Patient weighs 70 kg and is assigned to receive 0.3 mg/kg
	a. 70 kg x 0.3 mg/kg = 21 mg
	b. 21 mg = 21 mL
	c. 21 mL/5mL per vial = 4.2 vials, therefore 5 vials are required
	d. 70 ml (total volume) – 21 mL (study med volume) = 49 mL (saline solution)

20

The labeled, filled infusion syringe was sent to the patient unit for infusion, making sure that all clamps on the infusion set were closed to prevent leakage of the study medication and/or normal saline. All caps were secured in place to maintain a closed system. The sponsor provided the label for the infusion syringe and this label will contain the following:

25

- space to record the patient study ID and initial
- space to record the date and time the study medication was prepared along with the expiration date and time
- space to record the initials of the person who prepared the study medication and the infusion set
- Infusion instructions:

30

“Caution: New Drug-Limited by Federal Law To Investigational Use”

Administer infusion over 2 hours via syringe pump

Do not mix with any other medication.*

- Space to specify the infusion rate based upon the total volume. For a 70 mL volume, the infusion rate would be 35 mL/hour.

The person preparing the study medication was responsible for completing the
5 above information on the label.

For the infusion, most patients had an indwelling central line, therefore a new catheter was not be required as long as there is a dedicated line for the infusion of ABX-CBL. During the administration of ABX-CBL no other medications were to be
10 infused via the specific port or IV line. If a central line was not available, ABX-CBL could also be infused in a peripheral intravenous line. Because this was a trial, ABX-CBL was not mixed with other medications. If another medication was previously
15 infused in the port, the lumen was flushed with 3-5 cc of normal saline (depending on the size catheter, lumen used, and patient's size) to clear any pre-existing medications from the line and the new infusion setup from the pharmacist was attached to the port or 3-way stopcock (not piggy backed onto another line) for infusion.

The protocol was composed of four study periods: screen, treatment, treatment follow up, and long term follow up.

20

1. Screen Period

The screen period began the day the patient or the patient's legal guardian signs the informed consent and ends at treatment assignment notification. Patients
25 could be screened for enrollment into this study up to 100 days after stem cell transplant. Patients who failed to develop steroid-resistant acute GVHD were not enrolled into the study.

Each patient must understand and have signed an IRB approved informed consent form. If the patient was a minor, the patient's legal guardian was to sign the
30 informed consent form.

The following procedures were to be completed after the informed consent form is signed but prior to requesting treatment assignment. The results of these

procedures were not more than 8 hours old unless otherwise indicated. These procedures include:

- a. Complete medical history
- 5 b. Complete physical examination, which includes weight (this is the weight to be used to determine the required dose of study medication throughout the study) and height
- c. Vital signs (oral temperature, resting pulse, respiration, and blood pressure)
- 10 d. Medication history and stem cell transplant treatment history from 30 days prior to requesting treatment assignment
- e. Modified IBMTR Severity Index for acute GVHD
- f. Assessment of intercurrent illness(es)
- 15 g. Karnofsky Performance Scale (KPS) (age \geq 16 years) or Lansky Scale (age < 16 years)
- h. The following lab results were obtained if not obtained within 48 hours prior to randomization:
 - CBC with diff and platelets
 - Serum Chemistry (refer to Appendix V)
 - 20 -Baseline CPK-III isoenzyme (mm)
 - Serum Pregnancy test. This may be waived for women who are not of child bearing potential or who, in the opinion of the investigator, are sterile due to the pre conditioning for the stem cell transplant
 - 25 -Urinalysis
- i. CXR if not completed within the previous 7 days
- j. ECG if not completed within the previous 7 days for all patients 16 years of age or older.
- 30 k. Obtain serum specimen to be assayed by Abgenix for the determination of a positive HACA/HAMA for any patient who previously received a murine chimeric or fully murine product. This sample was to be shipped on dry ice overnight to Abgenix

and results were generally available within 24 hours of Abgenix's receipt of the sample.

After the above were completed and the investigator determined that the patient was eligible for treatment, the clinical center requested (via fax) the cohort assignment from the sponsor. The clinical center generally received notification of the treatment assignment by fax within 3 hours of the request.

2. Treatment Period

10

The treatment period began when the clinical site received the patient's treatment assignment and ended when the patient completed the infusion regimen (11 doses). This period generally lasted a maximum of three weeks. The patient was considered "on study" once the patient was dosed and was considered "off study" after the completion of the week 10 visit procedures or when the patient withdrew from the study.

3. Week 0, day 0

20 Pre-Infusion Procedures:

The pharmacist would prepare the study medication for infusion while the following visit procedures are being completed:

25

- a. Update any changes in concomitant medications or intercurrent illnesses
- b. Modified IBMTR Severity Index if the previous score was obtained greater than 8 hours prior to the start of the infusion
- c. Blood draw for the following:
 - CBC with diff and platelets (if previous results are > 8 hours from the start of the infusion of study medication)

30

- Serum chemistry (if previous results are > 8 hours from the start of the infusion of study medication)
- CD 3, 4, 8, & 19
- Baseline HAMA (patients who had blood drawn for HAMA as part of their eligibility screen procedure do not need to have this sample obtained)
- Baseline pK sample up to 10 minutes prior to the start of the infusion (for assigned patients only)

Study medication infusion procedures:

The pharmacist prepared the study medication such that the maximum total volume to be infused is dependent upon the patient's weight and cohort assignment (total volume of study medication and normal saline). The study medication was generally infused over 2 hours and the patient was closely monitored during the infusion and for the following 4 hours for any untoward reactions to the infusion. As of the start of the infusion of the study medication, the patient was monitored for adverse events on an ongoing basis. The sponsor was notified immediately of any suspected infusion related adverse experiences (cytokine release syndrome: fever, chills, rigors/shakes; hypotension, and rash or hypersensitivity reaction: fever, chills, bradycardia/cardiac arrest, respiratory arrest, acute respiratory distress syndrome, rash/urticaria, pancytopenia, increased liver transaminases, and arthralgias/myalgias). If an infusion reaction is suspected and the patient experiences myalgias or any muscular problems, CPK-III isoenzyme (mm) were obtained.

Infusion Vital Signs:

During the infusion, vital signs (T, P, R, BP) were obtained just prior to the start of the infusion (a maximum of 10 minutes prior to the start of the infusion), every 15 minutes during the first hour of the infusion (4 sets), followed by 90 minutes after the start of the infusion, and at the completion of the infusion (120 minutes after the start of the infusion). Vital signs were generally obtained hourly for the next 4

hours (4 sets at 180, 240, 300, and 360 minutes after the start of the infusion). After the infusion vital signs have been completed, vital signs were monitored according to the established guidelines used by the clinical center.

5 Pharmacokinetic blood samples:

Blood for pK analysis was obtained from at least 5 patients in each cohort. All patients enrolled in study who previously received a murine product had pK assessments completed. Blood samples were generally obtained at the following
10 times after the completion of the first infusion; 15 and 30 minutes, 1, 2, 4, 8, 12, 18, and 24 hours. The 24 hour post infusion sample was obtained prior to the start of the second infusion of ABX-CBL.

15 4. Week 0, days 1-6

The patient received a daily infusion of the study medication for 7 consecutive days (induction regimen). Each subsequent infusion generally began at the same time as the first infusion (\pm 60 minutes). The dose was based upon the pre-enrollment weight, therefore, the patient will receive the same dose throughout the treatment
20 period. Data was collected on any patients having an ECG or CXR completed at any time during the treatment period, otherwise routine ECGs and CXRs were not required. The same will hold true for any biopsies completed during this period.

The following procedures were generally completed within 12 hours prior to
25 the start of each infusion unless otherwise noted:

- a. Abbreviated physical exam (refer to Appendix II)
- b. Weight
- c. KPS or Lansky Scale
- 30 d. Modified IBMTR Severity Index
- e. Update any changes in concomitant medications or intercurrent illnesses

- f. Adverse experience assessment
- g. Blood draw for the following (refer to Appendix V for test to be processed by the local labs and those to be processed by the central lab):
 - CBC with diff and platelets
 - Serum chemistry
 - CD 3, 4, 8, & 19
 - Pharmacokinetic sample for assigned patients only and obtain prior to the start of the Day 1 infusion only (this is the 24 hour post infusion 1 sample).

Study Medication Infusion:

The study medication was infused over 2 hours following the above procedures. If an infusion reaction was suspected and the patient experiences myalgias or any muscular problems, CPK-III isoenzyme (mm) were obtained.

Infusion Vital Signs:

Vital signs (T, P, R, BP) were obtained according to the schedule described for the first infusion.

5. Week 1 (study days 9 and 13)

At the completion of the induction regimen, the patients were infused with the study medication twice a week for two weeks (maintenance regimen). The start time of each infusion in the maintenance regimen was generally ± 60 minutes from the start time of the first infusion (Day 0). The following procedures were generally completed within 12 hours prior to the start of each infusion unless otherwise noted:

- a. Abbreviated physical exam
- b. Weight

- c. KPS or Lansky Scale
- d. Modified IBMTR Severity Index
- e. Update any changes in concomitant medications or intercurrent illnesses
- 5 f. Adverse experience assessment
- g. Urinalysis (study day 9 only)
- h. Blood draw for the following(refer to Appendix V for test to be processed by the local labs and those to be processed by the central lab):
 - 10 • CBC with diff and platelets
 - Serum chemistry
 - CD 3, 4, 8, & 19 (day 9 only)
 - HAMA (day 9 only)

15 Study Medication Infusion:

The study medication was infused over 2 hours and the procedures described above were again followed. If an infusion reaction was suspected and the patient experiences myalgias or any muscular problems, CPK-III isoenzyme (mm) were
20 obtained.

Infusion Vital Signs:

Vital sign regimen described above was utilized.

Pharmacokinetic sample:

25 A blood sample for pK analysis was obtained about 4 hours after the completion of the Day 9 infusion.

6. Week 2 (study days 16 and 20)

30 This was the second week of the maintenance regimen (dosing is twice a week for two consecutive weeks). The start time of each infusion was generally ± 60

minutes from the start time of the Day 0 infusion. The following procedures were generally completed within 12 hours prior to the start of each infusion unless otherwise noted:

- 5 a. Abbreviated physical exam
- b. Weight
- c. KPS or Lansky
- d. Modified IBMTR Severity Index
- e. Update any changes in concomitant medications or intercurrent
- 10 illnesses
- f. Adverse experience assessment
- g. Urinalysis (day 16 only)
- h. Blood draw for the following (refer to Appendix V for test to be processed by the local labs and those to be processed by the
- 15 central lab):
 - CBC with diff and platelets
 - Serum chemistry
 - CD 3, 4, 8, & 19 (day 16 only)

20 Study Medication Infusion:

The study medication was infused over 2 hours and the same procedures described above were followed. If an infusion reaction was suspected and the patient experiences myalgias or any muscular problems, CPK-III isoenzyme (mm) were

25 obtained.

Infusion Vital Signs:

Vital sign regimen described above was utilized.

30 Pharmacokinetic sample:

A blood sample for pK analysis was obtained about 4 hours after the completion of the Day 20 infusion.

7. Treatment Follow up Period (Weeks 3 – 10)

5

The treatment follow up period began after the completion of the Day 20 visit and ended at the completion of the week 10 visit. There were five visits during this period. When the patient completed the week 10 visit the patient was considered “off study”. If a patient is discharged from the clinical center during this study period, every attempt was made to complete a telephone assessment in place of an office visit. Weeks 3, 4, 5, 6, and 10 were treatment follow up visits. Safety, efficacy or signs of relapse was assessed at these visits. Patients who were partial or complete responders and have a flare of their GVHD were allowed to withdraw from the study and enroll into a separate open label, compassionate treatment protocol. Any biopsies, ECGs, and/or CXRs completed during the treatment follow up period were completed per routine patient care as specified at each clinical center, however, the data from these procedures was collected. Any patients who experienced a suspected infusion related adverse experience with myalgias or any muscular problems and who had elevated mm (isoenzyme which becomes elevated when there is muscular necrosis or inflammation) levels generally had a routine CPK-III (mm) sample obtained throughout the remainder of the study.

10

15

20

8. Week 3 (study day 23)

25

The following procedures were completed at this visit:

- a. Complete physical exam, vital signs, and weight
- b. KPS or Lansky
- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- e. Adverse experience assessment
- f. Hospitalization status (in patient or discharge)

30

g. Blood draw for the following:

- CBC with diff and platelets
- Serum chemistry (refer to Appendix V)
- CD 3, 4, 8, & 19

5

9. Week 4 (study day 30 ± 1)

The following procedures were completed at this visit:

- a. Complete physical exam, vital signs, and weight
- b. KPS or Lansky
- 10 c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- e. Adverse experience assessment
- f. Hospitalization status (in/outpatient or discharge from clinical center)
- 15 g. Urinalysis
- h. Blood draw for the following:
 - CBC with diff and platelets
 - Serum chemistry (refer to Appendix V)
 - 20 • CD 3, 4, 8, & 19
 - HAMA

10. Week 5 (study day 37 ± 1)

The following procedures were completed at this visit:

- 25 a. Complete physical exam, vital signs, and weight
- b. KPS or Lansky
- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- 30 e. Adverse experience assessment

f. Hospitalization status (in/outpatient or discharge from clinical center)

g. Blood draw for the following:

- CBC with diff and platelets
- Serum chemistry (refer to Appendix V)
- CD 3, 4, 8, & 19

11. Week 6 (study day 44 ± 1)

The following procedures were completed at this visit:

- a. Complete physical exam, vital signs, and weight
- b. KPS or Lansky
- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- e. Adverse experience assessment
- f. Hospitalization status (in/outpatient or discharge from clinical center)
- g. Urinalysis
- h. Blood draw for the following:
 - CBC with diff and platelets
 - Serum chemistry (refer to Appendix V)
 - CD 3, 4, 8, & 19
 - HAMA

12. Week 10 (study day 72 ± 2)

At the completion of this visit the patient was considered "off study".

The following procedures were completed at this visit:

- a. Complete physical exam, vital signs, and weight
- b. KPS or Lansky

- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- e. Adverse experience assessment
- 5 f. Hospitalization status (in/outpatient or discharge from clinical center)
- g. Urinalysis
- h. Blood draw for the following:
 - CBC with diff and platelets
 - 10 • Serum chemistry (refer to Appendix V)
 - CD 3, 4, 8, & 19
 - HAMA (if any patient has a positive HAMA, blood draws for HAMA will be requested during the Long Term Follow up Period)

15

13. Additional Visit Timepoint (Day 100 post stem cell transplant)

Most patients were assessed 100 days post stem cell transplant. The order in which this visit occurs in relationship to the protocol visits varied on a patient by patient basis depending on when acute GVHD develops post stem cell transplant. Regardless of when day 100 occurs, the following procedures were completed at this visit (if the patient had been discharged from the clinical center every effort was made to obtain this information through a phone call to the patient and the patient's private physician):

25

- a. Abbreviated physical exam, vital signs, and weight
- b. KPS or Lansky
- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- 30 e. Adverse experience assessment

f. Hospitalization status (in/outpatient or discharge from clinical center)

g. Blood draw for the following:

- CBC with diff and platelets
- Serum chemistry (refer to Appendix V)

14. Long Term Follow up Period

The long term follow up period begins the day after the completion of the week 10 visit and is planned to continue for 10 years or until the patient withdraws consent to be followed. The primary purpose of the long term follow up period is to determine long term safety of ABX-CBL and to determine the long term survival. The patient will be assessed every 6 months from their week 10 visit. These assessments will occur either by telephone interview or by office visit. Long term follow up data may be obtained by the sponsor, Abgenix, Inc., from the primary physician provided that the patient/legal guardian has provided written consent. All data will be entered into the database using the patient's unique study ID. The following information should be obtained during these phone calls or visits:

- a. Determine the patient's assessment of their health status, this includes the closeout any AE's that were ongoing at the last "on study" visit
- b. Determine the onset of any of the following:
 - Death
 - Opportunistic Infections
 - Other immune impairments
 - Other cancer(s)
 - Congenital abnormality
 - If female, if pregnant, status of baby (after pregnancy)
- c. Determine if the patient is active in any other research (investigative products and/or devices) since the previous visit/call.

If the long term follow up visit data is obtained by the transplant team at the clinical center, a copy of each visit assessment will be faxed to the sponsor within 10 working days of the phone call/visit.

5 C. Determination of HAMA

This assay was designed to study the immunogenicity of ABX-CBL in human subjects to detect human antibodies against ABX-CBL (human anti-mCBL antibody) in human serum (human anti-murine antibody, HAMA, response).

10 Materials:

Negative Control, pool of HAMA negative sera (from Blood Centers of the Pacific, Irwin Blood Center, SF, CA) tested and pooled, stored at -20°C

Positive Control, pool of HAMA positive sera (from immunizing XenoMouse mice (Abgenix, Inc.) with ABX-CBL and removal and pooling of
15 serum), stored at -20°C

ABX-CBL, 5 µg/50 µL (100 µg/mL), Abgenix, Lot No. 097-104-1, stored at -20°C or equivalent

Biotinylated ABX-CBL (ABX-CBL-biotin), Abgenix, Lot No. J090-112 or equivalent

20 Streptavidin-HRP, Southern Biotechnology, Cat. No. 7100-05 or equivalent

O-phenylenediamine dihydrochloride (OPD) Substrate Tablets, 20 mg, Sigma, Cat. No. P-7288 or equivalent

O-phenylenediamine dihydrochloride (OPD) Substrate Tablets, 10 mg,
25 Sigma, Cat. No. P-8287 or equivalent

Hydrogen Peroxide, 30%, Sigma, Cat. No. H-1009 or equivalent

Deionized, reverse osmosis purified water (DiH₂O) or equivalent

Coating ELISA Plate: Thaw a vial of ABX-CBL 5 µg/50 µL (100 µg/mL) at room temperature for 2-5 minutes. Vortex on low speed for 3-5 seconds. Add 48 µL

of ABX-CBL 5 µg/50 µL (100 µg/mL) to 12 mL of Coating Buffer (NaHCO₃ at 16.8 gms/1.8L DiWater to pH 9.6 w/ 5N NaOH)) in a 15 mL conical tube. Vortex the coating solution on low speed for 3-5 seconds. Pour the coating solution into a reagent reservoir. Using a multi-channel pipettor, add 100 µL of coating solution to each well.

5 Cover plate with plastic plate sealer. Incubate plate at 2-8°C for 16-24 hours. Wash the plates with 1X Wash Buffer (50 mL Tween 20 in 10 L 10 X PBS diluted by 10) using a plate washer. Using the multi-channel pipettor, add 100 µL of Blocking Buffer (20 gms BSA in 400 mL 10 X PBS, 0.4 gms. Thimerosal, 4 mL Tween 20, diluted to 4 L DiWater) to each well. Cover plate with plate sealer and incubate for 1

10 hour at room temperature.

Preparation of Positive Control: Thaw 1 vial of positive control (HAMA positive serum) at room temperature for 10-20 minutes. Vortex positive control for 3-5 seconds on low speed. Avoid air bubbles. Add 20 µL of positive control to 180 µL of Blocking Buffer in a microcentrifuge tube. In well A1 and A2 of a low binding 96-

15 well plate, add 20 µL of diluted positive control above to 180 µL of Blocking Buffer. Mix. Mix well by aspirating and dispensing the solution 5 times. Avoid air bubbles. Prepare 2 fold serial dilutions of the positive control. Note: Each plate should include the positive control in duplicate in columns 1 and 2. The following procedure is for one plate. Add 100 µL of Blocking Buffer to wells B3, B4 through H3, H4 on the

20 plate as above. Using a multi-channel pipettor, transfer 100 µL of the solution in wells A1 and A2 to B1 and B2, respectively. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Transfer 100 µL of the solution from wells B1 and B2 to wells C1 and C2, respectively. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Continue dilutions down

25 the plate from row to row with the last dilution in Row G (wells G1 and G2). Leave the Blocking Buffer in Row H as blank controls.

Preparation of Negative Control: Thaw negative control at room temperature for 20-30 minutes. Vortex the negative control for 3-5 seconds on low speed before transferring to the ELISA plate. Dilute negative control by adding 20 µL to 980 µL

30 of blocking Buffer.

Preparation of Sample: Note 1: Serum samples should be prepared in a designated area. Note 2: Wear gloves when handling serum and follow Universal

Precautions. Thaw serum samples at room temperature for 20-30 minutes. Vortex serum samples for 3-5 seconds on low speed. Dilute serum samples 1:50 by adding 20 μ L of a serum sample to 980 μ L Blocking Buffer in a titer tube. Mix the diluted samples by aspirating and dispensing 50 μ L of the solution 5 times. Avoid bubbles.

- 5 Wash the coated ELISA plate from Step 7.3.2 using a plate washer. Transfer 50 μ L of positive control, negative control, samples and blank to the ELISA plate as above. Cover the ELISA plate with plastic plate sealer and incubate for two hours at room temperature. Shake the plate on low speed.

- Preparation of ABX-CBL-biotin: **Note:** Minimum of 10 mL of diluted
10 ABX-CBL-biotin is needed for each ELISA plate. Final dilution may be adjusted according to the potency of the reagent. Vortex ABX-CBL-biotin for 3-5 seconds on low speed. Dilute 15 μ L of ABX-CBL-biotin into 1.485 mL of Blocking Buffer in a microcentrifuge tube. Total dilution is 1:100. Dilute 1200 μ L of 1:100 diluted ABX-CBL-biotin into 10.80 mL of Blocking Buffer. Total dilution is 1:1000. Vortex for 3-
15 5 seconds on low speed. Wash the coated ELISA plate using a plate washer. Using a multi-channel pipettor, add 100 μ L of 1:1000 diluted ABX-CBL-biotin to each well of the ELISA plate. Cover the plate with plastic plate sealer and incubate for 1 hour at room temperature.

- Preparation of Streptavidin-HRP: **Note:** Minimum of 10 mL of diluted
20 Streptavidin-HRP is needed for each ELISA plate. Final dilution may be adjusted according to the potency of the reagent. Vortex Streptavidin-HRP for 3-5 seconds on low speed. Dilute 10 μ L of Streptavidin-HRP into 990 μ L of Blocking Buffer in a microcentrifuge tube. Total dilution is 1:100. Dilute 250 μ L of 1:100 diluted Streptavidin-HRP into 12.25 mL of Blocking Buffer. Total dilution is 1:5000. Vortex
25 for 3-5 seconds on low speed. Wash the ELISA plate from above using a plate washer. Using multi-channel pipettor, add 100 μ L of 1:5,000 diluted Streptavidin-HRP to each well of the ELISA plate. Incubate the plate for 15 min at room temperature.

- Preparation of Substrate Solution: **Note 1:** Minimum of 10 mL of Substrate
30 Solution is needed for each ELISA plate. **Note 2:** Prepare Substrate Solution fresh prior to use. To make 12 mL of Substrate Solution, add one 10 mg OPD tablet, and 12 μ L of 30% H_2O_2 into 12 mL of Substrate Buffer in a conical tube. Dissolve the

tablet by leaving the tube at room temperature for 3-5 minutes. Vortex the solution for 3-5 seconds prior to adding to the plate. Wash the ELISA plate from above using a plate washer. Using a multi-channel pipettor, add 100 μ L of Substrate Solution into each well and incubate for 15 minutes. Using a multi-channel pipettor, add 50 μ L of
5 Stop Solution (2 M H_2SO_4) to each well.

Reading ELISA plate(s): Set wavelength at 492 nm and check automix function to premix plate for 5 seconds before reading plate. Use reduction function (Check L1) to subtract the calculated blank for the assay. Samples and controls are blanked against the buffer blank. Read plate using the SPECTRAmax 250
10 spectrophotometer within 30 minutes of stopping the assay.

As discussed above, the present assay was utilized for patient samples in connection with the present clinical trials and no patients tested positive for a HAMA response.

15 D. Determination of pK

The present assay was utilized in connection with pharmacokinetic (pK) studies to measure the presence of ABX-IL8 in human serum.

Materials:

20 ABX-CBL, anti-mouse CBL antibody, 5 μ g/50 μ L (100 μ g/mL),
Abgenix, Lot No 69-21-4 or equivalent

High, Medium and Low Positive Controls, ABX-CBL: 69-21-3, 69-21-2, 69-21-1 or equivalent

25 Goat anti-mouse IgM, Caltag, Cat. No. M31500, Lot No. 3501 or
equivalent

Goat anti-mouse IgM-HRP, Caltag, Cat. No. M31507, Lot No. 2301 or
equivalent

Normal human serum

O-phenylenediamine dihydrochloride (OPD) Substrate Tablets, 20 mg,
Sigma, Cat. No. P-7288 or equivalent.

O-phenylenediamine dihydrochloride (OPD) Substrate Tablets, 10 mg,
Sigma, Cat. No. P-8287 or equivalent

5 Hydrogen Peroxide, 30%, Sigma, Cat. No. H-1009 or equivalent

Deionized, reverse osmosis purified water (DiH_2O) or equivalent

Buffers and solutions that are used herein are the same as the buffers
and solutions described in connection with the HAMA assay unless described
otherwise

10 Coating ELISA Plate: Note: Minimum of 10 mL of coating solution is
needed for each ELISA plate. Pull vial of goat anti-mouse IgM (1 mg/mL) from the
2-8°C refrigerator. Let stand for 2-5 minutes at room temperature. Vortex on low
speed for 3-5 seconds. Add 3 μL goat anti-mouse IgM (1 mg/mL) to 15 mL of
Coating Buffer in a 15 mL conical tube. Vortex the coating solution on low speed for
15 3-5 seconds. Pour the coating solution into a reagent reservoir. Using a multi-
channel pipettor, add 100 μL of coating solution to each well. Cover the plate with a
plastic plate sealer. Incubate at 2-8°C for 16-24 hours. Wash the plate with 1X Wash
Buffer using a plate washer.

Blocking ELISA Plate: Using the multi-channel pipettor, add 200 μL of
20 Blocking Buffer to each well. Cover plate with plastic plate sealer and incubate for 1
hour at room temperature.

Preparation of Standard: Note 1: Blocking Buffer used in Sections 8.4 and
8.6 (except 8.4.4.1 and 8.6.3) contains 1% serum from untreated human subjects.
Minimum of 9 mL of Blocking Buffer is needed for each plate. To make 10 mL of
25 Blocking Buffer containing 1% serum, add 100 μL serum to 9.9 mL of Blocking
Buffer in a conical tube. Vortex on low speed for 3-5 seconds. Thaw 1 vial of ABX-
CBL standard (100 $\mu\text{g/mL}$) at room temperature for 10-20 minutes. Vortex 100
 $\mu\text{g/mL}$ ABX-CBL on low speed for 3-5 seconds. Avoid bubbles.

Initial Dilution of Standard: Using a single channel pipette, add 40 μL of 100
30 $\mu\text{g/mL}$ stock to 360 μL of Blocking Buffer in a 1.7 mL microcentrifuge tube. Mix

well. This is a 1:10 dilution equal to 10 µg/mL. Using a single channel pipette, add 40 µL of the previous 1:10 dilution (10 µg/mL) into 460 µL of Blocking Buffer in a 1.7 mL microcentrifuge tube. Mix well. This dilution is equal to a concentration of 800 ng/mL. Mix the diluted standard by vortexing on low speed for 3-5 seconds.

- 5 Avoid bubbles. Prepare 2 fold serial dilutions of the standard. Note: Each blank low binding ELISA plate should include the standard in duplicate in columns 1 and 2. The following procedure is for one plate. Add 100 µL of Blocking Buffer to Wells B1, B2 through H1, H2. Transfer 200 µL of 800 ng/mL standard to Wells A1 and A2. Using a multi-channel pipette, transfer 100 µL of the solution in Wells A1 and A2 to
10 Wells B1 and B2, respectively. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Transfer 100 µL of the solution from Wells B1 and B2 to Wells C1 and C2, respectively. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Continue dilutions down the plate from row to row with the last dilution in Wells H1 and H2.

- 15 Preparation of Positive Controls: Note: One vial of high, medium and low control is needed for each assay plate. Thaw 1 vial of high, medium and low controls at room temperature for 10-20 minutes. Vortex the controls for 3-5 seconds on low speed before transferring to the ELISA plate.

- Preparation of Sample: Thaw serum samples at room temperature for 30
20 minutes. Vortex serum samples on low speed for 3-5 seconds prior to dilutions. Dilute serum samples 1:10 by adding 20 µL of a serum sample to 180 µL Blocking Buffer (without 1% serum) in Row A of a blank plate. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Prepare two fold serial dilutions of the sample. Using a multi-channel pipette, add 100 µL of Blocking
25 Buffer to Row B through Row H. Transfer 100 µL of the diluted samples from Step 8.6.3 to Row B. Mix as above. Continue to transfer 100 µL of the samples from Row B to Row C, from Row C to Row D, and so on to Row H. Mix samples after each transfer by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Wash the plate with 1X Wash Buffer using a plate washer. Transfer 50 µL diluted
30 standard, controls and samples from blank plate to the ELISA plate. Start from Row H, then go to Row G and so on up to Row A. Check plate template to add additional

wells of buffer blank. Cover the plate with a plastic plate sealer and incubate for two hours at room temperature.

Prepare HRP-conjugated detection antibody: Note: Minimum of 10 mL of diluted HRP-conjugated antibody is needed for each plate. Mix goat anti-mouse IgM-HRP by vortexing on low speed for 3-5 seconds. Dilute goat anti-mouse IgM-HRP to 1:1500 by adding 8 μ L of goat anti-mouse IgM-HRP to 12 mL of Blocking Buffer in a 15 mL conical tube. Vortex. Wash the plate with 1X Wash Buffer using a plate washer. Using a multi-channel pipette, add 100 μ L of diluted goat anti-mouse IgM-HRP (from Step 8.10.2) to each well of the plate. Cover the plate with a plastic plate sealer and incubate for 1 hour at room temperature.

Prepare Substrate Solution: Note 1: Minimum of 10 mL of Substrate Solution is needed for each plate. Prepare Substrate Solution fresh prior to use. To make 12 mL of Substrate Solution, add one 10 mg OPD tablet and 12 μ L of 30% H_2O_2 to 12 mL of Substrate Buffer in a conical tube. Dissolve the tablet by leaving the tube at room temperature for 3-5 minutes. Vortex the solution for 3-5 seconds prior to adding to the plate. Wash the plate with 1X Wash Buffer using a plate washer. Using a multi-channel pipettor, add 100 μ L of Substrate Solution into each well and incubate for 15 minutes.

Stopping ELISA reaction: Using a multi-channel pipette, add 50 μ L of Stop Solution to each well.

Reading ELISA plate(s): Set wavelength at 492 nm and check automix function to premix plate for 5 seconds before reading plate. Use reduction function (check L1) to subtract the calculated blank for the assay. Standard, controls and samples are blanked against the buffer blank. Read plate(s) using the SPECTRAmax 250 or equivalent spectrophotometer within 30 minutes of stopping the assay, Operation and Maintenance of the Molecular Devices SPECTRAmax 250 Microplate Spectrophotometer.

Data Analysis: The OD for the standard is used to calculate the standard curve. Use "4-parameter fit" to curve fit the standard. Sample and control concentrations are calculated automatically by the software from the standard curve. The following criteria must be met in order for the assay to be valid: Only use OD's

< 4.0 for standard, controls and samples. Compare the results for the assay controls (High, Medium and Low). The values for the controls must fall within 20% of expected concentration and with coefficient of variation (CV) $\leq 20\%$. The CV of the standards between ST03 and ST06 must be $\leq 20\%$. The correlation coefficient of the standard curve of the assay must be ≥ 0.990 .

The present assay was utilized for determining the pharmacokinetics of the ABX-CBL antibody in the present clinical trials. The results from our preliminary determinations of PKs in patients utilizing the above-assay are shown in Figure 1.

10 E. Results

Herein, we describe the results that were observed in the treatment of patients with acute GVHD with ABX-CBL.

In the trial, twenty-seven patients were enrolled across the four dose levels. The lower doses were completed prior to enrolling in the higher dose cohorts. Patients who were treated at the higher dose in the original third cohort (0.3 mg/kg) experienced myalgia or myalgia-like symptoms. Abgenix determined this dose to be the Maximum Tolerated Dose (MTD) and revised the last dose from 1.0 mg/kg to 0.2 mg/kg (mid dose between the MTD and the dose prior to the MTD).

Once the 4 dose cohorts were filled, additional patients were enrolled at a dose level of 0.15 mg/kg to 0.2 mg/kg. As of January 13, 1999, a total of 44 patients (17 additional patients) have been enrolled. Data continues to be collected on these additional 17 patients. This data will be presented as it becomes available.

All data presented herein are based upon the initial 27 patients except for the Serious Adverse Event (SAE) Summaries. The SAE Summaries relate to all patients as of January 13, 1999.

Patients had to receive a minimum of 4 infusions of ABX-CBL to be evaluated for efficacy. Of the twenty-seven patients enrolled, 23 met this criteria. Excluding the patients in cohort 1 (the no-effect dose). There was an overall response rate of 73% with a mean duration of 32 days.

Other than the incidence of myalgia, ABX-CBL was well tolerated. All patients were, and remain, negative for HAMA, and no reports of hypersensitivity to ABX-CBL have been received.

5

1. Demographics:

Of the twenty-seven patients enrolled, 21 were adults (age 16 or older) and 6 were pediatric (Table 4). Twenty-four patients were recipients of an allogeneic bone marrow transplant, and the other three received peripheral stem cells. The mean duration from the date of transplant to enrollment into this study was 48 days. Seven patients were entered into the study with an IBMTR grade of B, 10 with a grade of C and 10 with D. (Table 5). Table 6 lists the baseline score for the 23 patients evaluated for efficacy.

15

TABLE 6

GENDER/AGE CATEGORY			
	MALE	FEMALE	TOTAL
ADULT	13	8	21
PEDIATRIC (<16 YRS)	4	2	6
TOTAL	17	10	27

20

TABLE 7

BASELINE IBMTR SEVERITY SCORE-ALL PATIENTS				
COHORT	B n(%)	C n(%)	D n(%)	TOTAL N
1 (0.01 mg/kg)	2 (22%)	3 (33%)	4 (44%)	9
2 (0.1 mg/kg)	2 (29%)	3 (42%)	2 (29%)	7
3 (0.3 mg/kg)	1 (50%)	1 (50%)	0	2
4 (0.2 mg/kg)	2 (22%)	3 (33%)	4 (44%)	9
TOTAL	7	10	10	27

TABLE 8

BASELINE IBMTR SEVERITY SCORE FOR <i>EVALUABLE</i> PATIENTS				
COHORT	<u>B</u> n(%)	<u>C</u> n(%)	<u>D</u> n(%)	<u>TOTAL</u> N
1 (0.01 mg/kg)	2 (25%)	3 (38%)	3 (38%)	8
2 (0.1 mg/kg)	1 (17%)	3 (50%)	2 (33%)	6
3 (0.3 mg/kg)	1 (50%)	1 (50%)	0	2
4 (0.2 mg/kg)	2 (29%)	2 (29%)	3 (43%)	7
TOTAL	6	9	8	23

5

2. Efficacy:

Patients eligible for enrollment into this study required a minimum IBMTR score of B. Patients who demonstrated at least a 2 index decrease in overall IBMTR score were considered responders. Those who decreased to no score, meaning there was no acute GvHD present, were considered to be complete responders. Only patients who received 4 or more infusions of ABX-CBL are included in the efficacy analyses. (Table 7)

15

TABLE 9

EFFICACY SUMMARY			
COHORT	EVALUATED FOR EFFICACY (n)	RESPONDERS n (%)	MEAN DURATION OF RESPONSE (n)
1 (0.01 mg/kg)	8	3 (38%)	24 days (3)
2 (0.1 mg/kg)	6	4 (67%)	11 days (3)
3 (0.3 mg/kg)	2	2 (100%)	69 days (1)
4 (0.2 mg/kg)	7	4 (57%)*	41 days (3)
TOTAL	23	13 (57%)	36 days

*One patient responded to additional therapy with ABX-CBL in the ABX-CB-9702 protocol and is not included in the above table.

20

Overall, thirteen (57%) of the twenty-three patients demonstrated a response to ABX-CBL in ABX-CB-9701. The mean duration was 36 days. One additional patient who rolled over into protocol described below responded to additional therapy.

This brings the overall response rate to 61%. The assumption going into the study was that the dose of 0.01 mg/kg would be the no effect dose. Assuming this dose to have no effect, the response rate was 73% (11 of 15 patients). With this assumption, the mean duration of response was 32 days.

5 The duration of response seems to increase as the dose is increased. One patient, [0108], was an outlier for duration in the first cohort. This patient's duration lasted at least 59 days. The duration may be longer, but the study ended at Day 72.

 [Patient 0816] experienced severe myalgia at the 0.3 mg/kg dose level during the first infusion. This patient was continued at a decreased dose of 0.2 mg/kg for all
10 subsequent infusions. Because of the change in dose, this patient is evaluated in the 0.2 mg/kg cohort for efficacy and in the 0.3 mg/kg for safety.

 Only one patient in the lowest dose cohort and both patients in the highest dose level completed the study through Day 72. Four of the six patients in the 0.1 mg/kg dose group completed the study, and 4 of the 7 in the 0.2 mg/kg dose group
15 completed. All patients who demonstrated a complete response also completed this study through Day 72.

3. Safety:

20 All patients who received any amount of ABX-CBL were evaluated for safety. ABX-CBL was well tolerated with the exception of myalgia, which became the Dose Limiting Toxicity (DLT). The incidence of myalgia increased in relationship to an increase in the dose administered. This led to the Maximum Tolerated Dose (MTD) at 0.3 mg/kg. The onset of the myalgia ranged from 20-60 minutes into the infusion
25 and usually resolved within 1-2 hours after the completion of the infusion. Of the 14 patients who experienced any grade of myalgia, two required being withdrawn from this study due to the myalgia. All myalgias resolved without sequelae except for one patient in whom myalgia persisted. This last incidence is under further evaluation and clarification. Table 6 summarizes the incidence of myalgia by severity and dose.
30 Patients with adverse events listed as myalgia graded as "not related" or "unlikely" and with a baseline disease of myalgia are not included in the this table.

TABLE 10

INCIDENCE OF MYALGIA AND OUTCOME								
	0.01 mg/kg (n=9)		0.1 mg/kg (n=7)		0.3 mg/kg (n=3)		0.2 mg/kg (n=8)	
SEVERITY	n (%)	Study status	n (%)	Study status	n (%)	Study status	n (%)	Study status
SEVERE			1	W/D	1 1	con't dec. dose	3 1	con't W/D
MODERATE	2	Con't	1	Con't			1	Con't
MILD	1	Con't	1	Con't			1	Con't

W/D = withdrew from the study related to the myalgia

5

Abgenix continues to investigate the causality of myalgia and any possible inter-relationships. The following causes have been ruled out as a predisposing factor to those who do develop myalgia:

- 10
- alteration in electrolytes
 - responders vs non responders
 - type of transplant
 - type of donor
 - steroid dose

15

Eleven Serious Adverse Experiences in eleven patients have been reported with ABX-CBL. Five "severe" events, all myalgia related, are listed as "probable" for the relationship to ABX-CBL. One event, "hepatic failure of unknown etiology" is listed as "suspected". The remaining SAEs are listed as "unlikely" or "not related".

20

Twenty-three of these events were evaluated as probably related to ABX-CBL and 7 as suspected. All other events were reported as "unlikely" or "not related".

Of the 23 "probable" adverse events, all except 2 were myalgia related. One patient experienced moderate "fatigue" which resolved without sequelae. The other experienced moderate "hemolysis" which resolved with a sequelae of increased Liver Function Tests (LFT).

25

Of the seven events evaluated as "suspected" to be related to ABX-CBL, 1 event was severe, 4 were moderate, and 2 were mild in severity. All of these events resolved without sequelae. The severe event was "edema". The four moderate events occurred in 4 patients and consisted of "moderate decrease in uric acid", "fever/chills", "hypotension", and "fever". The two mild events occurred in two patients and consisted of "low grade fever following study drug" and "chills".

HAMA testing on all 27 patients has been negative through the patients' last study visit.

Lymphocyte counts were drawn from all patients just prior to the first infusion and at regular intervals throughout the study. Of the patients who enrolled into ABX-CB-9701, approximately 50% could not be evaluated on the basis of the immunocompromised state secondary to both BMT and their ongoing GvHD. Patients who are post stem cell transplant are immunodeficient secondary to their conditioning regimen as well as an exacerbation of their immunodeficient state from acute GvHD. To date, ABX-CBL does not appear to have an untoward effect on the T-cell counts.

Phase II Clinical Trial of ABX-CBL -- Rescue Protocol

As patients completed the above-described Phase II trial, we also initiated a second Phase II continuation trial for such patients to continue to receive ABX-CBL for any flares of GVHD experienced. The continuation trial was designed as an open-label clinical trial for patients with acute GVHD who have previous exposure to ABX-CBL. Those patients who had acute GVHD of grades II/III/IV severity, as discussed above, were eligible.

In the trial, all patients are receiving, or will receive, up to 7 intravenous doses (1st treatment course) of ABX-CBL. The medication will be infused over 2 hours via a syringe pump for 7 consecutive days. The dose will be 0.2 mg/kg (approximate dose used effectively in clinical trial described above. If the first treatment course produced a therapeutic effect (complete or partial response), patients may receive a second treatment course prior to the onset of chronic GVHD, or day 200 post primary transplant whichever is reached first. The second treatment course with ABX-CBL

will be handled on a case by case basis through a discussion with the medical monitor and the investigator.

The objectives of this trial were as follows:

5 To assess the safety of continued dosing with ABX-CBL in patients with acute GVHD.

To determine the clinical effect of repeat treatments of ABX-CBL in patients with flare of acute GVHD or patients who were previous treatment failures with ABX-CBL.

10 To allow treatment for patients who failed to demonstrate a clinical effect at a lower dose of ABX-CBL and/or to provide treatment for previous responders to ABX-CBL who are experiencing a flare of their acute GVHD.

To assess flare rates after initial treatment with ABX-CBL.

15 All of the procedures described above in connection with the initial clinical trial were utilized in connection with this study, with only minor modifications.

Dosing, Dose Regimen, and Treatment with ABX-CBL

20 In view of the foregoing discussion and results, ABX-CBL provides a profound treatment for GVHD and likely other disease etiologies wherein lymphatic cells are deleteriously or undesirably activated. The results presented herein demonstrate that through administration of a dose of ABX-CBL greater than about 0.1 mg/kg and less than about 0.4 mg/kg of the antibody is efficacious in connection with
25 the treatment of such disease etiologies. Preferably, the dose is from about 0.1 mg/kg to about 0.3 mg/kg and more preferably from about 0.15 mg/kg to about 0.2 mg/kg. Further, the dosing regimen disclosed herein of an induction regimen (plural daily infusions, herein daily for 7 days) followed by a maintenance regimen (periodic infusions, herein twice weekly for two weeks) appears to assist in remission of GVHD
30 and certainly lessens the severity of patients' GVHD between flares of the disease.

As will be appreciated, both the purified ABX-CBL, discussed in detail in the present invention and other anti-CD147 antibodies, such as those discussed herein, will be similarly efficacious.

In addition to GVHD, therapeutics in accordance with the present invention will likely be efficacious with respect to diseases having an etiology characterized by a harmful presence of activated T cells, B cells, or monocytes. As an example, GVHD is one such disease. However, many inflammatory diseases and autoimmune diseases can be characterized as sharing such an etiology. Further the therapies of the invention will likely be efficacious in the following disease etiologies, including, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases (including without limitations arthritis, rheumatoid arthritis), and others.

EXPERIMENT 22 **SURROGATE ANTIBODIES THAT BIND TO MURINE GP42 FOR ANIMAL MODELS**

As discussed above, certain animal models are contemplated in connection with the present invention. One of the simplest animal models is the mouse. The 2.6.1 antibody did not bind to mouse gp42 (basigin or mouse CD147). Accordingly, we undertook the generation of anti-mouse gp42 antibodies from rats that could be utilized as a surrogate antibody to ABX-CBL and/or the 2.6.1 antibodies for use in such models. Described below is cloning strategy utilized to prepare fusion proteins for immunization of rats and the preliminary characterization of antibodies generated therefrom. The cloning strategy described below is further detailed in Figures 51 and 52.

Cloning of Hu-CD147IgG2 fusion protein

The following PCR primers were utilized, based on the CD147 sequence reported by Miyauchi et al. *J.Biochem.*110:770-774 (1991) (Gene Bank Accession # D45131) :

5 prime: 5'-GACTACGAATTCGGACCGGCGAGGAATAGGAATCATG-3' (SEQ ID NO:58) and

5 3 prime: 5'-GGATGGTGTGTTGGTAGCTAGCACGCGGAGCGTGATGATGGCCTG-3' (SEQ ID NO:59)

A 626bp PCR product was amplified from CD147/pBKCMV plasmid DNA template that encoded the amino terminal 202 amino acid residues of the extracellular domain of CD147. The PCR product was digested with EcoR1 and Nhe1 and ligated into pIK1.1Hu-CD4IgG2 expression vector digested with EcoR1 and Nhe1. The resulting construct, pIKHu-CD147IgG2 encodes a fusion protein consisting of the N-terminal 202 amino acids of CD147 the last four C-terminal residues of the extracellular domain of CD4 in frame with the hinge CH2 and CH3 domains of Hu IgG2.

Cloning of Mu-GP42IgG2 fusion protein

The following PCR primers were utilized, based on the GP42 sequence reported by Kanekura et al. *Cell Struct. Funct.* 16:23-30 (1991) (Gene Bank Accession # Y16256):

5 prime: 5'-GACTACGAATTCACGAGGCGACATGGCGGCGGC-3' (SEQ ID NO:60) and

25 3 prime: 5'-GGATGGTGTGTTGGTAGCTAGCACACGCAGTGAGATGGTTTCCCG-3' (SEQ ID NO:61)

A 659bp PCR product was amplified from mouse lymph node cDNA and encodes the amino terminal 206 amino acid residues of the extracellular domain of GP42. The PCR product was digested with EcoR1 and Nhe1 and ligated into

pIK1.1Hu- CD4IgG2 expression vector digested with EcoR1 and Nhe1 to create pIKMu-GP42 IgG2.

Stable CHO Cell line Engineering

5

The EcoR1/Bgl2 fragments from pIKHu-CD147IgG2 and pIKMu-GP42IgG2 were cloned into the expression vector pWBFNP DHFR digested with EcoR1/Bgl2. PWBFP DHFR is a derivative of pWBFNP into which a DHFR cDNA under the transcriptional control of SV40 promoter/enhancer and SV40 poly A is cloned at the Not1 site. The resulting constructs, Hu-CD147IgG2 DHFR and Mu-GP42IgG2 DHFR were introduced into DHFR deficient CHO cell lines by CaPo₄ mediated transfection. Stable lines were selected for their ability to grow in the absence of exogenous thymidine, glycine and purines. Clones secreting elevated levels of fusion proteins as judged by SDS-PAGE were suspension adapted to spinner flasks in serum-free media. Mu-GP42IgG2 and Hu-CD147IgG2 fusion proteins were purified from culture media by protein A chromatography.

Following generation of the fusion proteins, rats were immunized using conventional techniques and hybridomas generated also using conventional techniques. Antibodies secreted by such hybridomas could then be utilized as surrogate antibodies in certain animal models, particularly, murine models.

INCORPORATION BY REFERENCE

All references cited herein, including patents, patent applications, papers, text books, and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated herein by reference in their entirety.

EQUIVALENTS

The foregoing description, Figures, and Examples detail certain preferred embodiments of the invention and describes the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the invention may be practiced in many ways and the invention

should be construed in accordance with the appended claims and any equivalents thereof.

CLAIMSWHAT WE CLAIM IS:

1. An isolated monoclonal antibody having an isotype that fixes
5 complement and a variable region that binds to the epitope on CD147 bound by the
IgM monoclonal antibody ABX-CBL, with the proviso that the antibody is not CBL1.
2. The antibody of Claim 1, wherein the antibody in the presence of
complement acts to selectively kill cells selected from the group consisting of
activated T-cells, activated B-cells, and monocytes but is substantially non-toxic to
10 resting T-cells and resting B-cells.
3. The antibody of Claim 1, wherein the antibody is a human antibody.
4. The antibody of Claim 1, wherein the isotype is selected from the
group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human
IgM, human IgG1, and human IgG3.
- 15 5. The antibody of Claim 2, wherein the antibody is a human antibody.
6. The antibody of Claim 2, wherein the isotype is selected from the
group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human
IgM, human IgG1, and human IgG3.
7. An isolated monoclonal antibody having an isotype that fixes
20 complement and a variable region that binds to CD147 on populations of activated T-
cells, activated B-cells, and resting or activated monocytes, that, in the presence of
complement, selectively depletes such populations through complement mediated
killing while being substantially nontoxic to other cells, with the proviso that the
antibody is not CBL1.
- 25 8. The antibody of Claim 7, wherein the antibody is a human antibody.
9. The antibody of Claim 7, wherein the isotype is selected from the
group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human
IgM, human IgG1, and human IgG3.
10. An isolated monoclonal antibody having the following characteristics:
30 (a) binds to CD147;
(b) shows a binding against CEM cell lysates on Western blot
similar to that provided in Figure 1;

- (c) an isotype selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3;
- (d) competes with ABX-CBL for binding to CD147;
- 5 (e) cross reacts with hn-RNP-k protein;
- (f) binds to a consensus sequence on CD147 comprising RVRSS;
- (g) selectively kills activated T-cells, activated B-cells, and monocytes in a MLR assay only in the presence of complement; and
- 10 (h) is substantially non-toxic to cells expressing CD55 and CD59, with and without the presence of complement,

with the proviso that the antibody is not CBL1.

11. A method to select an anti-CD147 antibodies for the treatment of disease, comprising:

- 15 generating antibodies that bind to CD147 and that are capable of binding complement;
- assaying the antibodies for one or more of the following properties:
- (a) competition with ABX-CBL for binding to CD147;
- (b) capability to selectively kill activated T-cells, activated B-cells, and
- 20 monocytes in a MLR assay only in the presence of complement; and
- (c) being substantially non-toxic to cells expressing CD55 and CD59, with and without the presence of complement,
- with the proviso that the antibody is not CBL1.
- 25 12. The method of Claim 11, further comprising the following property:
- (d) binding to CEM cell lysates on Western blot in a manner similar to that provided in Figure 1.
13. The method of Claim 11, further comprising the following property:
- (e) binding to a consensus sequence in a peptide of RXRS.
- 30 14. The method of Claim 11, further comprising the following property:
- (f) cross reacts with hn-RNP-k protein.
15. The method of Claim 11, further comprising the following property:

(g) binding to a form of CD147 expressed by COS cells and *E. coli* cells.

16. A method to treat disease, comprising providing an antibody that has an isotype that fixes complement and a variable region that binds to CD147 on populations of activated T-cells, activated B-cells, and resting or activated monocytes, that, in the presence of complement, selectively depletes such populations through complement mediated killing while being substantially nontoxic to other cells, with the proviso that the antibody is not CBL1.

17. The method of Claim 16, wherein the antibody is a human antibody.

18. The method of Claim 16, wherein the isotype is selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

19. A method to treat GVHD, comprising providing an antibody that has an isotype that fixes complement and a variable region that binds to CD147 on populations of activated T-cells, activated B-cells, and resting or activated monocytes, that, in the presence of complement, selectively depletes such populations through complement mediated killing while being substantially nontoxic to other cells, with the proviso that the antibody is not CBL1.

20. The method of Claim 19, wherein the antibody is a human antibody.

21. The method of Claim 19, wherein the isotype is selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

22. A monoclonal antibody that binds to an epitope on CD147 comprising the consensus sequence RVRSH, wherein the antibody is not CBL1.

23. The antibody of Claim 22, wherein the antibody is a human antibody.

24. An isolated peptide comprising the sequence selected from the group consisting of RXRS, RXRSH, RVRS, and RVRSH.

25. Use of the peptide of Claim 24 for the generation of antibodies.

26. A human monoclonal antibody that binds to CD147.

27. A kit for the treatment of diseases having an etiology characterized by a harmful presence of activated T cells, B cells, or monocytes, comprising:

(a) a liquid preparation comprising an amount of an anti-CD147 antibody in a pharmaceutically acceptable carrier and

(b) instructions on administering said preparation to a patient suffering from a disease having the etiology characterized by a harmful presence of activated T cells, B cells, or monocytes to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody.

28. The kit of Claim 27, wherein the antibody comprises ABX-CBL.

29. The kit of Claim 27, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

30. The kit of Claim 27, wherein the disease comprises GVHD.

31. An article of manufacture for use in the treatment of diseases having an etiology characterized by a harmful presence of activated T cells, B cells, or monocytes, comprising:

(a) a sterile vial;

(b) an anti-CD147 monoclonal antibody in a pharmaceutically acceptable carrier contained within the vial; and

(c) instructions for administration of the antibody to a patient suffering from such a disease in a manner to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

32. The article of Claim 31, wherein the antibody comprises ABX-CBL.

33. The article of Claim 31, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

34. The kit of Claim 31, wherein the disease comprises GVHD.

35. A kit for the treatment of diseases having an etiology characterized by
5 a harmful presence of activated T cells, B cells, or monocytes, comprising:

(a) a liquid preparation comprising an amount of an anti-CD147
antibody designated ABX-CBL in a pharmaceutically acceptable carrier and

(b) instructions on administering said preparation to a patient suffering
10 from a disease having the etiology characterized by a harmful presence of
activated T cells, B cells, or monocytes in a series of administrations to
provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of
the antibody in each administration.

36. The kit of Claim 35, wherein the instructions further include
15 instructions for the administration of the antibody in a series of administrations to
provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the
antibody in each administration.

37. The kit of Claim 35, wherein the disease comprises GVHD.
20

38. An article of manufacture for use in the treatment of diseases having an
etiology characterized by a harmful presence of activated T cells, B cells, or
monocytes, comprising:

(a) a sterile vial;

25 (b) an anti-CD147 monoclonal antibody designated ABX-CBL in a
pharmaceutically acceptable carrier contained within the vial; and

(c) instructions for administration of the antibody to a patient suffering
from such a disease in a manner to provide a dosage in the range of from about
0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.
30

39. The article of Claim 38, wherein the instructions further include
instructions for the administration of the antibody in a series of administrations to

provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

40. The article of Claim 38, wherein the disease comprises GVHD.

41. A kit for the treatment GVHD, comprising:

(a) a liquid preparation comprising an amount of an anti-CD147 antibody in a pharmaceutically acceptable carrier and

(b) instructions on administering said preparation to a patient suffering from GVHD in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

42. The kit of Claim 41, wherein the antibody comprises ABX-CBL.

43. The kit of Claim 41, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

44. An article of manufacture for use in the treatment of GVHD, comprising:

(a) a sterile vial;

(b) an anti-CD147 monoclonal antibody in a pharmaceutically acceptable carrier contained within the vial; and

(c) instructions for administration of the antibody to a patient suffering from GVHD in a manner to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

45. The article of Claim 44, wherein the antibody comprises ABX-CBL.

46. The article of Claim 44, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

5

47. A kit for the treatment of GVHD, comprising:

- (a) a liquid preparation comprising an amount of an anti-CD147 antibody designated ABX-CBL in a pharmaceutically acceptable carrier and
 - (b) instructions on administering said preparation to a patient suffering
- 10 from GVHD in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

48. The kit of Claim 47; wherein the instructions further include

15 instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

49. An article of manufacture for use in the treatment of GVHD,

20 comprising:

- (a) a sterile vial;
 - (b) an anti-CD147 monoclonal antibody designated ABX-CBL in a pharmaceutically acceptable carrier contained within the vial; and
 - (c) instructions for administration of the antibody to a patient suffering
- 25 from GVHD in a manner to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

50. The article of Claim 49, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to

30 provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

51. A pharmaceutical composition, comprising an anti-CD147 monoclonal antibody designated ABX-CBL in a pharmaceutically acceptable diluent, buffer, or excipient.

5 52. The pharmaceutical composition of Claim 51, wherein the antibody is provided in a dosage from about 0.1 mg/kg and about 0.2 mg/kg.

53. A method for the treatment of diseases having an etiology characterized by a harmful presence of activated T cells, B cells, or monocytes,
10 comprising administering a liquid preparation comprising an amount of an anti-CD147 antibody in a pharmaceutically acceptable carrier to a patient suffering from such disease.

54. The method of Claim 53, wherein the antibody comprises ABX-CBL.
15

55. The method of Claim 53, wherein the administration is conducted to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

20 56. The method of Claim 53, wherein the disease comprises GVHD.

57. A method for the treatment of GVHD comprising administering a liquid preparation comprising an amount of an anti-CD147 antibody in a pharmaceutically acceptable carrier to a patient suffering from GVHD.
25

58. The method of Claim 57, wherein the antibody comprises ABX-CBL.

59. The method of Claim 57, wherein the administration is conducted to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.
30

60. The human antibody according to Claim 26, wherein the heavy chain has an amino acid sequence selected from the group consisting of: SEQ ID NO: 23; SEQ ID NO: 25; SEQ ID NO: 27; SEQ ID NO: 29; SEQ ID NO: 31; SEQ ID NO: 33; SEQ ID NO: 35; SEQ ID NO: 37; SEQ ID NO: 39; SEQ ID NO: 40; and SEQ ID NO:

5

61. The human antibody according to claim 26, wherein the light chain has an amino acid sequence selected from the group consisting of: SEQ ID NO: 24; SEQ ID NO: 26; SEQ ID NO: 28; SEQ ID NO: 30; SEQ ID NO: 32; SEQ ID NO: 34; SEQ ID NO: 36; SEQ ID NO: 38; and SEQ ID NO: 41.

10

15

1/52




FIG. 1

2/52




FIG. 2A




FIG. 2B

3/52




FIG.3

4/52




FIG.4

5/52




FIG.5

6/52




FIG. 6B






FIG. 6A

7/52



8/52





FIG. 8B



M1: CD25 high depleted
M2: CD25 low undepleted
M3: CD25 null undepleted

9/52




FIG. 9B




FIG. 9D




FIG. 9A










FIG. 9C



10/52






FIG. 11A




FIG. 11C




FIG. 11E




FIG. 11B




FIG. 11D




FIG. 11F

12/52

CELL TYPE	SURFACE MARKERS	CDC DEPLETION
RESTING T CELLS	CD3 ⁺ CD25 ⁻	NO
ACTIVATED T CELLS	CD3 ⁺ (CD4 ⁺ /CD8 ⁺)CD25 ⁺	YES
RESTING B CELLS	CD20 ⁺ CD25 ⁻	NO
ACTIVATED B CELLS	CD20 ⁺ CD25 ⁺	YES
RESTING MONOCYTES	CD14 ⁺ CD25 ⁻	YES
ACTIVATED MONOCYTES	CD14 ⁺ CD25 ⁺	YES

FIG.12

CELL	CELL TYPE	CBL Ag EXPRESSION	CBL CDC
CEM	T CELL	++	+
JURKAT	T CELL	++	-
U937	MONOCYTE	++	+
A431	EPIDERMAL	++	-
SW948	COLON	+++	-
MDA468	BREAST	+	-

FIG.13

13/52

CELL	CELL TYPE	CBL EXPRESSION	CBL CDC	CD55	CD59
CEM	T CELL	++	+	-	+
JURKAT	T CELL	++	-	+	+
U937	MONOCYTE	++	+	+	-
A431	EPIDERMAL	++	-	+	+
SW948	COLON	+++	-	+	+
MDA468	BREAST	+	-	+	+

FIG.14

14/52




FIG. 15A




FIG. 15B




FIG. 15C

15/52




FIG. 16A




FIG. 16B




FIG. 16C

16/52




FIG. 17

17/52


ABX - CBL CONCENTRATION ($\mu\text{g/ml}$)

FIG. 18

18/52




FIG. 19A




FIG. 19B




FIG. 19C

19/52




FIG. 20A




FIG. 20B




FIG. 20C

20/52




FIG.21

21/52




FIG.22

22/52




FIG.23A

23/52




FIG.23B

IgM Antibody Sequences

24/52

CEM 10.1 C3 Heavy cDNA

GGACTGTTGA	AGCCTTCGGA	GACCCTGTCC	CTCACCTGCG	CTGTCTATGG	50
TGGGTCCTTC	AGTGGTTACT	ACTGGAGCTG	GATCCGCCAG	CCCCCAGGGA	100
AGGGGCTGGA	GTGGATTGGG	GAAATCAATC	ATAGTGGAAG	CACCAACTAC	150
AACCCGTCCT	TCAAGAGTCG	AGTCACCATA	TCAGTAGACA	CGTCCAAGAA	200
CCAGTTCTCC	CTGAAGCTGA	GCTCTGTGAC	CGCNGCGGAC	ACGGCTGTGT	250
ATTACTGTGC	GAGAGGCACT	ACGGAATATT	ACTACTACTA	CTACGGTATG	300
GACGTCTGGG	GCCAAGGGAC	CACGGTCACC	GTCTCCTCAG	GGAGTGCATC	350
CGCCCCAACC	CTTTTCCCCC	TCGTCTCCTG	TGAGAATTCC	CCGTCCGATA	400
CGAGCAGCGT	GGCCGTTGGC	TGCCTCGCAC	AGGACTTCCT	TCCCGACTYC	450
ATCACTTTCT	CCTGGAAATA	CAAGAACAAC	TCTGACATCA	GCAGCACCCG	500
GGGCTTCCCA	TCAGTCCTGA	GAGGGGGCAA	GTACGCAGCC	ACCTCACAGG	550
TGCTGCTGCC	TTCCAAGGAC	GTCATGCAGG	GCACAGACGA	ACACGTGGTG	600
ACGGGATCCA	AAGAGTA				617

(SEQ ID NO:62)

CEM 10.1 C3 Heavy Protein

GLLKPSETLS	LTCAVYGGSF	SGYYWSWIRQ	PPGKGLEWIG	EINHSGSTNY	50
NPSLKSRTVI	SVDTSKNQFS	LKLSSVTAAD	TAVYYCARGT	TEYYYYYYGM	100
DVWGQGTTVT	VSSGSASAPT	LFPLVSCENS	PSDTSSVAVG	CLAQDFLPDX	150
ITFSWKYKNN	SDISSTRGFP	SVLRGGKYAA	TSQVLLPSKD	VMQGTDEHVV	200
TGSKE					205

(SEQ ID NO:23)

CEM 10.1 C3 Kappa cDNA

CTCTCCCTGC	CCGTCACCCC	TGGAGAGCCG	GCCTCCATCT	CCTGCAGGTC	50
TAGTCAGAGC	CTCCTGCATA	GTAATGGATA	CAACTATTTG	GATTGGTACC	100
TGCAGAAGCC	AGGGCAGTCT	CCACAGCTCC	TGATCTATTT	GGGTTCTAAT	150
CGGGCCTCCG	GGGTCCCTGA	CAGGTTCACT	GGCAGTGGAT	CAGGCACAGA	200
TTTTACACTG	AAAATCAGCA	GAGTGGAGGC	TGAGGATGTT	GGGATTTATT	250
ACTGCATGCA	GACTCGACAA	ACTCCTCGGA	CGTTCGGCCA	AGGGACCAAG	300
GTGGAAATCA	AACGAACTGT	GGCTGCACCA	TCTGTCTTCA	TCTTCCC GCC	350
ATCTGATGAG	CAGTTGAAAT	CTGGAAGTGC	CTCTGTTGTG	TGCCTGCTGA	400
ATAACTTCTA	TCCCAGAGAG	GCCAAAGAGC	ATCAAAAGAG	TCCA	444

(SEQ ID NO:63)

CEM 10.1 C3 Kappa Protein

LSLPVTPGEP	ASISCRSSQS	LLHSNGYNYL	DWYLQKPGQS	POLLIYLGSN	50
RASGVDPDRF	SGSGTDFTL	KISRVEAEDV	GIYYCMQTRQ	TPRTFGQGTR	100
VEIKRTVAAP	SVFIFPPSDE	QLKSGTASVV	CLLNNFYPRE	AKEHQKSP	148

(SEQ ID NO:24)

FIG. 24

IgM Antibody Sequences

25/52

CEM 10.1 G10 Heavy cDNA

CTGGTGAAGC	CTTCGGAGAC	CCTGTCCCTC	ACCTGCACTG	TCTCTGGTGG	50
CTCCATCAGT	AGTTACTACT	GGAAGTGGAT	CCGGCAGCCC	CCAGGGAAGG	100
GACTGGAGTG	GATTGGGTAT	ATCTATTACA	GTGGGAGCAC	CAACTACAAC	150
CCCTCCCTCA	AGAGTCGAGT	CACCATATCA	GTAGACACGT	CCAAGAACCA	200
GTTCTCCCTG	AAGCTGAGCT	CTGTGACCGC	TGCGGACACG	GCCGTGTATT	250
ACTGTGCGAG	AGATAGGGGA	GTGGGAGCTA	CTGGTTTTGA	CTACTGGGGC	300
CAGGGAACCC	TGGTCACCGT	CTCCTCAGGG	AGTGCATCCG	CCCCAACCCCT	350
TTTCCCCCTC	GTCTCCTGTG	AGAATTCCCC	GTCGGATACG	AGCAGCGTGG	400
CCGTTGGCTG	CCTCGCACAG	GACTTCCTTC	CCGACTCCAT	CACTTTCTCC	450
TGGAAATACA	AGAACAACCTC	TGACATCAGC	AGCACCCGGG	GCTTCCCATC	500
AGTCCTGAGA	GGGGGCAAGT	ACGCAGCCAC	CTCACAGGTG	CTGCTGCCTT	550
CCAAGGACGT	CATGCAGGGC	ACAGACGAAC	ACAAGGTGTG	CGA	593

(SEQ ID NO:64)

CEM 10.1 G10 Heavy Protein

LVKPSETLSL	TCTVSGGSIS	SYYNWIRQP	PGKGLEWIGY	IYYSGSTNYN	50
PSLKSRTVIS	VDTSKNQFSL	KLSSVTAADT	AVYYCARDRG	VGATGFDYWG	100
QGTLVTVSSG	SASAPTLFPL	VSCENSPSDT	SSVAVGCLAQ	DFLPDSITFS	150
WKYKNNSDIS	STRGFPSVLR	GGKYAATSQV	LLPSKDVMQG	TDEHKVC	197

(SEQ ID NO:25)

CEM 10.1 G10 Kappa cDNA

AGCCAGTCTC	CATCCTCCCT	GTCTGCATCT	GTAGGAGAGA	GAGTCACCAT	50
CACTTGCCGG	GCAAGTCAGG	GCATTAGAGA	TGAATTAGGC	TGGTATCAGC	100
AGAAACCAGG	GAAAGCCCCT	AAGCGCCTGA	TCTATGTTGC	ATCCAGTTTG	150
CAAAGTGGGG	TCCCATCAAG	G TTCAGCGGC	AGTGGATCTG	GGACAGAATT	200
CACTCTCACA	ATCAGCAGCC	TGCAGCCTGA	AGATTTTGCA	ACTTATTACT	250
GTCTACAGCA	TAATGGTTAC	CCTCGGACGT	TCGGCCAAGG	GACCAAGGTG	300
GAAATCAAAC	GAAGTGTGGC	TGCACCATCT	GTCTTCATCT	TCCCGCCATC	350
TGATGAGCAG	TTGAAATCTG	GAAGTGCCTC	TGTTGTGTGC	CTGCTGAATA	400
ACTTCTATCC	CAGAGAGGCC	AAAGAGCATC	AAAAGAGTCC	A	441

(SEQ ID NO:65)

CEM 10.1 G10 Kappa Protein

SQSPSSLSAS	VGERVTITCR	ASQGIRDELG	WYQQKPGKAP	KRLIYVASSL	50
QSGVPSRFSG	SGSGTEFTLT	ISSLPEDFA	TYCYLQHNGY	PRTFGQGTKV	100
EIKRTVAAPS	VFIFPPSDEQ	LKSGTASVVC	LLNMFYPREA	KEHQKSP	147

(SEQ ID NO:26)

FIG. 25

IgM Antibody Sequences

26/52

CEM 10.12 F3 Heavy cDNA

AAGAAGCCTG	GGGCCTCAGT	GAAGGTCTCC	TGCAAGGCTT	CTGGATACAC	50
CTTCACCAGT	TATGATATCA	ACTGGGTGCG	ACAGGCCACT	GGACAAGGGC	100
TTGAGTGGAT	GGGATGGATG	AACCCTAACA	GTGGTAACAC	AGGCTATGCA	150
CAGAAGTTCC	AGGGCAGAGT	CACCATGAAC	AGGAACACCT	CCATAAGCAC	200
AGCCTACATG	GAGCTGAGCA	GCCTGAGATC	TGAGGACACG	GCCGTGTATT	250
ACTGTGCGAG	AGGGGGTCAT	GGTGGGAGCT	ACTTCTACTC	CTAYTACGGT	300
ATGGACGTCT	GGGGCCAGGG	GACCACGGTC	ACCGTCTCCT	CAGGGAGTGC	350
ATCCGCCCCA	ACCCTTTTCC	CCCTCGTCTC	CTGTGAGAAT	TCCCCGTCGG	400
ATACGAGCAG	CGTGGCCGTT	GGCTGCCTCG	CACAGGACTT	CCTTCCCGAC	450
TCCATCACTT	TCTCCTGGAA	ATACAAGAAC	AACTCTGACA	TCAGCAGCAC	500
CCGGGGCTTC	CCATCAGTCC	TGAGAGGGGG	CAAGTACGCA	GCCACCTCAC	550
AGGTGCTGCT	GCCTTCCAAG	GACGTCATGC	AGGGCACAGA	CGAACACGTG	600
GTGTGCAAAC					610

(SEQ ID NO:66)

CEM 10.12 F3 Heavy Protein

KKPGASVKVS	CKASGYTFTS	YDINWVRQAT	GQGLEWMGWM	NPNSGNTGYA	50
QKFQGRVTMN	RNTSISTAYM	ELSSLRSED	AVYYCARGGH	GGSYFYSYYG	100
MDVWGQGTTV	TVSSGSASAP	TLFPLVSCEN	SPSDTSSVAV	GCLAQDFLPD	150
SITFSWKYKN	NSDISSTRGF	PSVLRGGKYA	ATSQVLLPSK	DVMQGTDEHV	200
VCK					203

(SEQ ID NO:27)

CEM 10.12 F3 Kappa cDNA

CACTCCCTGG	CTGTGTCTCT	GGGCGAGAGG	GCCACCATCA	ACTGCAAGTC	50
CAGCCAGAGT	GTTTTATACA	GTTTTAACAA	TAAGAACTAC	TTAGCTTGGT	100
ACCAGCAGAA	ACCAGGACAG	CCTCCTAAGC	TGCTCATTTA	CTGGGCATCT	150
ACCCGGGAAT	CCGGGGTCCC	TGACCGATT	GGTGGCAGCG	GGTCTGGGAC	200
AGATTTCACT	CTCACCATCA	GCAGCCTGCA	GGCTGAAGAT	GTGGCAGTTT	250
ATTACTGTCA	GCAATATTAT	AGTACTCCTM	GGACGTTTCG	CCAAGGGACC	300
AAGGTGGAAA	TCAAACGAAC	TGTGGCTGCA	CCATCTGTCT	TCATCTTCCC	350
GCCATCTGAT	GAGCAGTTGA	AATCTGGAAC	TGCCTCTGTT	GTGTGCCTGC	400
TGAATAACTT	CTATCCCAGA	GAGGCCAAAG	AGCATCAAAA	GAGTCCA	447

(SEQ ID NO:67)

CEM 10.12 F3 Kappa Protein

HSLAVSLGER	ATINCKSSQS	VLYSFNNKNY	LAWYQQKPGQ	PPKLLIYWAS	50
TRESGVPDRF	GGSGSGTDFT	LTISSLQAE	VAVYYCQQYY	STPRTFGQGT	100
KVEIKRTVAA	PSVFIFPPSD	EQLKSGTASV	VCLLNNFYPR	EAKEHQKSP	149

(SEQ ID NO:28)

FIG. 26

SUBSTITUTE SHEET (RULE 26)

IgM Antibody Sequences

27/52

CEM 10.12 G5 Heavy

GAGGTGAAGA	AGCCTGGGGC	CTCAGTGAAG	GTCTCCTGCA	AGGCTTCTGG	50
ATACACCTTC	ACCAGTTATG	ATATCAACTG	GGTGCGACAG	GCCACTGGAC	100
AAGGGCTTGA	GTGGATGGGA	TGGATGAACC	CTAACAGTGG	TAACACAGGC	150
TATGCACAGA	AGTTCCAGGG	CAGAGTCACC	ATGACCAGGA	ACACCTCCAT	200
AAGCACAGCC	TACATGGAGC	TGAGCAGCCT	GAGATCTGAG	GACACGGCCG	250
TGTATTACTG	TGCGAGAGAG	GAGTGGCTGG	TACGTTACTA	CGGTATGGAC	300
GTCTGGGGCC	AAGGGACCAC	GGTCACCGTC	TCCTCAGGGA	GTGCATCCGC	350
CCCAACCCCTT	TTCCCCCTCG	TCTCCTGTGA	GAATTCCCCG	TCGGATACGA	400
GCAGCGTGGC	CGTTGGCTGC	CTCGCACAGG	ACTTCCTTCC	CGACTCCATC	450
ACTTTCTCCT	GGAAATACAA	GAACAACTCT	GACATCAGCA	GCACCCGGGG	500
CTTCCCATCA	GTCCTGAGAG	GGGGCAAGTA	CGCAGCCACC	TCACAGGTGC	550
TGCTGCCTTC	CAAGGACGTC	ATGCAGGGCA	CAGACGAACA	CAAGGTGTG	599

(SEQ ID NO:68)

CEM 10.12 G5 Heavy Protein

EVKKPGASVK	VCKASGYTF	TSYDINWVRQ	ATQGQLEWMG	WMNPNSGNTG	50
YAQKFQGRVT	MTRNTSISTA	YMESSLRSE	DTAVYYCARE	EWLVRYYGMD	100
VWGQGTTVTV	SSGSASAPTL	FPLVSCENSP	SDTSSVAVGC	LAQDFLPDSI	150
TFSWKYKNNS	DISSTRGEPS	VLRGGKYAAT	SQVLLPSKDV	MQGTDEHKV	199

(SEQ ID NO:29)

CEM 10.12 G5 Kappa cDna

GGCCAGTCTC	CATCCTCCCT	GTCTGCATCT	GTAGGAGACA	GAGTCACCAT	50
CACTTGCCGG	GCAAGTCAGG	ACATTAGAGA	TAATTTAGGC	TGGTATCAGC	100
AGAAACCAGG	GAAAGCCCCT	AAGCGCCTGA	TCTATGCTGC	ATCCAATTTG	150
CAAAGTGGGG	TCCCATCAAG	GTTCAGCGGC	AGTGGATCTG	GGACAGAATT	200
CACTCTCACA	ATCAGCAGCC	TGCAGCCTGA	AGATTTTGCA	ACTTATTACT	250
GTCTACAGTA	TAAAACTTAC	CCGTGGACGT	TCGGCCAAGG	GACCAAGGTG	300
GAAATCAAAC	GAAGTGTGGC	TGCACCATCT	GTCTTCATCT	TCCCGCCATC	350
TGATGAGCAG	TTGAAATCTG	GAAGTGCCTC	TGTTGTGTGC	CTGCTGAATA	400
ACTTCTATCC	CAGAGAGGMC	AAAGAGCATC	AAAAGAGTCC	A	441

(SEQ ID NO:69)

CEM 10.12 G5 Kappa Protein

GQSPSSLSAS	VGDRVITICR	ASQDIRDNLG	WYQQKPGKAP	KRLIYAASNL	50
QSGVPSRFSG	SGSGTEFTLT	ISSLQPEDFA	TYCYLQYKTY	PWTFGQGTKV	100
EIKRTVAAPS	VFIFPPSDEQ	LKSGTASVVC	LLNNFYPREX	KEHQKSP	147

(SEQ ID NO:30)

FIG. 27

IgM Antibody Sequences

28/52

CEM 13.12 Heavy cDNA

AAGCTTCCGG	AGACCCTGTC	CCTCACCTGC	GCTGTCTATG	GTGGGTCCTT	50
CAGTGGTTAC	TACTGGAGCT	GGATCCGCCA	GCCCCCAGGG	AAGGGGCTGG	100
AGTGGATTGG	GGAAATCAAT	CATAGTGGAA	GCACCAACTA	CAACCCGTCC	150
CTCAAGAGTC	GAGTCACCAT	ATCAGTAGAC	ACGTCCAAGA	ACCAGTTCTC	200
CCTGAAGCTG	AGCTCTGTGA	CCGCCGCGGA	CACGGCTGTG	TATTACTGTG	250
CGAGAGGGGC	AGCTGAATAT	TACTACTACT	ACTACGGTAT	GGACGTCTGG	300
GGCCAAGGGA	CCACGGTCAC	CGTCTCCTCA	GGGAGTGCAT	CCGCCCCAAC	350
CCTTTTCCCC	CTCGTCTCCT	GTGAGAATTC	CCCGTCGGAT	ACGAGCAGCG	400
TGGCCGTTGG	CTGCCTCGCA	CAGGACTTCC	TTCCCGACTY	CATCACTTTC	450
TYCTGGAAAT	ACAAGAACAA	CTCTGACATC	AGCAGCACCC	GGGGCTTCCC	500
ATCAGTCCTG	AGAGGGGGCA	AGTACGCAGC	CACCTCACAG	GTGCTGCTGC	550
CTTCCAAGGA	CGTCATGCAG	GGCACAGACG	AACACGTGGT	GACGGGATCC	600
AAAGAGT					607

(SEQ ID NO:70)

CEM 13.12 Heavy Protein

KLPETLSLTC	AVYGGSFSGY	YWSWIRQPPG	KGLEWIGEIN	HSGSTNYNPS	50
LKSRVTISVD	TSKNQFSLKL	SSVTAADTAV	YYCARGAAEY	YYYYYGMDVW	100
GQGTTVTVSS	GSASAPTLFP	LVSCENSPSD	TSSVAVGCLA	QDFLPDXITF	150
XWKYKNNSDI	SSTRGFPSVL	RGGKYAATSQ	VLLPSKDVMQ	GTDEHVVTGS	200
KE					202

(SEQ ID NO:31)

CEM 13.12 Kappa cDNA

ATGCCCCGTCA	CCCCTGGAGA	GCCGGCCTCC	ATCTCCTGCA	GGTCTAGTCA	50
GAGCCTCCTG	CATAGTAATG	GATACAACCTA	TTTGGACTGG	TACCTGCAGA	100
AGCCAGGGCA	GTCTCCACAG	CTCCTGATCT	ATTTGGGTTC	TAATCGGGCC	150
TCCGGGGTCC	CTGACAGGTT	CAGTGGCAGT	GGATCAGGCA	CAGATTTTAC	200
ACTGAAAATC	AGCAGAGTGG	AGGCTGAGGA	TGTTGGGATT	TATTACTGCA	250
TGCAAAGTCT	ACAAATTCCC	CGGCTTTTCG	GCCCTGGGAC	CAAAGTGGAT	300
ATCAAACGAA	CTGTGGCTGC	ACCATCTGTC	TTCATCTTCC	CGCCATCTGA	350
TGAGCAGTTG	AAATCTGGAA	CTGCCTCTGT	TGTGTGCCTG	CTGAGTAACT	400
TCTATCCCAG	AGAGGCCAAA	GTACAGTGGA	A		431

(SEQ ID NO:71)

CEM 13.12 Kappa Protein

MPVTPGEPAS	ISCRSSQSLL	HSNGYNYLDW	YLQKPGQSPQ	LLIYLGSNRA	50
SGVPDRFSGS	GGTDFTLKI	SRVEAEDVGI	YYCMQSLQIP	RLFGPGTKVD	100
IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LSNFYPREAK	VQW	143

(SEQ ID NO:32)

IgM Antibody Sequences

29/52

CEM 13.5 Heavy cDNA

TCGGAGACCC	TGTCCCTCAC	CTGCGCTGTC	TATGGTGGGT	CCTTCAGTGG	50
TTACTACTGG	AGCTGGATCC	GCCAGCCCCC	AGGGAAGGGG	CTGGAGTGGA	100
TTGGGGAAAT	CAATCATAGT	GGAAGCACCA	ACTACAACCC	GTCCCTCAAG	150
AGTCGAGTCA	CCATATCAGT	AGACACGTCC	AAGAACCAGT	TCTCCCTGAA	200
GCTGAGTTCT	GTGACCGCCG	CGGACACGGC	TGTGTATTAC	TGTGCGAGAG	250
GCGGGACTAC	AGTAACTTTT	GATGCTTTTG	ATATCTGGGG	CCAAGGGACA	300
ATGGTCACCG	TCTCTTCAGG	GAGTGCATCC	GCCCCAACCC	TTTTCCCCCT	350
CGTCTCCTGT	GAGAATTCCC	CGTCGGATAC	GAGCAGCGTG	GCCGTTGGCT	400
GCCTCGCACA	GGACTTCCTT	CCCGACTCCA	TCACCTTCTC	CTGGAAATAC	450
AAGAACAAC	CTGACATCAG	CAGCACCCGG	GGCTTCCCAT	CAGTCCTGAG	500
AGGGGGCAAG	TACGCAGCCA	CCTCACAGGT	GCTGCTGCCT	TCCAAGGACG	550
TCATGCAGGG	CACAGACGAA				570

(SEQ ID NO:72)

CEM 13.5 Heavy Protein

SETLSLTCAV	YGGSFSGYYW	SWIRQPPGKG	LEWIGEINHS	GSTNYPNPSLK	50
SRVTISVDTS	KNQFSLKLSS	VTAADTAVYY	CARGGTTVTF	DAFDIWQGT	100
MVTVSSGSAS	APTLPFLVSC	ENSPSDTSSV	AVGCLAQDFL	PDSITFSWKY	150
KNSDISSTR	GFPSVLRGGK	YAATSQVLLP	SKDVMQGTDE		190

(SEQ ID NO:33)

CEM [13.5] Kappa cDNA

CTGGCTGTGT	CTCTGGGCGA	GAGGGCCACC	ATCAACTGCA	AGTCCAGCCA	50
GAGTGTTTTA	TACAGTTTTA	ACAATAAGAA	CTACTTAGCT	TGGTACCAGC	100
AGAAACCAGG	ACAGCCTCCT	AAGCTGCTCA	TTTACTGGGC	ATCTACCCGG	150
GAATCCGGGG	TCCCTGACCG	ATTCAGTGGC	AGCGGTCTG	GGACAGATTT	200
CACTCTCACC	ATCAGCAGCC	TGCAGGCTGA	AGATGTGGCA	GTTTATTACT	250
GTCAGCAATA	TTATAGTACT	CCTCGGACGT	TCGGCCAAGG	GACCAAGGTG	300
GAAATCAAAC	GAAGTGTGGC	TGCACCATCT	GTCTTCATCT	TCCCGCCATC	350
TGATGAGCAG	TTGAAATCTG	GAAGTGCCTC	TGTTGTGTGC	CTGCTGAATA	400
ACTTCTATCC	CAGAGAGGCC	AAAGTACAGT	GGAAGGTGAT	C	441

(SEQ ID NO:73)

CEM 13.5 Kappa Protein

LAVSLGERAT	INCKSSQSVL	YSFNNKNYLA	WYQQKPGQPP	KLLIYWASTR	50
ESGVPDRFSG	SGSGTDFTLT	ISSLAEDVA	VYYCQQYYST	PRTFGQGTVK	100
EIKRTVAAPS	VFIFPPSDEQ	LKSGTASVVC	LLNNFYPREA	KVQWKVI	147

(SEQ ID NO:34)

FIG. 29

30/52

IgG Antibody Sequences2.4.4 Heavy cDNA

AACCCACAGA	CGACCCTCAC	GCTGACCTGC	ACCTTCTCTG	GGTTCTCACT	50
CATTACCCGT	GGAGTGGGTG	TGGATTGGAT	CCGTCAGCCC	CCAGGAAAGG	100
CCCTGCAGTG	GCTCGCACTC	ATTTATTGGA	ATGATGATAA	GCGCTACAGT	150
CCATCTCTGA	AGAGCAGGCT	CACCATCACC	AAGGACACCT	CCAAAAACCA	200
GGTGGTCCTC	ACAATGACCA	ACATGGACCC	TGTGGACACA	GCCACATATT	250
ACTGTGCACA	CCATTTCTTT	GATAGTAGTG	GTTATTACCC	TTTTGACTCC	300
TGGGGCCAGG	GAACCCTGGT	CTCCGTCTCC	TCAGCCTCCA	CCAAGGGCCC	350
ATCGGTCTTC	CCCCTGGCGC	CCTGCTCCAG	GAGCACCTCC	GAGAGCACAG	400
CGGCCCTGGG	CTGCCTGGTC	AAGGACTACT	TCCCCGAACC	GGTGACG	447

(SEQ ID NO:74)

2.4.4 Heavy Protein

NPQTTLTLTC	TFSGFSLITR	GVGVDWIRQP	PGKALQWLAL	IYWNDDKRYG	50
PSLKSRLTIT	KDTSKNQVVL	TMTNMDPVDI	ATYYCAHHFF	DSSGYYPFDS	100
WGQGTIVSVS	SASTKGPSVF	PLAPCSRSTS	ESTAALGCLV	KDYFPEPVT	149

(SEQ ID NO:35)

2.4.4 Kappa cDNA

GTGACTCAGT	CTCCACTCTC	TCTGTCCGTC	ACCCCTGGAC	AGCCGGCCTC	50
CATCTCCTGC	AAGTCTAGTC	AGAGCCTCCT	GCATAGTGAT	GGAAAGACCT	100
ATTTGTATTG	GTACCTGCAG	AAGCCAGGCC	AGCCTCCACA	GCTCCTGATC	150
TATGAAGCTT	TCAACCGGTT	CTCTGGAGTG	CCAGATAGGT	TCAGTGGCAG	200
CGGGTCAGGG	ACAGATTTCA	CACTGAAAAT	CAGCCGGGTG	GAGGCTGAGG	250
ATGTTGGACT	TTATTATTGC	ATGCAAAGTA	TAGAGCTTCC	GTTCACTTTC	300
GGCGGAGGGA	CCAAGGTGGA	GATCAAACGA	ACTGTGGCTG	CACCATCTGT	350
CTTCATCTTC	CCGCCATCTG	ATGAGCAGTT	GAAATCTGGA	ACTGCCTCTG	400
TTGTGTGCCT	GCTGAATAAC	TTCTATCCCA	GAAAAGAAAG	AGTCR	445

(SEQ ID NO:75)

2.4.4 Kappa Protein

VTQSPLSLSV	TPGQPASISC	KSSQSLLHSD	GKTYLYWYLQ	KPGQPQLLI	50
YEAENRFSGV	PDRFSGSGSG	TDFTLKISR	EAEDVGLYYC	MQSIELPFTF	100
GGGTKVEIKR	TVAAPSVFIF	PPSDEQLKSG	TASVVCLLNN	FYPRKERV	148

(SEQ ID NO:36)

FIG. 30

31/52

IgG Antibody Sequences2.1.1 Heavy cDNA

GGGAAGGCC	TGGTCAAGCC	TGGGGGGTCC	CTGAGACTCT	CCTGTGCAGC	50
CTCTGGATTC	ACCTTCAGTA	GCTATAGCAT	GAAGTGGGTC	CGCCAGGCTC	100
CAGGAAGGG	GCTGGAGTGG	GTCTCATCCA	TTAGTAGTAG	TAGTAGTTAC	150
ATATACTACG	CAGACTCAGT	GAAGGGCCGA	TTCACCATCT	CCAGAGACAA	200
CGCCAAGAAC	TCACTGTATC	TGCAAATGAA	CAGCCTGAGA	GCCGAGGACA	250
CGGCTGTGTA	TTACTGTGCG	AGGGATAGCA	GTGGCTGGTA	TGAGGACTAC	300
TTTGACTACT	GGGGCCAGGG	AACCCTGGTC	ACCGTCTCCT	CAGCCTCCAC	350
CAAGGGCCCA	TCGGTCTTCC	CCCTGGCGCC	CTGCTCCAGG	AGCACCTCCG	400
AGAGCACAGC	GGCCCTGGGC	TGCCTGGTCA	AGGACTACTT	CCCCGAACCG	450
GTGACGGTGT	CGTGGAAGTC	AGGCGCTCTG	ACCAGCGGCG	TGCACACCTT	500
CCCAGCTGTC	CTACAGTCA				519

(SEQ ID NO:76)

2.1.1 Heavy Protein

GEGLVKPGGS	LRLSCAASGF	TFSSYSMNWV	RQAPGKGLEW	VSSISSSSSY	50
IYYADSVKGR	FTISRDNKN	SLYLQMNLR	AEDTAVYYCA	RDSSGWYEDY	100
FDYWGQGLV	TVSSASTKGP	SVFPLAPCSR	STSESTAALG	CLVKDYFPEP	150
VTVSWNSGAL	TSGVHTFPAV	LQS			173

(SEQ ID NO:37)

2.1.1 Kappa cDNA

CTTGACATCC	AGCTGACCCA	GTCTCCGTCC	TCACTGTCTG	CATCTGTAGG	50
AGACAGAGTC	ACCATCACTT	GTCGGGCGAG	TCAGGACATT	AGCATTTATT	100
TAGCCTGGTT	TCAGCAGAGA	CCAGGGAAAG	CCCCTAAGTC	CCTGATCTAT	150
GCTGCATCCA	GTTTGCAAAG	TGGGGTCCCA	TCAAAGTTCA	GCGGCAGTGG	200
ATCTGGGACA	GATTTCACTC	TCACCATCAG	CAGCCTGCAG	CCTGAAGATT	250
TTGCAACTTA	TTACTGCCAA	CAATATAATA	GTTATCCATT	CACTTTCGGG	300
CCC					303

(SEQ ID NO:77)

2.1.1 Kappa Protein

LDIQLTQSPS	SLSASVGDRV	TITCRASQDI	SIYLAWFQQR	PGKAPKSLIY	50
AASSLQSGVP	SKFSGSGSGT	DFTLTISLQ	PEDFATYYCQ	QYNSYPFTFG	100
P					101

(SEQ ID NO:38)

FIG. 31

32/52

IgG Antibody Sequences2.3.2 Heavy cDNA

CTGACCTGCA	CCTTCTCTGG	GTTCTCACTC	ATTACCCGTG	GAGTGGGTGT	50
GGATTGGATC	CGTCAGCCCC	CAGGAAAGGC	CCTGCAGTGG	CTCGCACTCA	100
TTTATTGGAA	TGATGATAAG	CGCTACAGTC	CATCTCTGAA	GAGCAGGCTC	150
ACCATCACCA	AGGACACCTC	CAAAAACCAG	GTGGTCCTCA	CAATGACCAA	200
CATGGACCCT	GTGGACACAG	CCACATATTA	CTGTGCACAC	CATTTCTTTG	250
ATAGTAGTGG	TTATTACCCT	TTTGACTCCT	GGGGCCAGGG	AACCCTGGTC	300
TCCGTCTCCT	CAGCCTCCAC	CAAGGGCCCA	TCGGTCTTCC	CCCTGGCGCC	350
CTGCTCCAGG	AGCACCTCCG	AGAGCACAGC	GGCCCTGGGC	TGCCTGGTCA	400
AGGACTACTT	CCCCGAACCG	GTGACGGTGT	CGTGGAACTC	AGGCGCTCTG	450
ACCAGCGGCG	TGCACACCTT	CCAGCTG			477

(SEQ ID NO:78)

2.3.2 Heavy Protein

LTCTFSGFSL	ITRGVGVDWI	RQPPGKALQW	LALIYWDDK	RYSPSLKSRL	50
TITKDTSKNQ	VVLTMTNMDP	VDTATYYCAH	HFFDSSGYYP	FDSWGQGLV	100
SVSSASTKGP	SVFPLAPCSR	STSESTAALG	CLVKDYFPEP	VTVSWNSGAL	150
TSGVHTFQL					159

(SEQ ID NO:39)

FIG. 32

IgG Antibody Sequences

33/52

2.6.1 Heavy cDNA

GGGGGAGGCT	TGGTACAGCC	TGGGGGGTCC	CTGAGACTCT	CCTGTGCAGC	50
CTCTGGATTG	ACTTTTAGCA	GCTATGCCAT	GAGCTGGGTC	CGCCAGGCTC	100
CAGGGAAGGG	GCTGGAGTGG	GTCTCAACTA	TTAGTGTTAG	TGGTATTACC	150
ACATACTACG	TAGACTCCGT	GAAGGGCCGG	TTCACCATCT	CCAGAGACAA	200
TTCCAAGAAC	ATTCTGTATC	TGCAATGAA	CAGCCTGAGA	GCCGAGGACA	250
CGGCCGTATA	TTACTGTGCG	AAACGGATTT	TTGGAGTGGT	CTGGGGCCAG	300
GGAACCCTGG	TCACCGTCTC	CTCAGCCTCC	ACCAAGGGCC	CATCGGTCTT	350
CCCCCTGGCG	CCCTGCTCCA	GGAGCACCTC	CGAGAGCACA	GCGGCCCTGG	400
GCTGCCTGGT	CAAGGACTAC	TTCCCCGAAC	CGGTGACGGT	GTCGTGGAAC	450
TTAGGCGCTC	TGACCAGCGG	CGTGACACAC	TTCCCAGCTG	TCCTACAGTC	500
CTA					503

(SEQ ID NO:79)

2.6.1 Heavy Protein

GGGLVQPGGS	LRLSCAASGF	TFSSYAMSWV	RQAPGKGLEW	VSTISVSGIT	50
TYYVDSVKGR	FTISRDNSKN	ILYLQMNSLR	AEDTAVYYCA	KRIFGVVWGO	100
GTLVTVSSAS	TKGPSVFPLA	PCSRSTSEST	AALGGLVKDY	FPEPVTVSWN	150
LGALTSGVHT	FPAVLQS				167

(SEQ ID NO:40)

2.6.1 Kappa cDNA

GGAATTCGGC	TTGATATTCA	GCTGACTCAG	TCTCCATCCT	CACTGTCTGC	50
ATCTGTAGGA	GACAGAGTCA	CCATCACTTG	TCGGGCGAGT	CAGGGCATTG	100
GCATTTATTT	AGCCTGGTTT	CAGCAGAGAC	CAGGGAAAGC	CCCTAAGTCC	150
CTGATCTATG	CTGCATCCAG	TTTGCAAAGT	GGGGTCCCAT	CAAAGTTCAG	200
CGGCAGTGGA	TCTGGGACAG	ATTTCACTCT	CACCATCAGC	AGCCTGCAGC	250
CTGAAGATTT	TGCAACTTAT	TACTGCCAAC	AATATAATAG	TTACCCATTG	300
ACTTTCGGCC	CTGGGACCAA	AGTGGATATC	AAACGAACTG	TGGCTGCACC	350
ATCTGTCTTC	ATCTTCCCGC	CATCTGATGA	GCAGTTGAAA	TCTGGAAGTG	400
CCTCTGTTGT	GTGCCTGCTG	AATAACTTCT	ATCCCAGAGA	GGCCAAAGTA	450
CAGTGGAAGG	TGGATAACGC	CCTCCAATCG	GGTAAGCCGA	ATTC	494

(SEQ ID NO:80)

2.6.1 Kappa Protein

GIRLDIQLTQ	SPSSLSASVG	DRVTITCRAS	QGISIYLAWF	QQRPGKAPKS	50
LIYAASSLQS	GVPSKFSGSG	SGTDFTLTIS	SLQPEDFATY	YCQQYNSYPF	100
TFGPGTKVDI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPPREKV	150
QWKVDNALQS	GKPN				164

(SEQ ID NO:41)

IgM Antibody Sequences

CEM 10.1 C3 Heavy Protein

GLLKPSETLSLTCAVYGGFSGYWWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFS
CDR1
CDR2
LKLSSVTAADTAVYCYCARGTTEYYYYYGMVWGQGTTVTVSSGSAAPTLPFLVSCENSPDTSVAVG
CDR3
CLAQDFLPDXITFSWKYKYNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMMQGTDEHVVTGSKE

CEM 10.1 C3 Kappa Protein

LSLPVTPEPASISCRSSQSLHNSGNYLDWYLQKPGSQPLLIIYLGSNRASGVDPFRFSGSGGTDFTL
 CDR1 CDR2
 KISRVEAEDVGIIYCMQTRQTPRTFGQGTKVEIKRTVAAPSVEIFFPSDEQLKSGTASVVCLLNNFYPRE
 CDR3

AKEHQKSP

FIG. 34

CEM 10.1 G10 Heavy Protein

LVKPS^{ET}LSLTCTVSGGSISSYYNWI^{RQ}PPGKGLEWIGYIYYSGSTNYP^{SL}KSRVTISVDTSKNQ^{FS}L
 CDR1 CDR2
 KLSSVTAADTAVY^YCARDRGV^{AT}GTG^{EDY}WGQGLTVTVSSGSASAP^{TL}FPLVSCENSPSDTSSVAVGCLAQ
 CDR3
 DFLPDSITFSWKYKNNSDISSTRGF^{PS}VL^{RG}GKYAAT^{SQ}VLLP^{SK}DMQGTDEHKVC

CEM 10.1 G10 Kappa Protein

SQSPSSLSASVGERVTITCRASQGIRDELGWYQQKPGKAPKRLIYVASSLQSGVPSRFGSGSGTEFTLT
 CDR1 CDR2
 ISSLPEDFATYYCLOHNGYPRTFGGQTKVEIKRTVAAPSVFIEPPSDEQLKSGTASVVCLLNFEYPREA
 CDR3
 KEHQKSP

FIG. 35

36/52

IgM Antibody SequencesCEM 10.12 F3 Heavy Protein

KKPASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNENSGNTGYAQKCDR2FQGRVTMNRNTSISTAYM
 ELSSLRSEDTAVYYCARGGHGGSYFYSYGMDVWGQGTITVSSGSASAPTLFPLVSCENSPSDTSSVAV
 GCLAQDFLPDSITFSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMOGTDENVVCK

CEM 10.12 F3 Kappa Protein

HSLAVSLGERATINCKSSQSVLYSFNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPPDRFGSGSGTDFT
 LTISSLQAEDVAVYYCQQYYSTPRTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYP
 EAKEHQKSP

FIG. 36

CEM 10.12 G5 Heavy Protein

EVKKPGASVKVSCKASGYTFTSYDINWVRQATGGGLEWGMWNPENSGNTGYAQKFQGRVTMTTRNTSISTA
CDR1 CDR2
YMEISSLRSEDTAVYYCAREEWLVRYYYGMDVWGQGTTVTVSSGSASAPTLF?LVSCENSPSDTSSVAVGC
CDR3
LAQDFLPDSITFSWKYKNNSDISSTRGEFPSVLRGGKYAATSQVLLPSPKDVMQGTDEHKV

CEM 10.12 G5 Kappa Protein

KEHQKSP
CDR3
ISSLQPEDEATYYCLOYKTYPWTFGGQGTKVEIKRTVAAPSVFI^{PP}PSDEQLKSGTASVVCLLNFFYPREX

CDR1
GQSPSSLSASVGD^{RVTITCRASQDIRDNLGWYQQKPGKAPKRLIYAASN}LQS^{GVP}S^{RF}SGSGGTFTLT

FIG. 37

IgM Antibody Sequences

CEM 13.12 Heavy Protein

KLPETLSLTCAVYGGSFSGYVSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKL
 CDR1 CDR2
 SSVTAADTAVYYCARGAAEYYYYYGMVDVGQGTTVTVSSGSASAPTLFPLVSCENSPSDTSSVAVGCLA
 CDR3
 QDFLPDXITFXWKYKNNSDISSTRGFPSVLRGKGKYAATSOVLLPSKDVMQGTDEHVVTGSKE

CEM 13.12 Kappa Protein

MPVTPGEPASISCRSSQLLSHNSGYNLDWYLQKPGQSPQLLIYLGSNRASGVPDFRFGSGSGTDFTLKI
CDR1 CDR2
SRVEAEDVGIIYCMQSLQIPRLFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLSNFYFPREAK
CDR3

vq̄w

FIG. 38

CEM 13.5 Heavy Protein

SETLSLTCAVYGGSEFGYYSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSS
CDR1 CDR2
VTAADTAVYCYARGGTTVTFAFDIWGQGTMTVSSGSASAPTLFPLVSCENSPDTSVAVGCLAQDFL
CDR3
PDSITFSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDE

CEM 13.5 Kappa Protein

LAVSLGERATINCKSSQSVLYSEFNKNYLAWYQQKPGQPCDR1PKLLIYWASTRESGVDPDRFSGSGSGTDFTLT
KVQWKVI
ISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIKRTVAAPSVFIEPPSDEQLKSGTASVVCLLNFEYPREACDR3

FIG. 39

40/52

IgG Antibody Sequences2.4.4 Heavy Protein

NPQTTLTLC^{CDR1}TSGFSLITRGVGV^{CDR2}DWIRQPPGKALQWLALIYWNDDKRYSPSLKSR^{CDR3}LTITKDTSKNQVVL
 TMTNMDPVD^{CDR1}TATYYCAHHFFDSSGYYPFDSWGQGT^{CDR2}LVSVSSASTKGPSVFPLAPCSRSTSESTAALGCLV
 KDYFPEPVT

2.4.4 Kappa Protein

VTQSPLSVTPGQPASISCKSSQSL^{CDR1}LHSDGKTYLYWYLQKPGQPQLLIYEAFNRFSGVPDRFSGSGG
 TDFTLKISRVEAEDVGLYYCMQSI^{CDR2}ELPFTFGGG^{CDR3}TKVEIKRTVAAPSVFIFPPSDEQLKSGTASV^{CDR3}VCLLN
 FYPRKERV

FIG. 40

2.1.1 Heavy Protein

GEGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPKGKLEWVSSISSSSSYYIYADSVKGRFTISRDNAKN
 CDR1 CDR2
 SLYLQMNSLRAEDTAVYYCARDSSGWYEDYFDYWGQGLTVTVSSASTKGPSPVFLAPCSRSTSESTAALG
 CDR3
 CLVKDYFEPVTVSWNSGALTSGVHTFPAVLQS

2.1.1 Kappa Protein

LDIQLTQSPSSLSASVGDRTITCRASQDISIYLAWFQRRPGKAPKSLIYAASSLQSGVPSKFGSGSGT
CDR1 CDR2
DFTLTISLQPEDEATYYCQQYNSYPETFGP CDR3

FIG. 41

42/52

IgG Antibody Sequences2.3.2 Heavy Protein

LTCTFSGESLIIRGVGVVDWIRQPPGKALQWLALIYWNDDKRYSPSLKSRLLITTKDTSKNQVVLTMTNMDP
CDR1
VDTATYYCAHHFFDSSGGYYPFDSWGQGLVSVSSASTKGPSVFPFLAPCSRSTSESTAALGCLVKDYFPEP
CDR3
VTVSWNSGALTSGVHTFQL

2.3.2 Kappa Protein

FIG. 42

2.6.1 Heavy Protein

GGGLVQPGGSLRLSCAASGETFESSYAMSVWRQAPGKGLEWVSTISVSGITTYVDSVKGRFTISRDN SKN
CDR1 CDR2
IILYQMNSLRAEDTAVYCAKRIEFGVWGQGLTVTVSSASTKGPSPVFLAPCSRSTSESTAALGCLVKDY
CDR3
EPPEPTVSWNLGALTSGVHTFPAVLQ

2.6.1 Kappa Protein

GIRLDIQLTQSPSSLSASVGDRTITCRASQGIGISYLAWFQQRPFGKAPKSLIYAASSLQSGVP SKFSGSG
CDR1 CDR2

SGTDFTLTISSLOPEDEATYYCQQNSYPFTTFGPGTKVDIKRTVAAPSVEIFPPSDEQLKSGTASVVCLL
CDR3

NNFYPR~~EAKVQWKVDNALQSGKP~~N

FIG. 43




FIG. 44A




FIG. 44B




FIG.45A




FIG.45B




FIG.45C




FIG.46

47/52




FIG. 47

48/52




FIG.48

49/52




FIG.49

50/52







FIG.50A






FIG.50E




FIG.50F

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: ABGENIX, INC.

DAVIS, C. Geoffrey
BLACHER, Russell Wayne
CORVALAN, Jose Ramon
CULWELL, Alan Rhodes
GREEN, Larry
HAVRILLA, Nancy
HALES, Joanna
IVANOV, Vladimir E.
LIPANI, John A.
LIU, Qiang
WEBER, Richard F.
YANG, Xiao-dong

(ii) TITLE OF THE INVENTION: CD147 BINDING MOLECULES AS
THERAPEUTICS

(iii) NUMBER OF SEQUENCES: 81

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Fish & Neave
(B) STREET: 1251 Avenue of the Americas
(C) CITY: New York
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 10020

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 1.5

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: N/A
(B) FILING DATE: 03-MAR-1999
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 09/034,607

(B) FILING DATE: 03-MAR-1998

(A) APPLICATION NUMBER: 09/244,253

(B) FILING DATE: 03-FEB-1999

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Haley, James F., Jr., Esq.

(B) REGISTRATION NUMBER: 27,794

(C) REFERENCE/DOCKET NUMBER: ABX-CBLCD147

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212-596-9000

(B) TELEFAX: 212-596-9090

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ile Thr Leu Arg Val Arg Ser His

1 5

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Glu Glu Arg Leu Arg Ser Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Tyr Glu Arg Val Arg Trp Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Glu Glu Arg Leu Arg Ser Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ala Glu Arg Ile Arg Ser Ile

1 5

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Glu Glu Arg Leu Arg Ser Tyr

1 5

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Thr Val His Gly Asp Leu Arg Leu Arg Ser Leu Pro
1 5 10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Thr Asn Asp Ile Gly Leu Arg Gln Arg Ser His Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ser Pro Leu Leu Asp Gly Gln Arg Glu Arg Ser Tyr
1 5 10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Tyr Asp Leu Pro Met Arg Ser Arg Ser Tyr Pro Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Arg Xaa Arg Ser
1

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Lys Gly Ser Asp Gln Ala Ile Ile Thr Leu Arg Val Arg Ser His
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Arg Xaa Arg Ser His
1 5

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 269 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Ala Ala Ala Leu Phe Val Leu Leu Gly Phe Ala Leu Leu Gly Thr
1 5 10 15
His Gly Ala Ser Gly Ala Ala Gly Thr Val Phe Thr Thr Val Glu Asp
20 25 30

Leu Gly Ser Lys Ile Leu Leu Thr Cys Ser Leu Asn Asp Ser Ala Thr
 35 40 45
 Glu Val Thr Gly His Arg Trp Leu Lys Gly Gly Val Val Leu Lys Glu
 50 55 60
 Asp Ala Leu Pro Gly Gln Lys Thr Glu Phe Lys Val Asp Ser Asp Asp
 65 70 75 80
 Gln Trp Gly Glu Tyr Ser Cys Val Phe Leu Pro Glu Pro Met Gly Thr
 85 90 95
 Ala Asn Ile Gln Leu His Gly Pro Pro Arg Val Lys Ala Val Lys Ser
 100 105 110
 Ser Glu His Ile Asn Gln Gly Glu Thr Ala Met Leu Val Cys Lys Ser
 115 120 125
 Glu Ser Val Pro Pro Val Thr Asp Trp Ala Trp Tyr Lys Ile Thr Asp
 130 135 140
 Ser Glu Asp Lys Ala Leu Met Asn Gly Ser Glu Ser Arg Phe Phe Val
 145 150 155 160
 Ser Ser Ser Gln Gly Arg Ser Glu Leu His Ile Glu Asn Leu Asn Met
 165 170 175
 Glu Ala Asp Pro Gly Gln Tyr Arg Cys Asn Gly Thr Ser Ser Lys Gly
 180 185 190
 Ser Asp Gln Ala Ile Ile Thr Leu Arg Val Arg Ser His Leu Ala Ala
 195 200 205
 Leu Trp Pro Phe Leu Gly Ile Val Ala Glu Val Leu Val Leu Val Thr
 210 215 220
 Ile Ile Phe Ile Tyr Glu Lys Arg Arg Lys Pro Glu Asp Val Leu Asp
 225 230 235 240
 Asp Asp Asp Ala Gly Ser Ala Pro Leu Lys Ser Ser Gly Gln His Gln
 245 250 255
 Asn Asp Lys Gly Lys Asn Val Arg Gln Arg Asn Ser Ser
 260 265

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Pro Glu Arg Ile Leu Ser Ile

1 5

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Gly Gly Ser Arg Ala Arg Asn Leu Pro

1 5

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 463 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met Glu Thr Glu Gln Pro Glu Glu Thr Phe Pro Asn Thr Glu Thr Asn

1 5 10 15

Gly Glu Phe Gly Lys Arg Pro Ala Glu Asp Met Glu Glu Glu Gln Ala

20 25 30

Phe Lys Arg Ser Arg Asn Thr Asp Glu Met Val Glu Leu Arg Ile Leu

35 40 45

Leu Gln Ser Lys Asn Ala Gly Ala Val Ile Gly Lys Gly Gly Lys Asn

50 55 60

Ile Lys Ala Leu Arg Thr Asp Tyr Asn Ala Ser Val Ser Val Pro Asp

10

65 70 75 80
 Ser Ser Gly Pro Glu Arg Ile Leu Ser Ile Ser Ala Asp Ile Glu Thr
 85 90 95
 Ile Gly Glu Ile Leu Lys Lys Ile Ile Pro Thr Leu Glu Glu Gly Leu
 100 105 110
 Gln Leu Pro Ser Pro Thr Ala Thr Ser Gln Leu Pro Leu Glu Ser Asp
 115 120 125
 Ala Val Glu Cys Leu Asn Tyr Gln His Tyr Lys Gly Ser Asp Phe Asp
 130 135 140
 Cys Glu Leu Arg Leu Leu Ile His Gln Ser Leu Ala Gly Gly Ile Ile
 145 150 155 160
 Gly Val Lys Gly Ala Lys Ile Lys Glu Leu Arg Glu Asn Thr Gln Thr
 165 170 175
 Thr Ile Lys Leu Phe Gln Glu Cys Cys Pro His Ser Thr Asp Arg Val
 180 185 190
 Val Leu Ile Gly Gly Lys Pro Asp Arg Val Val Glu Cys Ile Lys Ile
 195 200 205
 Ile Leu Asp Leu Ile Ser Glu Ser Pro Ile Lys Gly Arg Ala Gln Pro
 210 215 220
 Tyr Asp Pro Asn Phe Tyr Asp Glu Thr Tyr Asp Tyr Gly Gly Phe Thr
 225 230 235 240
 Met Met Phe Asp Asp Arg Arg Gly Arg Pro Val Gly Phe Pro Met Arg
 245 250 255
 Gly Arg Gly Gly Phe Asp Arg Met Pro Pro Gly Arg Gly Gly Arg Pro
 260 265 270
 Met Pro Pro Ser Arg Arg Asp Tyr Asp Asp Met Ser Pro Arg Arg Gly
 275 280 285
 Pro Pro Pro Pro Pro Gly Arg Gly Gly Arg Gly Gly Ser Arg Ala
 290 295 300
 Arg Asn Leu Pro Leu Pro Pro Pro Pro Pro Pro Arg Gly Gly Asp Leu
 305 310 315 320
 Met Ala Tyr Asp Arg Arg Gly Arg Pro Gly Asp Arg Tyr Asp Gly Met
 325 330 335
 Val Gly Phe Ser Ala Asp Glu Thr Trp Asp Ser Ala Ile Asp Thr Trp
 340 345 350
 Ser Pro Ser Glu Trp Gln Met Ala Tyr Glu Pro Gln Gly Gly Ser Gly
 355 360 365
 Tyr Asp Tyr Ser Tyr Ala Gly Gly Arg Gly Ser Tyr Gly Asp Leu Gly
 370 375 380
 Gly Pro Ile Ile Thr Thr Gln Val Thr Ile Pro Lys Asp Leu Ala Gly
 385 390 395 400
 Ser Ile Ile Gly Lys Gly Gly Gln Arg Ile Lys Gln Ile Arg His Glu
 405 410 415
 Ser Gly Ala Ser Ile Lys Ile Asp Glu Pro Leu Glu Gly Ser Glu Asp
 420 425 430
 Arg Ile Ile Thr Ile Thr Gly Thr Gln Asp Gln Ile Gln Asn Ala Gln
 435 440 445

Tyr Leu Leu Gln Asn Ser Val Lys Gln Tyr Ser Gly Lys Phe Phe
 450 455 460

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 570 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr
 20 25 30
 Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Glu Ile Arg Leu Lys Ser Asn Asn Tyr Ala Thr His Tyr Ala Glu
 50 55 60
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
 65 70 75 80
 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr
 85 90 95
 Tyr Cys Thr Asp Tyr Asp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110
 Val Ser Ala Glu Ser Gln Ser Phe Pro Asn Val Phe Pro Leu Val Ser
 115 120 125
 Cys Glu Ser Pro Leu Ser Asp Lys Asn Leu Val Ala Met Gly Cys Leu
 130 135 140
 Ala Arg Asp Phe Leu Pro Ser Thr Ile Ser Phe Thr Trp Asn Tyr Gln
 145 150 155 160
 Asn Asn Thr Glu Val Ile Gln Gly Ile Arg Thr Phe Pro Thr Leu Arg
 165 170 175
 Thr Gly Gly Lys Tyr Leu Ala Thr Ser Gln Val Leu Leu Ser Pro Lys
 180 185 190
 Ser Ile Leu Glu Gly Ser Asp Glu Tyr Leu Val Cys Lys Ile His Tyr
 195 200 205
 Gly Gly Lys Asn Arg Asp Leu His Val Pro Ile Pro Ala Val Ala Glu
 210 215 220

Met Asn Pro Asn Val Asn Val Phe Val Pro Pro Arg Asp Gly Phe Ser
 225 230 235 240
 Gly Pro Ala Pro Arg Lys Ser Lys Leu Ile Cys Glu Ala Thr Asn Phe
 245 250 255
 Thr Pro Lys Pro Ile Thr Val Ser Trp Leu Lys Asp Gly Lys Leu Val
 260 265 270
 Glu Ser Gly Phe Thr Thr Asp Pro Val Thr Ile Glu Asn Lys Gly Ser
 275 280 285
 Thr Pro Gln Thr Tyr Lys Val Ile Ser Thr Leu Thr Ile Ser Glu Ile
 290 295 300
 Asp Trp Leu Asn Leu Asn Val Tyr Thr Cys Arg Val Asp His Arg Gly
 305 310 315 320
 Leu Thr Phe Leu Lys Asn Val Ser Ser Thr Cys Ala Ala Ser Pro Ser
 325 330 335
 Thr Asp Ile Leu Thr Phe Thr Ile Pro Pro Ser Phe Ala Asp Ile Phe
 340 345 350
 Leu Ser Lys Ser Ala Asn Leu Thr Cys Leu Val Ser Asn Leu Ala Thr
 355 360 365
 Tyr Glu Thr Leu Asn Ile Ser Trp Ala Ser Gln Ser Gly Glu Pro Leu
 370 375 380
 Glu Thr Lys Ile Lys Ile Met Glu Ser His Pro Asn Gly Thr Phe Ser
 385 390 395 400
 Ala Lys Gly Val Ala Ser Val Cys Val Glu Asp Trp Asn Asn Arg Lys
 405 410 415
 Glu Phe Val Cys Thr Val Thr His Arg Asp Leu Pro Ser Pro Gln Lys
 420 425 430
 Lys Phe Ile Ser Lys Pro Asn Glu Val His Lys His Pro Pro Ala Val
 435 440 445
 Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala
 450 455 460
 Thr Val Thr Cys Leu Val Lys Gly Phe Ser Pro Ala Asp Ile Ser Val
 465 470 475 480
 Gln Trp Leu Gln Arg Gly Gln Leu Leu Pro Gln Glu Lys Tyr Val Thr
 485 490 495
 Ser Ala Pro Met Pro Glu Pro Gly Ala Pro Gly Phe Tyr Phe Thr His
 500 505 510
 Ser Ile Leu Thr Val Thr Glu Glu Trp Asn Ser Gly Glu Thr Tyr
 515 520 525
 Thr Cys Val Val Gly His Glu Ala Leu Pro His Leu Val Thr Glu Arg
 530 535 540
 Thr Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu
 545 550 555 560
 Ile Met Ser Asp Thr Gly Gly Thr Cys Tyr
 565 570

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 206 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```

Lys Phe Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys
 1         5         10        15
Ala Ser Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro
 20        25        30
Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr
 35        40        45
Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr
 50        55        60
Phe Thr Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys
 65        70        75        80
Gln Gln Asp Tyr Ser Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu
 85        90        95
Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro
100       105       110
Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu
115       120       125
Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly
130       135       140
Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser
145       150       155       160
Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp
165       170       175
Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr
180       185       190
Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
195       200       205

```

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Ser Leu Ala Pro Leu Trp Tyr Tyr Ser Arg His Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

His Thr Pro Glu Thr Ala Pro Leu Pro Ala Thr Val
1 5 10

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 159 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

15

Met Lys Asn His Leu Leu Phe Trp Gly Val Leu Ala Val Phe Ile Lys
 1 5 10 15
 Ala Val His Val Lys Ala Gln Glu Asp Glu Arg Ile Val Leu Val Asp
 20 25 30
 Asn Lys Cys Lys Cys Ala Arg Ile Thr Ser Arg Ile Ile Arg Ser Ser
 35 40 45
 Glu Asp Pro Asn Glu Asp Ile Val Glu Arg Asn Ile Arg Ile Ile Val
 50 55 60
 Pro Leu Asn Asn Arg Glu Asn Ile Ser Asp Pro Thr Ser Pro Leu Arg
 65 70 75 80
 Thr Arg Phe Val Tyr His Leu Ser Asp Leu Cys Lys Lys Cys Asp Pro
 85 90 95
 Thr Glu Val Glu Leu Asp Asn Gln Ile Val Thr Ala Thr Gln Ser Asn
 100 105 110
 Ile Cys Asp Glu Asp Ser Ala Thr Glu Thr Cys Tyr Thr Tyr Asp Arg
 115 120 125
 Asn Lys Cys Tyr Thr Ala Val Val Pro Leu Val Tyr Gly Gly Glu Thr
 130 135 140
 Lys Met Val Glu Thr Ala Leu Thr Pro Asp Ala Cys Tyr Pro Asp
 145 150 155

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 205 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr
 1 5 10 15
 Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro
 20 25 30
 Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr
 35 40 45
 Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr
 50 55 60
 Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp
 65 70 75 80

16

Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Thr Glu Tyr Tyr Tyr Tyr
 85 90 95
 Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
 100 105 110
 Ser Gly Ser Ala Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu
 115 120 125
 Asn Ser Pro Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln
 130 135 140
 Asp Phe Leu Pro Asp Xaa Ile Thr Phe Ser Trp Lys Tyr Lys Asn Asn
 145 150 155 160
 Ser Asp Ile Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly
 165 170 175
 Lys Tyr Ala Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met
 180 185 190
 Gln Gly Thr Asp Glu His Val Val Thr Gly Ser Lys Glu
 195 200 205

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 148 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg
 1 5 10 15
 Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp
 20 25 30
 Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly
 35 40 45
 Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser
 50 55 60
 Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val
 65 70 75 80
 Gly Ile Tyr Tyr Cys Met Gln Thr Arg Gln Thr Pro Arg Thr Phe Gly
 85 90 95
 Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val
 100 105 110

Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser
 115 120 125
 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Glu His
 130 135 140
 Gln Lys Ser Pro
 145

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 197 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
 1 5 10 15
 Gly Ser Ile Ser Ser Tyr Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly
 20 25 30
 Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn
 35 40 45
 Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser
 50 55 60
 Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr
 65 70 75 80
 Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Val Gly Ala Thr Gly Phe
 85 90 95
 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ser Ala
 100 105 110
 Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu Asn Ser Pro Ser
 115 120 125
 Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln Asp Phe Leu Pro
 130 135 140
 Asp Ser Ile Thr Phe Ser Trp Lys Tyr Lys Asn Asn Ser Asp Ile Ser
 145 150 155 160
 Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly Lys Tyr Ala Ala
 165 170 175
 Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met Gln Gly Thr Asp
 180 185 190

Glu His Lys Val Cys
195

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 147 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

```

Ser Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Glu Arg Val Thr
 1         5         10        15
Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asp Glu Leu Gly Trp Tyr
 20        25        30
Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Val Ala Ser
 35        40        45
Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
 50        55        60
Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
 65        70        75        80
Thr Tyr Tyr Cys Leu Gln His Asn Gly Tyr Pro Arg Thr Phe Gly Gln
 85        90        95
Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
100        105       110
Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
115        120       125
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Glu His Gln
130        135       140
Lys Ser Pro
145

```

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 203 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

```

Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
 1         5         10        15
Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln
 20        25        30
Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly
 35        40        45
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Asn Arg Asn Thr Ser
 50        55        60
Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
 65        70        75        80
Ala Val Tyr Tyr Cys Ala Arg Gly Gly His Gly Gly Ser Tyr Phe Tyr
 85        90        95
Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val
100       105       110
Ser Ser Gly Ser Ala Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys
115       120       125
Glu Asn Ser Pro Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala
130       135       140
Gln Asp Phe Leu Pro Asp Ser Ile Thr Phe Ser Trp Lys Tyr Lys Asn
145       150       155       160
Asn Ser Asp Ile Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly
165       170       175
Gly Lys Tyr Ala Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val
180       185       190
Met Gln Gly Thr Asp Glu His Val Val Cys Lys
195       200

```

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 149 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

```

His Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys
 1      5      10      15
Ser Ser Gln Ser Val Leu Tyr Ser Phe Asn Asn Lys Asn Tyr Leu Ala
      20      25      30
Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp
      35      40      45
Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Gly Gly Ser Gly
      50      55      60
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp
65      70      75      80
Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Arg Thr Phe
      85      90      95
Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser
      100      105      110
Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala
      115      120      125
Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Glu
      130      135      140
His Gln Lys Ser Pro
145

```

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 199 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

```

Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
 1      5      10      15
Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr
      20      25      30
Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn
      35      40      45

```

21

Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn
 50 55 60
 Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
 65 70 75 80
 Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Glu Trp Leu Val Arg Tyr
 85 90 95
 Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 100 105 110
 Gly Ser Ala Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu Asn
 115 120 125
 Ser Pro Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln Asp
 130 135 140
 Phe Leu Pro Asp Ser Ile Thr Phe Ser Trp Lys Tyr Lys Asn Asn Ser
 145 150 155 160
 Asp Ile Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly Lys
 165 170 175
 Tyr Ala Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met Gln
 180 185 190
 Gly Thr Asp Glu His Lys Val
 195

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 147 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Gly Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
 1 5 10 15
 Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asp Asn Leu Gly Trp Tyr
 20 25 30
 Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Ala Ala Ser
 35 40 45
 Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
 50 55 60
 Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
 65 70 75 80

Thr Tyr Tyr Cys Leu Gln Tyr Lys Thr Tyr Pro Trp Thr Phe Gly Gln
 85 90 95
 Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
 100 105 110
 Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
 115 120 125
 Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Xaa Lys Glu His Gln
 130 135 140
 Lys Ser Pro
 145

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 202 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Lys Leu Pro Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser
 1 5 10 15
 Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly
 20 25 30
 Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn
 35 40 45
 Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn
 50 55 60
 Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val
 65 70 75 80
 Tyr Tyr Cys Ala Arg Gly Ala Ala Glu Tyr Tyr Tyr Tyr Tyr Gly
 85 90 95
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Ser
 100 105 110
 Ala Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu Asn Ser Pro
 115 120 125
 Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln Asp Phe Leu
 130 135 140
 Pro Asp Xaa Ile Thr Phe Xaa Trp Lys Tyr Lys Asn Asn Ser Asp Ile
 145 150 155 160

23

Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly Lys Tyr Ala
 165 170 175
 Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met Gln Gly Thr
 180 185 190
 Asp Glu His Val Val Thr Gly Ser Lys Glu
 195 200

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 143 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Met Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser
 1 5 10 15
 Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu
 20 25 30
 Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn
 35 40 45
 Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
 50 55 60
 Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Ile
 65 70 75 80
 Tyr Tyr Cys Met Gln Ser Leu Gln Ile Pro Arg Leu Phe Gly Pro Gly
 85 90 95
 Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
 100 105 110
 Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
 115 120 125
 Cys Leu Leu Ser Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
 130 135 140

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 190 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

```

Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser
 1         5         10        15
Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
 20        25        30
Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser
 35        40        45
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
 50        55        60
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
 65        70        75        80
Cys Ala Arg Gly Gly Thr Val Thr Phe Asp Ala Phe Asp Ile Trp
 85        90        95
Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Ser Ala Ser Ala Pro
100       105       110
Thr Leu Phe Pro Leu Val Ser Cys Glu Asn Ser Pro Ser Asp Thr Ser
115       120       125
Ser Val Ala Val Gly Cys Leu Ala Gln Asp Phe Leu Pro Asp Ser Ile
130       135       140
Thr Phe Ser Trp Lys Tyr Lys Asn Asn Ser Asp Ile Ser Ser Thr Arg
145       150       155       160
Gly Phe Pro Ser Val Leu Arg Gly Gly Lys Tyr Ala Ala Thr Ser Gln
165       170       175
Val Leu Leu Pro Ser Lys Asp Val Met Gln Gly Thr Asp Glu
180       185       190

```

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 147 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO

25

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

```

Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser
 1         5         10        15
Gln Ser Val Leu Tyr Ser Phe Asn Asn Lys Asn Tyr Leu Ala Trp Tyr
 20        25        30
Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser
 35        40        45
Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly
 50        55        60
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala
 65        70        75        80
Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Arg Thr Phe Gly Gln
 85        90        95
Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
100        105        110
Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
115        120        125
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
130        135        140
Lys Val Ile
145

```

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 149 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

```

Asn Pro Gln Thr Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser
 1         5         10        15
Leu Ile Thr Arg Gly Val Gly Val Asp Trp Ile Arg Gln Pro Pro Gly
 20        25        30
Lys Ala Leu Gln Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg

```

35 40 45
 Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser
 50 55 60
 Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr
 65 70 75 80
 Ala Thr Tyr Tyr Cys Ala His His Phe Phe Asp Ser Ser Gly Tyr Tyr
 85 90 95
 Pro Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Ser Val Ser Ser Ala
 100 105 110
 Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser
 115 120 125
 Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
 130 135 140
 Pro Glu Pro Val Thr
 145

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 148 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Val Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala
 1 5 10 15
 Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ser Asp Gly Lys
 20 25 30
 Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Pro Pro Gln Leu
 35 40 45
 Leu Ile Tyr Glu Ala Phe Asn Arg Phe Ser Gly Val Pro Asp Arg Phe
 50 55 60
 Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val
 65 70 75 80
 Glu Ala Glu Asp Val Gly Leu Tyr Tyr Cys Met Gln Ser Ile Glu Leu
 85 90 95
 Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
 100 105 110
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys

27

115 120 125
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140
 Lys Glu Arg Val
 145

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 173 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Gly Glu Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
 1 5 10 15
 Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln
 20 25 30
 Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Ser
 35 40 45
 Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
 50 55 60
 Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg
 65 70 75 80
 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ser Gly Trp
 85 90 95
 Tyr Glu Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
 100 105 110
 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys
 115 120 125
 Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys
 130 135 140
 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
 145 150 155 160
 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
 165 170

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

```

Leu Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
 1       5       10      15
Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ile
 20      25      30
Tyr Leu Ala Trp Phe Gln Gln Arg Pro Gly Lys Ala Pro Lys Ser Leu
 35      40      45
Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser
 50      55      60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
 65      70      75      80
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro
 85      90      95
Phe Thr Phe Gly Pro
 100

```

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 159 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

```

Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Arg Gly Val Gly
 1       5       10      15

```

Val Asp Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Gln Trp Leu Ala
 20 25 30
 Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser
 35 40 45
 Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr
 50 55 60
 Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His
 65 70 75 80
 His Phe Phe Asp Ser Ser Gly Tyr Tyr Pro Phe Asp Ser Trp Gly Gln
 85 90 95
 Gly Thr Leu Val Ser Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 100 105 110
 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
 115 120 125
 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 130 135 140
 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Gln Leu
 145 150 155

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 167 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
 1 5 10 15
 Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln
 20 25 30
 Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Ser Val Ser Gly
 35 40 45
 Ile Thr Thr Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
 50 55 60
 Arg Asp Asn Ser Lys Asn Ile Leu Tyr Leu Gln Met Asn Ser Leu Arg
 65 70 75 80
 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Arg Ile Phe Gly Val
 85 90 95

Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 100 105 110
 Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu
 115 120 125
 Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 130 135 140
 Val Thr Val Ser Trp Asn Leu Gly Ala Leu Thr Ser Gly Val His Thr
 145 150 155 160
 Phe Pro Ala Val Leu Gln Ser
 165

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 164 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Gly Ile Arg Leu Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser
 1 5 10 15
 Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
 20 25 30
 Ile Ser Ile Tyr Leu Ala Trp Phe Gln Gln Arg Pro Gly Lys Ala Pro
 35 40 45
 Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser
 50 55 60
 Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80
 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn
 85 90 95
 Ser Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Lys Pro Asn

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GACTACGAAT TCTTGTAGGA CCGGCGAGGA ATAGG

35

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GACTACGGGC CCGGTGAGAA CTTGGAATCT TGCAAGC

37

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

32

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GCAGTCTCCT AAAGTGCT

18

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

ACCTGCAAGG CCAGT

15

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

CACTCATTCC TGTTGAAG

18

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 500 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

```
TCAGAAGAAG TGAAGTCAAG ATGAAGAACC ATTTGCTTTT
CTGGGGGAGTC CTGGCGGTTT   60
TTATTAAGGC TGTTTCATGTG AAAGCCCAAG AAGATGAAAG
GATTGTTCTT GTTGACAACA   120
AATGTAAGTG TGCCCGGATT ACTTCCAGGA TCATCCGTTT
TTCCGAAGAT CCTAATGAGG   180
ACATTGTGGA GAGAAACATC CGAATTATTG TTCCTCTGAA
CAACAGGGAG AATATCTCTG   240
ATCCACCTC ACCATTGAGA ACCAGATTTG TGTACCATTG GTCTGACCTC
TGTA AAAAAT   300
GTGATCCTAC AGAAGTGGAG CTGGATAATC AGATAGTTAC
TGCTACCCAG AGCAATATCT   360
GTGATGAAGA CAGTGCTACA GAGACCTGCT ACACTTATGA
CAGAAACAAG TGCTACACAG   420
CTGTGGTCCC ACTCGTATAT GGTGGTGAGA CAAAATGGT
GGAAACAGCC TTAACCCAG   480
ATGCCTGCTA TCCTGACTAA           500
```

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

34

GAATTCAGAA GAAGTGAAGT C

21

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GTCGACTATG CAGTCAGCAA TGAC

24

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

TGCAGGAATC AGACCCAGTC

20

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

35

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

GTCAGGCTGG AACTGAGGAG CA

22

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

TCATTGCTG ATCAGCACT

19

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GCTAGCTGAG GAGACGGTGA CCAGG

25

(2) INFORMATION FOR SEQ ID NO:54:

36

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

TCATTTGGTG ATCAGCACT

19

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GGATCCTGAG GAGACGGTGA CG

22

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

37

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

GGATTAGCAT CCGCCCCAAC CCTT

24

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GTCGACGCAC ACACAGAGCG GCCA

24

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

GACTACGAAT TCGGACCGGC GAGGAATAGG AATCATG

37

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

GGATGGTGTT GGTAGCTAGC ACGCGGAGCG TGATGATGGC CTG

43

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

GACTACGAAT TCACGAGGCG ACATGGCGGC GGC

33

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

GGATGGTGTGTT GGTAGCTAGC ACACGCAGTG AGATGGTTTC CCG
43

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 617 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

GGACTGTTGA AGCCTTCGGA GACCCTGTCC CTCACCTGCG
CTGTCTATGG TGGGTCCTTC 60
AGTGGTACT ACTGGAGCTG GATCCGCCAG CCCCAGGGA
AGGGGCTGGA GTGGATTGGG 120
GAAATCAATC ATAGTGGAAG CACCAACTAC AACCCGTCCC
TCAAGAGTCG AGTCACCATA 180
TCAGTAGACA CGTCCAAGAA CCAGTTCTCC CTGAAGCTGA
GCTCTGTGAC CGCNGCGGAC 240
ACGGCTGTGT ATTACTGTGC GAGAGGCACT ACGGAATATT
ACTACTACTA CTACGGTATG 300
GACGTCTGGG GCCAAGGGAC CACGGTCACC GTCTCCTCAG
GGAGTGCATC CGCCCCAACC 360
CTTTTCCCCC TCGTCTCCTG TGAGAATTCC CCGTCGGATA
CGAGCAGCGT GGCCGTTGGC 420
TGCCTCGCAC AGGACTTCCT TCCCGACTYC ATCACTTTCT CCTGGAAATA
CAAGAACAAC 480
TCTGACATCA GCAGCACCCG GGGCTTCCCA TCAGTCCTGA
GAGGGGGCAA GTACGCAGCC 540
ACCTCACAGG TGCTGCTGCC TTCCAAGGAC GTCATGCAGG
GCACAGACGA ACACGTGGTG 600
ACGGGATCCA AAGAGTA 617

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 444 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

```
CTCTCCCTGC CCGTCACCCC TGGAGAGCCG GCCTCCATCT
CCTGCAGGTC TAGTCAGAGC   60
CTCCTGCATA GTAATGGATA CAACTATTTG GATTGGTACC
TGCAGAAGCC AGGGCAGTCT   120
CCACAGCTCC TGATCTATTT GGGTTCTAAT CGGGCCTCCG
GGGTCCCTGA CAGGTTCACT   180
GGCAGTGGAT CAGGCACAGA TTTTACACTG AAAATCAGCA
GAGTGGAGGC TGAGGATGTT   240
GGGATTTATT ACTGCATGCA GACTCGACAA ACTCCTCGGA
CGTTCGGCCA AGGGACCAAG   300
GTGGAAATCA AACGAACTGT GGCTGCACCA TCTGTCTTCA
TCTTCCCGCC ATCTGATGAG   360
CAGTTGAAAT CTGGAAGTGC CTCTGTTGTG TGCCTGCTGA
ATAACTTCTA TCCCAGAGAG   420
GCCAAAGAGC ATCAAAGAG TCCA   444
```

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 593 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

```
CTGGTGAAGC CTTCGGAGAC CCTGTCCCTC ACCTGCACTG
TCTCTGGTGG CTCCATCAGT   60
AGTTACTACT GGAAGTGGAT CCGGCAGCCC CCAGGGAAGG
GACTGGAGTG GATTGGGTAT   120
ATCTATTACA GTGGGAGCAC CAACTACAAC CCCTCCCTCA
```

41

AGAGTCGAGT CACCATATCA 180
GTAGACACGT CCAAGAACCA GTTCTCCCTG AAGCTGAGCT
CTGTGACCGC TCGGACACG 240
GCCGTGTATT ACTGTGCGAG AGATAGGGGA GTGGGAGCTA
CTGGTTTTGA CTACTGGGGC 300
CAGGGAACCC TGGTCACCGT CTCCTCAGGG AGTGCATCCG
CCCCAACCTT TTTCCCCCTC 360
GTCTCCTGTG AGAATTCCCC GTCGGATACG AGCAGCGTGG
CCGTTGGCTG CCTCGCACAG 420
GACTTCCTTC CCGACTCCAT CACTTTCTCC TGGAAATACA
AGAACAATC TGACATCAGC 480
AGCACCCGGG GCTTCCCATC AGTCCTGAGA GGGGGCAAGT
ACGCAGCCAC CTCACAGGTG 540
CTGCTGCCTT CCAAGGACGT CATGCAGGGC ACAGACGAAC
ACAAGGTGTG CGA 593

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 441 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

AGCCAGTCTC CATCCTCCCT GTCTGCATCT GTAGGAGAGA
GAGTCACCAT CACTTGCCGG 60
GCAAGTCAGG GCATTAGAGA TGAATTAGGC TGGTATCAGC
AGAAACCAGG GAAAGCCCCT 120
AAGCGCCTGA TCTATGTTGC ATCCAGTTTG CAAAGTGGGG
TCCCATCAAG GTTCAGCGGC 180
AGTGGATCTG GGACAGAATT CACTCTCACA ATCAGCAGCC
TGCAGCCTGA AGATTTTGCA 240
ACTTATTACT GTCTACAGCA TAATGGTTAC CCTCGGACGT
TCGGCCAAGG GACCAAGGTG 300
GAAATCAAAC GAACTGTGGC TGCACCATCT GTCTTCATCT
TCCCGCCATC TGATGAGCAG 360
TTGAAATCTG GAACTGCCTC TGTTGTGTGC CTGCTGAATA ACTTCTATCC
CAGAGAGGCC 420
AAAGAGCATC AAAAGAGTCC A 441

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 610 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

```
AAGAAGCCTG GGCCTCAGT GAAGGTCTCC TGCAAGGCTT
CTGGATACAC CTTACCAAGT   60
TATGATATCA ACTGGGTGCG ACAGGCCACT GGACAAGGGC
TTGAGTGGAT GGGATGGATG   120
AACCCTAACA GTGGTAACAC AGGCTATGCA CAGAAGTTCC
AGGGCAGAGT CACCATGAAC   180
AGGAACACCT CCATAAGCAC AGCCTACATG GAGCTGAGCA
GCCTGAGATC TGAGGACACG   240
GCCGTGTATT ACTGTGCGAG AGGGGGTTCAT GGTGGGAGCT
ACTTCTACTC CTAYTACGGT   300
ATGGACGTCT GGGGCCAGGG GACCACGGTC ACCGTCTCCT
CAGGGAGTGC ATCCGCCCA   360
ACCCTTTTCC CCCTCGTCTC CTGTGAGAAT TCCCCGTGCG
ATACGAGCAG CGTGGCCGTT   420
GGCTGCCTCG CACAGGACTT CCTTCCCGAC TCCATCACTT
TCTCCTGGAA ATACAAGAAC   480
AACTCTGACA TCAGCAGCAC CCGGGGCTTC CCATCAGTCC
TGAGAGGGGG CAAGTACGCA   540
GCCACCTCAC AGGTGCTGCT GCCTTCCAAG GACGTCATGC
AGGGCACAGA CGAACACGTG   600
GTGTGCAAAC                               610
```

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 447 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

43

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

CACTCCCTGG CTGTGTCTCT GGGCGAGAGG GCCACCATCA
ACTGCAAGTC CAGCCAGAGT 60
GTTTTATACA GTTTTAACAA TAAGAACTAC TTAGCTTGGT
ACCAGCAGAA ACCAGGACAG 120
CCTCCTAAGC TGCTCATTTA CTGGGCATCT ACCCGGGAAT
CCGGGGTCCC TGACCGATT 180
GGTGGCAGCG GGTCTGGGAC AGATTTCACT CTCACCATCA
GCAGCCTGCA GGCTGAAGAT 240
GTGGCAGTTT ATTACTGTCA GCAATATTAT AGTACTCCTM
GGACGTTCGG CCAAGGGACC 300
AAGGTGGAAT TCAAACGAAC TGTGGCTGCA CCATCTGTCT
TCATCTTCCC GCCATCTGAT 360
GAGCAGTTGA AATCTGGAAC TGCCTCTGTT GTGTGCCTGC
TGAATAACTT CTATCCCAGA 420
GAGGCCAAAG AGCATCAAAA GAGTCCA

447

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 599 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GAGGTGAAGA AGCCTGGGGC CTCAGTGAAG GTCTCCTGCA
AGGCTTCTGG ATACACCTTC 60
ACCAGTTATG ATATCAACTG GGTGCGACAG GCCACTGGAC
AAGGGCTTGA GTGGATGGGA 120
TGGATGAACC CTAACAGTGG TAACACAGGC TATGCACAGA
AGTTCCAGGG CAGAGTCACC 180
ATGACCAGGA ACACCTCCAT AAGCACAGCC TACATGGAGC
TGAGCAGCCT GAGATCTGAG 240

44

GACACGGCCG TGTATTACTG TGCGAGAGAG GAGTGGCTGG
TACGTTACTA CGGTATGGAC 300
GTCTGGGGCC AAGGGACCAC GGTCAACGTC TCCTCAGGGA
GTGCATCCGC CCCAACCCTT 360
TCCCCCTCG TCTCCTGTGA GAATTCCCCG TCGGATACGA
GCAGCGTGGC CGTTGGCTGC 420
CTCGCACAGG ACTTCCTTCC CGACTCCATC ACTTTCTCCT GGAAATACAA
GAACAACTCT 480
GACATCAGCA GCACCCGGGG CTTCCCATCA GTCCTGAGAG
GGGGCAAGTA CGCAGCCACC 540
TCACAGGTGC TGCTGCCTTC CAAGGACGTC ATGCAGGGCA
CAGACGAACA CAAGGTGTG 599

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 441 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

GGCCAGTCTC CATCCTCCCT GTCTGCATCT GTAGGAGACA
GAGTCACCAT CACTTGCCGG 60
GCAAGTCAGG ACATTAGAGA TAATTTAGGC TGGTATCAGC
AGAAACCAGG GAAAGCCCCT 120
AAGCGCCTGA TCTATGCTGC ATCCAATTTG CAAAGTGGGG
TCCCATCAAG GTTCAGCGGC 180
AGTGGATCTG GGACAGAATT CACTCTCACA ATCAGCAGCC
TGCAGCCTGA AGATTTTGCA 240
ACTTATTACT GTCTACAGTA TAAAACTTAC CCGTGGACGT
TCGGCCAAGG GACCAAGGTG 300
GAAATCAAAC GAACTGTGGC TGCACCATCT GTCTTCATCT
TCCCGCCATC TGATGAGCAG 360
TTGAAATCTG GAACTGCCTC TGTTGTGTGC CTGCTGAATA ACTTCTATCC
CAGAGAGGMC 420
AAAGAGCATC AAAAGAGTCC A 441

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 607 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

AAGCTTCCGG AGACCCTGTC CCTCACCTGC GCTGTCTATG
GTGGGTCCTT CAGTGGTTAC 60
TACTGGAGCT GGATCCGCCA GCGCCAGGG AAGGGGCTGG
AGTGGATTGG GGAAATCAAT 120
CATAGTGGAA GCACCAACTA CAACCCGTCC CTCAAGAGTC
GAGTCACCAT ATCAGTAGAC 180
ACGTCCAAGA ACCAGTTCTC CCTGAAGCTG AGCTCTGTGA
CCGCCGCGGA CACGGCTGTG 240
TATTACTGTG CGAGAGGGGC AGCTGAATAT TACTACTACT
ACTACGGTAT GGACGTCTGG 300
GGCCAAGGGA CCACGGTCAC CGTCTCCTCA GGGAGTGCAT
CCGCCCCAAC CCTTTTCCCC 360
CTCGTCTCCT GTGAGAATTC CCCGTCGGAT ACGAGCAGCG
TGGCCGTTGG CTGCCTCGCA 420
CAGGACTTCC TTCCCGACTY CATCACTTTC TYCTGGAAAT
ACAAGAACAA CTCTGACATC 480
AGCAGCACCC GGGGCTTCCC ATCAGTCCTG AGAGGGGGCA
AGTACGCAGC CACCTCACAG 540
GTGCTGCTGC CTTCCAAGGA CGTCATGCAG GGCACAGACG
AACACGTGGT GACGGGATCC 600
AAAGAGT 607

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 431 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

```
ATGCCCCGTCA CCCCTGGAGA GCCGGCCTCC ATCTCCTGCA
GGTCTAGTCA GAGCCTCCTG   60
CATAGTAATG GATACAACTA TTTGGACTGG TACCTGCAGA
AGCCAGGGCA GTCTCCACAG   120
CTCCTGATCT ATTTGGGTTC TAATCGGGCC TCCGGGGTCC
CTGACAGGTT CAGTGGCAGT   180
GGATCAGGCA CAGATTTTAC ACTGAAAATC AGCAGAGTGG
AGGCTGAGGA TGTGGGATT   240
TATTACTGCA TGCAAAGTCT ACAAATCCC CGGCTTTTCG
GCCCTGGGAC CAAAGTGGAT   300
ATCAAACGAA CTGTGGCTGC ACCATCTGTC TTCATCTTCC
CGCCATCTGA TGAGCAGTTG   360
AAATCTGGAA CTGCCTCTGT TGTGTGCCTG CTGAGTAACT
TCTATCCCAG AGAGGCCAAA   420
GTACAGTGGA A
```

431

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 570 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

```
TCGGAGACCC TGTCCCTCAC CTGCGCTGTC TATGGTGGGT
CCTTCAGTGG TTACTACTGG   60
AGCTGGATCC GCCAGCCCCC AGGGAAGGGG CTGGAGTGGA
TTGGGGAAAT CAATCATAGT   120
GGAAGCACCA ACTACAACCC GTCCCTCAAG AGTCGAGTCA
CCATATCAGT AGACACGTCC   180
AAGAACCAGT TCTCCCTGAA GCTGAGTTCT GTGACCGCCG
CGGACACGGC TGTGTATTAC   240
TGTGCGAGAG GCGGGACTAC AGTAACTTTT GATGCTTTTG
ATATCTGGGG CCAAGGGACA   300
```

47

ATGGTCACCG TCTCTTCAGG GAGTGCATCC GCCCAACCC TTTTCCCCCT
CGTCTCCTGT 360
GAGAATTCCC CGTCGGATAC GAGCAGCGTG GCCGTTGGCT
GCCTCGCACA GGA CTTCTT 420
CCCGACTCCA TCACTTTCTC CTGGAAATAC AAGAACAAC
CTGACATCAG CAGCACCCGG 480
GGCTTCCCAT CAGTCCTGAG AGGGGGCAAG TACGCAGCCA
CCTCACAGGT GCTGCTGCCT 540
TCCAAGGACG TCATGCAGGG CACAGACGAA 570

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 441 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

CTGGCTGTGT CTCTGGGCGA GAGGGCCACC ATCAACTGCA
AGTCCAGCCA GAGTGTTT 60
TACAGTTTTA ACAATAAGAA CTA CTTAGCT TGGTACCAGC
AGAAACCAGG ACAGCCTCCT 120
AAGCTGCTCA TTTACTGGGC ATCTACCCGG GAATCCGGGG
TCCCTGACCG ATTCAGTGGC 180
AGCGGGTCTG GGACAGATTT CACTCTCACC ATCAGCAGCC
TGCAGGCTGA AGATGTGGCA 240
GTTTATTACT GTCAGCAATA TTATAGTACT CCTCGGACGT
TCGGCCAAGG GACCAAGGTG 300
GAAATCAAAC GAACTGTGGC TGCACCATCT GTCTTCATCT
TCCCGCCATC TGATGAGCAG 360
TTGAAATCTG GAACTGCCTC TGTTGTGTGC CTGCTGAATA ACTTCTATCC
CAGAGAGGCC 420
AAAGTACAGT GGAAGGTGAT C 441

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 447 base pairs
- (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

AACCCACAGA CGACCCTCAC GCTGACCTGC ACCTTCTCTG
GGTTCTCACT CATTACCCGT 60
GGAGTGGGTG TGGATTGGAT CCGTCAGCCC CCAGGAAAGG
CCCTGCAGTG GCTCGCACTC 120
ATTTATTGGA ATGATGATAA GCGCTACAGT CCATCTCTGA
AGAGCAGGCT CACCATCACC 180
AAGGACACCT CAAAAACCA GGTGGTCCTC ACAATGACCA
ACATGGACCC TGTGGACACA 240
GCCACATATT ACTGTGCACA CCATTTCTTT GATAGTAGTG GTTATTACCC
TTTGTACTCC 300
TGGGGCCAGG GAACCCTGGT CTCCGTCTCC TCAGCCTCCA
CCAAGGGCCC ATCGGTCTTC 360
CCCCTGGCGC CCTGCTCCAG GAGCACCTCC GAGAGCACAG
CGGCCCTGGG CTGCCTGGTC 420
AAGGACTACT TCCCCGAACC GGTGACG 447

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 445 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

GTGACTCAGT CTCCACTCTC TCTGTCCGTC ACCCCTGGAC
AGCCGGCCTC CATCTCCTGC 60
AAGTCTAGTC AGAGCCTCCT GCATAGTGAT GGAAAGACCT
ATTTGTATTG GTACCTGCAG 120

49

AAGCCAGGCC AGCCTCCACA GCTCCTGATC TATGAAGCTT
TCAACCGGTT CTCTGGAGTG 180
CCAGATAGGT TCAGTGGCAG CGGGTCAGGG ACAGATTTCA
CACTGAAAAT CAGCCGGGTG 240
GAGGCTGAGG ATGTTGGACT TTATTATTGC ATGCAAAGTA
TAGAGCTTCC GTTCACTTTC 300
GGCGGAGGGA CCAAGGTGGA GATCAAACGA ACTGTGGCTG
CACCATCTGT CTTATCTTC 360
CCGCCATCTG ATGAGCAGTT GAAATCTGGA ACTGCCTCTG
TTGTGTGCCT GCTGAATAAC 420
TTCTATCCCA GAAAAGAAAG AGTCR 445

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 519 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

GGGGAAGGCC TGGTCAAGCC TGGGGGGTCC CTGAGACTCT
CCTGTGCAGC CTCTGGATTC 60
ACCTTCAGTA GCTATAGCAT GAACTGGGTC CGCCAGGCTC
CAGGGAAGGG GCTGGAGTGG 120
GTCTCATCCA TTAGTAGTAG TAGTAGTTAC ATATACTACG
CAGACTCAGT GAAGGGCCGA 180
TTCACCATCT CCAGAGACAA CGCCAAGAAC TCACTGTATC
TGCAAATGAA CAGCCTGAGA 240
GCCGAGGACA CGGCTGTGTA TTACTGTGCG AGGGATAGCA
GTGGCTGGTA TGAGGACTAC 300
TTTGACTACT GGGGCCAGGG AACCCTGGTC ACCGTCTCCT
CAGCCTCCAC CAAGGGCCCA 360
TCGGTCTTCC CCCTGGCGCC CTGCTCCAGG AGCACCTCCG
AGAGCACAGC GGCCCTGGGC 420
TGCCTGGTCA AGGACTACTT CCCCGAACCG GTGACGGTGT
CGTGGAATC AGGCGCTCTG 480
ACCAGCGGCG TGCACACCTT CCCAGCTGTC CTACAGTCA
519

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 303 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

```
CTTGACATCC AGCTGACCCA GTCTCCGTCC TCACTGTCTG
CATCTGTAGG AGACAGAGTC   60
ACCATCACTT GTCGGGCGAG TCAGGACATT AGCATTTATT
TAGCCTGGTT TCAGCAGAGA  120
CCAGGGAAAG CCCCTAAGTC CCTGATCTAT GCTGCATCCA
GTTTGCAAAG TGGGGTCCCA  180
TCAAAGTTCA GCGGCAGTGG ATCTGGGACA GATTTCACTC
TCACCATCAG CAGCCTGCAG  240
CCTGAAGATT TTGCAACTTA TTA CTGCCAA CAATATAATA GTTATCCATT
CACTTTCGGG  300
CCC                                     303
```

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 477 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

```
CTGACCTGCA CCTTCTCTGG GTTCTCACTC ATTACCCGTG
GAGTGGGTGT GGATTGGATC   60
CGTCAGCCCC CAGGAAAGGC CCTGCAGTGG CTCGCACTCA
```

TTTATTGGAA TGATGATAAG 120
CGCTACAGTC CATCTCTGAA GAGCAGGCTC ACCATCACCA
AGGACACCTC CAAAAACCAG 180
GTGGTCCTCA CAATGACCAA CATGGACCCT GTGGACACAG
CCACATATTA CTGTGCACAC 240
CATTTCTTTG ATAGTAGTGG TTATTACCCT TTTGACTCCT
GGGGCCAGGG AACCTGGTC 300
TCCGTCTCCT CAGCCTCCAC CAAGGGCCCA TCGGTCTTCC
CCCTGGCGCC CTGCTCCAGG 360
AGCACCTCCG AGAGCACAGC GGCCCTGGGC TGCCTGGTCA
AGGACTACTT CCCCGAACCG 420
GTGACGGTGT CGTGGAAGTC AGGCGCTCTG ACCAGCGGCG
TGCACACCTT CCAGCTG 477

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 503 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

GGGGGAGGCT TGGTACAGCC TGGGGGGTCC CTGAGACTCT
CCTGTGCAGC CTCTGGATTC 60
ACTTTTAGCA GCTATGCCAT GAGCTGGGTC CGCCAGGCTC
CAGGGAAGGG GCTGGAGTGG 120
GTCTCAACTA TTAGTGTTAG TGGTATTACC ACATACTACG
TAGACTCCGT GAAGGGCCGG 180
TTCACCATCT CCAGAGACAA TTCCAAGAAC ATTCTGTATC
TGCAAATGAA CAGCCTGAGA 240
GCCGAGGACA CGGCCGTATA TTACTGTGCG AAACGGATTT
TTGGAGTGGT CTGGGGCCAG 300
GGAACCCTGG TCACCGTCTC CTCAGCCTCC ACCAAGGGCC
CATCGGTCTT CCCCCTGGCG 360
CCCTGCTCCA GGAGCACCTC CGAGAGCACA GCGGCCCTGG
GCTGCCTGGT CAAGGACTAC 420
TTCCCCGAAC CGGTGACGGT GTCGTGGAAC TTAGGCGCTC
TGACCAGCGG CGTGCACACC 480
TTCCCAGCTG TCCTACAGTC CTA 503

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 494 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GGAATTCGGC TTGATATTCA GCTGACTCAG TCTCCATCCT CACTGTCTGC
ATCTGTAGGA 60
GACAGAGTCA CCATCACTTG TCGGGCGAGT CAGGGCATT
GCATTTATTT AGCCTGGTTT 120
CAGCAGAGAC CAGGGAAAGC CCCTAAGTCC CTGATCTATG
CTGCATCCAG TTTGCAAAGT 180
GGGGTCCCAT CAAAGTTCAG CGGCAGTGGA TCTGGGACAG
ATTTCACTCT CACCATCAGC 240
AGCCTGCAGC CTGAAGATTT TGCAACTTAT TACTGCCAAC
AATATAATAG TTACCCATTC 300
ACTTTTCGGCC CTGGGACCAA AGTGGATATC AAACGAACTG
TGGCTGCACC ATCTGTCTTC 360
ATCTTCCCGC CATCTGATGA GCAGTTGAAA TCTGGAACTG
CCTCTGTTGT GTGCCTGCTG 420
AATAACTTCT ATCCAGAGA GGCCAAAGTA CAGTGGAAGG
TGGATAACGC CCTCCAATCG 480
GGTAAGCCGA ATTC 494

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1774 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

ATGTACTTGG GACTGAACTA TGTATTCATA GTTTTTCTCT TAAATGGTGT
CCAGAGTGAA 60
GTGAAGCTTG AGGAGTCTGG AGGAGGCTTG GTGCAACCTG
GAGGATCCAT GAAACTCTCC 120
TGTGTTGCCT CTGGATTAC TTTAGTAAC TACTGGATGA
ACTGGGTCCG CCAGTCTCCA 180
GAGAAGGGGC TTGAGTGGGT TGCTGAAATT AGATTGAAAT
CTAATAATTA TGCAACACAT 240
TATGCGGAGT CTGTGAAAGG GAGGTCACC ATCTCAAGAG
ATGATTCCAA AAGTAGTGTC 300
TACCTGCAAA TGAACAACTT AAGAGCTGAA GAACTGGCA
TTTATTACTG TACGGATTAC 360
GATGCTTACT GGGGCCAAGG GACTCTGGTC ACTGTCTCTG
CAGAGAGTCA GTCCTTCCCA 420
AATGTCTTCC CCCTCGTCTC CTGCGAGAGC CCCCTGTCTG
ATAAGAATCT GGTGGCCATG 480
GGCTGCCTGG CCCGGGACTT CCTGCCCAGC ACCATTTCCT
TCACCTGGAA CTACCAGAAC 540
AACACTGAAG TCATCCAGGG TATCAGAACC TTCCCAACAC
TGAGGACAGG GGGCAAGTAC 600
CTAGCCACCT CGCAGGTGTT GCTGTCTCCC AAGAGCATCC
TTGAAGGTTC AGATGAATAC 660
CTGGTATGCA AAATCCACTA CGGAGGCAAA AACAGAGATC
TGCATGTGCC CATTCCAGCT 720
GTCGCAGAGA TGAACCCCAA TGTAATGTG TTCGTCCCAC
CACGGGATGG CTTCTCTGGC 780
CCTGCACCAC GCAAGTCTAA ACTCATCTGC GAGGCCACGA
ACTTCACTCC AAAACCGATC 840
ACAGTATCCT GGCTAAAGGA TGGAAGCTC GTGGAATCTG
GCTTACCAC AGATCCGGTG 900
ACCATCGAGA ACAAAGGATC CACACCCCAA ACCTACAAGG
TCATAAGCAC ACTTACCATC 960
TCTGAAATCG ACTGGCTGAA CCTGAATGTG TACACCTGCC
GTGTGGATCA CAGGGGTCTC 1020
ACCTTCTTGA AGAACGTGTC CTCCACATGT GCTGCCAGTC
CCTCCACAGA CATCCTAACC 1080
TTCACCATCC CCCCTCCTT TGCCGACATC TTCCTCAGCA AGTCCGCTAA
CCTGACCTGT 1140
CTGGTCTCAA ACCTGGCAAC CTATGAAACC CTGAATATCT
CCTGGGCTTC TCAAAGTGGT 1200
GAACCACTGG AAACCAAAAT TAAATCATG GAAAGCCATC
CCAATGGCAC CTTAGTGCT 1260
AAGGGTGTGG CTAGTGTTTG TGTGGAAGAC TGGAATAACA
GGAAGGAATT TGTGTGTACT 1320
GTGACTCACA GGGATCTGCC TTCACCACAG AAGAAATTCA

TCTCAAAACC CAATGAGGTG 1380
CACAAACATC CACCTGCTGT GTACCTGCTG CCACCAGCTC
GTGAGCAACT GAACCTGAGG 1440
GAGTCAGCCA CAGTCACCTG CCTGGTGAAG GGCTTCTCTC
CTGCAGACAT CAGTGTGCAG 1500
TGGCTTCAGA GAGGGCAACT CTTGCCCCAA GAGAAGTATG
TGACCAGTGC CCCGATGCCA 1560
GAGCCTGGGG CCCAGGCTT CTACTTTACC CACAGCATCC
TGACTGTGAC AGAGGAGGAA 1620
TGGA ACTCCG GAGAGACCTA TACCTGTGTT GTAGGCCACG
AGGCCCTGCC ACACCTGGTG 1680
ACCGAGAGGA CCGTGGACAA GTCCACTGGT AAACCCACAC
TGTACAATGT CTCCTGATC 1740
ATGTCTGACA CAGGCGGCAC CTGCTATTGA CCAT 1774



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 16/28, G01N 33/577, A61K 39/395, C07K 14/705	A3	(11) International Publication Number: WO 99/45031 (43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: PCT/US99/04583 (22) International Filing Date: 3 March 1999 (03.03.99) (30) Priority Data: 09/034,607 3 March 1998 (03.03.98) US 09/244,253 3 February 1999 (03.02.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 09/034,607 (CIP) Filed on 3 March 1998 (03.03.98) US 09/244,253 (CIP) Filed on 3 February 1999 (03.02.99) (71) Applicant (for all designated States except US): ABGENIX, INC. [US/US]; 7601 Dumbarton Circle, Fremont, CA 94555 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVIS, C., Geoffrey [US/US]; 1132 Vancouver Avenue, Burlingame, CA 94010 (US). BLACHER, Russell, W. [US/US]; 16800 Columbia Drive, Castro Valley, CA 94552 (US). CORVALAN, Jose, R. [US/US]; 125 Williams lane, Foster City, CA		94404 (US). CULWELL, Alan, R. [US/US]; 290A Hemlock Avenue, Carlsbad, CA 92008 (US). GREEN, Larry, L. [US/US]; Apartment 12, 70 Crestline Drive, San Francisco, CA 94131 (US). HALES, Joanna [GB/US]; 5180 Selma Avenue, Fremont, CA 94536 (US). HAVRILLA, Nancy [US/US]; 6 Marlin Cove, Oakland, CA 94618 (US). IVANOV, Vladimir, E. [RU/US]; 4275 Tanager Common, Fremont, CA 94555 (US). LIPANI, John, A. [US/US]; 2263 Latour Avenue, Livermore, CA 94550 (US). LIU, Qiang [CN/US]; 55 Williams Lane, Foster City, CA 94404 (US). WEBER, Richard, F. [US/US]; 2537 Pacheco Street, San Francisco, CA 94116 (US). YANG, Xiao-Dong [CN/US]; 2833 Bryant Street, Palo Alto, CA 94306 (US). (74) Agents: HALEY, James, F. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. (88) Date of publication of the international search report: 2 March 2000 (02.03.00)
(54) Title: CD147 BINDING MOLECULES AS THERAPEUTICS (57) Abstract <p>In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 99/04583

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K16/28 G01N33/577 A61K39/395 C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>W. KASINRERK ET AL.: "Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse basigin, and chicken HT7 molecule."</p> <p>THE JOURNAL OF IMMUNOLOGY, vol. 149, no. 3, 1 August 1992 (1992-08-01), pages 847-854, XP002116746 Baltimore, MD, USA cited in the application material and methods, subsection 'mAb' abstract</p> <p style="text-align: center;">--- -/--</p>	1-61



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 September 1999

Date of mailing of the international search report

12/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/04583

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	R. BILLING ET AL.: "Monoclonal and heteroantibody reacting with different antigens common to human blast cells and monocytes." HYBRIDOMA, vol. 1, no. 3, 1982, pages 303-311, XP002116747 New York, NY, USA cited in the application abstract discussion	1-61
A	M. MENDEZ ET AL.: "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice." NATURE GENETICS, vol. 15, 1 February 1997 (1997-02-01), pages 146-156, XP002067603 New York, NY, USA cited in the application abstract discussion	1-61
A	E. BENAÏM ET AL.: "Activity of monoclonal antibody CBL1 in corticosteroid resistant acute graft versus host disease." BLOOD, vol. 84, no. 10 suppl. 1, 15 November 1994 (1994-11-15), page 540A XP002116748 New York, NY, USA abstract 2145	1-61
A	DATABASE WPI Week 9437, 26 September 1991 (1991-09-26) Derwent Publications Ltd., London, GB; AN 94-298798 XP002116750 & JP 06 225763 A (NIPPON KOTAI KENKYUSHKO KK ET AL.), 16 August 1994 (1994-08-16) abstract	1-61
P,X	K. VON APPEN: "ABX-CBL." IDRUGS, vol. 2, no. 1, 1999, pages 65-68, XP002116749 the whole document	1-61

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/04583

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 16-21 and 53-59 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT, US 99/04583

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 6225763 A	16-08-1994	NONE	



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 16/28, G01N 33/577, A61K 39/395, C07K 14/705		A2	(11) International Publication Number: WO 99/45031 (43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: PCT/US99/04583 (22) International Filing Date: 3 March 1999 (03.03.99) (30) Priority Data: 09/034,607 3 March 1998 (03.03.98) US 09/244,253 3 February 1999 (03.02.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 09/034,607 (CIP) Filed on 3 March 1998 (03.03.98) US 09/244,253 (CIP) Filed on 3 February 1999 (03.02.99) (71) Applicant (for all designated States except US): ABGENIX, INC. [US/US]; 7601 Dumbarton Circle, Fremont, CA 94555 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVIS, C., Geoffrey [US/US]; 1132 Vancouver Avenue, Burlingame, CA 94010 (US). BLACHER, Russell, W. [US/US]; 16800 Columbia Drive, Castro Valley, CA 94552 (US). CORVALAN, Jose, R. [US/US]; 125 Williams lane, Foster City, CA		94404 (US). CULWELL, Alan, R. [US/US]; 290A Hemlock Avenue, Carlsbad, CA 92008 (US). GREEN, Larry, L. [US/US]; Apartment 12, 70 Crestline Drive, San Francisco, CA 94131 (US). HALES, Joanna [GB/US]; 5180 Selma Avenue, Fremont, CA 94536 (US). HAVRILLA, Nancy [US/US]; 6 Marlin Cove, Oakland, CA 94618 (US). IVANOV, Vladimir, E. [RU/US]; 4275 Tanager Common, Fremont, CA 94555 (US). LIPANI, John, A. [US/US]; 2263 Latour Avenue, Livermore, CA 94550 (US). LIU, Qiang [CN/US]; 55 Williams Lane, Foster City, CA 94404 (US). WEBER, Richard, F. [US/US]; 2537 Pacheco Street, San Francisco, CA 94116 (US). YANG, Xiao-Dong [CN/US]; 2833 Bryant Street, Palo Alto, CA 94306 (US). (74) Agents: HALEY, James, F. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: CD147 BINDING MOLECULES AS THERAPEUTICS			
(57) Abstract In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CD147 BINDING MOLECULES AS THERAPEUTICS

5

BACKGROUND OF THE INVENTION

1. Summary of the Invention

In accordance with the present invention, we have discovered that the
10 molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or
monocytes, can be utilized as a target for the treatment of a variety of diseases. In
particular, we have demonstrated that an antibody that binds to CD147 and that results
in the killing of such cells, for example, through the binding of complement, is
efficacious in the treatment of diseases. Diseases in which such treatment appears
15 efficacious include, without limitation: graft versus host disease (GVHD), organ
transplant rejection diseases (including, without limitation, renal transplant, ocular
transplant, and others), cancers (including, without limitation, cancers of the blood
(i.e., leukemias and lymphomas) and pancreatic), autoimmune diseases (including,
without limitation, lupus), inflammatory diseases (including, without limitation,
20 arthritis), and others.

2. Background of the Technology

In about 1982, a group from UCLA reported the generation of antibodies
cytotoxic to human leukemia cells in mice through immunization with acute leukemia
25 cells followed by formation of hybridomas and screening of the hybridomas in a
microcytotoxicity assay in which toxicity of the antibody against the immunizing cells
and normal lymphocytes was assayed. See U.S. Patent Nos. 5,330,896 and 5,643,740,
the disclosures of which are hereby incorporated by reference in their entirety. One
hybridoma was recovered that was cytotoxic to tumor cells but non-toxic to normal
30 cells (except activated T-cells, activated B-cells, and monocytes were also killed).
Such hybridoma was cloned and isolated and deposited with the ATCC as HB 8214.
The monoclonal antibody expressed by this hybridoma was designated CBL1, and is a
murine IgM. The group further demonstrated that the antibody was reactive with an

antigenic determinant that appeared to be present in the cytoplasm of both activated and nonactivated cells. However, the antigenic determinant appeared to be present on the extracellular membrane of only certain circulating cells, including, activated T-cells, activated B-cells, and resting and activated monocytes, but not present
5 extracellularly on other circulating nonactivated cells.

The group also endeavored to isolate the antigen responsible for the observations. The patents characterize the antigenic determinant recognized by the CBL-1 antibody as being a molecule that:

- 10 (i) is present on the cell membrane and within the cytoplasm of tumor cells and activated lymphocytes;
- (ii) is present in the cytoplasm of unstimulated normal peripheral blood lymphocytes but when these cells are stimulated by antigens or by mitogens, said antigen appears also on the cell membrane;
- (iii) is present on lymphocytes activated in vitro by mitogens;
- 15 (iv) is capable of binding to CBL1 monoclonal antibody which is produced by the hybridoma cell line having the ATCC number HB8214;
- (v) functions as an autocrine growth factor produced by tumor cells and activated lymphocytes;
- (vi) binds to the surface membrane of tumor cells and stimulates the
20 growth of these cells and cells of the lymphoid series;
- (vii) is present in the medium from growing cancer cells and in the serum of patients with cancer and diseases in which activated lymphocytes are present; and
- (viii) has a molecular weight of approximately 15,000 daltons.

25

No improved identification of the antigen to which the CBL1 antibody binds has been accomplished with respect to the UCLA group's papers and patents. Nevertheless, the CBL1 antibody has been effective in patients in the treatment of a variety of diseases including: graft versus host disease (GVHD) and kidney transplant
30 rejection. See e.g., Heslop et al. *The Lancet* 346:805-806 (1995) (GVHD); Benamin *Clinical Trial Monitor* Abstract No. 13385 (1995); Takahashi et al. *The Lancet* 2:1155-1158 (1983) (kidney allograft rejection); Takahashi *Transplantation*

Proceedings 17:10-12 (1985) (kidney allograft rejection); Oei et al. *Transplantation Proceedings* 17:13-16 (1985) (kidney allograft rejection). In connection with such studies, there has been no evidence of safety concerns or cross-reactivity. The following papers relate to additional characterization of the CBL1 antibody: Billing et al. *Hybridoma* 1:303-311 (1982); Billing et al. *Clin. Exp. Immunol.* 49:142-148 (1982); Chatterjee et al. *Hybridoma* 1:369-377 (1982); Billing R. and Chatterjee S. *Transplantation Proceedings* 15:649-650 (1983); Kinukawa T. and Terasaki P.I. *Transplantation Proceedings* 1:993-998 (1985); Billing in *Monoclonal Antibodies: Diagnostic and Therapeutic Use in Tumor and Transplantation* Ch. 9, 85-90 (Chatterjee ed., PSG Publ. Co., Inc. (1985)); Billing et al. in *Monoclonal Antibodies: Diagnostic and Therapeutic Use in Tumor and Transplantation* Ch. 2, 11-19 (Chatterjee ed., PSG Publ. Co., Inc. (1985)).

Human Graft Versus Host Disease (GVHD) was first described by Mathe et al. in 1960 (Mathe et al. "Nouveaux essais de greffe de moelle osseuse homologue apres irradiation totale chez des enfants atteints de leucemie aigue en remission. Le probleme du syndrome secondaire chez l'homme" *Rev Fr Etud Clin Biol* 15:115-161 (1960)). Essentially GVHD is the clinical manifestation of an immunological reaction between donor cells and host tissue. The clinical syndrome consists of skin rash, gastro-intestinal symptoms, and hepatic dysfunction seen usually within two weeks of allogeneic bone marrow transplant. The immunopathogenesis requires recognition of host antigens by immunocompetent donor cells; immunosuppressed host (recipient); and alloantigenic differences to exist between donor and recipient. The immunocompetent donor cells are mature T-cells (Ferrara JL and Deeg HJ "Graft versus Host Disease" *NEJM* 324:667 (1991) and the clinical severity of the disease correlates with the number of T-cells transferred to the patient (Ferrara JL and Deeg HJ "Graft versus Host Disease" *NEJM* 324:667 (1991)).

The clinical features of acute GvHD include dermatitis, jaundice and gastro-intestinal involvement. These symptoms may occur alone or in any combination and can range from mild to life-threatening. Skin involvement is the most common manifestation. The most severe manifestation of skin involvement includes bullous lesions similar to third degree burns. Jaundice is brought about from an elevated bilirubin with and without alteration of other liver enzymes. Gastro-intestinal

involvement includes watery diarrhea. This diarrhea can be voluminous and bloody, causing life-threatening fluid and electrolyte losses as well as a portal of entry for infections. Other patients may experience severe ileus. Upper GI involvement is less common. This presents as anorexia, dyspepsia, food intolerance and nausea/vomiting.

5 Most patients with GI involvement require total parenteral nutrition (TPN) support.

Strategies for prevention and possibly treatment should be and sometimes are, directed towards removal of T-cells from the donor marrow or toward blocking their activation. However, the T- depleted marrow results in a higher rate of graft failure that is usually fatal. An additional concern associated with T-depleted marrow is the
10 increased relapse rate in marrow recipients with a primary diagnosis of leukemia. A graft versus leukemia effect, mediated by donor T-cells, also mitigates against using a T-depleted marrow in allogeneic bone marrow transplantation.

Clinically significant acute GVHD (Grades II – IV) occurs in up to 50% of patients who receive a marrow from a HLA genotypically identical sibling. If
15 unrelated matched donors are used, the incident increases to 80% in some studies. The greater the HLA incompatibility, the greater the incidence and severity of GVHD.

The primary treatment for acute GvHD is prevention. Prevention regimens include the use of immunosuppression therapy and T-cell depletion of the donor cells. “Standard” first-line therapy consists of glucocorticoids. Approximately 20-25% of
20 patients achieve a complete response and patients who do not respond have a poor outcome. Those patients who continue to require treatment with steroids are susceptible to all of the untoward effects of steroid use. These untoward effects include increased susceptibility to infections, GI bleed, altered metabolic states, hypertension, etc.

25 Glucocorticoids, cyclosporine, methotrexate, cyclophosphamide have all been used in prevention as well as treatment of GVHD. Anti-thymocyte globulin (ATG) has been used for many years. All of these agents are potentially quite toxic. Monoclonal antibodies such as anti-Interleukin-2 and immunotoxins like anti-CD5-ricin have been used and found to be of limited success. A humanized anti-TAC was
30 used for prophylaxis of GVHD but failed in the treatment protocols.

Because of the indication that CBL1 was effective in treating GVHD, we undertook additional investigations of the CBL1 antibody. In connection with such

additional work, we have now demonstrated that the CBL1 antibody, in fact, appears to bind to and be efficacious with respect to the CD147 antigen as expressed on certain cells, such as T-cells, B-cells, and/or monocytes through the process of complement dependent cytotoxicity (killing).

5 CD147 is a member of the immunoglobulin (Ig) superfamily that is expressed on a large number of different cells in a variety of tissues. It was originally named human Basigin (for basic immunogloblin superfamily) and was first cloned in about 1991. (Miyauchi et al. *J Biochem (Tokyo)* 110:770-774 (1991); Kanekura et al. *Cell Struct Funct* 16:23-30 (1991); Miyauchi et al. *J Biochem (Tokyo)* 110:770-774
10 (1991)). The molecule is composed of approximately 269 amino acids (Miyauchi et al. *J Biochem (Tokyo)* 110:770-774 (1991)) and is a glycoprotein with about 40% of its molecular weight made up of carbohydrate, having a predicted deglycosylated molecular weight of approximately 27 KD and a fully glycosylated molecular weight of between 43-66 KD (Kanekura et al. *Cell Struct Funct* 16:23-30 (1991)). The
15 Basigin gene was mapped to Chromosome 19p13.3 (Kaname et al. *Cytogenet Cell Genet* 64:195-197 (1993)).

The molecule has been identified to possess homology with, or identity to, a number of other molecules, including:

Mouse Basigin (Miyauchi et al. *J Biochem (Tokyo)* 107:316-323 (1990);
20 Joseph et al. *Adv Exp Med Biol* 342:389-391 (1993); Kaname et al. *J Biochem (Tokyo)* 118:717-724 (1995));

Rabbit Basigin (Schuster et al. *Biochim Biophys Acta* 1311:13-19 (1996));

Mouse gp42 (Altruda et al. *Gene* 85:445-451 (1989); Imboden et al. *J Immunol* 143:3100-3103 (1989); Cheng et al. *Biochim Biophys Acta* 1217:307-311
25 (1994));

Chicken HT7 or 5A11 (Albrecht et al. *Brain Res* 535:49-61 (1990);
Seulberger et al. *EMBO J* 9:2151-2158 (1990); Miyauchi et al. *J Biochem (Tokyo)* 110:770-774 (1991); Janzer et al. *Adv Exp Med Biol* 331:217-221 (1993); Lobrinus et al. *Brain Res Dev Brain Res* 70:207-211 (1992); Seulberger et al. *Neurosci Lett*
30 140:93-97 (1992); Fadool JM & Linser PJ *J Neurochem* 60:1354-136 (1993); Fadool JM & Linser PJ *Dev Dyn* 196:252-262 (1993); Unger et al. *Adv Exp Med Biol* 331:211-215 (1993); Rizzolo LJ & Zhou S *J Cell Sci* 108:3623-3633 (1995); Ikeda et

al. *Neurosci Lett* **209**:149-152 (1996) ; Fadool JM & Linser PJ *Biochem Biophys Res Commun* **229**:280-286 (1996));

Neurothelin (Schlosshauer B & Herzog KH *J Cell Biol* **110**:1261-1274 (1990); Schlosshauer B *Development* **113**:129-140 (1991); Schlosshauer B *BioEssays* **15**:341-346 (1993); Schlosshauer et al. *Eur J Cell Biol* **68**:159-166 (1995));

M6 leukocyte activation antigen (Felzmann et al. *J Clin Immunol* **11**:205-212 (1991); Gadd et al. *Rheumatol Int* **12**:153-157 (1992); Kasinrerker et al. *J Immunol* **149**:847-854 (1992));

OX-47 (Fossum et al. *Eur J Immunol* **21**:671-679 (1991); Fossum et al. *Eur J Immunol* **21**:671-679 (1991); Cassella et al. *J Anat* **189**:407-415 (1996));

Mo3 (Mizukami et al. *J Immunol* **147**:1331-1337 (1991));

CE9 (Petruszak et al. *J Cell Biol* **114**:917-927 (1991); Scott LJ & Hubbard AL *J Biol Chem* **267**:6099-6106 (1992); Nehme et al. *J Cell Biol* **120**:687-694 (1993); Cesario MM & Bartles JR *J Cell Sci* **107**:561-570 (1994); Cesario et al. *Dev Biol* **169**:473-486 (1995); Nehme et al. *Biochem J* **310**:693-698 (1995));

EMMPRIN (Biswas et al. *Cancer Res* **55**:434 (1995); DeCastro et al. *J Invest Dermatol* **106**:1260-1265 (1996));

RET-PE2 (Finnemann et al. *Invest Ophthalmol Vis Sci* **38**:2366-2374 (1997));

Ok^a Blood Group Antigen (Spring et al. *Eur J Immunol* **27**:891-897 (1997));

and

1W5 (Seulberger et al. *EMBO J* **9**:2151-2158 (1990)).

Indeed, Seulberger et al. *Neurosci Lett* **140**:93-97 (1992) demonstrated that HT7, Neurothelin, Basigin, gp42 and OX-47 were each names for one molecule which is a developmentally regulated immunoglobulin-like surface glycoprotein which is present on blood-brain barrier endothelium, epithelial tissue barriers, and neurons. Further, Kasinrerker et al. *J Immunol* **149**:847-854 (1992) demonstrated that the human leukocyte activation antigen M6 is a member of the Ig superfamily and is the species homologue of rat OX47, mouse Basigin, and chicken HT7 antigens. EMMPRIN was demonstrated to be identical to the M6 antigen and human Basigin (Biswas et al. *Cancer Res* **55**:434 (1995)). See also Guo et al. "Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix

metalloproteinases" *Gene* 220:99-108 (1998) conducted additional characterization of the gene for human EMMPRIN;

Through its homology with the related molecules, CD147 has been shown or postulated to have a role in a number of physiological processes, diseases, and/or conditions. For example, an early role postulated for the molecule was activity in the blood-brain barrier. Such relationship was first demonstrated with respect to the chick HT7 antigen (Risau et al. *EMBO J* 5:3179-3183 (1986); Albrecht et al. *Brain Res* 535:49-61 (1990); Seulberger et al. *EMBO J* 9:2151-2158 (1990); Janzer et al. *Adv Exp Med Biol* 331:217-221 (1993); Lobrinus et al. *Brain Res Dev* 70:207-211 (1992); Unger et al. *Adv Exp Med Biol* 331:211-215 (1993)). A similar relationship was observed in connection with Neurothelin (Schlosshauer B & Herzog KH *J Cell Biol* 110:1261-1274 (1990); Schlosshauer B *Development* 113:129-140 (1991); Schlosshauer B *BioEssays* 15:341-346 (1993); Schlosshauer et al. *Eur J Cell Biol* 68:159-166 (1995)). The molecule has also been postulated to be involved in development and activation of various cells, for example: lymphocyte activated killer (LAK) cell activation (Imboden et al. *J Immunol* 143:3100-3103 (1989)), T-cell activation (Paterson et al. *Mol Immunol* 24:1281-1290 (1987); Kirsch et al. *Tissue Antigens* 50:147-152 (1997)), leukocyte activation (Fossum et al. *Eur J Immunol* 21:671-679 (1991); Fossum et al. *Eur J Immunol* 21:671-679 (1991)), and mononuclear phagocyte activation (Mizukami et al. *J Immunol* 147:1331-1337 (1991)). Other regulatory, signaling, and recognition functions have also been postulated, for instance: MHC function (Miyauchi et al. *J Biochem (Tokyo)* 107:316-323 (1990)), signal transduction and membrane transport (Kasinrerk et al. *J Immunol* 149:847-854 (1992); Berditchevski et al. *J Biol Chem* 272:29174-29180 (1997)), cellular recognition (Fadool JM & Linser PJ *Dev Dyn* 196:252-262 (1993); Kaname et al. *Cytogenet Cell Genet* 64:195-197 (1993)), cellular adhesion (Miyauchi et al. *J Biochem (Tokyo)* 110:770-774 (1991); Seulberger et al. *Neurosci Lett* 140:93-97 (1992); Joseph et al. *Adv Exp Med Biol* 342:389-391 (1993); Sudou et al. *J Biochem (Tokyo)* 117:271-275 (1995)), intercellular stimulation and matrix metalloproteinase synthesis (Biswas et al. *Cancer Res* 55:434 (1995)), tissue remodeling (Guo et al. *J Biol Chem* 272:24-27 (1997)), metabolism, and sperm development and maturation (Petruszak et al. *J Cell Biol* 114:917-927 (1991); Nehme et al. *J Cell Biol* 120:687-

694 (1993); Cesario MM & Bartles JR *J Cell Sci* 107:561-570 (1994); Cesario et al. *Dev Biol* 169:473-486 (1995)). CD147 also appears to have a role in retinal development and disease, see Marmorstein et al. "Morphogenesis of the retinal pigment epithelium: toward understanding retinal degenerative diseases" *Ann N Y Acad Sci* 857:1-12 (1998) (suggested that N-CAM and EMMPRIN are potentially important molecules in other RPE functions necessary for photoreceptor survival). See also Marmorstein et al. "Apical polarity of N-CAM and EMMPRIN in retinal pigment epithelium resulting from suppression of basolateral signal recognition" *J Cell Biol* 142:697-710 (1998).

10 The molecule has also been investigated for a potential association in both rheumatoid and reactive arthritis (Felzmann et al. *J Clin Immunol* 11:205-212 (1991); Gadd et al. *Rheumatol Int* 12:153-157 (1992)) and renal disease (Schuster et al. *Biochim Biophys Acta* 1311:13-19 (1996)). Moreover, certain clear associations between the molecule and cancer have also been indicated (Biswas *Biochem Biophys Res Commun* 109:1026 (1982); Miyauchi et al. *J Biochem (Tokyo)* 110:770-774 (1991); Biswas et al. *Cancer Res* 55:434 (1995); Guo et al. *J Biol Chem* 272:24-27 (1997); Guo et al. *J Biol Chem* 272:24-27 (1997)). See also Lim et al. "Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38" *FEBS Lett* 441:88-92 (1998); van den Oord et al. "Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin" *Am J Pathol* 151:665-70 (1997); Polette et al. "Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers" *J Histochem Cytochem* 45:703-9 (1997).

25 A mouse model in which the Basigin gene was knocked-out has been examined (Igakura et al. *Biochem Biophys Res Commun* 224:33-36 (1996)). The work indicated that the molecule was not necessarily active in the blood-brain barrier. However, the work indicated that there was enhanced interaction in connection with lymphocyte activation as well as an abnormal response to irritating odors. Later work indicated certain abnormalities in sensory and memory functions in such model (Naruhashi et al. *Biochem Biophys Res Commun* 236:733-737 (1997)).

In connection with the expression of CD147, see Woodhead et al. "From sentinel to messenger: an extended phenotypic analysis of the monocyte to dendritic cell transition" *Immunology* 94:552-9 (1998) demonstrated that CD147 was expressed on dendritic cells, Ghannadan et al. "Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies" *J Invest Dermatol* 111:689-95 (1998) demonstrated that clustered CD antigens (including CD147) were detectable foreskin mast cells, Mutin et al. "Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules" *Tissue Antigens* 50:449-58 (1997) discussed quantitative analysis of cell surface molecules on cultured endothelial cells (HUVEC).

In view of the foregoing, CD147 has been implicated as a potentially useful target for the treatment of diseases. However, at the same time, CD147 is expressed in and on many cells that are widely distributed amongst many tissues. For example, the Ok^a blood group antigen is expressed on virtually all cells (Williams et al. *Immunogenetics* 27:322-329 (1988)). OX-47 has been disclosed to be on most immature cells, endothelial cells, and cells with excitable membranes (Fossum et al. *Eur J Immunol* 21:671-679 (1991)). Similarly, Basigin was demonstrated to be expressed not only in endothelial cells but was also found in a variety of tissues, including, the spleen, small intestine, kidney, and liver in relatively high levels and in small quantities in the testes (Kanekura et al. *Cell Struct Funct* 16:23-30 (1991)). CE9 was disclosed to be widely expressed on rat hepatocytes (Scott LJ & Hubbard AL *J Biol Chem* 267:6099-6106 (1992)). Seulberger et al. *Neurosci Lett* 140:93-97 (1992) demonstrated that the HT7 molecule (which is identical to Neurothelin, Basigin, gp42, and OX-47) was expressed on the blood-brain barrier, choroid plexus (blood-CNS fluid barrier), retinal epithelium (blood-eye barrier), neurons, kidney tubules, some endothelium, epithelium, and epithelial tissue barriers. The CE9 antigen (which was demonstrated to possess identity to the OX-47 antigen) is expressed, to some extent, in virtually all rat tissues (Nehme et al. *Biochem J* 310:693-698 (1995)). Because of the broad tissue distribution, there would be a number of concerns related to the safety of any therapy that inhibited or killed cells expressing it.

There is some evidence that there may be different forms of CD147, stemming from, for example, differential glycosylation or alternative splicing of the molecule (Kanekura et al. *Cell Struct Funct* 16:23-30 (1991) (Basigin); Schlosshauer B *Development* 113:129-140 (1991) (Neurothelin); Fadool JM & Linser PJ *J Neurochem* 60:1354-136 (1993) (5A11/HT7); Nehme et al. *J Cell Biol* 120:687-694 (1993) (CE9); DeCastro et al. *J Invest Dermatol* 106:1260-1265 (1996) (EMMPRIN); Spring et al. *Eur J Immunol* 27:891-897 (1997) (Ok^a)).

BRIEF DESCRIPTION OF THE DRAWING FIGURES

Figure 1 is a 12% SDS-PAGE/Western Blot showing the binding of particular antibodies to CEM cell membrane extracts lysates. Lane A: rabbit-anti-mouse-hn-RNP-K protein antibody; Lane B: ABX-CBL antibody; Lane C: 2.6.1 antibody (also referred to herein as cem2.6 and ABX-Rb2); Lane D: anti-CD147 antibody (Pharmingen); and Lane E: anti-CD147 antibody (RDI). Sample: 5 microliters CEM Cell Extract.

Figures 2A-2B is an analysis of the components obtained from the CBL1 antibody produced by the hybridoma cell line having ATCC Deposit No. HB 8214. The data demonstrate that the CBL1 IgM antibody produced by the HB 8214 hybridoma is the active component that inhibits MLR in the presence of complement.

Figure 3 is a graph comparing the inhibition of MLR using antibodies from various CBL1 subclones in comparison to CBL1.

Figure 4 is a graph comparing MLR inhibition utilizing ABX-CBL in the presence of rabbit and human complement.

Figure 5 is a graph comparing the activity of the ABX-CBL antibody and the 2.6.1 antibody (also referred to as cem 2.6) in inhibiting the MLR assay. The data demonstrate that the 2.6.1 antibody is not an effective inhibitor.

Figures 6A-6B: FACS analyses of activated lymphocytes demonstrating co-expression of CD147 and CD25.

Figures 7A-7D: FACS analyses of PBMC demonstrating the selective upregulation of CD25 upon stimulation, and the specific depletion of the same cells after treatment with ABX-CBL and complement. **Fig. 7A:** untreated PBMC. **Figs. 7B and**

7D: PBMC stimulated with ConA. Figure 7C: PBMC stimulated with ConA, then treated with ABX-CBL plus complement.

Figures 8A-8D compare FACS analyses of PBMC demonstrating the selective upregulation of CD25 upon stimulation, and the specific depletion of the same cells after treatment with ABX-CBL and complement. Fig. 8A: PBMC + ConA; Fig. 8B: CBL-1 only/Medium; Fig. 8C: Complement only/Medium; Fig. 8D: CBL-1 + complement/Medium. M1: CD25 high (depleted); M2: CD25 low (undepleted); M3: CD25 null (undepleted).

Figures 9A-9D show another series of FACS analyses of PBMC demonstrating the selective upregulation of CD25 and CD147 upon stimulation.

Figures 10A-10F show a comparison of activated T-cells (Figs. 10A-10B), activated monocytes, (Figs. 10C-10-D) and activated B-cells (Figs. 10E-10F) before and after treatment with ABX-CBL and complement and demonstrating the specific depletion of the same cells upon treatment with ABX-CBL and complement.

Figures 11A-11F shows a similar comparison of subpopulations of activated T-cells (Figures 11A-11B), activated B-cells (Figures 11C-11D), and activated monocytes (Figures 11E-11F) before and after treatment with ABX-CBL and complement. The data demonstrate the specific depletion of the same cells upon treatment with ABX-CBL and complement.

Figure 12 illustrates that the mode of action of ABX-CBL is by depleting leukocyte subpopulations. The table compares cell type, surface markers, and Complement-Dependent Cytotoxicity (CDC) depletion of leukocyte subpopulations.

Figure 13 is a table comparing cell, cell type, CD147 expression, and CDC after treatment of the cells with ABX-CBL and complement. The data demonstrate that not all cells that express CD147 are killed upon such treatment.

Figure 14 is a table summarizing the expression of CDC resistant molecules on CBL-1⁺ cells. The chart compares cell, cell type, CD147 expression, CDC after treatment of the cells with ABX-CBL and complement, and expression of the complement inhibitory molecules CD55 and CD59. The data demonstrate that of these cells, only cells that do not express both CD55 and CD59 are killed upon such treatment.

Figures 15A-15C present FACS analyses showing the expression of CD147 on the human endothelial cell line ECV-304.

Figures 16A-16C present FACS analyses showing the expression of CD147 on the human endothelial cell line HUVEC-C.

Figure 17 is a graph showing the effects of ABX-CBL and complement on the human endothelial cell line ECV-304 in comparison to the effects of the same on CEM cells.

Figure 18 is a graph showing the effect of ABX-CBL on human endothelial cell line HUVEC-C in comparison to the effects of the same on CEM cells.

Figures 19A-19C present FACS analyses showing the expression of the complement inhibitory molecules CD46, CD55, and CD59 on the human endothelial cell line ECV-304.

Figures 20A-20C present FACS analyses showing the expression of the complement inhibitory molecules CD46, CD55, and CD59 on the human endothelial cell line HUVEC-C.

Figure 21 is a schematic diagram of the vector utilized for cloning and expression of CD147 cDNA in COS cells.

Figure 22 is a schematic diagram of the pBK-CMV phagemid vector utilized for cloning and expression of CD147 cDNA in COS and *E. coli* cells.

Figure 23 is a SDS-PAGE/Western Blot of CD147 expressed in COS cells (Figure 23A) and *E. coli* (Figure 23B). **Figs. 23A-23B:** Antibodies: Pharmingen (panel A), 2.6.1 (panel B), and ABX-CBL (panel C). **Fig. 23A:** 5 μ L CEM cell membrane extract (Lane 1); 7.5 μ L control vector transfected COS cell extract (Lane 2); 7.5 μ L CD147 transfected COS cell extract (Lane 3). **Fig. 23B:** Clone 1: CD147-Transfected, uninduced (Lane 1); Clone 1: CD147-Transfected, induced (Lane 2); Clone 5: Control Vector Transfected, uninduced (Lane 3); Clone 5: Control Vector Transfected, induced (Lane 4).

Figures 24-33 are heavy chain and kappa chain cDNA and protein sequences of or for the antibodies: CEM 10.1 C3 (Fig. 24), CEM 10.1 G10 (Fig. 25), CEM 10.12 F3 (Fig. 26), CEM 10.12 G5 (Fig. 27), CEM 13.12 (Fig. 28), CEM 13.5 (Fig. 29), 2.4.4 (Fig. 30), 2.1.1 (Fig. 31), 2.3.2 (Fig. 32), and 2.6.1 (Fig. 33).

Figures 34-43 are heavy chain and kappa chain protein sequences of or for the antibodies: CEM 10.1 C3 (Fig. 34), CEM 10.1 G10 (Fig. 35), CEM 10.12 F3 (Fig. 36), CEM 10.12 G5 (Fig. 37), CEM 13.12 (Fig. 38), CEM 13.5 (Fig. 39), 2.4.4 (Fig. 40), 2.1.1 (Fig. 41), 2.3.2 (Fig. 42), and 2.6.1 (Fig. 43) showing CDR positions.

Figures 44A-44B show the amino acid sequences and structure of human heavy chains derived from CBL-1 specific hybridomas showing alignment against the germline V-segment genes.

Figures 45A-45C and Figure 46 show amino acid sequences and structure of human kappa chains derived from CBL-1 specific hybridomas, showing alignment against the germline V-segment genes.

Figure 47 is a restriction map of the vector pWBFNP MCS that was utilized for the construction and cloning of certain constructs in accordance with the invention.

Figure 48 is a schematic restriction map of the vector pIK6.1+Puro that was utilized for the construction and cloning of certain constructs in accordance with the invention.

Figure 49 shows a comparison of the activity of the ABX-CBL antibody and the 2.6.1 multimeric IgM antibody (also known as ABX-Rb2) in inhibiting the MLR assay, demonstrating that the 2.6.1 multimeric IgM antibody is effective in inhibition of MLR. C: Rabbit complement.

Figures 50A-50F provide additional detail of the cloning strategy utilized in connection with the generation of CD147-IgG2 and gp42-IgG2 fusion proteins for use in connection with the generation of surrogate antibodies for use in animal models.

SUMMARY OF THE INVENTION

In accordance with a first aspect of the present invention, there is provided an isolated monoclonal antibody having an isotype that fixes complement and a variable
5 region that binds to the epitope on CD147 bound by the IgM monoclonal antibody ABX-CBL, with the proviso that the antibody is not CBL1. In a preferred embodiment, the antibody in the presence of complement acts to selectively kill cells selected from the group consisting of activated T-cells, activated B-cells, and monocytes but is substantially non-toxic to resting T-cells and resting B-cells. In
10 another preferred embodiment, the antibody is a human antibody. In another preferred embodiment, the antibody has an isotype selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

In accordance with a second aspect of the present invention, there is provided
15 an isolated monoclonal antibody having an isotype that fixes complement and a variable region that binds to CD147 on populations of activated T-cells, activated B-cells, and resting or activated monocytes, that, in the presence of complement, selectively depletes such populations through complement mediated killing while being substantially nontoxic to other cells, with the proviso that the antibody is not
20 CBL1. In a preferred embodiment, the antibody is a human antibody. In another preferred embodiment, the antibody has an isotype selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

In accordance with a third aspect of the present invention, there is provided an
25 isolated monoclonal antibody having the following characteristics: binds to CD147; shows a binding against CEM cell lysates on Western blot similar to that provided in Figure 1; an isotype selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3; competes with ABX-CBL for binding to CD147; cross reacts with hn-RNP-k protein; binds to a
30 consensus sequence on CD147 comprising RVRSS; selectively kills activated T-cells, activated B-cells, and monocytes in a MLR assay only in the presence of complement;

and is substantially non-toxic to cells expressing CD55 and CD59, with and without the presence of complement, with the proviso that the antibody is not CBL1.

In accordance with a fourth aspect of the present invention, there is provided a method to select an anti-CD147 antibodies for the treatment of disease, comprising:
5 generating antibodies that bind to CD147 and that are capable of binding complement; assaying the antibodies for one or more of the following properties: competition with ABX-CBL for binding to CD147; capability to selectively kill activated T-cells, activated B-cells, and monocytes in a MLR assay only in the presence of complement; and being substantially non-toxic to cells expressing CD55 and CD59, with and
10 without the presence of complement, with the proviso that the antibody is not CBL1. In a preferred embodiment, the method comprises assaying the antibodies for binding to CEM cell lysates on Western blot in a manner similar to that provided in Figure 1. In another preferred embodiment, the method comprises assaying the antibodies for binding to a consensus sequence in a peptide of RXRS. In another preferred
15 embodiment, the method comprises assaying the antibodies for cross reaction with hn-RNP-k protein. In another preferred embodiment, the method comprises assaying the antibodies for binding to a form of CD147 expressed by COS cells and *E. coli* cells.

In accordance with a fifth aspect of the present invention, there is provided a method for preventing or lessening the severity of disease, comprising providing to a
20 subject in need of such treatment an antibody that has an isotype that fixes complement and a variable region that binds to CD147 on populations of activated T-cells, activated B-cells, and resting or activated monocytes, that, in the presence of complement, selectively depletes such populations through complement mediated killing while being substantially nontoxic to other cells, with the proviso that the
25 antibody is not CBL1. In a preferred embodiment, the antibody is a human antibody. In another preferred embodiment, the antibody has an isotype is selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

In accordance with a sixth aspect of the present invention, there is provided a
30 method to prevent or lessen the severity of GVHD, comprising providing to a subject in need of such treatment an antibody that has an isotype that fixes complement and a variable region that binds to CD147 on populations of activated T-cells, activated B-

cells, and resting or activated monocytes, that, in the presence of complement, selectively depletes such populations through complement mediated killing while being substantially nontoxic to other cells, with the proviso that the antibody is not CBL1. In a preferred embodiment, the antibody is a human antibody. In another preferred embodiment, the antibody has an isotype selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

In accordance with a seventh aspect of the present invention, there is provided a monoclonal antibody that binds to an epitope on CD147 comprising the consensus sequence RVRSH, wherein the antibody is not CBL1. In a preferred embodiment, the antibody is a human antibody.

In accordance with an eighth aspect of the present invention, there is provided an isolated peptide comprising the sequence selected from the group consisting of RXRS, RXRSH, RVRS, and RVRSH. In a preferred embodiment, the peptide is used for the generation of antibodies.

In accordance with a ninth aspect of the present invention, there is provided a human monoclonal antibody that binds to CD147.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Discussion of the Present Invention

The pharmaceutical agent ABX-CBL was derived from the hybridoma cell line expressing the CBL1 antibody. CBL1 is a murine IgM, anti-human lymphoblastoid monoclonal antibody that was raised in Balb/c mice immunized with the T cell acute lymphoblastic leukemia cell line (T-ALL) CEM (Billing et al. "Monoclonal and heteroantibody reacting with different common antigens common to human blast cells and monocytes" *Hybridoma* 1:303-311 (1982)). Following fusion of the splenocytes and selection in HAT medium, supernatants from hybridoma-containing wells were screened by microcytotoxicity assay for reactivity with CEM cells. Hybridomas that tested positive in this assay were further screened for their ability to discriminate between resting lymphocytes and blast cells. CBL1 was selected for further study because it showed selectivity for blast cells (Billing et al.

"Monoclonal and heteroantibody reacting with different common antigens common to human blast cells and monocytes" *Hybridoma* 1:303-311 (1982)). The CBL1 antibody was deposited with the ATCC as HB 8214.

The assignee of the present application, Abgenix, Inc., Fremont, CA, acquired
5 CBL1 in 1997 and determined that the hybridoma line deposited with the ATCC as HB 8214 was not entirely pure. Rather, it was actually a mix of two distinct hybridoma lines, one producing an IgG and one producing an IgM. Following subcloning, a pure IgM producer as well as a pure IgG producer were derived. Through a series of *in vitro* experiments described herein, it was demonstrated that the
10 IgM antibody mediated the activities previously attributed to the CBL1 hybridoma. Only the IgM is biologically active in inhibition of complement mediated lysis of cells in a mixed lymphocyte reaction assay (MLR). The mechanism of inhibition is via antibody mediated complement-dependent cytotoxicity (CDC) because the inhibition is specific and complement-dependent, as discussed herein. Therefore, in
15 connection with our work described herein, using conventional techniques, we subcloned the line to produce a cell line producing solely the IgM. Further, the HB 8214 cell line expressing the CBL1 antibody possessed a second kappa light chain (MOPC-21) which appears to have been derived from the myeloma fusion partner, a P3 myeloma cell line, that was used to prepared the original hybridoma cell line. Our
20 subcloned hybridoma cell line possesses and expresses both light chains and the ABX-CBL antibody appears to contain both light chains. IgM antibodies generally possess a pentameric structure, where five heavy and light chain dimers are associated. With the two light chains in the ABX-CBL antibody, we expect that the IgM pentameric structure of the ABX-CBL antibody contains both light chains in
25 various ratios of light chains to form pentamers with homodimeric, heterodimeric, and homo- and heterodimeric combinations.

In order to manufacture the ABX-CBL antibody for use in preclinical and clinical development, we utilized hollow fiber cell culture technology through contract manufacturing with Goodwin Biotechnology, Plantation, Florida. The
30 growth medium is a serum free formulation HYBRIDOMA-SFM supplied by Gibco Life Technologies.

The stability of the Master Cell Bank (MCB) of ABX-CBL was determined by single cell subcloning. Cells were subcloned showing >95% stability for the single cell colony producers. The ABX-CBL MCB also showed stable antibody production for more than 130 generations in culture. The manufacturing process in hollow fiber
5 bioreactors is an approximately 40 day growth process that is equivalent to approximately 130 generations.

Primary purification of the monoclonal antibody from the cell culture supernatant is performed using Protein A affinity chromatography. Incubation at low pH following elution is performed as a viral inactivation step. The material is further
10 purified by anion exchange chromatography. This provides for residual protein A and DNA removal. The final step in the purification process is a filtration of the material to provide additional viral removal.

The formulated bulk drug substance is stored at 2-8°C prior to vialing. Using aseptic techniques, the antibody is filled in liquid form from the bulk containers into 5
15 mL glass vials. The vials are stored and shipped at 2-8°C. ABX-CBL is a murine IgM, anti-human lymphoblastoid monoclonal antibody raised to a T-ALL (Acute Lymphoblastic Leukemia) cell line (CEM). ABX-CBL is formulated in 20 mM sodium citrate and 120 mM sodium chloride at a pH of 6.0.

As used herein, the term "ABX-CBL" is used to refer to the purified and
20 reactive IgM antibody derived from the original cell line deposited with the ATCC as HB 8214. The sequence of the ABX-CBL heavy and light chains are discussed above and presented as SEQ ID NO.: 18 and SEQ ID NO.: 19, respectively.

We have now demonstrated that the active agent of the CBL1 antibody and ABX-CBL binds to the CD147 antigen as expressed on certain cells, such as T-cells,
25 B-cells, and/or monocytes. Accordingly, it is expected that the CD147 antigen, can be utilized as a target for the treatment of a variety of diseases. Since the CBL1 antibody has been effective in patients in the treatment of the diseases mentioned above, and based upon the results discussed herein, it is expected that additional CD147 based therapeutics will be similarly effective. Thus, in accordance with the
30 present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies

that bind to CD147 and that result in the killing of such cells, for example, through the activation of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without
5 limitation, renal transplant, corneal transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), and pancreatic), autoimmune diseases, inflammatory diseases, and others.

As was mentioned above, CBL1 had not previously been indicated to bind to CD147. Further, the particular epitope or antigen to which the CBL1 antibody bound
10 was unknown or at least relatively uncharacterized. Thus, because of the apparent safety and therapeutic efficacy of the CBL1 antibody, we were interested in determining the precise antigen or epitope to which the CBL1 and our ABX-CBL antibody bound. Further, we were interested in further understanding the manner in which the CBL1 antibody was efficacious, particularly in connection with the
15 treatment of GVHD.

By way of reference, the hybridoma line deposited with the ATCC as HB 8214 was not entirely pure. The line produced an IgG antibody and an IgM antibody. Only the IgM is biologically active in inhibition of complement mediated lysis of cells in a mixed lymphocyte reaction assay (MLR). The mechanism of inhibition is
20 via antibody mediated complement-dependent cytotoxicity (CDC) because the inhibition is specific and complement-dependent, as discussed herein. Therefore, in connection with our work described herein, we subcloned the line to produce a cell line producing solely the IgM. Further, the HB 8214 cell line expressing the CBL1 antibody possessed a second kappa light chain (MOPC-21) which appears to have
25 been derived from the myeloma fusion partner, a P3 myeloma cell line, that was used to prepare the original hybridoma cell line. Our subcloned hybridoma cell line possesses and expresses both light chains and the ABX-CBL antibody appears to contain both light chains. IgM antibodies generally possess a pentameric structure, where five heavy and light chain dimers are associated. With the two light chains in
30 the ABX-CBL antibody, we expect that the IgM pentameric structure of the ABX-CBL antibody contains both light chains in various ratios of light chains to form pentamers with homodimeric, heterodimeric, and homo- and heterodimeric

combinations.

The role of the MOPC-21 light chain in CBL1 and ABX-CBL binding was unknown. In connection with our work, we endeavored to clarify the role of the MOPC-21 light chain through, for example, preparation of hybridoma subclones that
5 express only the ABX-CBL light chain or the MOPC-21 light chain. One approach that we utilized was to fuse the ABX-CBL hybridoma with a mouse myeloma cell line to achieve light chain shuffling. Upon generation of hybridomas expressing only the MOPC-21 light chain or the ABX-CBL light chain, we were able to conduct certain characterizations to distinguish the role of the two light chains in ABX-CBL binding.

10

Definitions

Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by
15 those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well known and commonly used in the
20 art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection, etc.). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures are generally performed according
25 to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al. *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference. The nomenclatures utilized in connection with,
30 and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for

chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

The term "isolated polynucleotide" as used herein shall mean a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which by virtue of its origin the "isolated polynucleotide" (1) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence.

The term "isolated protein" referred to herein means a protein of cDNA, recombinant RNA, or synthetic origin or some combination thereof, which by virtue of its origin, or source of derivation, the "isolated protein" (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g. free of murine proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.

20

The term "polypeptide" is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein, fragments, and analogs are species of the polypeptide genus.

The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally-occurring.

30

The term "operably linked" as used herein refers to positions of components so described are in a relationship permitting them to function in their intended manner.

A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

5 The term "control sequence" as used herein refers to polynucleotide sequences that are necessary to effect the expression and processing of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes,
10 generally, such control sequences include promoters and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

15

 The term "polynucleotide" as referred to herein means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double stranded forms of DNA.

20

 The term "oligonucleotide" referred to herein includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring oligonucleotide linkages. Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer. Preferably oligonucleotides are
25 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g. for probes; although oligonucleotides may be double stranded, e.g. for use in the construction of a gene mutant. Oligonucleotides of the invention can be either sense or antisense oligonucleotides.

30

 The term "naturally occurring nucleotides" referred to herein includes deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred

to herein includes nucleotides with modified or substituted sugar groups and the like. The term "oligonucleotide linkages" referred to herein includes oligonucleotide linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. See e.g., LaPlanche et al. *Nucl. Acids Res.* **14**:9081 (1986); Stec et al. *J. Am. Chem. Soc.* **106**:6077 (1984); Stein et al. *Nucl. Acids Res.* **16**:3209 (1988); Zon et al. *Anti-Cancer Drug Design* **6**:539 (1991); Zon et al. *Oligonucleotides and Analogues: A Practical Approach*, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)); Stec et al. U.S. Patent No. 5,151,510; Uhlmann and Peyman *Chemical Reviews* **90**:543 (1990), the disclosures of which are hereby incorporated by reference. An oligonucleotide can include a label for detection, if desired.

The term "selectively hybridize" referred to herein means to detectably and specifically bind. Polynucleotides, oligonucleotides and fragments thereof in accordance with the invention selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments of the invention and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%. Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff,

M.O., in *Atlas of Protein Sequence and Structure*, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 to this volume, pp. 1-10. The two sequences or parts thereof are more preferably homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the
5 ALIGN program. The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. In contradistinction, the term "complementary to" is used herein to mean that the
10 complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA".

15 The following terms are used to describe the sequence relationships between two or more polynucleotide or amino acid sequences: "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger
20 sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing or may comprise a complete cDNA or gene sequence. Generally, a reference sequence is at least 18 nucleotides or 6 amino acids in length, frequently at least 24 nucleotides or 8 amino acids in length, and often at least 48 nucleotides or 16 amino acids in length. Since two polynucleotides or amino acid sequences may each
25 (1) comprise a sequence (i.e., a portion of the complete polynucleotide or amino acid sequence) that is similar between the two molecules, and (2) may further comprise a sequence that is divergent between the two polynucleotides or amino acid sequences, sequence comparisons between two (or more) molecules are typically performed by comparing sequences of the two molecules over a "comparison window" to identify
30 and compare local regions of sequence similarity. A "comparison window", as used herein, refers to a conceptual segment of at least 18 contiguous nucleotide positions or 6 amino acids wherein a polynucleotide sequence or amino acid sequence may be

compared to a reference sequence of at least 18 contiguous nucleotides or 6 amino acid sequences and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions, deletions, substitutions, and the like (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson and Lipman *Proc. Natl. Acad. Sci. (U.S.A.)* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, (Genetics Computer Group, 575 Science Dr., Madison, Wis.), Geneworks, or MacVector software packages), or by inspection, and the best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by the various methods is selected.

The term "sequence identity" means that two polynucleotide or amino acid sequences are identical (i.e., on a nucleotide-by-nucleotide or residue-by-residue basis) over the comparison window. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) or residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the

reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence.

5 As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See *Immunology - A Synthesis* (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino
10 acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ -N-methylarginine, and
15 other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the righthand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

20 Similarly, unless specified otherwise, the lefthand end of single-stranded polynucleotide sequences is the 5' end; the lefthand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and
25 which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences".

30 As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity,

preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity, and most preferably at least 99 percent sequence identity. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic-aspartic, and asparagine-glutamine.

As discussed herein, minor variations in the amino acid sequences of antibodies or immunoglobulin molecules are contemplated as being encompassed by the present invention, providing that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99%. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. More preferred families are: serine and threonine are aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a

major effect on the binding or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site. Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Assays are described in
5 detail herein. Fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains. Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequence databases.
10 Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-dimensional structure are known. Bowie et al. *Science* 253:164 (1991). Thus, the foregoing examples demonstrate that those of skill in the art can recognize
15 sequence motifs and structural conformations that may be used to define structural and functional domains in accordance with the invention.

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for
20 forming protein complexes, (4) alter binding affinities, and (5) confer or modify other physicochemical or functional properties of such analogs. Analogs can include various muteins of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence
25 (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent
30 sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in *Proteins, Structures and Molecular Principles* (Creighton, Ed., W. H. Freeman and Company, New York (1984)); *Introduction to Protein Structure* (C.

Branden and J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); and Thornton et al. *Nature* 354:105 (1991), which are each incorporated herein by reference.

5 The term "polypeptide fragment" as used herein refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence deduced, for example, from a full-length cDNA sequence. Fragments typically are at least 5, 6, 8 or 10 amino acids long, preferably at least 14
10 amino acids long, more preferably at least 20 amino acids long, usually at least 50 amino acids long, and even more preferably at least 70 amino acids long. The term "analog" as used herein refers to polypeptides which are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of a deduced amino acid sequence and which has at least one of the following properties: (1) specific binding
15 to a CD147, under suitable binding conditions, (2) ability to modify CD147's binding to its ligand or receptor, or (3) ability to kill or inhibit growth of CD147 expressing cells *in vitro* or *in vivo*. Typically, polypeptide analogs comprise a conservative amino acid substitution (or addition or deletion) with respect to the naturally-occurring sequence. Analog typically are at least 20 amino acids long, preferably at
20 least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types
25 of non-peptide compound are termed "peptide mimetics" or "peptidomimetics". Fauchere, *J. Adv. Drug Res.* 15:29 (1986); Veber and Freidinger *TINS* p.392 (1985); and Evans et al. *J. Med. Chem.* 30:1229 (1987), which are incorporated herein by reference. Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically
30 useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biochemical property or pharmacological activity), such

as human antibody, but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH₂NH--, --CH₂S--, --CH₂-CH₂--, --CH=CH--(cis and trans), --COCH₂--, --CH(OH)CH₂--, and --CH₂SO--, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) may be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo and Gierasch *Ann. Rev. Biochem.* 61:387 (1992), incorporated herein by reference); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

"Antibody" or "antibody peptide(s)" refer to an intact antibody, or a binding fragment thereof that competes with the intact antibody for specific binding. Binding fragments are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab', F(ab')₂, Fv, and single-chain antibodies. An antibody other than a "bispecific" or "bifunctional" antibody is understood to have each of its binding sites identical. An antibody substantially inhibits adhesion of a receptor to a counterreceptor when an excess of antibody reduces the quantity of receptor bound to counterreceptor by at least about 20%, 40%, 60% or 80%, and more usually greater than about 85% (as measured in an *in vitro* competitive binding assay).

The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids, sugar, or other carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is $\leq 1 \mu\text{M}$, preferably $\leq 100 \text{ nM}$ and most preferably $\leq 10 \text{ nM}$.

The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.

5 As used herein, the terms "label" or "labeled" refers to incorporation of a detectable marker, e.g., by incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinylated moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). In certain situations, the label or marker can also
10 be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., ^3H , ^{14}C , ^{15}N , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, β -galactosidase, luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups, predetermined
15 polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

20

The term "pharmaceutical agent or drug" as used herein refers to a chemical compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient. Other chemistry terms herein are used according to conventional usage in the art, as exemplified by *The McGraw-Hill Dictionary of*
25 *Chemical Terms* (Parker, S., Ed., McGraw-Hill, San Francisco (1985)), incorporated herein by reference).

The term "substantially non-toxic to resting T-cells and resting B-cells" as used herein means, preferably, that the antibody in the presence of complement at at
30 least a 2-fold lower level of depletion of resting cells occurs than the level of depletion of activated T- and B-cells. More preferably, there is at least a 5-fold lower

level of cell depletion of resting cells compared to the level of depletion of activated cells. And, most preferably, there would be no detectable depletion of resting cells.

ABX-CBL Antigen Identification and Characterization

5

We undertook two primary approaches to the identification and characterization of the antigen to which the ABX-CBL antibody bound (i) an immunoaffinity purification approach and (ii) a classical protein purification approach.

10

Immunoaffinity Purification

We investigated immunoaffinity purification of the antigen to which the CBL1 antibody bound. The antigen to which the CBL1 antibody bound appeared to be highly expressed on CEM cells which is a T lymphoblastoid cell line derived by Foley et al. *Cancer* 18:522-529 (1965) and available from the ATCC, Rockville, MD (ATCC No. CCL-119). Immunoaffinity purification using the native ABX-CBL antibody was frustrated by the fact that the ABX-CBL antibody is an IgM antibody having a pentameric structure and prone to nonspecific interactions *in vitro*. Therefore, we prepared human IgG2 antibodies against CEM cells and tested for competition with the ABX-CBL antibody in binding assays with CEM cells. Such human antibodies were prepared in accordance with Mendez et al. *Nature Genetics* 15:146-156 (1997) and U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996, the disclosures of which are hereby incorporated by reference herein in their entirety, through the immunization of XenoMouseTM animals with CEM cells, followed by fusions, and screening of the resulting hybridoma supernatants against CEM cells and in FACS competition assays with the ABX-CBL antibody. In the FACS competition assays, inhibition of the binding of ABX-CBL antibodies, labeled with FITC, to CEM cells was analyzed, both alone and in the presence of hybridoma supernatants containing human antibodies reactive with the CEM cells.

30

Four hybridoma clones were isolated and determined, in this manner, to be that were highly competitive with the ABX-CBL antibody in binding to the CEM

cells. One hybridoma clone, designated 2.6.1, was selected for further analysis. We generated ascites to each of the hybridomas, including the 2.6.1 hybridoma, in SCID mice and purified the 2.6.1 antibody using a Protein A affinity purification process using standard conditions. From the purified 2.6.1 antibody, we prepared an immunoaffinity column. To prepare the column, the purified 2.6.1 antibody was conjugated to CNBr activated Sepharose-4B, according to the manufacturer's specifications. Approximately 8.4 mg of the antibody was conjugated to about 2.0 g of the activated Sepharose. We passed cell lysates of CEM cells through the column and eluted the components that bound. The elution product was analyzed by Western blotting and probing with both the ABX-CBL antibody and the 2.6.1 antibody. Based upon preliminary data, the 2.6.1 antibody bound most intensely to a molecule or molecules contained within a diffuse band from about 45-55 KD, while the ABX-CBL antibody showed binding with a low intensity to a similar diffuse band from about 45-55 KD. Through use of preparative gel electrophoresis and electroblotting techniques, we isolated a portion of the 45-55 KD band and obtained a partial amino acid sequence of the molecule (35/40 residues). The resulting sequence information was analyzed through a protein database search (Protein Identification Resource (PIR) R47.0, December 1995) and the sequence comparison data indicated that the molecule was CD147.

Protein Purification and Sequencing

In connection with our work related to the characterization of the antigen to which the ABX-CBL antibody bound, we saw significant ABX-CBL binding on Western blots to molecules localized in relatively sharp bands at 35 KD and 62 KD. The intensity of this 35 KD band appeared to vary from prep to prep, depending on culture age and other conditions not completely understood. Therefore, we initially purified the 62 KD material. Because the N-terminus was blocked, we cleaved the protein with CNBr and sequenced two of the peptides that resulted from the cleavage. The resulting sequence information was analyzed through a protein database search (Protein Identification Resource (PIR) R47.0, December 1995) and the sequence comparison data indicated that the molecule was heterogeneous ribonuclear protein k (hnRNP-k). Such molecule is an intracellular component, and, accordingly, does not

conform to the observations that the ABX-CBL antibody appeared to recognize an extracellular component. Nevertheless, the identification of this molecule may be useful in connection with further understanding of the binding of ABX-CBL to CD147, for example in connection with epitope elucidation.

- 5 Characterization of the 35 KD band can also be undertaken for similar reasons. In such an approach, the 35 KD molecule can be purified in a similar manner to that utilized in connection with the 62 KD band mentioned above. The purified material from the 35 KD band can be characterized to further understand any potential structural differences between material contained in the 45-55 KD CD147 band. The
10 material contained in the 35 KD band can be sequenced to either demonstrate that the material is CD147 or to determine epitopic information related to ABX-CBL's binding to CD147.

Further Elucidation of CD147 Binding and Epitopic Analysis of ABX-CBL

- 15 As was discussed above, another area of exploration is in connection with the elucidation of the binding of the ABX-CBL antibody to the CD147 molecule. Because of the safety and efficacy of the ABX-CBL antibody, we expect that molecules, particularly antibodies, that mimic the binding of the ABX-CBL antibody to CD147 should possess a similar safety profile. Thus, in order to further understand
20 the binding of the ABX-CBL antibody to CD147, we have undertaken, or designed, experiments in order to elucidate the same. Our experiments include (i) cloning of CD147 and expression in eukaryotic (COS) cells, (ii) expression in prokaryotic (*E. coli*) cells, and (iii) screening of random peptide libraries utilizing phage display techniques.

25

Cloning of CD147 and Expression in COS Cells

- We cloned CD147 cDNA from a Jurkat library (Stratagene), prepared constructs for transfection, and transfected COS cells with the CD147 cDNA. Transfected cells were analyzed for expression of CD147 utilizing FACS analysis and
30 Western blotting in connection with the ABX-CBL antibody, the 2.6.1 antibody, and the Pharmingen antibody mentioned above. COS cells transfected with CD147 cDNA showed binding to each of the antibodies in each of the FACS and Western blot

analyses. In contrast, COS cells transfected with control vectors were negative for binding with each of the 2.6.1 and ABX-CBL antibodies. With respect to the Pharmingen antibody, certain background staining was observed in cells transfected with control vectors on FACS and no binding on Western blot analysis. The transfected cells showed significant binding over background on FACS and were positive on Western blot analysis. Our results confirm that the ABX-CBL and the 2.6.1 antibodies bind to CD147.

Expression of CD147 in *E. Coli* Cells

Utilizing a slightly modified vector, we also transfected *E. coli* cells with the CD147 cDNA. The *E. coli* cells so transfected were capable of expression of the CD147 molecule as evidenced by Western blotting analysis of each of the ABX-CBL, 2.6.1, and Pharmingen antibodies. Since the prokaryotic *E. coli* cells should not glycosylate the expressed CD147, it was expected that the molecular weight of the CD147 expressed by the *E. coli* should closely approximate the predicted, unglycosylated molecular weight of CD147 of about 27 KD. Indeed, in each case, binding of the three antibodies on Western blot analysis was observed to a band between about 27 and 30 KD.

This data further confirms that the ABX-CBL and the 2.6.1 antibodies bind to CD147. Further, the evidence indicates that ABX-CBL binding to CD147 is not directly based on carbohydrate binding, i.e., that ABX-CBL does not bind directly to a carbohydrate epitope on CD147. Such data, however, does not eliminate the possibility that binding to CD147 is influenced by the presence of carbohydrate or glycosylation.

Screening Utilizing Phage Display

In order to further elucidate the binding of the ABX-CBL antibody to CD147, we undertook phage display experiment. Such experiments were conducted through panning a phage library expressing random peptides for binding with the ABX-CBL and 2.6.1 antibodies to determine if we could isolate peptides that bound. If successful, certain epitope information can be gleaned from the peptides that bind.

In general, the phage libraries expressing random peptides were purchased from New England Biolabs (7-mer and 12-mer libraries, Ph.D.-7 Peptide 7-mer

Library Kit and Ph.D.-12 Peptide 12-mer Library Kit, respectively) based on a bacteriophage M13 system. The 7-mer library represents a diversity of approximately 2.0×10^9 independent clones, which represents most, if not all, of the $20^7 = 1.28 \times 10^9$ possible 7-mer sequences. The 12-mer library contains approximately 1.9×10^9 independent clones and represents only a very small sampling of the potential sequence space of $20^{12} = 4.1 \times 10^{15}$ 12-mer sequences. Each of 7-mer and 12-mer libraries were panned or screened in accordance with the manufacturer's recommendations in which plates were coated with an antibody to capture the appropriate antibody (goat anti-human IgG Fc for the 2.6.1 antibody and goat anti-mouse μ chain for the ABX-CBL antibody) followed by washing. Bound phage were eluted with 0.2 M glycine-HCl, pH 2.2. After 3 rounds of selection/amplification at constant stringency (0.5% Tween), through use of DNA sequencing, we characterized a total of 5 clones from the 7-mer library and 6 clones from the 12-mer library reactive with the ABX-CBL antibody and a total of 6 clones from each of the 7-mer and 12-mer libraries reactive with the 2.6.1 antibody. Reactivity of the peptides was determined by ELISA. For an additional discussion of epitope analysis of peptides see also Scott, J.K. and Smith, G.P. *Science* **249**:386-390 (1990); Cwirla et al. *PNAS USA* **87**:6378-6382 (1990); Felici et al. *J. Mol. Biol.* **222**:301-310 (1991), and Kuwabara et al. *Nature Biotechnology* **15**:74-78 (1997).

No consensus sequence was readily apparent for reactivity of the 2.6.1 antibody with CD147. However, sequence alignment of the characterized 7-mer and 12-mer sequences against the amino acid sequence of CD147 yielded a number of matches for a single sequence within CD147 from residue number 177 through residue number 188 (ITLRVRSH (SEQ ID NO:1)). In particular, each of the 7-mers contained sequence matches (represented by *) to 3 or more residues within this sequence of CD147:

7-mer sequences

30				*	*	*	
	1.	EE	RLR	S	Y		(SEQ ID NO:2)
				*	*	*	
	2.	YE	RVR	W	Y		(SEQ ID NO:3)

3. EE * * *
 RLR S Y (SEQ ID NO:4)
- 5 4. AE * * *
 RIR S I (SEQ ID NO:5)
5. EE * * *
 RLR S Y (SEQ ID NO:6)

10 Further, 4 of the 12-mers contained sequence matches (represented by *) to 3 or more residues within this sequence of CD147, with 4 matches for 12-mer peptide number 1 and for 6 matches of 12-mer peptide number 2:

12-mer sequences

- 15 * * * *
1. TVHGDL RLR S LP (SEQ ID NO:7)
- 20 * * * * * *
2. TNDIGL RQR S HS (SEQ ID NO:8)
- * * *
3. SPLLDGQ RER S Y (SEQ ID NO:9)
- 25 * * *
4. YDLPM RSR S YPG (SEQ ID NO:10)

 These results indicate a consensus sequence of RXRS (SEQ-ID NO:11) that is present in 10 of the sequenced clones. Accordingly, we had a synthetic peptide
30 prepared (AnaSpec Incorporated, San Jose, CA) which spanned residues 169-183 of CD147 with the following sequence (with -OH representing carboxy terminus):

 KGSDQAIITLRVRSH-OH (SEQ ID NO:12)

35 | |
 169 184

 Below, the amino acid sequence of CD147 is provided with the 15-mer peptide's sequence indicated by double underlining and the RXRSH (SEQ ID NO:13) consensus sequence indicated in bold. In addition, putative N-linked glycosylation
40 sites of CD147 are shown as underlined and italics:

CD147 Sequence

MAAALFVLLGFALLGTHGASGAAGTVFTTVEDLGSKILLTCSLNDSATEVTG
 HRWLKGGVVLKEDALPGQKTEFKVDSDDQWGEYSCVFLPEPMGTANIQLHG
 PPRVKAVKSSEHINEGETAMLVCKSESVPVTDWAWYKITDSEDKALMNGSE
 5 SRFFVSSSQGRSELHIENLNMEADPGQYRCNGTSSKGSDOAIITLRVRSHLAAL
 WPFLGIVAEVLVLVTIIFIYEKRRKPEDVLDDDDAGSAPLKSSGQHQNCKGKN
 VRQRNSS (SEQ ID NO:14)

The 15-mer peptide was assayed using ELISA and it was determined that the
 10 ABX-CBL antibody specifically bound to the peptide. Further, neither the 2.6.1
 antibody nor a control murine IgM antibody bound to the peptide. However, based on
 a competition study between the CD147 antigen and the 15-mer peptide, the ABX-
 CBL antibody's binding to the 15-mer peptide can only be measured when the 15-mer
 peptide is coated on plates and not when the peptide is in solution. Indeed, in
 15 competition experiments in which the ABX-CBL antibody is bound to either the
 peptide or the CD147 antigen coated to plates, the ABX-CBL antibody is not removed
 or replaced by the peptide in solution even at high concentrations. Nevertheless, the
 binding of the ABX-CBL antibody to the 15-mer peptide can be specifically
 competed by the CD147 antigen and positive phage preparations mentioned above but
 20 not with non-specific antigen (i.e., L-Selectin isolated from cell membrane or human
 plasma) or the negative phage preparations mentioned above. Similarly, the binding
 of the ABX-CBL antibody to the CD147 antigen can be specifically competed by
 positive phage preparations as compared to negative phage preparation in competition
 assays using preincubation.

25 These results indicate that while the sequence within CD147 that contains the
 consensus sequence RXRSH is important to the binding of the ABX-CBL antibody to
 CD147, it does not fully explain ABX-CBL's binding to CD147. Indeed, the data
 also suggests that the consensus sequence contained either in the 15-mer peptide when
 bound to the plate or the reactive phage materials when tethered to the phage coat
 30 protein binds more tightly to the ABX-CBL antibody than does the free peptide in
 solution. Taken together, while not wishing to bound to any particular theory or mode
 of operation, it is possible that CD147 possesses certain conformations that are not

well mimicked in the 15-mer peptide in solution. Nevertheless, the above epitopic information is important to understanding the manner in which the ABX-CBL antibody binds to CD147 and to producing other candidate molecules against CD147 as a therapeutic target.

5 It is interesting to note that in addition to the results above in connection with the presence of the RXRSH consensus sequence within CD147, we also looked for the presence of the consensus sequence within the hn-RNP-k protein to which ABX-CBL also appears to bind. Such analyses were conducted by sequence alignment against the phage derived peptides discussed above. Two sequences were found
10 which possessed statistically interesting matches:

First, there was a match (indicated by *) of 5 amino acids with the 7-mer peptide number 4:

15 * ** **
 PE RIL SI (SEQ ID NO:15)
 |
 84

20 Second, there was a match (indicated by *) of 5 amino acids with the 12-mer peptide number 1:

 * * * **
 GGS RAR NLP (SEQ ID NO:16)
25 | |
 300 306

The amino acid sequence of the hn-RNP-k protein is provided below with such sequences indicated by double underlining. In addition, a number of RXR
30 sequence motifs are present in the hn-RNP-k protein's sequence which are also indicated by underlining:

hn-RNP-k Protein Sequence

METEQPEETFPNTETNGEFGKRPAEDMEEEQAFKRSRNTDEMVELRILLQSKN
35 AGAVIGKGGKNIKALRTDYNASVSPDSSGPERILSISADIETIGEILKKIIPTE
EGLQLPSPTATSQLPLESDAVECLNYQHYKGSDFDCELRLLIHQSLAGGIIGVK

GAKIKELRENTQTTIKLFQECCPHSTDRVVLIGGKPDRVVECIKILDLISESPIK
 GRAQPYDPNFYDETYDYGFTMMFDDRRGRPVGFPMRGRGGFDRMPPGRG
 GRPMPPSRDYDDMSPRRGPPPPPPGRGGGRGGSRRARNLPLPPPPPPRGGDLMA
 YDRRGRPGDRYDGMVGFSADETWDSAITWSPSEWQMA YEPQGGSGYDYS
 5 YAGGRGSYGDLGGPIITTQVTIPKDLAGSIIGKGGQRIKQIRHESGASIKIDEPLE
 GSEDRIITITGTQDQIQNAQYLLQNSVKQYSGKFF (SEQ ID NO:17)

Without wishing to be bound to any particular theory or mode of operation, it is possible that the binding of the ABX-CBL antibody to the hn-RNP-k protein is
 10 partially explained by the presence of these motifs within the protein.

Discussion of Results of Antigen Identification and Analysis

It is interesting to note that the ABX-CBL antibody appears to bind to the 45-
 55 KD band with less intensity than it does the 35 KD band in CEM cell lysates.
 15 However, without wishing to be bound to any particular theory or mode of operation
 of the ABX-CBL antibody, the 35 KD band could either represent another epitope or
 could be an alternative form of CD147. Indeed, as discussed above, there is evidence
 in the literature for alternative splicings of CD147 or differential glycosylation. See
 e.g., Kanekura et al. *Cell Struct Funct* 16:23-30 (1991) (Basigin); Schlosshauer B
 20 *Development* 113:129-140 (1991) (Neurothelin); Fadool JM & Linser PJ *J*
Neurochem 60:1354-136 (1993) (5A11/HT7); Nehme et al. *J Cell Biol* 120:687-694
 (1993) (CE9); DeCastro et al. *J Invest Dermatol* 106:1260-1265 (1996) (EMMPRIN);
 Spring et al. *Eur J Immunol* 27:891-897 (1997) (Ok^a). Anecdotal evidence indicates
 that a 35 KD band could correspond to a singly-glycosylated form of CD147. See
 25 Kanekura et al. *Cell Struct Funct* 16:23-30 (1991). Further, it is also interesting to
 note that in comparisons of Western blots produced by two commercially available
 anti-CD147 antibodies (RDI-CBL535 (an anti-CD147 IgG2 antibody), available from
 RDI, Flanders, NJ, and 36901A (an anti-CD147 IgG1 antibody), available from
 Pharmingen, San Diego, CA) to the ABX-CBL and 2.6.1 antibodies indicates that
 30 each of the commercially available antibodies recognize a molecule that has a
 molecular weight around 35 KD and appearing similar to the 35 KD band recognized

by the ABX-CBL antibody. However, the 45-55 KD diffuse band is more intense. See Figure 1.

Based upon preliminary data, another interesting observation is that in the immunoaffinity purification mentioned above, when the effluent product from the 2.6.1 antibody was probed with the ABX-CBL antibody, the 35 KD band was no longer visible by Western blot. Rather, the ABX-CBL antibody appeared to bind to the diffuse band from 45-55 KD with relatively low intensity.

Further, our results in phage display experiments indicates that the ABX-CBL antibody and the 2.6.1 antibody bind to different epitopes. However, from our work related to the expression of CD147 in *E. coli* cells and based on the phage display work, the ABX-CBL antibody appears to recognize a protein epitope of CD147 and glycosylation, alone, does not appear responsible for ABX-CBL binding to CD147.

Nevertheless, in light of all of the foregoing, taken together, our results and data indicate that the ABX-CBL antibody does bind to the CD147 antigen. However, the ABX-CBL antibody appears to preferentially recognize a different epitope than recognized by the 2.6.1 or commercially available antibodies. Our finding that the ABX-CBL antibody binds to the CD147 antigen is indicative that a form of CD147 as expressed on particular cells is a viable therapeutic target for the treatment of disease.

Functional Understanding of the Mode of CD147 Therapy

As mentioned above, the CBL1 antibody has been used extensively in the treatment of GVHD in patients. Indeed, about a number of GVHD patients have been treated using the CBL1 antibody with a high percent success rate. Corneal and renal transplant studies have shown similar efficacy. Further, no signs of safety concerns or adverse effects have been observed. This is striking, given that, as discussed above, CD147 is so widely expressed in various tissues and cells of man. One would be concerned that an antibody to CD147 could cause a variety of adverse effects. Accordingly, we also endeavored to study the mechanism through which the CBL1 antibody operated to result in the treatment of disease, focused on models relevant to the reversal of GVHD. Understanding the mechanism could assist in elucidating why the CBL1 antibody is efficacious in patients and could also provide an understanding

of how to use the antigen to which the CBL1 antibody binds, CD147, in the treatment of disease.

There are several possible explanations related to the safety and specificity of the CBL1 antibody in the treatment of disease. Without limitation, these include (i) that there is a unique role of complement mediated cell killing (complement dependent cytotoxicity, CDC), (ii) that certain cells in becoming activated become sensitive to CBL1 binding and cell killing, (iii) that there are particular protective elements in certain cellular populations that render the cells resistant to CBL1 induced CDC, (iv) that CD147 expression levels are higher in given populations of cells (which could also be relevant to CDC), and (v) that the CBL1 antibody binds to a particular form of CD147 expressed on certain cellular populations (as discussed above). Each of these roles will be discussed in additional detail below.

Complement Mediated Killing of Cells

The role of complement mediated cell killing (complement dependent cytotoxicity, CDC) in connection with the CBL1 antibody has been studied previously and we have additionally studied its role extensively.

Past Work with CBL1

The UCLA group mentioned above (*see e.g.*, U.S. Patent Nos. 5,330,896 and 5,643,740) provided certain evidence that the CBL1 antibody operated through killing of certain activated cell populations while the antibody did not react with non-activated cells. For example, in microcytotoxicity assays, the CBL1 antibody was disclosed to kill activated lymphocytic cells but not non-activated lymphocytic or other normal cells. Further, the patents disclose that the cell killing operated through complement mediated killing of the cells.

Further Demonstration of the Role of CDC

Indeed, in our work, we have further demonstrated that CBL1 and ABX-CBL operates through complement mediated cell killing. We have utilized a mixed lymphocyte reaction (MLR) assay or a modified MLR assay in our work. The MLR assay provides an *in vitro* system for assaying proliferation of alloreactive T-

lymphocytes. In this manner, the MLR assay is an excellent model of GVHD in patients receiving bone marrow transplant (BMT). In the MLR assay, MHC mismatch lymphocytes from two individuals are co-cultured. Typically the assays are set up so that the lymphocytes from one patient are inactivated by, for example, radiation (the "stimulators") and the lymphocytes from the other patient are able to act as "Responders" and proliferate and undergo extensive blast transformation. After a suitable period of co-culture, the extent of proliferation of the cells can be quantified by adding tritium-labeled thymidine ($[^3\text{H}]$ thymidine) to the culture medium and monitoring uptake of the label into the DNA of the Responder lymphocytes.

In our work, use of the CBL1 antibody by itself, the isotype-matched control mouse IgM antibody by itself (Figure 2), or complement (either human or rabbit) by itself in an MLR or ConA induced lymphocyte proliferation assay is ineffective in inhibiting T-cell proliferation. See Figures 2-5. However, when both complement and the CBL1 and/or ABX-CBL antibody are present, T-cell proliferation is inhibited in a dose dependent manner. See Figures 2-5. The human IgG2 antibody 2.6.1 is ineffective in inhibiting T-cell proliferation in the same assay, either by itself, or in combination with complement. See Figure 5. This is expected, since the 2.6.1 antibody as a gamma-2 isotype is notoriously less efficient in complement mediated lysis than is an IgM antibody, such as the CBL1 or ABX-CBL antibody.

Role of Cellular Activation Levels

We have also studied whether certain cells in becoming activated become sensitive to ABX-CBL binding and cell killing.

Indeed, we have demonstrated in our work that the T-cell activation marker, CD25 (the alpha-2 subunit of the IL-2 receptor), appears to be expressed in high levels in the same cellular populations as those expressing the antigen to which the ABX-CBL antibody binds. See Figure 6. This finding provided a useful marker to detect whether activated cells were depleted in connection with the MLR assay. Where the MLR assay is conducted utilizing ABX-CBL alone, complement alone, or ABX-CBL and complement in combination, it is only in those experiments where ABX-CBL and complement are used in combination that CD25 expressing cell populations are depleted. See Figures 7-11. In particular, Figure 8 shows cells

expressing low levels of CD25. The selective killing of different cell populations are shown in Figures 10-12.

Role of Density or Expression Levels of CD147 in CDC

5 We have also considered whether CD147 expression levels are higher in given populations of cells (which could also be relevant to CDC).

In flow cytometry studies with peripheral blood mononuclear cells (PBMC) with the ABX-CBL antibody, we have noticed that, prior to the addition of complement, there are populations of cells that appear to express high and low levels of CD147. After complement is added, there are populations of cells that appear to correspond to the low level expressers mentioned above. It appears that these results could be indicative of density of CD147 expression levels on the cell surface. Density can play a role in CDC through providing additional antigen binding sites to allow for distortion of the antibody which is the first step in triggering the complement cascade. Upon distortion of the antibody, the factor C1q binds first and the cascade proceeds.

Whether the expression level (or, density) of CD147 in cellular populations plays a role in the therapeutic efficacy of the ABX-CBL antibody can be assayed through analyzing the expression levels of the CD147 molecule in various cellular populations. Generally, the experiments are conducted where beads having various known quantities of the CD147 antigen on their surface are prepared and analyzed on FACS (i.e., utilizing a FITC-labeled anti-CD147 IgG antibody) in order to generate approximately 10-20 data points of different quantities of antigen on the beads. A linear regression curve is prepared from such data. Thereafter, cells expressing the CD147 antigen can be run through FACS and the relative quantities of antigen on the surface of the cells can be calculated from the linear regression curve.

Presence and Role of Protective Elements in Cellular Populations

We have also studied whether there is a correlation between certain cellular protective elements in particular cellular populations that inhibit CDC induced by ABX-CBL binding and fixing of complement.

In connection with this work, we have investigated various cells to which the ABX-CBL antibody binds and considered whether such cells were (i) killed and (ii) if

so, was the mechanism similar to complement mediated lysis. In the experiment, we looked for ABX-CBL antibody binding to a number of cells (and, thus, the antigen to which the ABX-CBL antibody binds is expressed upon such cells). Those cells to which ABX-CBL would bind were then tested for complement mediated lysis through
5 treatment with the ABX-CBL antibody and complement. Two T-cell lines (CEM and Jurkat cells), a monocyte line (U937 cells), and three tumor cell lines (A431 (epidermal), SW948 (colon), and MDA468 (breast)), each of which bound the ABX-CBL antibody were examined. Despite the expression on such cells lines, the ABX-CBL antibody is very specific about which cells are killed, being restricted to the
10 CEM T-cell line and U937 monocyte line. See Figure 13. We also analyzed two endothelial cell lines (i) ECV-304 (ATCC CRL-1998) is a spontaneously transformed immortal EC established from the vein of an apparently normal human umbilical cord and carrying EC characteristics and (ii) HUVEC-C (ATCC CRL-1730) is an EC line derived from the vein of a normal human umbilical cord. Using FACS, we found
15 that the ECV-304 and HUVEC-C lines each stained positive against the 2.6.1, Pharmingen, and ABX-CBL antibodies suggesting that these ECs do express CD147 on the surface. Figures 15 and 16, respectively. We then carried out in vitro Alamar-blue based CDC assay and demonstrated that both EC lines were resistant to ABX-CBL mediated CDC in the presence of human complement. See Figures 17 and 18,
20 respectively.

In order to further understand why cells that all appear to express CD147 would not be killed by the ABX-CBL antibody in the presence of complement, we looked into CD46, CD55, and CD59 expression in such cells. Each of CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, DAF), and
25 CD59 (membrane attack complex inhibitor, MACI) have been implicated as complement inhibitory molecules. See e.g., Liszewski et al. *Annu. Rev. Immunol.* 9:431 (1991) and Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59" *Transpl. Proc.* 26:1070 (1994) related to CD46, Kinoshita et al. "Distribution of decay-accelerating factor in the
30 peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria" *J. Exp. Med.* 162:75 (1985) and Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59"

Transpl. Proc. 26:1070 (1994) related to CD55, and Whitlow et al. "H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement" *Cell. Immunol.* 126: 176 (1990), Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59" *Transpl. Proc.* 26:1070 (1994), and Davies, A. and Lachmann, P.J. "Membrane defense against complement lysis: the structure and biological properties of CD59" *Immunol. Res.* 12: 258 (1993) related to CD59. Accordingly, we considered whether there was differential expression of either, or both, of these molecules on the cell lines tested above. Indeed, all of the cells, except the CEM line and the U937 line, expressed both of the molecules. And, indeed, the endothelial cell line ECV-304 expressed all three, CD46, CD55, and CD59. Figures 19 and 20, respectively. In contrast, the CEM line expressed only CD59 and the U937 line expressed only CD55. See Figure 14. This data is useful in connection with the prediction of cells that could be selectively eradicated by ABX-CBL and consequently targeted in connection with anti-CD147 in accordance with the present invention.

Discussion of Function of ABX-CBL/CD147 Based Therapy

From the foregoing, it is clear that CBL1 and ABX-CBL operates to kill cells through the activation of complement. The combination of ABX-CBL and complement only kill activated T-cells (both CD4⁺ and CD8⁺), activated B-cells, and monocytes, but does not effect resting T-cells and B-cells because such cells do not appear to express CD147 at the same level as the activated cells. It is important, to note that monocytes are also killed by ABX-CBL and complement. This data provides an explanation for the operation of ABX-CBL therapy in diseases, such as GVHD, because, ABX-CBL selectively depletes those effector cells (activated T- and B-cells) and the antigen presenting cells (monocytes and B-cells) which ordinarily would lead to further T-cell activation.

The mode of operation of the ABX-CBL antibody, and future therapeutic molecules directed against CD147, in this regard appears to be at least partially related to, or dependent upon, each of the above-discussed functional characteristics: (i) complement mediated lysis, (ii) cellular activation, (iii) expression levels of CD147 and/or density of CD147 on the cell surface, and (iv) the absence of

expression of one or more of the complement inhibitory molecules on the cell surface. Accordingly, through use of this information, it is possible to design functional assays for the prediction of efficacy of a CD147 based therapeutic.

Indeed, the desirability of mimicking ABX-CBL binding and efficacy is highlighted based upon a preliminary tissue distribution study of the ABX-CBL antibody. In the study, ABX-CBL is widely distributed throughout a variety of tissues. However, the majority of the distribution is likely to be due to nonspecific binding. Nevertheless, there appears to be specific binding in endothelial cells (venules, arterioles, but not capillary beds), smooth muscle, and some mesothelium. Also, the lymphoreticular tissues appear to be bound, although, the staining seems to be restricted to large lymphocytes, presumably activated blasts. From the study conducted, it was difficult to distinguish intracellular from extracellular staining. A certain amount of cytoplasmic staining was clearly evident and could have been related to hn-RNP-k binding.

Discussion of Results; Utilization of the ABX-CBL Antibody for the Design of Therapeutics

The above *in vitro* work with the ABX-CBL antibody, in combination with the association of the ABX-CBL antibody with the CD147 antigen herein, provide the first evidence that antibodies to CD147 that are capable of complement mediated killing could provide an efficacious approach to the treatment of disease. Moreover, because of CD147's wide distribution and expression in the body and the tissue binding information that indicates that the CBL1 and ABX-CBL antibody associates with many tissues, the excellent prior clinical experience with the CBL1 antibody was difficult to reconcile unless CBL1 and ABX-CBL are, for example, specific to forms of CD147 expressed on certain cells or that other factors associated with complement mediated cell killing limit the CBL1 and ABX-CBL antibody's effects to particular tissues or perhaps a combination thereof.

Criteria for Generation of CD147 Based Therapeutics

From the foregoing, it is clear that the ABX-CBL antibody provides a powerful tool for the development of other CD147 based therapeutics. First, because

of the extreme safety demonstrated to date with the CBL1 and ABX-CBL antibody, it is desirable to mimic the binding of the ABX-CBL antibody as closely as possible. Second, because of the apparent efficacy of the CBL1 antibody it is desirable, at least initially, that any new therapeutic mediate complement fixation and lysis. Accordingly, in connection with the design of other CD147 based therapeutics, it is expected that through simulating the binding (or structural aspects) and mode of operation (or functional aspects) of ABX-CBL in the therapeutic candidates, safety and efficacy can be expected.

Structural Considerations

In connection with simulating or mimicking the structural aspects of ABX-CBL binding, we expect to be able readily generate antibodies that bind to CD147 in a similar manner as ABX-CBL. With the information discussed above, we know at least three levels of detail related to ABX-CBL's binding to CD147: (i) ABX-CBL appears to bind, if not preferentially, to a form of CD147 expressed on the population of cells selected from the group consisting of activated T-cells, activated B-cells, and monocytes, (ii) ABX-CBL shows clear and specific binding to 62 KD and 35 KD molecular species on Western blot analysis, and (iii) ABX-CBL appears very specific to an epitope on CD147 (and potentially a similar epitope on hn-RNP-k protein) defined by the consensus sequence RXRSH. In addition, ABX-CBL can be utilized to "structurally" compare, screen, or act as a functional assay for additional antibody candidates to CD147 through competition studies.

As will be appreciated, the above information provides highly useful information to the generation of additional antibody candidates. Put another way, antibody candidates that are generated that possess one or more of the above-characteristics are more likely to possess similar activity to the ABX-CBL antibody. An antibody candidate that possesses greater numbers of similar characteristics is likely to be a very close mimic to the ABX-CBL antibody and, accordingly, would likely exhibit similar safety and efficacy data as the ABX-CBL antibody.

In addition, as was discussed above, we expect to be able to generate additional information related to the binding of the ABX-CBL antibody to CD147

through certain experiments designed to elucidate ABX-CBL binding, for example, through:

- Additional mapping experiments related to the binding of CD147 to the ABX-CBL antibody. One such set of experiments relate to depletion experiments in which the ABX-CBL antibody bound to CD147 is cleaved with protease and the resulting products scanned with mass spectroscopy and the process repeated as necessary. Another such set of experiments relate to the isolation, purification, and understanding of the 35 KD species recognized by the ABX-CBL antibody. One method of accomplishing this is though the classical purification of the 35 KD molecule as discussed above in connection with the 62 KD species (hn-RNP-k protein). Another approach is the immunoaffinity purification of the 35 KD band through the generation of, for example, Fab fragments of the ABX-CBL antibody and binding the same to a column as discussed above in connection with the immunoaffinity purification conducted with the 2.6.1 antibody.
- Experiments directed to understanding CD147 cellular development. For example, the development of CD147 on the cell surface can be gleaned through conducting "pulse-chase" experiments. In such experiments, cells (such as CEM cells) growing in culture (Met⁽⁻⁾ media) are "pulsed" with S³⁵-Met for a sufficient time periods (and varied time periods) for the label to be enrolled into the cellular protein synthesis. Thereafter, cells are washed with "cold" medium and CD147 on the cell surface can be immunoprecipitated and subjected to autoradiography. Information can be gained related to potential alternative splicings, glycosylation levels, and other developmental differences of the expressed CD147 molecules.
- Experiments related to the role of glycosylation levels to ABX-CBL binding to CD147 can also be queried through reaction of CD147 with various glycosidases (*see e.g.*, Mizukami et al. *J. Immunol.* **147**:1331-1337 (1991), Schlosshauer *Development* **113**:129-140 (1991), Fadool and Linser *J. Neurochemistry* **60**:1354-1364 (1993)) and considering ABX-CBL binding to the various forms.

Functional Considerations

Once, or, concurrently with determining whether, one is satisfied with the "structure" of an antibody candidate (i.e., in connection with the antibody's binding to CD147), in accordance with the present invention, we have provided detailed functional criteria that appear important to the ABX-CBL antibody's *in vivo* efficacy that can be utilized to determine whether an antibody candidate is likely to operate in a similar manner to the ABX-CBL antibody. Such features include (i) cell killing through CDC, (ii) apparent effect of density or expression of the CD147 molecule on cellular populations, and (iii) the role of protective factors (for example, CD46, CD55, and CD59) on cellular populations.

As will be appreciated, the above information provides highly useful information to the generation of additional antibody candidates. Put another way, antibody candidates that are generated that possess one or more of the above-characteristics are more likely to possess similar activity to the ABX-CBL antibody. An antibody candidate that possesses greater numbers of similar characteristics is likely to be a very close mimic to the ABX-CBL antibody and, accordingly, would likely exhibit similar safety and efficacy data as the ABX-CBL antibody.

In Vivo Models

Each of the foregoing features, whether structural or functional, can essentially be carried out *in vitro*. Of course, however, prior to proceeding into man with therapeutic candidates it is desirable to generate *in vivo* data to ensure that operation of the antibody candidate will be safe and efficacious *in vivo*. In connection with GVHD, there are several animal models that have been shown to be highly predictive of the operation of therapeutic candidates in man. Such models include:

- Murine model (Hakim FT & Mackall CL "The Immune System: Effector and Target of Graft-Versus-Host Disease" in *Graft-vs.Host Disease* (Ferrara et al. eds, 2d edition, Marcel Dekker, Inc., NY (1997)).
- Canine Model (Storb et al. *Blood* 89:3048-3054 (1997); Yu et al. *Bone Marrow Transplantation* 17:649-653 (1996); Raff et al.

Transplantation 54:813-820 (1992); and Deeg et al. *Transplantation* 37:62-65 (1984))

- Primate Skin Graft Model (Chatterjee et al. *Hybridoma* 1:369-377 (1982) and Billing R. and Chatterjee S. *Transplantation Proceedings* 15:649-650 (1983))

5

As will be appreciated, in order such models to predictive, it is necessary that the antibody candidate is reactive with the endogenous form of CD147 in the animal.

10 *Construction of Antibodies*

An excellent model in which to generate therapeutic molecules targeting CD147 is in connection with the generation of antibodies. Antibodies can be generated with relative ease and are also capable of ready screening. In recent years, it has become possible to generate different "types" of antibodies; from conventional
15 murine antibodies through human antibodies generated from transgenic animals. Within that spectrum, antibodies can also be generated through display techniques (i.e, phage), murine or other antibodies can be humanized, and the like. Some of these techniques are discussed below.

In connection with the generation of antibodies through immunization
20 techniques, both classical and advanced immunization techniques can be used. By classical, we mean that animals can simply be immunized with the antigen, lymphocytic cells fused with myeloma cells, and hybridomas screened therefrom. By advanced, we mean that either immunization schemes can be biased or, instead of simply forming hybridomas, lymphocytic cells can be used directly to form display
25 libraries and screened using, for example, phage or other display technologies. Such techniques are conventional in the art and are discussed in additional detail below. In connection with biasing immunizations, one can immunize with CD147, followed by immunization with peptides, such as the 15-mer peptide mentioned above. In this manner, there is a higher probability of generating antibodies that possess specificity
30 and affinity for selected epitopes for example. Thus, it is expected that antibodies having specificity for the RXRSH consensus sequence in CD147, as discussed above, can be more readily generated. It will be appreciated that such immunization

techniques can be utilized in connection with standard fusions and screening procedures or advanced screening procedures. Another set of advanced immunization techniques are related to techniques of antigen presentation (i.e., DEC systems) and techniques to augment the immune response (i.e., CD140 systems) in the animal in
5 which the immunization is being undertaken.

Generation of Human Antibodies from Transgenic Animals

The generation of fully human antibodies, for example, from transgenic animals, is very attractive. Fully human antibodies are expected to minimize the
10 immunogenic and allergic responses intrinsic to mouse or mouse-derived Mabs and thus to increase the efficacy and safety of the administered antibodies. The use of fully human antibodies can be expected to provide a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation, autoimmunity, and cancer, which often require repeated antibody administrations.

15 One approach that has been utilized in connection with the generation of human antibodies is the construction of mouse strains that are deficient in mouse antibody production but that possess large fragments of the human Ig loci so that such mice would produce a large repertoire of human antibodies in the absence of mouse antibodies. Large human Ig fragments preserve the large variable gene diversity as
20 well as the proper regulation of antibody production and expression. By exploiting the mouse machinery for antibody diversification and selection and the lack of immunological tolerance to human proteins, the reproduced human antibody repertoire in these mouse strains yields high affinity antibodies against any antigen of interest, including human antigens. Using hybridoma technology, antigen-specific
25 human Mabs with the desired specificity can be readily produced and selected.

This general strategy was demonstrated in connection with the generation of the first XenoMouse strains as published in 1994. *See* Green et al. *Nature Genetics* 7:13-21 (1994). The XenoMouse strains were engineered with 245 kb and 190 kb-sized germline configuration fragments of the human heavy chain loci and kappa
30 light chain loci, respectively, which contained core variable and constant region sequences. *Id.* The human Ig containing yeast artificial chromosomes (YACs) proved to be compatible with the mouse system for both rearrangement and

expression of antibodies, and were capable of substituting for the inactivated mouse Ig genes. This was demonstrated by their ability to induce B-cell development and to produce an adult-like human repertoire of fully human antibodies and to generate antigen-specific human Mabs. These results also suggested that introduction of larger portions of the human Ig loci containing greater numbers of V genes, additional regulatory elements, and human Ig constant regions might recapitulate substantially the full repertoire that is characteristic of the human humoral response to infection and immunization.

Such approach is further discussed and delineated in U.S. Patent Application Serial Nos. 07/466,008, filed January 12, 1990, 07/610,515, filed November 8, 1990, 07/919,297, filed July 24, 1992, 07/922,649, filed July 30, 1992, filed 08/031,801, filed March 15, 1993, 08/112,848, filed August 27, 1993, 08/234,145, filed April 28, 1994, 08/376,279, filed January 20, 1995, 08/430, 938, April 27, 1995, 08/464,584, filed June 5, 1995, 08/464,582, filed June 5, 1995, 08/463,191, filed June 5, 1995, 08/462,837, filed June 5, 1995, 08/486,853, filed June 5, 1995, 08/486,857, filed June 5, 1995, 08/486,859, filed June 5, 1995, 08/462,513, filed June 5, 1995, 08/724,752, filed October 2, 1996, and 08/759,620, filed December 3, 1996. *See also* European Patent No., EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published February 3, 1994, International Patent Application No., WO 96/34096, published October 31, 1996, and PCT Application No. PCT/US96/05928, filed April 29, 1996. The disclosures of each of the above-cited patents and applications are hereby incorporated by reference in their entirety.

In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" strategy. In the minilocus strategy, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H genes, one or more J_H genes, a μ constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Patent No. 5,545,807 to Surani et al., U.S. Patent Nos. 5,545,806, 5,625,825, 5,661,016, 5,633,425, and 5,625,126, each to Lonberg and Kay, U.S. Patent No. 5,643,763 to Dunn and Choi, U.S. Patent No. 5,612,205 to Kay et al., U.S. Patent No. 5,591,669 to Krimpenfort and Berns, and GenPharm International U.S. Patent

Application Serial Nos. 07/574,748, filed August 29, 1990, 07/575,962, filed August 31, 1990, 07/810,279, filed December 17, 1991, 07/853,408, filed March 18, 1992, 07/904,068, filed June 23, 1992, 07/990,860, filed December 16, 1992, 08/053,131, filed April 26, 1993, 08/096,762, filed July 22, 1993, 08/155,301, filed November 18, 5 1993, 08/161,739, filed December 3, 1993, 08/165,699, filed December 10, 1993, 08/209,741, filed March 9, 1994, 08/544,404, filed October 10, 1995, the disclosures of which are hereby incorporated by reference. *See also* International Patent Application Nos. WO 97/13852, published April 17, 1997, WO 94/25585, published November 10, 1994, WO 93/12227, published June 24, 1993, WO 92/22645, 10 published December 23, 1992, WO 92/03918, published March 19, 1992, the disclosures of which are hereby incorporated by reference in their entirety. *See further* Taylor et al., 1992, Chen et al., 1993, Tuailon et al., 1993, Choi et al., 1993, Lonberg et al., (1994), Taylor et al., (1994), and Tuailon et al., (1995), the disclosures of which are hereby incorporated by reference in their entirety.

15 The inventors of Surani et al., cited above, and assigned to the Medical Research Counsel (the "MRC"), produced a transgenic mouse possessing an Ig locus through use of the minilocus approach. The inventors on the GenPharm International work, cited above, Lonberg and Kay, following the lead of the present inventors, proposed inactivation of the endogenous mouse Ig locus coupled with substantial 20 duplication of the Surani et al. work.

An advantage of the minilocus approach is the rapidity with which constructs including portions of the Ig locus can be generated and introduced into animals. Commensurately, however, a significant disadvantage of the minilocus approach is that, in theory, insufficient diversity is introduced through the inclusion of small 25 numbers of V, D, and J genes. Indeed, the published work appears to support this concern. B-cell development and antibody production of animals produced through use of the minilocus approach appear stunted. Therefore, the present inventors have consistently urged introduction of large portions of the Ig locus in order to achieve greater diversity and in an effort to reconstitute the immune repertoire of the animals.

30 It will be appreciated that through use of the above-technology, human antibodies can be generated to, for example, CD147 expressing cells, CD147 itself, forms of CD147, epitopes or peptides thereof, and expression libraries thereto (*see*

e.g. U.S. Patent No. 5,703,057) through immunization of a transgenic mouse therewith, forming hybridomas, and screening the resulting hybridomas as described above for the activities described above.

Indeed, through use of the above-discussed technology, we prepared a panel of
5 human monoclonal antibodies that bind CD147 through immunization of
XenoMouseTM strains of transgenic mice (*see* Mendez et al., (1997), *supra*. and U.S.
Patent Application, No. 08/759,620, filed December 3, 1996), available from
Abgenix, Inc., Fremont, CA. Such antibodies were further screened for their ability to
compete with ABX-CBL for binding with CD147. In such panel, both human IgG2
10 and human IgM antibodies were detected that bound to CD147 and were capable of
competition with ABX-CBL for binding to CD147. The hybridomas expressing such
antibodies were designated as follows:

IgMs: CEM 10.1 C3, CEM 10.1 G10, CEM 10.12 F3, CEM 10.12 G5 CEM
15 13.12, CEM 13.5; and

IgG2s: 2.4.4, 2.1.1, 2.3.2, 2.6.1.

Each of the above antibodies were sequenced through isolating cDNAs
20 encoding them from the corresponding hybridomas through RT-PCR. Germline gene
identifications were made and the sequences of the antibodies compared to the
germline sequences. Germline gene identifications are provided in the following
Table:

25

30

TABLE 1

Antibody	Heavy/Light	V _H or V _K	D	J _H or J _K
CEM 10-1 C3	Heavy	V4-34	D2/D2-15	JH6b
	Light	A3/A19/DPK 15		JK1
CEM 10.1 G10	Heavy	DP71 (V4-59)	D1-26	JH6b
	Light	A30		JK1 (not identical seq)
CEM 10.12 F3	Heavy	DP15 (V1-8)	D1-26	JH6b
	Light	B3/DPK24		JK1
CEM 10.12 G5	Heavy	DP15 (V1-8)	D6-19	JH6b
	Light	A30		JK1
CEM 13.12	Heavy	V4-34	D2-2/D4	JH6b
	Light	A3/A19/DPK 15		JK3
CEM 13.5	Heavy	DP77-WH16 (3-21)	D6-19	JH4b
	Light	B3/DPK24		JK1 (not identical seq)
2.4.4	Heavy	VII-5	D21-9/D3-22	JH4b
	Light	A2 DPK12		JK4
2.1.1	Heavy	DP77	D6-19	JH4b
	Light	LFVK431		JK3
2.3.2	Heavy	VII-5	D21-9/D3-22	JH4b
	Light	A2 DPK12		JK4
2.6.1	Heavy	DP47	DXP4	JH4b
	Light	LFVK431		JK3

5

Germline sequences of the V_H, D, J_H, V_K, and J_K genes are available on GenBank. The sequences of certain of the antibodies were compared to transcripts of the germline V-gene segments to observe somatic mutations in the amino acid sequences. Such sequence comparisons are shown in Figures 44 through 46. cDNA sequences and protein transcripts of and for each of the antibodies are shown in Figures 24 through 33. In addition, CDRs, according to Kabat numbering scheme, of the heavy chains and kappa light chains of the antibodies are shown in Figures 34 through 43.

10

It will be appreciated that CDRs of the above antibodies are generally very important in connection with antibody binding to an antigen. Accordingly, it will be understood that a variety of FR and other modifications can be made in and to antibodies that do not modify an antibodies binding the epitope on an antigen. Thus, an important factor in an antibody's activity is the epitope on an antigen to which an antibody binds. So long as the epitope binding is conserved, in many ways it may matter little if the primary sequence of the antibody is modified. Therefore, where sequences are discussed herein, it is submitted that the sequence of an antibody may initially define an efficacious epitope on the antigen, however, once the epitope is identified by the antigen, any antibody that binds to the same epitope on the is contemplated herein.

In view of a number of tests that were conducted, the 2.6.1 IgM antibody was chosen for additional development. As will be appreciated, all of the IgMs that were generated were monovalent. Accordingly, in order to prepare a fully human multimeric IgM antibody, we cloned the human J-chain gene from human buffy coat cells, prepared a first expression vector containing the 2.6.1 kappa light chain cDNA and the J-chain cDNA and a second expression vector containing the 2.6.1 heavy chain cDNA, cotransfected DHFR⁺ Chinese hamster ovary cells with the two vectors, and selected clones expressing the multimeric IgM.

The 2.6.1 IgM + J-Chain antibody was capable of acting in ADCC as shown in Figure 50.

Humanization and Display Technologies

As was discussed above in connection with human antibody generation, there are advantages to producing antibodies with reduced immunogenicity. To a degree, this can be accomplished in connection with techniques of humanization and display techniques using appropriate libraries. It will be appreciated that murine antibodies or antibodies from other species can be humanized or primatized using techniques well known in the art. See e.g., Winter and Harris *Immunol Today* 14:43-46 (1993) and Wright et al. *Crit, Reviews in Immunol.* 12:125-168 (1992). Further, human antibodies or antibodies from other species can be generated through display-type technologies, including, without limitation, phage display, retroviral display, ribosomal display, and

other techniques, using techniques well known in the art and the resulting molecules can be subjected to additional maturation, such as affinity maturation, as such techniques are well known in the art. Wright and Harris, *supra.*, Hanes and Plutchau *PNAS USA* 94:4937-4942 (1997) (ribosomal display), Parmley and Smith *Gene* 173:305-318 (1988) (phage display), Scott *TIBS* 17:241-245 (1992), Cwirla et al. *PNAS USA* 87:6378-6382 (1990), Russel et al. *Nucl. Acids Research* 21:1081-1085 (1993), Hoganboom et al. *Immunol. Reviews* 130:43-68 (1992), and Chiswell and McCafferty *TIBTECH* 10:80-84 (1992). If display technologies are utilized to produce antibodies that are not human, such antibodies can be humanized as described above.

Using these techniques, antibodies can be generated to CD147 expressing cells, CD147 itself, forms of CD147, epitopes or peptides thereof, and expression libraries thereto (*see e.g.* U.S. Patent No. 5,703,057) which can thereafter be screened as described above for the activities described above.

Further, the sequence for the active antibody from the deposited hybridoma cell line expressing the ABX-CBL antibody was previously unknown. In view of our findings discussed above that the IgM antibody was the entity responsible for the activity of the CBL1 antibody and the fact that neither the presence nor the absence of the MOPC21 light chain appeared to be advantageous nor detrimental to the activity of the antibody, we cloned the heavy chain and the kappa light chains from the IgM (ABX-CBL) producing hybridoma through RT-PCR and sequenced the cDNAs. The results of such sequencing studies, including the cDNA sequences of the heavy chain and kappa light chain and the protein transcripts thereof are shown below:

ABX-CBL Heavy Chain Nucleotide Sequence

25	ATGTA	CTTGG	GACTG	AACTA	TGTAT	TTCATA	GTTTT	TCTCT	TAAAT	GGTGT	50
	CCAGAG	TGAA	GTGAAG	CTTG	AGGAG	TCTGG	AGGAGG	CTTG	GTGCA	ACCTG	100
	GAGGAT	CCAT	GAAACT	CTCC	TGTGT	TGCCCT	CTGGAT	TCCAC	TTTCAG	TAAC	150
	TACTGG	ATGA	ACTGGG	TCCG	CCAGT	CTCCA	GAGAAG	GGGGC	TTGAGT	GGGT	200
	TGCTGA	AAAT	AGATTG	AAAT	CTAATA	AATTA	TGCAAC	ACAT	TATGCG	GAGT	250
30	CTGTGA	AAAG	GAGGTT	CACC	ATCTCA	AGAG	ATGATT	CCAA	AAGTAG	TGTC	300
	TACCTG	CAAA	TGAACA	ACTT	AAGAG	CTGAA	GACACT	GGCA	TTTATT	ACTG	350
	TACGGAT	TAC	GATGCT	TACT	GGGGCA	AAG	GACTCT	GGTC	ACTGT	CTCTG	400
	CAGAGAG	TCA	GTCCTT	CCCA	AATGT	CTTCC	CCCTCG	TCTC	CTGCG	AGAGC	450
	CCCCTG	CTG	ATAAGA	ATCT	GGTGG	CCATG	GGCTGC	CTTG	CCCGGG	ACTT	500
35	CCTGCC	CAGC	ACCATT	TCCT	TCACCT	TGGAA	CTACCA	GAAAC	AACACT	GGAAG	550
	TCATCCA	GGG	TATCAGA	ACC	TTCCCA	ACAC	TGAGGA	CAGG	GGGCA	AGTAC	600
	CTAGCCA	CCT	CGCAGG	TGTT	GCTGT	CTCCC	AAGAG	CATCC	TTGAAG	GTTC	650
	AGATGA	ATAC	CTGGT	ATGCA	AAATCC	ACTA	CGGAGG	CAAA	AACAG	AGATC	700
	TGCATG	TGCC	CATTCC	AGCT	GTCGC	AGAGA	TGAAC	CCCCA	TGTAA	TGTG	750

58

	TTCGTCCAC	CACGGGATGG	CTTCTCTGGC	CCTGCACCAC	GCAAGTCTAA	800
	ACTCATCTGC	GAGGCCACGA	ACTTCACTCC	AAAACCGATC	ACAGTATCCT	850
	GGCTAAAGGA	TGGGAAGCTC	GTGGAATCTG	GCTTCACCAC	AGATCCGGTG	900
	ACCATCGAGA	ACAAAGGATC	CACACCCCAA	ACCTACAAGG	TCATAAGCAC	950
5	ACTTACCATC	TCTGAAATCG	ACTGGCTGAA	CCTGAATGTG	TACACCTGCC	1000
	GTGTGGATCA	CAGGGGTCTC	ACCTTCTTGA	AGAACGTGTC	CTCCACATGT	1050
	GCTGCCAGTC	CCTCCACAGA	CATCCTAACC	TTCACCATCC	CCCCCTCCTT	1100
	TGCCGACATC	TTCCTCAGCA	AGTCCGCTAA	CCTGACCTGT	CTGGTCTCAA	1150
	ACCTGGCAAC	CTATGAAACC	CTGAATATCT	CCTGGGCTTC	TCAAAGTGGT	1200
10	GAACCACTGG	AAACCAAAAT	TAAAATCATG	GAAAGCCATC	CCAATGGCAC	1250
	CTTCAGTGCT	AAGGGTGTGG	CTAGTGTTTG	TGTGGAAGAC	TGGAATAACA	1300
	GGAAGGAATT	TGTGTGTACT	GTGACTCACA	GGGATCTGCC	TTCACCACAG	1350
	AAGAAATTCA	TCTCAAAACC	CAATGAGGTG	CACAAACATC	CACCTGCTGT	1400
	GTACCTGCTG	CCACCAGCTC	GTGAGCAACT	GAACCTGAGG	GAGTCAGCCA	1450
15	CAGTCACCTG	CCTGGTGAAG	GGCTTCTCTC	CTGCAGACAT	CAGTGTGCAG	1500
	TGGCTTCAGA	GAGGGCAACT	CTTGCCCCAA	GAGAAGTATG	TGACCAGTGC	1550
	CCCGATGCCA	GAGCCTGGGG	CCCCAGGCTT	CTACTTTACC	CACAGCATCC	1600
	TGACTGTGAC	AGAGGAGGAA	TGGAACCTCG	GAGAGACCTA	TACCTGTGTT	1650
	GTAGGCCACG	AGGCCCTGCC	ACACCTGGTG	ACCGAGAGGA	CCGTGGACAA	1700
20	GTCCACTGGT	AAACCCACAC	TGTACAATGT	CTCCCTGATC	ATGTCTGACA	1750
	CAGGCGGCAC	CTGCTATTGA	CCAT			1774

(SEQ ID NO: 81)

ABX-CBL Heavy Chain Protein Sequence

25	EVKLEESGGG	LVQPGGSMKL	SCVASGFTFS	NYWMNWVRQS	PEKGLEWVAE	50
	IRLKSNNYAT	HYAESVKGRF	TISRDDSKSS	VYLQMNLR	EDTGIYYCTD	100
	YDAYWQGTL	VTVAESQSF	PNVFPLVSCE	SPLSDKNLVA	MGCLARDFLP	150
	STISFTWNYQ	NNTEVIQGIT	TFPTLRTGGK	YLATSQVLLS	PKSILEGSDE	200
30	YLVCKIHVYG	KNRDLHVPI	AVAEMNPVN	VFVPPRDGFS	GPAPRKSCLI	250
	CEATNFTPKP	ITVSWLKDGL	LVESGFTTDP	VTIENKGSTP	QTYKVISTLT	300
	ISEIDWLNLN	VYTCRVDHRG	LTFLKNVSST	CAASPSTDIL	TFTIPPSFAD	350
	IFLSKSANLT	CLVSNLATYE	TLNISWASQS	GEPLETKIKI	MESHPNGTFS	400
	AKGVASVCVE	DWNNRKEFVC	TVTHRDLPSP	QKKFISKPNE	VHKHPPAVYL	450
35	LPPAREQLNL	RESATVTCLV	KGFSPADISV	QWLQRGQLLP	QEKYVTSAPM	500
	PEPGAPGFYF	THSILTVTEE	EWNSGETYTC	VVGHEALPHL	VTERTVDKST	550
	GKPTLYNVSL	IMSDTGGTCY				570

(SEQ ID NO: 18)

ABX-CBL Light Chain Protein Sequence

40	KFLLVSAGDR	VTITCKASQS	VSNDVAWYQQ	KPGQSPKLLI	YYASNRYTGV	50
	PDRFTGSGYG	TDFTFTISTV	QAEDLAVYFC	QQDYSSPYTF	GGGKLEIKR	100
	ADAAPTVSIF	PPSSEQLTSG	GASVVCFLNN	FYPKDINVKW	KIDGSEQRNG	150
45	VLNSWTDQDS	KDSTYSMSST	LTLTKDEYER	HNSYTCEATH	KTSTSPIVKS	200
	FNRNEC					206

(SEQ ID NO: 19)

As will be appreciated, through utilization of the sequence, it is possible to prepare a humanized version of the ABX-CBL antibody. In general, the nucleotide sequences encoding the CDRs are grafted into human framework (FR) sequences using conventional techniques. Alternatively, amino acid residues in the framework

regions surrounding the CDRs (i.e., residues in FR1 and FR2, surrounding CDR1, FR2 and FR3, surrounding CDR2, and/or FR3 and FR4, surrounding CDR3) are modified through mutagenesis of cDNAs encoding the same also using conventional techniques. In either case, the modified cDNAs encoding the humanized kappa light chain and the heavy chain are generally then introduced into a cell line for expression (i.e., NSO, CHO, or the like) either directly, through cotransfection, or through use of the cell-cell fusion techniques described in U.S. Patent Application, Serial No. 08/730,639, filed October 11, 1996 or International Patent Application No. WO 98/16654, published April 23, 1998. Thereafter, the humanized antibodies are expressed and assayed for binding and other functional attributes. The molecules can be iteratively modified at the DNA level as desired or necessary to achieve improved binding or other functional attributes of the antibodies. For example, in certain cases, it is necessary to reintroduce murine sequences within the human FRs to improve binding. A good step-by-step introduction to humanization and demonstrating how conventional humanization has become in the art is provided on the internet <http://www.cryst.bbk.ac.uk/~ubcg07s/>.

In general, at the same time, or during the process, the constant region would be switched from the murine IgM to another human constant region (such as a human IgM constant region, without or without the J-chain, as discussed above) to prepare a humanized chimeric antibody.

Additional Criteria for Antibody Therapeutics

As discussed herein, the function of the ABX-CBL antibody appears important to at least a portion of its mode of operation. By function, we mean, by way of example, the activity of the ABX-CBL antibody is CDC. Accordingly, it is desirable in connection with the generation of antibodies as therapeutic candidates against CD147 that the antibodies be capable of fixing complement and participating in CDC. There are a number of isotypes of antibodies that are capable of the same, including, without limitation, the following: murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3. It will be appreciated that antibodies that are generated need not initially possess such an isotype but, rather, the antibody as generated can possess any isotype and the antibody

can be isotype switched thereafter using conventional techniques that are well known in the art. Such techniques include the use of direct recombinant techniques (*see e.g.*, U.S. Patent No. 4,816,397), cell-cell fusion techniques (*see e.g.*, U.S. Patent Application No. 08/730,639, filed October 11, 1996), among others.

5 In the cell-cell fusion technique, a myeloma or other cell line is prepared that possesses a heavy chain with any desired isotype and another myeloma or other cell line is prepared that possesses the light chain. Such cells can, thereafter, be fused and a cell line expressing an intact antibody can be isolated.

By way of example, the 2.6.1 antibody discussed herein is a human anti-
10 CD147 IgG2 antibody. If such antibody possessed desired binding to the CD147 molecule, it could be readily isotype switched to generate a human IgM, human IgG1, or human IgG3 isotype, while still possessing the same variable region (which defines the antibody's specificity and some of its affinity). Such molecule would then be capable of fixing complement and participating in CDC, in a similar manner to the
15 ABX-CBL antibody.

Accordingly, as antibody candidates are generated that meet desired "structural" attributes as discussed above, they can generally be provided with at least certain of the desired "functional" attributes through isotype switching.

20 *Design and Generation of Other Therapeutics*

In accordance with the present invention and based on the activity of the ABX-CBL antibody with respect to CD147, it is now also possible to design other therapeutic modalities beyond ordinary antibody moieties, including, without limitation, advanced antibody therapeutics, such as bispecific antibodies,
25 immunotoxins, and radiolabeled therapeutics, generation of peptide therapeutics, gene therapies, particularly intrabodies, antisense therapeutics, and small molecules.

In connection with the generation of advanced antibody therapeutics, it may be possible to sidestep the dependence on complement for cell killing that we have demonstrated is necessary for the function of the ABX-CBL antibody through the use
30 of bispecifics, immunotoxins, or radiolabels, for example.

For example, in connection with bispecific antibodies, bispecific antibodies can be generated that comprise (i) two antibodies one with a specificity to CD147 and

another to a second molecule that are conjugated together, (ii) a single antibody that has one chain specific to CD147 and a second chain specific to a second molecule, or (iii) a single chain antibody that has specificity to CD147 and the other molecule. Such bispecific antibodies can be generated using techniques that are well known for example, in connection with (i) and (ii) *see e.g.*, Fanger et al. *Immunol Methods* 4:72-81 (1994) and Wright and Harris, *supra.* and in connection with (iii) *see e.g.*, Traunecker et al. *Int. J. Cancer (Suppl.)* 7:51-52 (1992). In each case, the second specificity can be made to the heavy chain activation receptors, including, without limitation, CD16 or CD64 (*see e.g.*, Deo et al. 18:127 (1997)) or CD89 (*see e.g.*, Valerius et al. *Blood* 90:4485-4492 (1997)). Bispecific antibodies prepared in accordance with the foregoing would be likely to kill cells expressing CD147, and particularly those cells in which the ABX-CBL antibody is effective.

In connection with immunotoxins, antibodies can be modified to act as immunotoxins utilizing techniques that are well known in the art. *See e.g.*, Vitetta *Immunol Today* 14:252 (1993). *See also* U.S. Patent No. 5,194,594. In connection with the preparation of radiolabeled antibodies, such modified antibodies can also be readily prepared utilizing techniques that are well known in the art. *See e.g.*, Junghans et al. in *Cancer Chemotherapy and Biotherapy* 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996)). *See also* U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (RE 35,500), 5,648,471, and 5,697,902. Each of immunotoxins and radiolabeled molecules would be likely to kill cells expressing CD147, and particularly those cells in which the ABX-CBL antibody is effective.

In connection with the generation of therapeutic peptides, through the utilization of structural information related to CD147 and antibodies thereto, such as the ABX-CBL antibody (as discussed below in connection with small molecules) or screening of peptide libraries, therapeutic peptides can be generated that are directed against CD147. Design and screening of peptide therapeutics is discussed in connection with Houghten et al. *Biotechniques* 13:412-421 (1992), Houghten *PNAS USA* 82:5131-5135 (1985), Pinalla et al. *Biotechniques* 13:901-905 (1992), Blake and Litzi-Davis *BioConjugate Chem.* 3:510-513 (1992). Immunotoxins and radiolabeled molecules can also be prepared, and in a similar manner, in connection with peptidic moieties as discussed above in connection with antibodies.

Assuming that the CD147 molecule (or a form, such as a splice variant or alternate form) is functionally active in a disease process, it will also be possible to design gene and antisense therapeutics thereto through conventional techniques. Such modalities can be utilized for modulating the function of CD147. In connection therewith the discovery of the present invention allows design and use of functional assays related thereto. A design and strategy for antisense therapeutics is discussed in detail in International Patent Application No. WO 94/29444. Design and strategies for gene therapy are well known. However, in particular, the use of gene therapeutic techniques involving intrabodies could prove to be particularly advantageous. See e.g., Chen et al. *Human Gene Therapy* 5:595-601 (1994) and Marasco *Gene Therapy* 4:11-15 (1997). General design of and considerations related to gene therapeutics is also discussed in International Patent Application No. WO 97/38137.

Small molecule therapeutics can also be envisioned in accordance with the present invention. Drugs can be designed to modulate the activity of CD147 based upon the present invention. Knowledge gleaned from the structure of the CD147 molecule and its interactions with other molecules in accordance with the present invention, such as the ABX-CBL antibody, CD46, CD55, CD59, and others can be utilized to rationally design additional therapeutic modalities. In this regard, rational drug design techniques such as X-ray crystallography, computer-aided (or assisted) molecular modeling (CAMP), quantitative or qualitative structure-activity relationship (QSAR), and similar technologies can be utilized to focus drug discovery efforts. Rational design allows prediction of protein or synthetic structures which can interact with the molecule or specific forms thereof which can be used to modify or modulate the activity of CD147. Such structures can be synthesized chemically or expressed in biological systems. This approach has been reviewed in Capsey et al. *Genetically Engineered Human Therapeutic Drugs* (Stockton Press, NY (1988)). Further, combinatorial libraries can be designed and synthesized and used in screening programs, such as high throughput screening efforts.

Therapeutic Administration and Formulations

It will be appreciated that administration of therapeutic entities in accordance with the invention will be administered with suitable carriers, excipients, and other

agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences (15th ed, Mack Publishing Company, Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. *See also* Powell et al. "Compendium of excipients for parenteral formulations" *PDA J Pharm Sci Technol.* 52:238-311 (1998) and the citations therein for additional information related to excipients and carriers well known to pharmaceutical chemists.

EXAMPLES

The following examples, including the experiments conducted and results achieved, are provided for illustrative purposes only and are not to be construed as limiting upon the present invention.

EXPERIMENT 1

GENERATION OF HUMAN ANTIBODIES

Human antibodies were prepared in accordance with Mendez et al. *Nature Genetics* 15:146-156 (1997) and U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996, the disclosures of which are hereby incorporated by reference herein in their entirety, through the immunization of XenoMouseTM animals with CEM cells, followed by fusions, and screening of the resulting hybridoma supernatants against CEM cells and in competition assays with the ABX-CBL antibody (Example 2).

EXPERIMENT 2 IMMUNO-AFFINITY PURIFICATION OF ABX-CBL ANTIGEN

We undertook immunoaffinity purification of the antigen to which the ABX-CBL antibody bound. The antigen to which the CBL1 and ABX-CBL antibody bound appeared to be highly expressed on CEM cells. Immunoaffinity purification using the native ABX-CBL antibody was frustrated by the fact that the ABX-CBL antibody is an IgM antibody having a pentameric structure. Therefore, we prepared human IgG2 antibodies (Example 1), followed by fusions, and screening of the resulting hybridoma supernatants against CEM cells and tested for competition with the ABX-CBL antibody in binding assays with CEM cells using FACS. In the FACS competition assays, inhibition of the binding of ABX-CBL antibodies, labeled with FITC, to CEM cells was analyzed, both alone and in the presence of the anti-CEM human antibodies.

We obtained four hybridoma clones from the fusions that produced monoclonal antibodies that bound to the CEM cells and that were highly competitive with the ABX-CBL antibody in binding to the CEM cells. One hybridoma clone, designated 2.6.1 appeared most competitive.

We generated ascites to each of the four hybridoma clones, including the 2.6.1 hybridoma, in SCID mice and purified the 2.6.1 antibody using a Protein A affinity purification process using standard conditions. From the purified 2.6.1 antibody, we prepared an immunoaffinity column. To prepare the column, the purified 2.6.1 antibody was conjugated to CNBr activated Sepharose-4B, according to the manufacturer's specifications. Approximately 8.4 mg of the antibody was conjugated to about 2.0 g of the activated Sepharose. We passed cell lysates of CEM cells through the column and eluted the components that bound. The elution product was analyzed by SDS-PAGE electrophoresis, Western blotting, ELISAs, and BiaCore reactivity against CEM cell lysates.

The elution product that was purified from CEM cell lysates was demonstrated to be CD147 upon our sequencing of the diffuse band corresponding to 45-55 KD that we observed on Western Blot analysis after reaction with each of the 2.6.1 antibody and the ABX-CBL antibody. As will be observed from Figure 1, the 2.6.1 antibody bound most intensely to a molecule or molecules contained within a diffuse band

from about 45-55 KD, while the ABX-CBL antibody showed binding with a lower intensity to a similar band from about 45-55 KD.

Sequencing was accomplished upon a portion of the 45-55 KD band that was isolated through use of preparative gel electrophoresis and electroblotting techniques using a Perkin Elmer sequencer. We obtained a partial amino acid sequence of the molecule (between 35 through 40 residues). The resulting sequence information was analyzed through a protein database search (Protein Identification Resource (PIR) R47.0, December 1995) and the sequence comparison data indicated that the molecule was CD147.

Western blots on CEM lysates were generally accomplished as follows:

CEM cells were homogenized in 10mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, and protease inhibitors to generate CEM extracts at 5×10^8 cells/ml. The extract (5 μ l) were electrophoresed on 12% SDS-PAGE gels and then blotted onto PVDF. The blot was cut into 5 strips in preparation for antibody staining. All first antibody staining was done at 1 μ g/ml in 1% gelatin/PBST buffer. All AP labeled second antibody was done at a dilution of 1:1000 in the same buffer. The rabbit-anti-mouse-hnRNP-k Protein antibody was supplied to us by Dr. Karol Bomstzyk at the University of Washington. Each of the ABX-CBL, Pharmingen, and 2.6.1 antibodies are described further herein.

EXPERIMENT 3 PURIFICATION OF 62 KD BAND

In order to purify the material contained in the 62 KD band, CEM whole cell lysates were prepared from approximately 3×10^{10} cells. The lysates were extracted and concentrated to provide about 3.8 mg of protein. A portion of the recovered protein was subjected to a series of chromatography steps: size exclusion, anion exchange, hydrophobic interaction, reversed phase, and microbore reversed phase. In each step, the fraction showing binding to the ABX-CBL antibody on Western blot was carried on to the next step. Following microbore reversed phase chromatography, approximately 5×10^{-6} grams of protein was recovered and a portion of the protein subjected to gel electrophoresis and electroblotting to generate approximately 90% pure 62 KD protein.

A direct N-terminal sequence was attempted, however, the molecule possessed a blocked N-terminus. Thus, the material was digested with CNBr and preparative gel electrophoresis and electroblotting were conducted, yielding bands at approximately 12 KD and 32.5 KD. The blotted fragments were sequenced and the resulting sequence results were analyzed through protein database searches (Protein Identification Resource (PIR) R47.0, December 1995). The sequence comparison data indicated that the molecule was heterogeneous ribonuclear protein k (hnRNP-k), with the 12 KD band having residues 360 and up (after Methionine; 359) and the 32.5 KD band having residues 43 and up (after Methionine; 42).

EXPERIMENT 4 CD147 ELISA ASSAY

We have utilized the enriched purified antigen obtained from CEM cell lysates to develop a specific ELISA assay for the detection of the expression of CD147 in a secreted or membrane bound form. In the assay, we immobilize the CD147 antigen (for example, the CD147 antigen that is affinity purified from CEM cell lysates) in the wells of plates. Binding of the antigen can be accomplished using conventional techniques. Thereafter, the plates containing the antigen can be used for the detection of antibodies that are reactive with it using conventional techniques. We have demonstrated that each of the commercially available anti-CD147 antibodies (RDI-CBL535 (a murine anti-CD147 IgG2b antibody), available from RDI, Flanders, NJ, and 36901A (a murine anti-CD147 IgG1 antibody), available from Pharmingen, San Diego, CA), the ABX-CBL antibody, and the human antibodies that we have generated in Example 2 react specifically in this assay.

The present ELISA assay is useful as a screening system for detecting antibodies that bind to the CD147 antigen.

EXPERIMENT 5 EVIDENCE RELATED TO ROLE OF 35 KD BAND

As mentioned above, anecdotal evidence indicates that a 35 KD band could correspond to a singly-glycosylated form of CD147. See Kanekura et al. *Cell Struct Funct* 16:23-30 (1991). Further, it is also interesting to note that in comparisons of Western blots produced by two commercially available anti-CD147 antibodies (RDI-CBL535 (a murine anti-CD147 IgG2b antibody), available from RDI, Flanders, NJ,

and 36901A (a murine anti-CD147 IgG1 antibody), available from Pharmingen, San Diego, CA) to the ABX-CBL and 2.6.1 antibodies indicates that each of the commercially available antibodies recognize a molecule that has a molecular weight around 35 KD and appearing similar to the 35 KD band recognized by the ABX-CBL antibody. *See* Figure 1. Another interesting observation is that in the immunoaffinity purification mentioned above, when the effluent product from the 2.6.1 antibody was probed with the ABX-CBL antibody, the 35 KD band was no longer visible by Western blot. Rather, the ABX-CBL antibody appeared to bind to the diffuse band from 45-55 KD with relatively low intensity (similar to that shown in Figure 1). This evidence indicates that the ABX-CBL antibody could bind preferentially to a different epitope on, or a different form of, CD147 than the 2.6.1 antibody and the commercially available antibodies.

EXPERIMENT 6 COMPLEMENT MEDIATED CELL KILLING

The UCLA group mentioned above (*see e.g.*, U.S. Patent Nos. 5,330,896 and 5,643,740) provided certain evidence that the CBL1 antibody operated through killing of certain activated cell populations while the antibody did not react with non-activated cells. For example, in a microcytotoxicity assay, the CBL1 antibody was disclosed to kill activated lymphocytic cells but not other normal cells.

In connection with this experiment, the following materials and procedures were utilized:

Mixed lymphocyte reaction

Mixed lymphocyte reaction (MLR) is an *in vitro* system for assaying T lymphocyte proliferation in cell-mediated responses. A cell-mediated response is an *in vitro* assay of effector cytotoxic function, which can also be assayed *in vivo* by graft-versus-host reaction in experimental animals. When co-culturing allogeneic lymphocytes in MLR the cells undergo extensive blast transformation and cell proliferation. Thus, MLR can be quantified by adding tritium-labeled thymidine ($[^3\text{H}]$ thymidine) to the culture medium and monitoring uptake of label into DNA of the dividing lymphocytes.

To determine the function and quality CBL-1 and ABX-CBL antibody we used MLR to test the ability of CBL-1 and ABX-CBL to inhibit lymphocyte proliferative responses. Peripheral blood mononuclear cells were isolated from two HLA mismatched individuals by Ficoll-Paque gradient centrifugation. Allogeneic lymphocytes were mixed (1:1) and co-cultured (total of 5×10^5 cells/well in 96-well plate) *in vitro* for six days. Lymphocytes from one individual were irradiated with 3000 rads prior to the culture. CBL-1 and ABX-CBL antibody plus either 10 % rabbit or 25% human complement were added to the culture 24 h prior to the end of the culture. The culture was pulsed with [3 H]methyl-thymidine (Amersham) overnight and harvested on day 6. Lymphocyte proliferative response was determined by measuring [3 H]-thymidine incorporation. Percentage inhibition was calculated as the cpm in the absence of antibody minus the cpm in the presence of antibody divided by the cpm in the absence of antibody.

15 ***ConA stimulated lymphocyte proliferation***

Human PBMC were isolated as described above and stimulated by the mitogen Concanavalin A (ConA) at 5ug/ml for 48 h. Antibodies with or without 10% complement were added to the culture 24 h prior to the end of the culture. The culture was pulsed with [3 H]-methyl-thymidine overnight and harvested next day. Lymphocyte proliferative response was determined by measuring [3 H]-thymidine incorporation. Percentage inhibition was calculated as the cpm in the absence of antibody minus the cpm in the presence of antibody divided by the cpm in the absence of antibody.

25 ***FACS analysis of cell surface molecules***

For cell surface expression of different surface molecules, immunofluorescent staining and analysis on a FACSVantage (Becton Dickinson, San Jose, CA) have been described (*FACScan Manual*. Becton Dickinson, San Jose, CA). Monoclonal antibodies anti-CD3-PE, anti-CD4-PE, anti-CD8-PE, anti-CD14-PE, anti-CD20-PE, anti-CD25-FITC and anti-CD25-PE were obtained from Becton Dickinson. Anti-CD55-FITC and anti-CD59-FITC were purchased from Pharmingen (San Diego, CA).

ABX-CBL and cem2.6.1 were conjugated with FITC and PE, respectively, at Abgenix.

Complement-dependent cytotoxicity assay using Alamar blue

5 Complement-dependent cytotoxicity (CDC) assay was performed as described (Gazzano-Santoro et al. "A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody" *J. Immunol. Methods* 202:163-171 (1997). Fifty microliters of a cell suspension of 10^6 cells/ml, 50 μ l of various concentrations of antibodies and 50 μ l of a 10% rabbit or human complement were added to flat-bottomed 96-well tissue culture plate and incubated for 2 hours at 37°C and 5% CO₂.
10 Fifty microliters of Alamar blue (Accumed International) were then added (final 10%) and the incubation continued for another 5 hours. The plates were allowed to cool to room temperature for 10 minutes on a shaker and the fluorescence was read using a 96-well fluorometer with excitation at 530 nm and emission at 590 nm. Results were
15 expressed in relative fluorescence units (RFU).

In our work, we have demonstrated that CBL1 and ABX-CBL operate through complement mediated cell killing. Use of the CBL1 antibody by itself, the isotype-matched control mouse IgM antibody by itself (Figure 2), or complement (either human or rabbit) by itself in the MLR or modified MLR assay (ConA induced
20 lymphocyte proliferation assay) is ineffective in inhibiting T-cell proliferation. See Figures 2-5. However, when both complement and the CBL1 or ABX-CBL antibody are present, T-cell proliferation is inhibited in a dose dependent manner. See Figures 2-5. The human IgG2 antibody 2.6.1 is ineffective in inhibiting T-cell proliferation in the same assay, either by itself, or in combination with complement. See Figure 5.
25 This is expected, since the 2.6.1 antibody as a gamma-2 is notoriously less efficient in complement mediated lysis than is an IgM antibody, such as the ABX-CBL antibody.

The combination of CBL1 or ABX-CBL and complement only kill activated T-cells (both CD4⁺ and CD8⁺), activated B-cells, and monocytes, but does not effect resting T-cells and B-cells because such cells do not express CD147. It is important,
30 to note that monocytes are also killed by ABX-CBL and complement. This data provides an explanation for the operation of ABX-CBL therapy in diseases, such as GVHD, because, ABX-CBL selectively depletes those effector cells (activated T- and

B-cells) and the antigen presenting cells (monocytes and B-cells) which ordinarily would lead to further T-cell activation.

EXPERIMENT 7 EVIDENCE RELATED TO CELLULAR ACTIVATION

5 Using techniques described in Experiment 6, we also demonstrated that the CD25 marker appears to be expressed in high levels in the same cellular populations as those expressing the antigen to which the ABX-CBL antibody binds. *See* Figure 6. This finding provided a useful marker to detect whether the cells expressing CD25 were depleted in connection with the MLR assay. Where the MLR assay is conducted
10 utilizing a variety of activated cell populations, CD25 expressing cell populations are depleted only in those treated with the ABX-CBL antibody plus complement. *See* Figures 7-11. The selective killing of different cell populations are shown in Figures 10-12.

15 EXPERIMENT 8 EVIDENCE RELATED TO THE ROLE OF EXPRESSION LEVELS OF CD147

We have also considered whether CD147 expression levels are higher in given populations of cells (which could also be relevant to CDC).

20 In flow cytometry studies with peripheral blood mononuclear cells (PBMC) with the ABX-CBL antibody, we have noticed that, prior to the addition of complement, there are populations of cells that appear to express high and low levels of CD147. After complement is added, there are populations of cells that appear to correspond to the low level expressers mentioned above. It appears that these results could be indicative of density of CD147 expression levels on the cell surface. Density
25 can play a role in CDC through providing additional antigen binding sites to allow for distortion of the antibody which is the first step in triggering the complement cascade. Upon distortion of the antibody, the factor c1q binds first and the cascade proceeds.

Whether the expression level (or, density) of CD147 in cellular populations plays a role in the therapeutic efficacy of the ABX-CBL antibody can be assayed
30 through analyzing the expression levels of the CD147 molecule in various cellular populations. Generally, the experiments are conducted where beads having various known quantities of the CD147 antigen on their surface are prepared and analyzed on

FACS (i.e., utilizing a FITC-labeled anti-CD147 IgG antibody) in order to generate approximately 10-20 data points of different quantities of antigen on the beads. A linear regression curve is prepared from such data. Thereafter, cells expressing the CD147 antigen can be run through FACS and the relative quantities of antigen on the surface of the cells can be calculated from the linear regression curve.

EXPERIMENT 9 **EVIDENCE RELATED TO THE ROLE OF COMPLEMENT**
INHIBITORY MOLECULES

Further, in order to consider the cellular specificity of the mode of operation of the ABX-CBL antibody, we investigated various cells to which the ABX-CBL antibody binds and considered whether such cells were killed in a manner similar to complement mediated lysis. In connection with this work, we have investigated various cells to which the ABX-CBL antibody binds and considered whether such cells were (i) killed and (ii) if so, was the mechanism similar to complement mediated lysis. In the experiment, we looked for ABX-CBL antibody binding to a number of cells (and, thus, the antigen to which the ABX-CBL antibody binds is expressed upon such cells). Those cells to which ABX-CBL would bind were then tested for complement mediated lysis through treatment with the ABX-CBL antibody and complement. Two T-cell lines (CEM and Jurkat cells), a monocyte line (U937 cells), and three tumor cell lines (A431 (epidermal), SW948 (colon), and MDA468 (breast)), each of which bound the ABX-CBL antibody were examined. Despite the expression on such cells lines, the ABX-CBL antibody is very specific about which cells are killed, being restricted to the CEM T-cell line and U937 monocyte line. See Figure 13. We also analyzed two endothelial cell lines (i) ECV-304 (ATCC CRL-1998) is a spontaneously transformed immortal EC established from the vein of an apparently normal human umbilical cord and carrying EC characteristics and (ii) HUV-EC-C (ATCC CRL-1730) is an EC line derived from the vein of a normal human umbilical cord. Using FACS, we found that each of the ECV-304 and HUVEC-C lines stained positive against the 2.6.1, Pharmingen, and ABX-CBL antibodies suggesting that these ECs do express CD147 on the surface. Figures 15 and 16, respectively. We then carried out in vitro Alamar-blue based CDC assay and demonstrated that both

EC lines were resistant to ABX-CBL mediated CDC in the presence of human complement. See Figures 17 and 18, respectively.

In order to further understand why cells that all appear to express CD147 would not be killed by the ABX-CBL antibody in the presence of complement, we
5 looked into CD46, CD55, and CD59 expression in such cells. Each of CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, DAF), and CD59 (membrane attack complex inhibitor, MACI) have been implicated as complement inhibitory molecules. See e.g., Liszewski et al. *Annu. Rev. Immunol.* 9:431 (1991) and Loveland et al. "Coordinate functions of multiple complement
10 regulating molecules, CD46, CD55 and CD59" *Transpl. Proc.* 26:1070 (1994) related to CD46, Kinoshita et al. "Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria" *J. Exp. Med.* 162:75 (1985) and Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59"
15 *Transpl. Proc.* 26:1070 (1994) related to CD55, and Whitlow et al. "H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement" *Cell. Immunol.* 126: 176 (1990), Loveland et al. "Coordinate functions of multiple complement regulating molecules, CD46, CD55 and CD59" *Transpl. Proc.* 26:1070 (1994), and Davies, A. and Lachmann, P.J. "Membrane
20 defense against complement lysis: the structure and biological properties of CD59" *Immunol. Res.* 12: 258 (1993) related to CD59. Accordingly, we considered whether there was differential expression of either, or both, of these molecules on the cell lines tested above. Indeed, all of the cells, except the CEM line and the U937 line, expressed both of the molecules. And, indeed, the endothelial cell lines HUVEC-C
25 and ECV-304 expressed all three, CD46, CD55, and CD59. Figures 19 and 20, respectively. In contrast, the CEM line expressed only CD59 and the U937 line expressed only CD55. See Figure 14. This data is useful in connection with the prediction of cells that could be selectively eradicated by ABX-CBL and consequently targeted in connection with anti-CD147 in accordance with the present
30 invention.

EXPERIMENT 10 **CLONING AND EXPRESSION OF CD147 IN EUKARYOTIC CELLS**
AND BINDING OF ANTIBODIES

In the present experiment, we cloned full length CD147 cDNA through use of PCR in connection with the Jurkat Zapp Express phagemid DNA (Stratagene).

5 The following PCR primers were utilized, based on the CD147 sequence reported by Miyauchi et al. *J. Biochem.* **110**:770-774 (1991) (Gene Bank Accession No. D45131):

5': 5'-GACTACGAATTCTTGTAGGACCGGCGAGGAATAGG-3'
10 (SEQ ID NO:42)

3': 5'-GACTACGGGCCCCGGTGAGAACTTGAATCTTGCAAGC-3'
 (SEQ ID NO:43)

15 A 949 base pair PCR product was isolated whose open reading frame encoded the 269 amino acid CD147 protein. The PCR product was digested with EcoR1 and Apa1 and ligated into the EcoR1 and Apa1 sites of mammalian expression vectors pWBFNP (Figure 21) and pBKCMV (Stratagene) (Figure 22) (digested with NheI/SpeI to remove the lac promoter and the lacZ ATG between positions 1300 and
20 1098) to create the vectors CD147/pWBFNP and CD147/pBKCMV(delta-NheI/SpeI) respectively. In the constructs, eukaryotic expression of CD147 is driven from the cytomegalovirus (CMV) immediate early promoter. CD147/pWBFNP, CD147/pBKCMV(delta-NheI/SpeI) and control vectors pWBFNP and pBKCMV were transiently transfected into monkey kidney (COS-7) cells by the CAPO₄ method.
25 Cells were harvested 60 hours later, washed in PBS and stained with anti-ABX-CBL-FITC, anti-CEM2.6.1./anti-HuIgG-FITC, or anti-CD147-FITC (Pharmingen) and analyzed by FACS analysis and Western blot analysis (*see* Figure 23A). The blot was accomplished using procedures described in Example 3.

30 FACS analysis revealed an increase in specific cell surface staining with all three antibodies only on COS cells transfected with vectors expressing CD147 cDNA (CD147/pWBFNP and CD147/pBKCMV (delta-NheI/SpeI)). COS cells transfected with CD147 cDNA showed binding to each of the antibodies in each of the FACS and Western blot analyses. In contrast, COS cells transfected with control vectors were

negative for binding with each of the 2.6.1 and ABX-CBL antibodies. With respect to the Pharmingen antibody, certain background staining was observed in cells transfected with control vectors on FACS and no binding on Western blot analysis. The transfected cells showed significant binding over background on FACS and were positive on Western blot analysis. Our results confirm that the ABX-CBL and the 2.6.1 antibodies bind to CD147.

**EXPERIMENT 11 CLONING AND EXPRESSION OF CD147 IN EUKARYOTIC CELLS
AND BINDING OF ANTIBODIES**

Utilizing a slightly modified vector, we also transfected *E. coli* cells with the CD147 cDNA. In the experiment, CD147 cDNA generated as above was subcloned into pBKCMV (Stratagene) (Figure 22). CD147/pBKCMV plasmid DNA was transformed into *E. coli* strain XL1-Blue MRF' (Stratagene). Cultures were grown in LB media supplemented with kanamycin at 50µg/ml to OD₆₀₀ of 0.7 then for an additional 3 hours in the presence of 1mM isopropyl-B-D-thio-galactopyranoside (IPTG). Cells were harvested by centrifugation and stored frozen at -20° C. The *E. coli* cells so transfected were capable of expression of the CD147 molecule as evidenced by Western blotting analysis of each of the ABX-CBL, 2.6.1, and Pharmingen antibodies. Since the prokaryotic *E. coli* cells should not glycosylate the expressed CD147, it was expected that the molecular weight of the CD147 expressed by the *E. coli* should closely approximate the predicted, unglycosylated molecular weight of CD147 of about 27 KD. Indeed, in each case, binding of the three antibodies on Western blot analysis was observed to a band between about 27 and 30 KD. Figure 23B. The blot was accomplished using procedures described in Example 3.

This data further confirms that the ABX-CBL and the 2.6.1 antibodies bind to CD147. Further, the evidence indicates that ABX-CBL binding to CD147 is not directly based on carbohydrate binding, i.e., that ABX-CBL does not bind directly to a carbohydrate epitope on CD147. Such data, however, does not eliminate the possibility that binding to CD147 is influenced by the presence of carbohydrate or glycosylation.

EXPERIMENT 12 EPITOPE ANALYSIS

In order to further elucidate the binding of the ABX-CBL antibody to CD147, we undertook phage display experiment. Such experiments were conducted through panning a phage library expressing random peptides for binding with the ABX-CBL and 2.6.1 antibodies to determine if we could isolate peptides that bound. If successful, certain epitope information can be gleaned from the peptides that bind.

In general, the phage libraries expressing random peptides were purchased from New England Biolabs (7-mer and 12-mer libraries, Ph.D.-7 Peptide 7-mer Library Kit and Ph.D.-12 Peptide 12-mer Library Kit, respectively) based on a bacteriophage M13 system. The 7-mer library represents a diversity of approximately 2.0×10^9 independent clones, which represents most, if not all, of the $20^7 = 1.28 \times 10^9$ possible 7-mer sequences. The 12-mer library contains approximately 1.9×10^9 independent clones and represents only a very small sampling of the potential sequence space of $20^{12} = 4.1 \times 10^{15}$ 12-mer sequences. Each of 7-mer and 12-mer libraries were panned or screened in accordance with the manufacturer's recommendations in which plates were coated with an antibody to capture the appropriate antibody (goat anti-human IgG Fc for the 2.6.1 antibody and goat anti-mouse μ chain for the ABX-CBL antibody) followed by washing. Bound phage were eluted with 0.2 M glycine-HCl, pH 2.2. After 3 rounds of selection/amplification at constant stringency (0.5% Tween), through use of DNA sequencing, we characterized a total of 5 clones from the 7-mer library and 6 clones from the 12-mer library reactive with the ABX-CBL antibody and a total of 6 clones from each of the 7-mer and 12-mer libraries reactive with the 2.6.1 antibody. Reactivity of the peptides was determined by ELISA. For an additional discussion of epitope analysis of peptides see also Scott, J.K. and Smith, G.P. *Science* 249:386-390 (1990); Cwirla et al. *PNAS USA* 87:6378-6382 (1990); Felici et al. *J. Mol. Biol.* 222:301-310 (1991), and Kuwabara et al. *Nature Biotechnology* 15:74-78 (1997).

No consensus sequence was readily apparent for reactivity of the 2.6.1 antibody with CD147. However, sequence alignment of the characterized 7-mer and 12-mer sequences against the amino acid sequence of CD147 yielded a number of matches for a single sequence within CD147 from residue number 177 through residue number 188 (ITLRVRSH (SEQ ID NO:1)). In particular, each of the 7-mers

contained sequence matches (represented by *) to 3 or more residues within this sequence of CD147:

7-mer sequences

5						
			*	*	*	
	1.	EE	RLR	S	Y	(SEQ ID NO:2)
			*	*	*	
10	2.	YE	RVR	W	Y	(SEQ ID NO:3)
			*	*	*	
	3.	EE	RLR	S	Y	(SEQ ID NO:4)
15			*	*	*	
	4.	AE	RIR	S	I	(SEQ ID NO:5)
			*	*	*	
	5.	EE	RLR	S	Y	(SEQ ID NO:6)
20						

Further, 4 of the 12-mers contained sequence matches (represented by *) to 3 or more residues within this sequence of CD147, with 4 matches for 12-mer peptide number 1 and for 6 matches of 12-mer peptide number 2:

25 12-mer sequences

		* * *				
	1.	TVHGD L	R L R	S	L P	(SEQ ID NO:7)
30		* *	* *	*	*	
	2.	TNDIG L	R Q R	S	H S	(SEQ ID NO:8)
			* *	*		
	3.	SPLLDGQ	R E R	S	Y	(SEQ ID NO:9)
35			* *	*		
	4.	YDLPM	R S R	S	Y P G	(SEQ ID NO:10)
			*			
40	5.	SLAPLWY	Y S R	H	G	(SEQ ID NO:20)
	6.	HTPETAPLPATV				(SEQ ID NO:21) (no binding)

These results indicate a consensus sequence of RXRS (SEQ ID NO:11) that is present in 10 of the sequenced clones. Accordingly, we had a synthetic peptide prepared (AnaSpec Incorporated, San Jose, CA) which spanned residues 169-183 of CD147 with the following sequence (with -OH representing carboxy terminus):

5 KGSDQAIITLRVRSH-OH (SEQ ID NO:12)
 | |
 170 184

10 Below, the amino acid sequence of CD147 is provided with the 15-mer peptide's sequence indicated by double underlining and the RXRSH (SEQ ID NO:13) consensus sequence indicated in bold. In addition, putative N-linked glycosylation sites of CD147 are shown as underlined and italics:

15 CD147 Sequence

MAAALFVLLGFALLGTHGASGAAGTVFTTVEDLGSKILLTCSL*NDS*SATEVTG
 HRWLKGGVVVKEDALPGQKTEFKVDSDDQWGEYSCVFLPEPMGTANIQLHG
 PPRVKAVKSSEHINEGETAMLVCKSESVPVTDWAWYKITDSEDKALM*NGSE*
 SRFFVSSSQGRSELHIENLNMEADPGQYRC*NGTSSKGS**DOAIITLRVRSH*LAAL
 20 WPFLGIVAELVLVTIIFIYEKRRKPEDVLDDDDAGSAPLKSSGQHQNKGKN
 VRQRNSS (SEQ ID NO:14)

The 15-mer peptide was assayed using ELISA and it was determined that the ABX-CBL antibody specifically bound to the peptide. Further, neither the 2.6.1
 25 antibody nor a control murine IgM antibody bound to the peptide. However, based on a competition study between the CD147 antigen and the 15-mer peptide, the ABX-CBL antibody's binding to the 15-mer peptide can only be measured when the 15-mer peptide is coated on plates and not when the peptide is in solution. Indeed, in competition experiments in which the ABX-CBL antibody is bound to either the
 30 peptide or the CD147 antigen coated to plates, the ABX-CBL antibody is not removed or replaced by the peptide in solution even at high concentrations. Nevertheless, the binding of the ABX-CBL antibody to the 15-mer peptide can be specifically competed by the CD147 antigen and positive phage preparations mentioned above but not with non-specific antigen (i.e., L-Selectin isolated from cell membrane or human

plasma) or the negative phage preparations mentioned above. Similarly, the binding of the ABX-CBL antibody to the CD147 antigen can be specifically competed by positive phage preparations as compared to negative phage preparation in competition assays using preincubation.

5 These results indicate that while the sequence within CD147 that contains the consensus sequence RXRSH is important to the binding of the ABX-CBL antibody to CD147, it does not fully explain ABX-CBL's binding to CD147. Indeed, the data also suggests that the consensus sequence contained either in the 15-mer peptide when bound to the plate or the reactive phage materials when tethered to the phage coat
10 protein binds more tightly to the ABX-CBL antibody than does the free peptide in solution. Taken together, while not wishing to bound to any particular theory or mode of operation, it is possible that CD147 possesses certain conformations that are not well mimicked in the 15-mer peptide in solution. Nevertheless, the above epitopic information is important to understanding the manner in which the ABX-CBL
15 antibody binds to CD147 and to producing other candidate molecules against CD147 as a therapeutic target.

It is interesting to note that in addition to the results above in connection with the presence of the RXRSH consensus sequence within CD147, we also looked for the presence of the consensus sequence within the hn-RNP-k protein to which ABX-
20 CBL also appears to bind. Such analyses were conducted by sequence alignment against the phage derived peptides discussed above. Two sequences were found which possessed statistically interesting matches:

First, there was a match (indicated by *) of 5 amino acids with the 7-mer
25 peptide number 4:

	*	**	**	
	PE	RIL	SI	(SEQ ID NO:15)
30	84			

Second, there was a match (indicated by *) of 5 amino acids with the 12-mer peptide number 1:

	*		* *	**	
5	GGS		RAR	NLP	(SEQ ID NO:16)
	300			306	

The amino acid sequence of the hn-RNP-k protein is provided below with such sequences indicated by double underlining. In addition, a number of RXR sequence motifs are present in the hn-RNP-k protein's sequence which are also indicated by underlining:

hn-RNP-k Protein Sequence

15 METEQPEETFPNTETNGEFGKRPAEDMEEEQAFKRSRNTDEMVELRILLQSKN
 AGAVIGKGGKNIKALRTDYNASVSVPDSSGPERILSISADIETIGEILKKIPTLE
 EGLQLPSPTATSQLPLESDAVECLNYQHYKGSDFDCELRLLIHQSLAGGIIGVK
 GAKIKELRENTQTTIKLFQECCPHSTDRVVLIGGKPDRVVECIKILDLISESPIK
 GRAQPYDPNFYDETYDYGGFTMMFDDRRGRPVGFPMRGRGGFDRMPGGRG
 20 GRPMPPSRRDYDDMSPRRGPPPPPPGRGGGRGSRARNLPLPPPPPPRGGDLMA
 YDRRGRPGDRYDGMVGFSADETWDSAITWSPSEWQMA YEPQGGSGYDYS
 YAGGRGSYGD LGGP IITTQVTIPKDLAGSIIGKGGQRIKQIRHESGASIKIDEPLE
 GSEDRIITITGTQDQIQNAQYLLQNSVKQYSGKFF (SEQ ID NO:17)

25 Without wishing to be bound to any particular theory or mode of operation, it is possible that the binding of the ABX-CBL antibody to the hn-RNP-k protein is partially explained by the presence of these motifs within the protein.

EXPERIMENT 13 EXPRESSION OF CD147 AND BINDING OF ANTIBODIES

30 Indeed, the desirability of mimicking ABX-CBL binding and efficacy is highlighted based upon a preliminary tissue distribution study of the ABX-CBL antibody. In the study, ABX-CBL is widely distributed throughout a variety of tissues. However, the majority of the distribution is likely to be due to nonspecific binding. Nevertheless, there appears to be specific binding in endothelial cells

(venules, arterioles, but not capillary beds), smooth muscle, and some mesothelium. Also, the lymphoreticular tissues appear to be bound, although, the staining seems to be restricted to large lymphocytes, presumably activated blasts. From the study conducted, it was difficult to distinguish intracellular from extracellular staining. A
5 certain amount of cytoplasmic staining was clearly evident and could have been related to hn-RNP-k binding.

**EXPERIMENT 14 ANALYSIS OF ACTIVITY OF MOPC21 LIGHT CHAIN ACTIVITY
IN ABX-CBL ANTIBODY**

10 Two different techniques were utilized to endeavor to study the role of the MOPC21 light in ABX-CBL activity. In each technique, efforts were made to segregate the MOPC21 light chain from the cell line producing the IgM antibody. In the first technique, segregation was effected by fusion of the ABX-CBL IgM producing cell line with another cell line (NSO). In the second technique, segregation
15 by spontaneous loss variants was endeavored. The fusion technique was successful and work was stopped on the second technique.

In the fusion technique, in general, NSO cells were transfected with a puromycin containing vector to create a puromycin⁺ NSO cell line. The ABX-CBL IgM producing cell line was grown in HAT medium was fused with the puromycin⁺
20 NSO cell line.

In general, fusions are accomplished in accordance with the following techniques and procedures:

Preparation of cells

25

Prior to fusion, parental cell lines for use in the fusion are grown up and maintained in medium containing DMEM high, 10% FBS, 1% non-essential amino acids, 1% pen-strep, and 1% L-glutamine.

On the day prior to fusion, each of the parental cell lines are prepared and split
30 to provide a cell density of approximately 10^5 cells/ml. On the day of the fusion, cells are counted and the fusion is commenced when, and assuming, that cell count for each of the parental cell lines are within the range of about $1.5-2.5 \times 10^5$ cells/ml. Sufficient quantities of each of the parental cell lines to make up 5×10^6 cells each are

withdrawn from the cultures and added to a 50ml centrifugation tube and the cells are pelleted at 1200 rpm for approximately 5 minutes. Concurrently with the preparation of the cells, incomplete DMEM, PEG, and double selection media are prewarmed in an incubator bath. Following pelleting, cells are resuspended in 20 ml incomplete DMEM and pelleted again. Thereafter, the cells are resuspended in 5 ml incomplete DMEM and the two parental cell lines are pooled in a single tube and pelleted again to form a co-pellet containing both of the parental cell lines. The co-pellet is resuspended in 10 ml incomplete DMEM and again pelleted. All of the supernatant is then removed from the co-pellet and the cells are ready for fusion.

Fusion

Following removal of all of the supernatant, 1 ml PEG-1500 is added over the course of 1 minute to the co-pellet while stirring. After addition of the PEG is completed, either gentle stirring with a pipet is continued for 1 minute or the suspended co-pellet can be allowed to stand for 1 minute. Thereafter, 10 ml of incomplete DMEM is added to the co-pellet over the course of 5 minutes with slow stirring. The mixture is then centrifuged at about 1200 rpm for 5 minutes and following centrifugation, the supernatant is aspirated off, and 10 ml of complete double selection medium is added and gently stirred into the cells. The cells are then plated at 100 μ l/well into 10 96-well microtiter plates and placed into an incubator (37° C with 10% CO₂) where they are not disturbed for 1 week. After the passage of a week, plates are fed by adding 100 μ l of complete double selection medium to each well.

Double selection medium is prepared depending upon the marker gene utilized in connection with the parental cell lines. In the majority of our experiments, the selectable markers conferring puromycin, hygromycin, of hypoxanthine and thymidine resistance are utilized. Concentrations required to obtain complete cell killing of NS/O cells were determined through use of kill curves and resulted in our use of 6 micrograms/ml of puromycin and 350 micrograms/ml of hygromycin. In

connection with HPRT resistance, we used HAT media supplement from Sigma using standard conditions.

In the present case, cells were selected for puromycin⁺/HAT resistance. Individual clones were picked based on selection and clones were expanded in 96-well plates. Plates were split (½ for freezer stock, ½ for growth). Total RNA was isolated from the growth plates using the Qiagen 96-well RNA isolation kit according to the manufacturer's instructions. Primers were designed based on conserved sites on the MOPC21 and the ABX-CBL kappa chains that would amplify fragments of the chains which contained unique restriction sites in the respective chains, as follows:

	<u>Restriction site</u>	<u>Chain</u>	<u>Position</u>
	AgeI (BsrFI)	MOPC21	135
	BstYI	MOPC21	173
15	KpnI	ABX-CBL	85
	NsiI	ABX-CBL	130
	XcmI	MOPC21	58
20	5 prime:	5'-GCA GTC TCC TAA ACT GCT (SEQ ID NO:44) positions 99-116 allows analysis of BstYI restriction site; or	
	5 prime:	5'-ACC TGC AAG GCC AGT (SEQ ID NO:45) positions 40-54 allows analysis of NsiI or KpnI restriction sites,	
25	3 prime:	5'-CAC TCA TTC CTG TTG AAG (SEQ ID NO:46).	

Accordingly, through amplification with the above primers, followed by digestion with the appropriate restriction enzymes, presence or absence of MOPC21 or ABX-CBL could be readily detected on agarose gel electrophoresis. Through use of the above techniques, at least 6 variants were obtained that lost the MOPC21 light chain expression but retained the ABX-CBL kappa. No variants were directly obtained that lost ABX-CBL kappa chain expression and retained the MOPC21 chain

expression. However, we isolated a cell line that appeared to be a minimal producer of ABX-CBL light chain and subcloned the line. It turned out to be a mixed cell line of a heterogeneous MOPC21/ABX-CBL light chain producer and a MOPC21 light chain only producer. Accordingly, we isolated the MOPC21 only producer after
5 subcloning.

MOPC21 only light chain containing and ABX-CBL only light chain containing antibodies were compared and supported the conclusion that the presence or absence of the MOPC21 light chain did not appear to substantially impact antibody binding or properties of the antibodies. Although, it did appear that the MOPC21
10 only light chain containing antibody did not bind as intensely on Western blotting to CEM cells or CD147.

EXPERIMENT 15 GENERATION AND CHARACTERIZATION OF HUMAN ANTIBODIES TO CD147

15 In accordance with Experiment 1, we generated a panel of fully human anti-CD147 antibodies. Antibodies were screened by ELISA for binding with CD147 and FACs for ability to compete with ABX-CBL. Certain of such antibodies were sequenced. The sequences of certain of the antibodies were compared to transcripts of the germline V-gene segments to somatic mutations in the amino acid
20 sequences. Such sequence comparisons are shown in Figures 44 through 46. cDNA sequences and protein transcripts of and for each of the antibodies are shown in Figures 24 through 33. In addition, CDRs, according to Kabat numbering scheme, of the heavy chains and kappa light chains of the antibodies are shown in Figures 34 through 43.

25 In view of a number of tests that were conducted, particularly, competition studies between ABX-CBL and the certain of the antibodies, the 2.6.1 IgM antibody was chosen for additional development.

As will be appreciated, all of the IgMs that were generated from XenoMouse animals were monovalent. Accordingly, in order to prepare a fully human multimeric IgM antibody, we first were required to clone the human J-chain gene. from human buffy coat cells. The sequence of the human J-chain cDNA is shown below with the 5'-untranslated portion shown in bold, italics and underlining:

(SEQ ID NO:47)

(SEQ ID NO:22)

The following primers, retrofitted with the indicated restriction sites for further cloning, were designed for amplifying the human J-chain cDNA out of RT-PCR prepared materials from human Buffy coat cells:

5 5'- GAA TTC AGA AGA AGT GAA GTC (SEQ ID NO:48)
 EcoRI

 3'- GTC GAC TAT GCA GTC AGC AAT GAC (SEQ ID NO:49)
 SalI

10

The J-chain cDNA and the 2.6.1 kappa gene isolated through RT-PCR were amplified using the above primers and a 500 base pair PCR product was isolated whose open reading frame encoded the 159 amino acid J-chain protein. The PCR product was cloned into the TA cloning kit (Invitrogen) and had an EcoRI restriction site on each end. This vector was digested with EcoRI and the digest cloned into pWBFNP MCS (Figure 47) that was cut with EcoRI and treated with CIP. Orientation of the insert was determined through digestion with PvuII which created differently sized fragments based on orientation (PvuII sites were present in the pWBFNP MCS vector as shown in Figure 47 and at position 421 in the J-chain insert.

15 This vector was called pWBJ1

The 2.6.1 kappa chain was amplified by RT-PCR using the following primers:

5 prime: 5' TGC AGG AAT CAG ACC CAG TC (SEQ ID NO:50)

25 3 prime: 5' GTC AGG CTG GAA CTG AGG AGC A (SEQ ID NO:51)

using the TA cloning kit providing EcoRI sites on each end of the VJCK insert. The kappa chain was sequenced. The kappa cDNA was EcoRI digested and cloned into the EcoRI site in pWBFNP MCS. Orientation was determined based on fragment size by NotI and PstI digestion of the NotI site in pWBFNP MCS and the PstI site contained at position 243 of the kappa insert shown in Figure 33. This vector was called pWBK1.

30

In order to allow insertion of the J-chain expression cassette into pWBK1 from pWBJ1, pWBK1 was cut with PacI and blunted and recut with AvrII and pWBJ1 was cut with SpeI and blunted and recut with AvrII and the blunted SpeI/AvrII fragment was cloned into pWBK1 blunt PacI/AvrII to yield pWBK1(J). pWBK1(J) contained
5 expression cassettes for both the 2.6.1 kappa chain and the J-chain.

pWBK1(J) was further modified to contain DHFR resistance through cloning DHFR through NotI digestion from a vector pWB DHFR (containing DHFR at NotI) into pWBK1(J) at the NotI site. This vector was called pWBK1(J) DHFR.

In order to make an IgG1 expression vector, the 2.6.1 heavy chain was
10 amplified through RT-PCR using the TA cloning vector (Invitrogen) using the following primers:

5 prime: 5' TCA TTT GGT GAT CAG CAC T (SEQ ID NO:52)

15 3 prime: 5' GCT AGC TGA GGA GAC GGT GAC CAG G
(SEQ ID NO:53)

3' gamma 1 NheI (introduces a NheI restriction site)

The resulting product contained only the VDJ cDNA sequences and not the constant
20 region. The sequence was confirmed by sequencing. This vector was utilized to prepare an IgG1 expression vector as described below.

pWBFNP MCS was digested with EcoRI and treated with CIP and the EcoRI digest from the TA vector, above, was cloned into the vector. Orientation was determined by size through digestion with NheI, which confirmed the insertion,
25 followed by digestion with NotI. This vector was called pWBVDJ261NheI. PWBVDJ261NheI was cut with XhoI and blunted and recut with NheI. A human gamma1 construct was cloned in from a pWBFNP vector containing the gamma1 constant region between NheI and EcoRI sites was cut with EcoRI and blunted and recut with NheI. This vector was called pWBVDJ261G1 (or pWBIgG1). A
30 puromycin cassette was cloned in from a pIK6.1+puro vector (Figure 48) which was cut with HindIII and blunted and recut with AvrII. The pWBIgG1 was cut with PacI

and blunted and recut with AvrII and the puro cassette was cloned therein. This vector was called pWBIgG1 Puro.

In order to make an IgM expression vector, the 2.6.1 heavy chain was amplified through RT-PCR using the TA cloning vector (Invitrogen) using the following primers:

5 prime: 5' TCA TTT GGT GAT CAG CAC T (SEQ ID NO:54)

3 prime: 5' GGA TCC TGA GGA GAC GGT GAC G (SEQ ID NO:55)

10 3' Mu BamHI (introduces BamHI restriction site)

The resulting product contained only the VDJ cDNA sequences and not the constant region. The sequence was confirmed by sequencing. This vector was utilized to prepare an IgM expression vector as described below.

15 pWBFNP MCS was digested with EcoRI and treated with CIP and the EcoRI digest from the TA vector, above, was cloned into the vector. Orientation was determined by size through digestion with BamHI, which confirmed the insertion, followed by digestion with NotI. This vector was called pWBVDJ261BamHI.

A human Mu construct was PCR amplified from a yeast artificial chromosome construct, YAC 2CM, described in Mendez et al., (1997), *supra*. and U.S. Patent Application, No. 08/759,620, filed December 3, 1996, through RT-PCR using the TA cloning vector (Invitrogen) using the following primers:

25 5 prime: 5'GGA TTA GCA TCC GCC CCA ACC CTT (SEQ ID NO:56)

(which introduced a BamHI restriction site on the 5' end)

3' prime: 5' GTC GAC GCA CAC ACA GAG CGG CCA (SEQ ID NO:57)

30

The vector pWBVDJ261BamI was cut with BamHI and recut with XhoI. The TA cloning vector containing the Mu insert was cut with BamHI and XhoI (which is

another site in the TA vector) and was cloned into the BamHI/XhoI sites of pWBVDJ261BamI. The resulting vector was called pWBVDJ261IgM (or pWBIgM). The vector was further equipped with a puromycin cassette in the same manner as described above in connection with the construction of pWBIgG1 Puro. The resulting
5 vector was called pWBIgM Puro.

EXPERIMENT 17 **GENERATION OF CELL LINE EXPRESSING 2.6.1 IGG1 ANTIBODIES**

In order to generate a cell line expressing the 2.6.1 IgG1 antibody, we
10 cotransfected DHFR⁻ CHO cells with The pWBIgG1 Puro vector and the pWBK1 DHFR vector through electroporation. This was accomplished by taking a stock of approximately 2×10^7 DHFR⁻ CHO cells and electroporating at 290 V, 960μFD, 200μg of linearized plasmid DNA plus 200μg of carrier DNA. Cells were seeded in α^+ medium and allowed to grow for two days. 8×10^5 cells were seeded in 10 cm
15 dish in α^- medium with 4μg/ml puromycin selection medium. Cells were incubated for 4-5 days and then transferred to α^- medium with 0.5μM MTX at 5×10^5 cells per 10 cm dish. Cells were incubated for approximately 14 days for selection and, thereafter, clones were picked and expanded and assayed for ability to bind to CD147 and the presence of IgG1.

20 We recovered a number of clones expressing a 2.6.1 antibody with a gamma-1 isotype that bound specifically to CD147.

EXPERIMENT 18 **GENERATION OF CELL LINE EXPRESSING 2.6.1 MULTIMERIC IGM ANTIBODIES**

25 In order to generate a cell line expressing the 2.6.1 multimeric IgM antibody, we cotransfected DHFR⁻ CHO cells with The pWBIgM Puro vector and the pWBK1(J) DHFR vector through electroporation. The same techniques described in Experiment 18 were utilized.

We recovered a number of clones expressing a 2.6.1 antibody with a
30 multimeric Mu isotype that bound specifically to CD147.

EXPERIMENT 19 **CHARACTERIZATION OF THE 2.6.1 IgG1 AND MULTIMERIC IgM ANTIBODIES**

In order to assess the function of the 2.6.1 IgG1 and multimeric IgM antibodies, we assayed the antibodies in several assays. Each of the 2.6.1 IgG1 and multimeric IgM bound to CEM cells and bound to CD25⁺ activated human peripheral blood cells in a similar manner to the CBL1 and ABX-CBL. The antibodies were assayed in a potency and a lysis assay, in the same manner described above. In connection with these experiments, the 2.6.1 multimeric IgM antibody appeared approximately as active as CBL1 and ABX-CBL. Further, the 2.6.1 multimeric IgM antibody was capable of acting in ADCC as shown in Figure 50.

EXPERIMENT 20 **AFFINITY MEASUREMENT OF THE 2.6.1 MULTIMERIC IgM ANTIBODIES**

We also examined the affinity of the the 2.6.1 multimeric IgM antibody in comparison to ABX-CBL and certain other forms of the 2.6.1 antibody. Affinity measurements were conducted as described in Mendez et al., (1997), *supra*. and U.S. Patent Application, No. 08/759,620, filed December 3, 1996. The results are shown in the following Table:

20

TABLE 2

Antibody	Ig class	On-rates ka (M ⁻¹ s ⁻¹)	Off-rates kd(s ⁻¹)	KA kd/ka (M ⁻¹)	KD ka/kd (M)	BIACore surface Hu rCD147- IgG [RU]
ABX-CBL	M IgM	7.25 x 10 ⁵	3.76 x 10 ⁻⁴	1.39 x 10 ⁹	5.18 x 10 ⁻¹⁰	791
ABX-CBL	M IgM monomer	6.34 x 10 ⁴	4.94 x 10 ⁻³	1.28 x 10 ⁷	7.84 x 10 ⁻⁸	791
CEM 2.6.1	Hu IgG2	8.20 x 10 ⁵	3.75 x 10 ⁻⁴	2.19 x 10 ⁹	4.57 x 10 ⁻¹⁰	791
CEM2.6.1	Hu IgG2	7.17 x 10 ⁵	4.03 x 10 ⁻⁴	1.78 x 10 ⁹	5.61 x 10 ⁻¹⁰	242
CEM2.6.1	Hu IgM	6.52 x 10 ⁵	2.03 x 10 ⁻⁴	3.21 x 10 ⁹	3.12 x 10 ⁻¹⁰	242
CEM2.6.1	Hu IgM monomer	2.63 x 10 ⁵	1.67 x 10 ⁻³	1.57 x 10 ⁸	6.39 x 10 ⁻⁹	242
CEM2.6.1	Hu IgG1	3.13 x 10 ⁵	2.01 x 10 ⁻⁴	1.55 x 10 ⁹	6.43 x 10 ⁻¹⁰	242

EXPERIMENT 21 **HUMAN CLINICAL TRIAL WITH ABX-CBL ANTIBODY****Phase II Clinical Trial of ABX-CBL**5 A. **Background**

As we mentioned above, in view of the positive results observed with respect to the CBL1 antibody, we undertook clinical trials utilizing ABX-CBL. The first such trial was a Phase II, multicenter, open label, dose escalation clinical trial examining multiple intravenous infusions of four doses of ABX-CBL in patients with steroid resistant GVHD. The trial enrolled patients with acute GVHD who were unresponsive to at least three days of treatment with corticosteroids and who had a severity index of at least B according to a modified IBMTR Severity Index (Rowlings et al. "IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with glucksberg grade" *British Journal of Haematology* 97: 855-864 (1997)). In the trial, four different doses were administered intravenously in a dose escalation design using an induction regimen of seven days followed by a maintenance dose of twice weekly for two weeks. Patients were followed for 8 weeks after completion of the treatment course. Long-term safety follow-up has been instituted.

The study was designed with three primary objectives and four secondary objectives under review, as follows:

Primary Objectives (i) to assess the safety of multiple doses of ABX-CBL in patients with steroid resistant acute GVHD; (ii) to determine the maximum tolerated IV dose of ABX-CBL in patients with steroid resistant acute GVHD; and (iii) to determine the pharmacokinetics of multiple doses of ABX-CBL in patients with steroid resistant acute GVHD.

Secondary Objectives (i) to assess the clinical efficacy of four different doses of ABX-CBL in patients with steroid resistant acute GVHD; (ii) to assess a dose response of ABX-CBL; (iii) to assess long-term safety in patients with acute GVHD who have received multiple doses of ABX-CBL; and (iv) to assess the long-term

survival in patients with acute GVHD who have received multiple doses of ABX-CBL.

Determination of the dosing for ABX-CBL was considered essential. As discussed above, the initial clinical trials conducted with the CBL1 antibody utilized ascites fluid that was not purified. Thus, the concentration of the antibody within the materials given to patients was not known. Further, because CBL1 was generated in a cell line that was not producing solely the IgM, but also an IgG, the concentration of the IgM antibody given to patients was even less clear.

In order to assess the above objectives, a four cohort trial plan was established with the following dose cohorts of patients:

Cohort 1: 0.01mg/kg

Cohort 2: 0.1 mg/kg

Cohort 3: 0.3mg/kg

Cohort 4: 1.0 mg/kg

Patients in all cohorts were to receive, and received, up to 11 intravenous infusions of ABX-CBL. ABX-CBL was infused over 2 hours via a syringe pump. The dosing schedule was as follows: daily times 7 days, followed by twice a week for two weeks. Safety evaluations were conducted prior to advancing to the next dose cohort. 27 patients were enrolled across all 4 of the dose cohorts.

During the conduct of the study, adverse events were observed in patients in the third cohort, receiving 0.3 mg/kg of ABX-CBL. There, several of the patients experienced myalgia or myalgia-like symptoms. As a result, the third dose cohort (0.3 mg/kg) was determined as the maximum tolerated dose. Thus, the fourth dose cohort was reduced to a dosage of 0.2 mg/kg so that the actual dosing utilized in the study was as follows:

Cohort 1: 0.01mg/kg

Cohort 2: 0.1 mg/kg

Cohort 3: 0.3mg/kg

Cohort 4: 0.2 mg/kg

The eligibility requirements for patients to enter the study were as follows:

- One year old or older
- 5 • Stem Cell transplant within 100 days
- Steroid resistant acute GVHD with a severity index of B, C, or D
- No experimental drugs or devices within 30 days of enrollment unless mutually agreed upon by the investigator, the sponsor's medical monitor, and the FDA
- 10 • ANC >500/mm³ with or without GCSF or GMCSF

Patients were screened and assigned to a treatment cohort once the patient met the eligibility criteria. Standard post stem cell transplant treatment was continued.

Once dosing was initiated, patients were infused with ABX-CBL the
15 applicable dose for their dose cohort daily for 7 days (referred to as an induction regimen) followed by infusions 2 times per week for two weeks (referred to as a maintenance regimen). Patients were followed for 8 weeks following their infusions (visits are weekly for 4 weeks followed by a visit 4 weeks later) for safety and clinical effect. Further, patients who received at least one infusion of ABX-CBL were
20 scheduled to participate in a long term follow up program to evaluate the long term safety of ABX-CBL and long term survival.

Safety was assessed by monitoring adverse events while on study as well as vital signs during the infusion of ABX-CBL. Further, patients received frequent physical exams and underwent extensive laboratory studies. Laboratory studies
25 included complete blood counts, T-cell subsets, serum chemistries, and urinalyses at regular intervals as outlined below. Baseline CPK with isoenzymes were obtained on all patients and patients who experienced any infusion related adverse experiences were reanalyzed with CPK and isoenzymes. In addition, patients were monitored for Human Anti Mouse Antibody (HAMA) response by ELISA. Further, five patients in
30 each cohort were assigned to have pharmacokinetic blood samples for pK profile.

Clinical effect of ABX-CBL was assessed by evaluating changes to the overall score of acute GVHD based upon the modified IBMTR Severity Index (Rowlings et

al. "IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with glucksberg grade" *British Journal of Haematology* 97: 855-864 (1997)), time to response, duration of response, time and incidence of flare of acute GVHD, and length of hospitalization.

5

B. Protocol Procedures

In connection with the trial, the following tests, observation schedules, preparations of the study medication were utilized:

TABLE 3 -- TESTS AND OBSERVATION SCHEDULE

		ON STUDY										
PERIOD	SCREEN	TREATMENT						TREATMENT FOLLOW UP			L.T. FOLLOW UP	
WEEK		0		1		2		3,4,5,6	10		Q 6 mos	
DAY		0	1-6	9	13	16	20	23,30,37,44	72	100^		
Visit #	1	2	3-8	9	10	11	12	13-16	17	Oth	19+	
Procedures:												
Informed Consent	X											
Elig for enrollment	X											
Medical History	X											
Serum pregnancy	X ⁴											
Hgt/Wgt ¹	X		X ¹	X ¹	X ¹	X ¹	X ¹	X	X	X		
Phys. Exam(C/A)	C		A ¹	A ¹	A ¹	A ¹	A ¹	C	C	A		
Vital Signs	X	X ⁶	X ⁶	X ⁶	X ⁶	X ⁶	X ⁶	X	X	X		
Mod IBMTR score	X	X ⁵	X ¹	X ¹	X ¹	X ¹	X ¹	X	X	X		
KPS/Lansky	X		X ¹	X ¹	X ¹	X ¹	X ¹	X	X	X		
CBC/DIFF/PLAT	X ²	X ⁵	X ¹	X ¹	X ¹	X ¹	X ¹	X	X	X		
Serum Chem	X ²	X ⁵	X ¹	X ¹	X ¹	X ¹	X ¹	X	X	X		
CPK-III (mm) ³	X ²		X ³	X ³	X ³	X ³	X ³	X ³	X ³			
CD 3, 4, 8, 19		X ⁷	X ¹	X ¹		X ¹		X	X			
Blood for HAMA	X ¹³	X ¹³		X ¹				X ⁹	X ¹⁰			
Blood for pK		X ⁸	X ⁸	X ⁸			X ⁸					
UA	X ²			X ¹		X ¹		X ⁹	X			
Study med adm		X	X	X	X	X	X					
Intercurrent Illness	X										X ¹¹	
AE'S		X										X ¹²
Concomitant meds	X										X ¹¹	
ECG/CXR	X*	Data will be collected as tests completed per routine patient care										
Biopsy assessment		Data will be collected on biopsies as they occur based on pt status										

^ This visit occurs 100 days post allogeneic stem cell transplant not post infusion of study medication

5 * Obtain if not completed within 7 days of randomization (ECG if patient is ≥ 16 years)

C/A C = Complete PE, A = Abbreviated PE

1 Obtain Height at first visit only

2 Obtain within 48 hours of randomization request

3 Obtain at baseline, obtain if patient experiences any infusion related AE's (refer to protocol)

10 4 Serum pregnancy will be obtained on females of child bearing potential (refer to protocol)

5 Obtain if results are > 8 hours from the start of the infusion of the study medication

6 Obtain vital signs (T, P, R, BP) prior to the start of the infusion (maximum of 10 mins), q 15 mins during the first hour of the infusion, followed by 90, 120, 180, 240, 300, and 360 minutes after the start of the infusion

15 7 Obtain prior to the start of the infusion (maximum of 12 hours)

8 Obtain just prior to the start of the first infusion and the following timepoints after the completion of the first infusion; 15 and 30 minutes, 1, 2, 4, 8, 12, 18, and 24 hours (before the 2nd infusion) and at 4 hours after the completion of the Days 9 and 20 infusions (assigned patients only)

20 9 Obtain at weeks 4 and 6 only

10 Obtain during long term follow up if + at end of study

11 GVHD status and current treatment(s)

12 Resolve any ongoing AEs

13 Obtain HAMA during screen if the patient previously received a murine derived product.

25 This needs to be negative in order for the patient to qualify. If the patient has never received a murine product, this is to be obtained on Day 0 prior to the start of the infusion

In connection with the trial, it was preferred that the modified IBMTR Severity Index scoring was completed by the same physician.

The following labs were to be completed by laboratory at each clinical site

5 (local lab):

HEMATOLOGY

CBC w/ differential
White blood cells count (WBC)
WBC differential (diff)
-bands/stabs
-neutrophils
-EOS
-basophils
-lymphocytes
-monocytes

Red blood cell count (RBC)
Hemoglobin (Hgb)
Hematocrit (Hct)
Platelet count (Plt)

URINALYSIS

Specific gravity
PH
Protein
Glucose
Ketones

SERUM CHEMISTRY

Sodium (Na)
Potassium (K)
Chloride (Cl)
Bicarbonate (HCO₃)
Glucose
Blood Urea Nitrogen (BUN)
Creatinine (Cr)
Uric acid
Albumin
Total protein
Total bilirubin (bili)
Alkaline Phosphatase (alk phos)
Alanine aminotransferase (ALT, SGPT)
Aspartate aminotransferase (AST, SGOT)
Calcium (Ca)
Phosphate (PO₄)
CPK-III isoenzyme* (mm) (skeletal muscle)

Females only: serum Pregnancy
(if applicable)

*Obtain CPK with isoenzymes at baseline and post infusion on any patients with infusion related AE's.

10

In addition, the following lab assessments were completed by a central testing laboratory:

- T cell subset (CD3, 4, 8) and CD19: lymphocyte count, %, and CD4:CD8 ratio)

15

Further, the following lab assessment were completed by Abgenix, Inc.:

- ELISA for HAMA

- pK (a minimum of 5 patients/cohort to include those who previously received a murine product)

The Study Medication (ABX-CBL) was prepared and administered as follows:

5

ABX-CBL is a protein so it requires gentle handling to avoid foaming. The avoidance of foaming during product handling, preparation, and administration is important because foaming can lead to denaturation of the protein product. The pharmacist prepared each dose of study medication. The dose was based upon the patient's weight prior to randomization and the patient's cohort assignment, therefore the patient will receive the same dose for all 11 infusions. The pharmacist prepared the syringe and filter (filter supplied by Abgenix) and sent this to the patient unit for patient dosing.

15 *Infusion setup:* The infusion syringe was prepared using aseptic techniques. The appropriate volume of study medication was drawn up into the syringe(s), followed by the calculated volume of the pyrogen-free 0.9% sodium chloride solution, USP (saline solution). A 0.22 micron low-protein binding filter was attached and the tubing was primed to minimize fluid loss and according to the manufacturer's instructions.

20

Infusion volume: The total infusion volume (study medication + saline solution) to be infused for each infusion (0.01, 0.1, 0.3, 0.2 mg/kg) is equal to the patient's weight in kg. Below are examples:

25

TABLE 4

Pt's Weight (kg)	Cohort Assignment	Total Infusion Volume (mL)
70 kg	0.01	70 mL
70 kg	0.1	70 mL
70 kg	0.3	70 mL
70 kg	0.2	70 mL

The formula below was used to determine the volume of study medication and saline solution for each dose.

- a. Dose required = patient's weight X mg/kg (mg/kg is based upon cohort assignment)
- b. ABX-CBL Volume required = dose/study medication concentration (1mg/mL)
- c. Number of vials required = volume of ABX-CBL required (b above)/5mL
(each vial contains 5 mL of ABX-CBL)
- d. Total volume to be administered: For all treatment cohorts the patients received a total volume which was equal to their weight in kg (a 15 kg patient will receive a total of 15 mL, a 70 kg will receive 70 mL, etc.)

TABLE 5

Example:

Patient weighs 70 kg and is assigned to receive 0.3 mg/kg

- a. $70 \text{ kg} \times 0.3 \text{ mg/kg} = 21 \text{ mg}$
- b. $21 \text{ mg} = 21 \text{ mL}$
- c. $21 \text{ mL} / 5 \text{ mL per vial} = 4.2 \text{ vials}$, therefore 5 vials are required
- d. $70 \text{ mL (total volume)} - 21 \text{ mL (study med volume)} = 49 \text{ mL (saline solution)}$

The labeled, filled infusion syringe was sent to the patient unit for infusion, making sure that all clamps on the infusion set were closed to prevent leakage of the study medication and/or normal saline. All caps were secured in place to maintain a closed system. The sponsor provided the label for the infusion syringe and this label will contain the following:

- space to record the patient study ID and initial
- space to record the date and time the study medication was prepared along with the expiration date and time
- space to record the initials of the person who prepared the study medication and the infusion set
- Infusion instructions:
 - “Caution: New Drug-Limited by Federal Law To Investigational Use”
 - Administer infusion over 2 hours via syringe pump
 - Do not mix with any other medication.*

- Space to specify the infusion rate based upon the total volume. For a 70 mL volume, the infusion rate would be 35 mL/hour.

The person preparing the study medication was responsible for completing the
5 above information on the label.

For the infusion, most patients had an indwelling central line, therefore a new catheter was not be required as long as there is a dedicated line for the infusion of ABX-CBL. During the administration of ABX-CBL no other medications were to be
10 infused via the specific port or IV line. If a central line was not available, ABX-CBL could also be infused in a peripheral intravenous line. Because this was a trial, ABX-CBL was not mixed with other medications. If another medication was previously infused in the port, the lumen was flushed with 3-5 cc of normal saline (depending on the size catheter, lumen used, and patient's size) to clear any pre-existing medications
15 from the line and the new infusion setup from the pharmacist was attached to the port or 3-way stopcock (not piggy backed onto another line) for infusion.

The protocol was composed of four study periods: screen, treatment, treatment follow up, and long term follow up.
20

1. Screen Period

The screen period began the day the patient or the patient's legal guardian signs the informed consent and ends at treatment assignment notification. Patients
25 could be screened for enrollment into this study up to 100 days after stem cell transplant. Patients who failed to develop steroid-resistant acute GVHD were not enrolled into the study.

Each patient must understand and have signed an IRB approved informed consent form. If the patient was a minor, the patient's legal guardian was to sign the
30 informed consent form.

The following procedures were to be completed after the informed consent form is signed but prior to requesting treatment assignment. The results of these

procedures were not more than 8 hours old unless otherwise indicated. These procedures include:

- a. Complete medical history
- 5 b. Complete physical examination, which includes weight (this is the weight to be used to determine the required dose of study medication throughout the study) and height
- c. Vital signs (oral temperature, resting pulse, respiration, and blood pressure)
- 10 d. Medication history and stem cell transplant treatment history from 30 days prior to requesting treatment assignment
- e. Modified IBMTR Severity Index for acute GVHD
- f. Assessment of intercurrent illness(es)
- 15 g. Karnofsky Performance Scale (KPS) (age \geq 16 years) or Lansky Scale (age < 16 years)
- h. The following lab results were obtained if not obtained within 48 hours prior to randomization:
 - CBC with diff and platelets
 - Serum Chemistry (refer to Appendix V)
 - 20 -Baseline CPK-III isoenzyme (mm)
 - Serum Pregnancy test. This may be waived for women who are not of child bearing potential or who, in the opinion of the investigator, are sterile due to the pre conditioning for the stem cell transplant
 - 25 -Urinalysis
- i. CXR if not completed within the previous 7 days
- j. ECG if not completed within the previous 7 days for all patients 16 years of age or older.
- 30 k. Obtain serum specimen to be assayed by Abgenix for the determination of a positive HACA/HAMA for any patient who previously received a murine chimeric or fully murine product. This sample was to be shipped on dry ice overnight to Abgenix

and results were generally available within 24 hours of Abgenix's receipt of the sample.

After the above were completed and the investigator determined that the patient was eligible for treatment, the clinical center requested (via fax) the cohort assignment from the sponsor. The clinical center generally received notification of the treatment assignment by fax within 3 hours of the request.

2. Treatment Period

10

The treatment period began when the clinical site received the patient's treatment assignment and ended when the patient completed the infusion regimen (11 doses). This period generally lasted a maximum of three weeks. The patient was considered "on study" once the patient was dosed and was considered "off study" after the completion of the week 10 visit procedures or when the patient withdrew from the study.

3. Week 0, day 0

20

Pre-Infusion Procedures:

The pharmacist would prepare the study medication for infusion while the following visit procedures are being completed:

25

- a. Update any changes in concomitant medications or intercurrent illnesses
- b. Modified IBMTR Severity Index if the previous score was obtained greater than 8 hours prior to the start of the infusion
- c. Blood draw for the following:
 - CBC with diff and platelets (if previous results are > 8 hours from the start of the infusion of study medication)

30

- Serum chemistry (if previous results are > 8 hours from the start of the infusion of study medication)
- CD 3, 4, 8, & 19
- Baseline HAMA (patients who had blood drawn for HAMA as part of their eligibility screen procedure do not need to have this sample obtained)
- Baseline pK sample up to 10 minutes prior to the start of the infusion (for assigned patients only)

Study medication infusion procedures:

The pharmacist prepared the study medication such that the maximum total volume to be infused is dependent upon the patient's weight and cohort assignment (total volume of study medication and normal saline). The study medication was generally infused over 2 hours and the patient was closely monitored during the infusion and for the following 4 hours for any untoward reactions to the infusion. As of the start of the infusion of the study medication, the patient was monitored for adverse events on an ongoing basis. The sponsor was notified immediately of any suspected infusion related adverse experiences (cytokine release syndrome: fever, chills, rigors/shakes, hypotension, and rash or hypersensitivity reaction: fever, chills, bradycardia/cardiac arrest, respiratory arrest, acute respiratory distress syndrome, rash/urticaria, pancytopenia, increased liver transaminases, and arthralgias/myalgias). If an infusion reaction is suspected and the patient experiences myalgias or any muscular problems, CPK-III isoenzyme (mm) were obtained.

Infusion Vital Signs:

During the infusion, vital signs (T, P, R, BP) were obtained just prior to the start of the infusion (a maximum of 10 minutes prior to the start of the infusion), every 15 minutes during the first hour of the infusion (4 sets), followed by 90 minutes after the start of the infusion, and at the completion of the infusion (120 minutes after the start of the infusion). Vital signs were generally obtained hourly for the next 4

hours (4 sets at 180, 240, 300, and 360 minutes after the start of the infusion). After the infusion vital signs have been completed, vital signs were monitored according to the established guidelines used by the clinical center.

5 Pharmacokinetic blood samples:

Blood for pK analysis was obtained from at least 5 patients in each cohort. All patients enrolled in study who previously received a murine product had pK assessments completed. Blood samples were generally obtained at the following
10 times after the completion of the first infusion; 15 and 30 minutes, 1, 2, 4, 8, 12, 18, and 24 hours. The 24 hour post infusion sample was obtained prior to the start of the second infusion of ABX-CBL.

4. Week 0, days 1-6

15

The patient received a daily infusion of the study medication for 7 consecutive days (induction regimen). Each subsequent infusion generally began at the same time as the first infusion (\pm 60 minutes). The dose was based upon the pre-enrollment weight, therefore, the patient will receive the same dose throughout the treatment
20 period. Data was collected on any patients having an ECG or CXR completed at any time during the treatment period, otherwise routine ECGs and CXRs were not required. The same will hold true for any biopsies completed during this period.

The following procedures were generally completed within 12 hours prior to
25 the start of each infusion unless otherwise noted:

- a. Abbreviated physical exam (refer to Appendix II)
- b. Weight
- c. KPS or Lansky Scale
- 30 d. Modified IBMTR Severity Index
- e. Update any changes in concomitant medications or intercurrent illnesses

- f. Adverse experience assessment
- g. Blood draw for the following(refer to Appendix V for test to be processed by the local labs and those to be processed by the central lab):
 - CBC with diff and platelets
 - Serum chemistry
 - CD 3, 4, 8, & 19
 - Pharmacokinetic sample for assigned patients only and obtain prior to the start of the Day 1 infusion only (this is the 24 hour post infusion 1 sample).

Study Medication Infusion:

The study medication was infused over 2 hours following the above procedures. If an infusion reaction was suspected and the patient experiences myalgias or any muscular problems, CPK-III isoenzyme (mm) were obtained.

Infusion Vital Signs:

Vital signs (T, P, R, BP) were obtained according to the schedule described for the first infusion.

5. Week 1 (study days 9 and 13)

At the completion of the induction regimen, the patients were infused with the study medication twice a week for two weeks (maintenance regimen). The start time of each infusion in the maintenance regimen was generally \pm 60 minutes from the start time of the first infusion (Day 0). The following procedures were generally completed within 12 hours prior to the start of each infusion unless otherwise noted:

- a. Abbreviated physical exam
- b. Weight

- 5 c. KPS or Lansky Scale
d. Modified IBMTR Severity Index
e. Update any changes in concomitant medications or intercurrent illnesses
f. Adverse experience assessment
g. Urinalysis (study day 9 only)
h. Blood draw for the following(refer to Appendix V for test to be processed by the local labs and those to be processed by the central lab):
- 10 • CBC with diff and platelets
• Serum chemistry
• CD 3, 4, 8, & 19 (day 9 only)
• HAMA (day 9 only)

15 Study Medication Infusion:

The study medication was infused over 2 hours and the procedures described above were again followed. If an infusion reaction was suspected and the patient experiences myalgias or any muscular problems, CPK-III isoenzyme (mm) were
20 obtained.

Infusion Vital Signs:

Vital sign regimen described above was utilized.

Pharmacokinetic sample:

25 A blood sample for pK analysis was obtained about 4 hours after the completion of the Day 9 infusion.

6. Week 2 (study days 16 and 20)

30 This was the second week of the maintenance regimen (dosing is twice a week for two consecutive weeks). The start time of each infusion was generally ± 60

minutes from the start time of the Day 0 infusion. The following procedures were generally completed within 12 hours prior to the start of each infusion unless otherwise noted:

- 5 a. Abbreviated physical exam
- b. Weight
- c. KPS or Lansky
- d. Modified IBMTR Severity Index
- e. Update any changes in concomitant medications or intercurrent
- 10 illnesses
- f. Adverse experience assessment
- g. Urinalysis (day 16 only)
- h. Blood draw for the following(refer to Appendix V for test to be
- processed by the local labs and those to be processed by the
- 15 central lab):
- CBC with diff and platelets
- Serum chemistry
- CD 3, 4, 8, & 19 (day 16 only)

20 Study Medication Infusion:

The study medication was infused over 2 hours and the same procedures described above were followed. If an infusion reaction was suspected and the patient experiences myalgias or any muscular problems, CPK-III isoenzyme (mm) were

25 obtained.

Infusion Vital Signs:

Vital sign regimen described above was utilized.

30 Pharmacokinetic sample:

A blood sample for pK analysis was obtained about 4 hours after the completion of the Day 20 infusion.

7. Treatment Follow up Period (Weeks 3 – 10)

5

The treatment follow up period began after the completion of the Day 20 visit and ended at the completion of the week 10 visit. There were five visits during this period. When the patient completed the week 10 visit the patient was considered “off study”. If a patient is discharged from the clinical center during this study period, every attempt was made to complete a telephone assessment in place of an office visit. Weeks 3, 4, 5, 6, and 10 were treatment follow up visits. Safety, efficacy or signs of relapse was assessed at these visits. Patients who were partial or complete responders and have a flare of their GVHD were allowed to withdraw from the study and enroll into a separate open label, compassionate treatment protocol. Any biopsies, ECGs, and/or CXRs completed during the treatment follow up period were completed per routine patient care as specified at each clinical center, however, the data from these procedures was collected. Any patients who experienced a suspected infusion related adverse experience with myalgias or any muscular problems and who had elevated mm (isoenzyme which becomes elevated when there is muscular necrosis or inflammation) levels generally had a routine CPK-III (mm) sample obtained throughout the remainder of the study.

10

15

20

8. Week 3 (study day 23)

25

The following procedures were completed at this visit:

- a. Complete physical exam, vital signs, and weight
- b. KPS or Lansky
- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- e. Adverse experience assessment
- f. Hospitalization status (in patient or discharge)

30

- g. Blood draw for the following:
 - CBC with diff and platelets
 - Serum chemistry (refer to Appendix V)
 - CD 3, 4, 8, & 19

5

9. Week 4 (study day 30 \pm 1)

The following procedures were completed at this visit:

- a. Complete physical exam, vital signs, and weight
- b. KPS or Lansky
- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- e. Adverse experience assessment
- f. Hospitalization status (in/outpatient or discharge from clinical center)
- g. Urinalysis
- h. Blood draw for the following:
 - CBC with diff and platelets
 - Serum chemistry (refer to Appendix V)
 - CD 3, 4, 8, & 19
 - HAMA

10

15

20

10. Week 5 (study day 37 \pm 1)

The following procedures were completed at this visit:

- Complete physical exam, vital signs, and weight
- KPS or Lansky
- Modified IBMTR Severity Index
- Update any changes in concomitant medications or intercurrent illnesses
- Adverse experience assessment

25

30

- f. Hospitalization status (in/outpatient or discharge from clinical center)
- g. Blood draw for the following:
- CBC with diff and platelets
 - Serum chemistry (refer to Appendix V)
 - CD 3, 4, 8, & 19

11. Week 6 (study day 44 ± 1)

The following procedures were completed at this visit:

- a. Complete physical exam, vital signs, and weight
- b. KPS or Lansky
- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- e. Adverse experience assessment
- f. Hospitalization status (in/outpatient or discharge from clinical center)
- g. Urinalysis
- h. Blood draw for the following:
- CBC with diff and platelets
 - Serum chemistry (refer to Appendix V)
 - CD 3, 4, 8, & 19
 - HAMA

12. Week 10 (study day 72 ± 2)

At the completion of this visit the patient was considered "off study".

The following procedures were completed at this visit:

- a. Complete physical exam, vital signs, and weight
- b. KPS or Lansky

- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- e. Adverse experience assessment
- 5 f. Hospitalization status (in/outpatient or discharge from clinical center)
- g. Urinalysis
- h. Blood draw for the following:
 - CBC with diff and platelets
 - 10 • Serum chemistry (refer to Appendix V)
 - CD 3, 4, 8, & 19
 - HAMA (if any patient has a positive HAMA, blood draws for HAMA will be requested during the Long Term Follow up Period)
- 15 13. Additional Visit Timepoint (Day 100 post stem cell transplant)

Most patients were assessed 100 days post stem cell transplant. The order in which this visit occurs in relationship to the protocol visits varied on a patient by patient basis depending on when acute GVHD develops post stem cell transplant. Regardless of when day 100 occurs, the following procedures were completed at this visit (if the patient had been discharged from the clinical center every effort was made to obtain this information through a phone call to the patient and the patient's private physician):

- a. Abbreviated physical exam, vital signs, and weight
- b. KPS or Lansky
- c. Modified IBMTR Severity Index
- d. Update any changes in concomitant medications or intercurrent illnesses
- 30 e. Adverse experience assessment

- f. Hospitalization status (in/outpatient or discharge from clinical center)
- g. Blood draw for the following:
 - CBC with diff and platelets
 - Serum chemistry (refer to Appendix V)

14. Long Term Follow up Period

The long term follow up period begins the day after the completion of the week 10 visit and is planned to continue for 10 years or until the patient withdraws consent to be followed. The primary purpose of the long term follow up period is to determine long term safety of ABX-CBL and to determine the long term survival. The patient will be assessed every 6 months from their week 10 visit. These assessments will occur either by telephone interview or by office visit. Long term follow up data may be obtained by the sponsor, Abgenix, Inc., from the primary physician provided that the patient/legal guardian has provided written consent. All data will be entered into the database using the patient's unique study ID. The following information should be obtained during these phone calls or visits:

- a. Determine the patient's assessment of their health status, this includes the closeout any AE's that were ongoing at the last "on study" visit
- b. Determine the onset of any of the following:
 - Death
 - Opportunistic Infections
 - Other immune impairments
 - Other cancer(s)
 - Congenital abnormality
 - If female, if pregnant, status of baby (after pregnancy)
- c. Determine if the patient is active in any other research (investigative products and/or devices) since the previous visit/call.

If the long term follow up visit data is obtained by the transplant team at the clinical center, a copy of each visit assessment will be faxed to the sponsor within 10 working days of the phone call/visit.

5 C. Determination of HAMA

This assay was designed to study the immunogenicity of ABX-CBL in human subjects to detect human antibodies against ABX-CBL (human anti-mCBL antibody) in human serum (human anti-murine antibody, HAMA, response).

10 Materials:

Negative Control, pool of HAMA negative sera (from Blood Centers of the Pacific, Irwin Blood Center, SF, CA) tested and pooled, stored at -20°C

15 Positive Control, pool of HAMA positive sera (from immunizing XenoMouse mice (Abgenix, Inc.) with ABX-CBL and removal and pooling of serum), stored at -20°C

ABX-CBL, 5 µg/50 µL (100 µg/mL), Abgenix, Lot No. 097-104-1, stored at -20°C or equivalent

Biotinylated ABX-CBL (ABX-CBL-biotin), Abgenix, Lot No. J090-112 or equivalent

20 Streptavidin-HRP, Southern Biotechnology, Cat. No. 7100-05 or equivalent

O-phenylenediamine dihydrochloride (OPD) Substrate Tablets, 20 mg, Sigma, Cat. No. P-7288 or equivalent

25 O-phenylenediamine dihydrochloride (OPD) Substrate Tablets, 10 mg, Sigma, Cat. No. P-8287 or equivalent

Hydrogen Peroxide, 30%, Sigma, Cat. No. H-1009 or equivalent

Deionized, reverse osmosis purified water (DiH₂O) or equivalent

Coating ELISA Plate: Thaw a vial of ABX-CBL 5 µg/50 µL (100 µg/mL) at room temperature for 2-5 minutes. Vortex on low speed for 3-5 seconds. Add 48 µL

- of ABX-CBL 5 µg/50 µL (100 µg/mL) to 12 mL of Coating Buffer (NaHCO₃ at 16.8 gms/1.8L DiWater to pH 9.6 w/ 5N NaOH)) in a 15 mL conical tube. Vortex the coating solution on low speed for 3-5 seconds. Pour the coating solution into a reagent reservoir. Using a multi-channel pipettor, add 100 µL of coating solution to each well.
- 5 Cover plate with plastic plate sealer. Incubate plate at 2-8°C for 16-24 hours. Wash the plates with 1X Wash Buffer (50 mL Tween 20 in 10 L 10 X PBS diluted by 10) using a plate washer. Using the multi-channel pipettor, add 100 µL of Blocking Buffer (20 gms BSA in 400 mL 10 X PBS, 0.4 gms. Thimerosal, 4 mL Tween 20, diluted to 4 L DiWater) to each well. Cover plate with plate sealer and incubate for 1
- 10 hour at room temperature.

- Preparation of Positive Control: Thaw 1 vial of positive control (HAMA positive serum) at room temperature for 10-20 minutes. Vortex positive control for 3-5 seconds on low speed. Avoid air bubbles. Add 20 µL of positive control to 180 µL of Blocking Buffer in a microcentrifuge tube. In well A1 and A2 of a low binding 96-
- 15 well plate, add 20 µL of diluted positive control above to 180 µL of Blocking Buffer. Mix. Mix well by aspirating and dispensing the solution 5 times. Avoid air bubbles. Prepare 2 fold serial dilutions of the positive control. **Note:** Each plate should include the positive control in duplicate in columns 1 and 2. The following procedure is for one plate. Add 100 µL of Blocking Buffer to wells B3, B4 through H3, H4 on the
- 20 plate as above. Using a multi-channel pipettor, transfer 100 µL of the solution in wells A1 and A2 to B1 and B2, respectively. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Transfer 100 µL of the solution from wells B1 and B2 to wells C1 and C2, respectively. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Continue dilutions down
- 25 the plate from row to row with the last dilution in Row G (wells G1 and G2). Leave the Blocking Buffer in Row H as blank controls.

- Preparation of Negative Control: Thaw negative control at room temperature for 20-30 minutes. Vortex the negative control for 3-5 seconds on low speed before transferring to the ELISA plate. Dilute negative control by adding 20 µL to 980 µL
- 30 of blocking Buffer.

Preparation of Sample: **Note 1:** Serum samples should be prepared in a designated area. **Note 2:** Wear gloves when handling serum and follow Universal

- Precautions. Thaw serum samples at room temperature for 20-30 minutes. Vortex serum samples for 3-5 seconds on low speed. Dilute serum samples 1:50 by adding 20 μ L of a serum sample to 980 μ L Blocking Buffer in a titer tube. Mix the diluted samples by aspirating and dispensing 50 μ L of the solution 5 times. Avoid bubbles.
- 5 Wash the coated ELISA plate from Step 7.3.2 using a plate washer. Transfer 50 μ L of positive control, negative control, samples and blank to the ELISA plate as above. Cover the ELISA plate with plastic plate sealer and incubate for two hours at room temperature. Shake the plate on low speed.

- Preparation of ABX-CBL-biotin: Note: Minimum of 10 mL of diluted
- 10 ABX-CBL-biotin is needed for each ELISA plate. Final dilution may be adjusted according to the potency of the reagent. Vortex ABX-CBL-biotin for 3-5 seconds on low speed. Dilute 15 μ L of ABX-CBL-biotin into 1.485 mL of Blocking Buffer in a microcentrifuge tube. Total dilution is 1:100. Dilute 1200 μ L of 1:100 diluted ABX-CBL-biotin into 10.80 mL of Blocking Buffer. Total dilution is 1:1000. Vortex for 3-
- 15 5 seconds on low speed. Wash the coated ELISA plate using a plate washer. Using a multi-channel pipettor, add 100 μ L of 1:1000 diluted ABX-CBL-biotin to each well of the ELISA plate. Cover the plate with plastic plate sealer and incubate for 1 hour at room temperature.

- Preparation of Streptavidin-HRP: Note: Minimum of 10 mL of diluted
- 20 Streptavidin-HRP is needed for each ELISA plate. Final dilution may be adjusted according to the potency of the reagent. Vortex Streptavidin-HRP for 3-5 seconds on low speed. Dilute 10 μ L of Streptavidin-HRP into 990 μ L of Blocking Buffer in a microcentrifuge tube. Total dilution is 1:100. Dilute 250 μ L of 1:100 diluted Streptavidin-HRP into 12.25 mL of Blocking Buffer. Total dilution is 1:5000. Vortex
- 25 for 3-5 seconds on low speed. Wash the ELISA plate from above using a plate washer. Using multi-channel pipettor, add 100 μ L of 1:5,000 diluted Streptavidin-HRP to each well of the ELISA plate. Incubate the plate for 15 min at room temperature.

- Preparation of Substrate Solution: Note 1: Minimum of 10 mL of Substrate
- 30 Solution is needed for each ELISA plate. Note 2: Prepare Substrate Solution fresh prior to use. To make 12 mL of Substrate Solution, add one 10 mg OPD tablet, and 12 μ L of 30% H_2O_2 into 12 mL of Substrate Buffer in a conical tube. Dissolve the

tablet by leaving the tube at room temperature for 3-5 minutes. Vortex the solution for 3-5 seconds prior to adding to the plate. Wash the ELISA plate from above using a plate washer. Using a multi-channel pipettor, add 100 μ L of Substrate Solution into each well and incubate for 15 minutes. Using a multi-channel pipettor, add 50 μ L of
5 Stop Solution (2 M H_2SO_4) to each well.

Reading ELISA plate(s): Set wavelength at 492 nm and check automix function to premix plate for 5 seconds before reading plate. Use reduction function (Check L1) to subtract the calculated blank for the assay. Samples and controls are blanked against the buffer blank. Read plate using the SPECTRAMax 250
10 spectrophotometer within 30 minutes of stopping the assay.

As discussed above, the present assay was utilized for patient samples in connection with the present clinical trials and no patients tested positive for a HAMA response.

15 D. Determination of pK

The present assay was utilized in connection with pharmacokinetic (pK) studies to measure the presence of ABX-IL8 in human serum.

Materials:

20 ABX-CBL, anti-mouse CBL antibody, 5 μ g/50 μ L (100 μ g/mL), Abgenix, Lot No 69-21-4 or equivalent

High, Medium and Low Positive Controls, ABX-CBL: 69-21-3, 69-21-2, 69-21-1 or equivalent

25 Goat anti-mouse IgM, Caltag, Cat. No. M31500, Lot No. 3501 or equivalent

Goat anti-mouse IgM-HRP, Caltag, Cat. No. M31507, Lot No. 2301 or equivalent

Normal human serum

O-phenylenediamine dihydrochloride (OPD) Substrate Tablets, 20 mg,
Sigma, Cat. No. P-7288 or equivalent

O-phenylenediamine dihydrochloride (OPD) Substrate Tablets, 10 mg,
Sigma, Cat. No. P-8287 or equivalent

5 Hydrogen Peroxide, 30%, Sigma, Cat. No. H-1009 or equivalent

Deionized, reverse osmosis purified water (DiH₂O) or equivalent

Buffers and solutions that are used herein are the same as the buffers
and solutions described in connection with the HAMA assay unless described
otherwise

10 Coating ELISA Plate: Note: Minimum of 10 mL of coating solution is
needed for each ELISA plate. Pull vial of goat anti-mouse IgM (1 mg/mL) from the
2-8°C refrigerator. Let stand for 2-5 minutes at room temperature. Vortex on low
speed for 3-5 seconds. Add 3 µL goat anti-mouse IgM (1 mg/mL) to 15 mL of
Coating Buffer in a 15 mL conical tube. Vortex the coating solution on low speed for
15 3-5 seconds. Pour the coating solution into a reagent reservoir. Using a multi-
channel pipettor, add 100 µL of coating solution to each well. Cover the plate with a
plastic plate sealer. Incubate at 2-8°C for 16-24 hours. Wash the plate with 1X Wash
Buffer using a plate washer.

Blocking ELISA Plate: Using the multi-channel pipettor, add 200 µL of
20 Blocking Buffer to each well. Cover plate with plastic plate sealer and incubate for 1
hour at room temperature.

Preparation of Standard: Note 1: Blocking Buffer used in Sections 8.4 and
8.6 (except 8.4.4.1 and 8.6.3) contains 1% serum from untreated human subjects.
Minimum of 9 mL of Blocking Buffer is needed for each plate. To make 10 mL of
25 Blocking Buffer containing 1% serum, add 100 µL serum to 9.9 mL of Blocking
Buffer in a conical tube. Vortex on low speed for 3-5 seconds. Thaw 1 vial of ABX-
CBL standard (100 µg/mL) at room temperature for 10-20 minutes. Vortex 100
µg/mL ABX-CBL on low speed for 3-5 seconds. Avoid bubbles.

Initial Dilution of Standard: Using a single channel pipette, add 40 µL of 100
30 µg/mL stock to 360 µL of Blocking Buffer in a 1.7 mL microcentrifuge tube. Mix

well. This is a 1:10 dilution equal to 10 µg/mL. Using a single channel pipette, add 40 µL of the previous 1:10 dilution (10 µg/mL) into 460 µL of Blocking Buffer in a 1.7 mL microcentrifuge tube. Mix well. This dilution is equal to a concentration of 800 ng/mL. Mix the diluted standard by vortexing on low speed for 3-5 seconds.

- 5 Avoid bubbles. Prepare 2 fold serial dilutions of the standard. Note: Each blank low binding ELISA plate should include the standard in duplicate in columns 1 and 2. The following procedure is for one plate. Add 100 µL of Blocking Buffer to Wells B1, B2 through H1, H2. Transfer 200 µL of 800 ng/mL standard to Wells A1 and A2. Using a multi-channel pipette, transfer 100 µL of the solution in Wells A1 and A2 to
10 Wells B1 and B2, respectively. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Transfer 100 µL of the solution from Wells B1 and B2 to Wells C1 and C2, respectively. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Continue dilutions down the plate from row to row with the last dilution in Wells H1 and H2.

- 15 Preparation of Positive Controls: Note: One vial of high, medium and low control is needed for each assay plate. Thaw 1 vial of high, medium and low controls at room temperature for 10-20 minutes. Vortex the controls for 3-5 seconds on low speed before transferring to the ELISA plate.

- Preparation of Sample: Thaw serum samples at room temperature for 30
20 minutes. Vortex serum samples on low speed for 3-5 seconds prior to dilutions. Dilute serum samples 1:10 by adding 20 µL of a serum sample to 180 µL Blocking Buffer (without 1% serum) in Row A of a blank plate. Mix well by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Prepare two fold serial dilutions of the sample. Using a multi-channel pipette, add 100 µL of Blocking
25 Buffer to Row B through Row H. Transfer 100 µL of the diluted samples from Step 8.6.3 to Row B. Mix as above. Continue to transfer 100 µL of the samples from Row B to Row C, from Row C to Row D, and so on to Row H. Mix samples after each transfer by aspirating and dispensing 100 µL of the solution 5 times. Avoid bubbles. Wash the plate with 1X Wash Buffer using a plate washer. Transfer 50 µL diluted
30 standard, controls and samples from blank plate to the ELISA plate. Start from Row H, then go to Row G and so on up to Row A. Check plate template to add additional

wells of buffer blank. Cover the plate with a plastic plate sealer and incubate for two hours at room temperature.

Prepare HRP-conjugated detection antibody: Note: Minimum of 10 mL of diluted HRP-conjugated antibody is needed for each plate. Mix goat anti-mouse IgM-HRP by vortexing on low speed for 3-5 seconds. Dilute goat anti-mouse IgM-HRP to 1:1500 by adding 8 μ L of goat anti-mouse IgM-HRP to 12 mL of Blocking Buffer in a 15 mL conical tube. Vortex. Wash the plate with 1X Wash Buffer using a plate washer. Using a multi-channel pipette, add 100 μ L of diluted goat anti-mouse IgM-HRP (from Step 8.10.2) to each well of the plate. Cover the plate with a plastic plate sealer and incubate for 1 hour at room temperature.

Prepare Substrate Solution: Note 1: Minimum of 10 mL of Substrate Solution is needed for each plate. Prepare Substrate Solution fresh prior to use. To make 12 mL of Substrate Solution, add one 10 mg OPD tablet and 12 μ L of 30% H_2O_2 to 12 mL of Substrate Buffer in a conical tube. Dissolve the tablet by leaving the tube at room temperature for 3-5 minutes. Vortex the solution for 3-5 seconds prior to adding to the plate. Wash the plate with 1X Wash Buffer using a plate washer. Using a multi-channel pipettor, add 100 μ L of Substrate Solution into each well and incubate for 15 minutes.

Stopping ELISA reaction: Using a multi-channel pipette, add 50 μ L of Stop Solution to each well.

Reading ELISA plate(s): Set wavelength at 492 nm and check automix function to premix plate for 5 seconds before reading plate. Use reduction function (check L1) to subtract the calculated blank for the assay. Standard, controls and samples are blanked against the buffer blank. Read plate(s) using the SPECTRAmax 250 or equivalent spectrophotometer within 30 minutes of stopping the assay, Operation and Maintenance of the Molecular Devices SPECTRAmax 250 Microplate Spectrophotometer.

Data Analysis: The OD for the standard is used to calculate the standard curve. Use "4-parameter fit" to curve fit the standard. Sample and control concentrations are calculated automatically by the software from the standard curve. The following criteria must be met in order for the assay to be valid: Only use OD's

< 4.0 for standard, controls and samples. Compare the results for the assay controls (High, Medium and Low). The values for the controls must fall within 20% of expected concentration and with coefficient of variation (CV) $\leq 20\%$. The CV of the standards between ST03 and ST06 must be $\leq 20\%$. The correlation coefficient of the standard curve of the assay must be ≥ 0.990 .

The present assay was utilized for determining the pharmacokinetics of the ABX-CBL antibody in the present clinical trials. The results from our preliminary determinations of pKs in patients utilizing the above-assay are shown in Figure 1.

10 E. Results

Herein, we describe the results that were observed in the treatment of patients with acute GVHD with ABX-CBL.

In the trial, twenty-seven patients were enrolled across the four dose levels. The lower doses were completed prior to enrolling in the higher dose cohorts. Patients who were treated at the higher dose in the original third cohort (0.3 mg/kg) experienced myalgia or myalgia-like symptoms. Abgenix determined this dose to be the Maximum Tolerated Dose (MTD) and revised the last dose from 1.0 mg/kg to 0.2 mg/kg (mid dose between the MTD and the dose prior to the MTD).

20 Once the 4 dose cohorts were filled, additional patients were enrolled at a dose level of 0.15 mg/kg to 0.2 mg/kg. As of January 13, 1999, a total of 44 patients (17 additional patients) have been enrolled. Data continues to be collected on these additional 17 patients. This data will be presented as it becomes available.

All data presented herein are based upon the initial 27 patients except for the Serious Adverse Event (SAE) Summaries. The SAE Summaries relate to all patients as of January 13, 1999.

25 Patients had to receive a minimum of 4 infusions of ABX-CBL to be evaluated for efficacy. Of the twenty-seven patients enrolled, 23 met this criteria. Excluding the patients in cohort 1 (the no-effect dose). There was an overall response rate of 73% with a mean duration of 32 days.

Other than the incidence of myalgia, ABX-CBL was well tolerated. All patients were, and remain, negative for HAMA, and no reports of hypersensitivity to ABX-CBL have been received.

1. Demographics:

Of the twenty-seven patients enrolled, 21 were adults (age 16 or older) and 6 were pediatric (Table 4). Twenty-four patients were recipients of an allogeneic bone marrow transplant, and the other three received peripheral stem cells. The mean duration from the date of transplant to enrollment into this study was 48 days. Seven patients were entered into the study with an IBMTR grade of B, 10 with a grade of C and 10 with D. (Table 5). Table 6 lists the baseline score for the 23 patients evaluated for efficacy.

TABLE 6

GENDER/AGE CATEGORY			
	MALE	FEMALE	TOTAL
<i>ADULT</i>	13	8	21
PEDIATRIC (<16 YRS)	4	2	6
TOTAL	17	10	27

TABLE 7

BASELINE IBMTR SEVERITY SCORE-ALL PATIENTS				
COHORT	<u>B</u> n(%)	<u>C</u> n(%)	<u>D</u> n(%)	<u>TOTAL</u> N
1 (0.01 mg/kg)	2 (22%)	3 (33%)	4 (44%)	9
2 (0.1 mg/kg)	2 (29%)	3 (42%)	2 (29%)	7
3 (0.3 mg/kg)	1 (50%)	1 (50%)	0	2
4 (0.2 mg/kg)	2 (22%)	3 (33%)	4 (44%)	9
TOTAL	7	10	10	27

TABLE 8

BASELINE IBMTR SEVERITY SCORE FOR <i>EVALUABLE</i> PATIENTS				
COHORT	<u>B</u> n(%)	<u>C</u> n(%)	<u>D</u> n(%)	<u>TOTAL</u> N
1 (0.01 mg/kg)	2 (25%)	3 (38%)	3 (38%)	8
2 (0.1 mg/kg)	1 (17%)	3 (50%)	2 (33%)	6
3 (0.3 mg/kg)	1 (50%)	1 (50%)	0	2
4 (0.2 mg/kg)	2 (29%)	2 (29%)	3 (43%)	7
TOTAL	6	9	8	23

5

2. Efficacy:

Patients eligible for enrollment into this study required a minimum IBMTR score of B. Patients who demonstrated at least a 2 index decrease in overall IBMTR score were considered responders. Those who decreased to no score, meaning there was no acute GvHD present, were considered to be complete responders. Only patients who received 4 or more infusions of ABX-CBL are included in the efficacy analyses. (Table 7)

10

TABLE 9

15

EFFICACY SUMMARY			
COHORT	EVALUATED FOR EFFICACY (n)	RESPONDERS n (%)	MEAN DURATION OF RESPONSE (n)
1 (0.01 mg/kg)	8	3 (38%)	24 days (3)
2 (0.1 mg/kg)	6	4 (67%)	11 days (3)
3 (0.3 mg/kg)	2	2 (100%)	69 days (1)
4 (0.2 mg/kg)	7	4 (57%)*	41 days (3)
TOTAL	23	13 (57%)	36 days

*One patient responded to additional therapy with ABX-CBL in the ABX-CB-9702 protocol and is not included in the above table.

20

Overall, thirteen (57%) of the twenty-three patients demonstrated a response to ABX-CBL in ABX-CB-9701. The mean duration was 36 days. One additional patient who rolled over into protocol described below responded to additional therapy.

This brings the overall response rate to 61%. The assumption going into the study was that the dose of 0.01 mg/kg would be the no effect dose. Assuming this dose to have no effect, the response rate was 73% (11 of 15 patients). With this assumption, the mean duration of response was 32 days.

5 The duration of response seems to increase as the dose is increased. One patient, [0108], was an outlier for duration in the first cohort. This patient's duration lasted at least 59 days. The duration may be longer, but the study ended at Day 72.

 [Patient 0816] experienced severe myalgia at the 0.3 mg/kg dose level during the first infusion. This patient was continued at a decreased dose of 0.2 mg/kg for all
10 subsequent infusions. Because of the change in dose, this patient is evaluated in the 0.2 mg/kg cohort for efficacy and in the 0.3 mg/kg for safety.

 Only one patient in the lowest dose cohort and both patients in the highest dose level completed the study through Day 72. Four of the six patients in the 0.1 mg/kg dose group completed the study, and 4 of the 7 in the 0.2 mg/kg dose group
15 completed. All patients who demonstrated a complete response also completed this study through Day 72.

3. Safety:

20 All patients who received any amount of ABX-CBL were evaluated for safety. ABX-CBL was well tolerated with the exception of myalgia, which became the Dose Limiting Toxicity (DLT). The incidence of myalgia increased in relationship to an increase in the dose administered. This led to the Maximum Tolerated Dose (MTD) at 0.3 mg/kg. The onset of the myalgia ranged from 20-60 minutes into the infusion
25 and usually resolved within 1-2 hours after the completion of the infusion. Of the 14 patients who experienced any grade of myalgia, two required being withdrawn from this study due to the myalgia. All myalgias resolved without sequelae except for one patient in whom myalgia persisted. This last incidence is under further evaluation and clarification. Table 6 summarizes the incidence of myalgia by severity and dose.
30 Patients with adverse events listed as myalgia graded as "not related" or "unlikely" and with a baseline disease of myalgia are not included in the this table.

TABLE 10

INCIDENCE OF MYALGIA AND OUTCOME								
	0.01 mg/kg (n=9)		0.1 mg/kg (n=7)		0.3 mg/kg (n=3)		0.2 mg/kg (n=8)	
SEVERITY	n (%)	Study status	n (%)	Study status	n (%)	Study status	n (%)	Study status
SEVERE			1	W/D	1 1	con't dec. dose	3 1	con't W/D
MODERATE	2	Con't	1	Con't			1	Con't
MILD	1	Con't	1	Con't			1	Con't

W/D = withdrew from the study related to the myalgia

5

Abgenix continues to investigate the causality of myalgia and any possible inter-relationships. The following causes have been ruled out as a predisposing factor to those who do develop myalgia:

- 10
- alteration in electrolytes
 - responders vs non responders
 - type of transplant
 - type of donor
 - steroid dose

15

Eleven Serious Adverse Experiences in eleven patients have been reported with ABX-CBL. Five "severe" events, all myalgia related, are listed as "probable" for the relationship to ABX-CBL. One event, "hepatic failure of unknown etiology" is listed as "suspected". The remaining SAEs are listed as "unlikely" or "not related".

20

Twenty-three of these events were evaluated as probably related to ABX-CBL and 7 as suspected. All other events were reported as "unlikely" or "not related".

Of the 23 "probable" adverse events, all except 2 were myalgia related. One patient experienced moderate "fatigue" which resolved without sequelae. The other experienced moderate "hemolysis" which resolved with a sequelae of increased Liver Function Tests (LFT).

25

Of the seven events evaluated as "suspected" to be related to ABX-CBL, 1 event was severe, 4 were moderate, and 2 were mild in severity. All of these events resolved without sequelae. The severe event was "edema". The four moderate events occurred in 4 patients and consisted of "moderate decrease in uric acid", "fever/chills", "hypotension", and "fever". The two mild events occurred in two patients and consisted of "low grade fever following study drug" and "chills".

HAMA testing on all 27 patients has been negative through the patients' last study visit.

Lymphocyte counts were drawn from all patients just prior to the first infusion and at regular intervals throughout the study. Of the patients who enrolled into ABX-CB-9701, approximately 50% could not be evaluated on the basis of the immunocompromised state secondary to both BMT and their ongoing GvHD. Patients who are post stem cell transplant are immunodeficient secondary to their conditioning regimen as well as an exacerbation of their immunodeficient state from acute GvHD. To date, ABX-CBL does not appear to have an untoward effect on the T-cell counts.

Phase II Clinical Trial of ABX-CBL -- Rescue Protocol

As patients completed the above-described Phase II trial, we also initiated a second Phase II continuation trial for such patients to continue to receive ABX-CBL for any flares of GVHD experienced. The continuation trial was designed as an open label clinical trial for patients with acute GVHD who have previous exposure to ABX-CBL. Those patients who had acute GVHD of grades II/III/IV severity, as discussed above, were eligible.

In the trial, all patients are receiving, or will receive, up to 7 intravenous doses (1st treatment course) of ABX-CBL. The medication will be infused over 2 hours via a syringe pump for 7 consecutive days. The dose will be 0.2 mg/kg (approximate dose used effectively in clinical trial described above. If the first treatment course produced a therapeutic effect (complete or partial response), patients may receive a second treatment course prior to the onset of chronic GVHD, or day 200 post primary transplant whichever is reached first. The second treatment course with ABX-CBL

will be handled on a case by case basis through a discussion with the medical monitor and the investigator.

The objectives of this trial were as follows:

- 5 To assess the safety of continued dosing with ABX-CBL in patients with acute GVHD.

To determine the clinical effect of repeat treatments of ABX-CBL in patients with flare of acute GVHD or patients who were previous treatment failures with ABX-CBL.

- 10 To allow treatment for patients who failed to demonstrate a clinical effect at a lower dose of ABX-CBL and/or to provide treatment for previous responders to ABX-CBL who are experiencing a flare of their acute GVHD.

To assess flare rates after initial treatment with ABX-CBL.

- 15 All of the procedures described above in connection with the initial clinical trial were utilized in connection with this study, with only minor modifications.

Dosing, Dose Regimen, and Treatment with ABX-CBL

- 20 In view of the foregoing discussion and results, ABX-CBL provides a profound treatment for GVHD and likely other disease etiologies wherein lymphatic cells are deleteriously or undesirably activated. The results presented herein demonstrate that through administration of a dose of ABX-CBL greater than about 0.1 mg/kg and less than about 0.4 mg/kg of the antibody is efficacious in connection with
- 25 the treatment of such disease etiologies. Preferably, the dose is from about 0.1 mg/kg to about 0.3 mg/kg and more preferably from about 0.15 mg/kg to about 0.2 mg/kg. Further, the dosing regimen disclosed herein of an induction regimen (plural daily infusions, herein daily for 7 days) followed by a maintenance regimen (periodic infusions, herein twice weekly for two weeks) appears to assist in remission of GVHD
- 30 and certainly lessens the severity of patients' GVHD between flares of the disease.

As will be appreciated, both the purified ABX-CBL, discussed in detail in the present invention and other anti-CD147 antibodies, such as those discussed herein, will be similarly efficacious.

In addition to GVHD, therapeutics in accordance with the present invention will likely be efficacious with respect to diseases having an etiology characterized by a harmful presence of activated T cells, B cells, or monocytes. As an example, GVHD is one such disease. However, many inflammatory diseases and autoimmune diseases can be characterized as sharing such an etiology. Further the therapies of the invention will likely be efficacious in the following disease etiologies, including, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases (including without limitations arthritis, rheumatoid arthritis), and others.

EXPERIMENT 22 **SURROGATE ANTIBODIES THAT BIND TO MURINE GP42 FOR ANIMAL MODELS**

As discussed above, certain animal models are contemplated in connection with the present invention. One of the simplest animal models is the mouse. The 2.6.1 antibody did not bind to mouse gp42 (basigin or mouse CD147). Accordingly, we undertook the generation of anti-mouse gp42 antibodies from rats that could be utilized as a surrogate antibody to ABX-CBL and/or the 2.6.1 antibodies for use in such models. Described below is cloning strategy utilized to prepare fusion proteins for immunization of rats and the preliminary characterization of antibodies generated therefrom. The cloning strategy described below is further detailed in Figures 51 and 52.

Cloning of Hu-CD147IgG2 fusion protein

The following PCR primers were utilized, based on the CD147 sequence reported by Miyauchi et al. *J.Biochem.* **110**:770-774 (1991) (Gene Bank Accession # D45131) :

5 prime: 5'-GACTACGAATTCGGACCGGCGAGGAATAGGAATCATG-3' (SEQ ID NO:58) and

5 3 prime: 5'-GGATGGTGTGTTGGTAGCTAGCACGCGGAGCGTGATGATGGCCTG-3' (SEQ ID NO:59)

A 626bp PCR product was amplified from CD147/pBKCMV plasmid DNA template that encoded the amino terminal 202 amino acid residues of the extracellular domain of CD147. The PCR product was digested with EcoR1 and Nhe1 and ligated into pIK1.1Hu-CD4IgG2 expression vector digested with EcoR1 and Nhe1. The resulting construct, pIKHu-CD147IgG2 encodes a fusion protein consisting of the N-terminal 202 amino acids of CD147 the last four C-terminal residues of the extracellular domain of CD4 in frame with the hinge CH2 and CH3 domains of Hu IgG2.

Cloning of Mu-GP42IgG2 fusion protein

The following PCR primers were utilized, based on the GP42 sequence reported by Kanekura et al. *Cell Struct. Funct.* 16:23-30 (1991) (Gene Bank Accession # Y16256):

5 prime: 5'-GACTACGAATTCACGAGGCGACATGGCGGCGGC-3' (SEQ ID NO:60) and

25

3 prime: 5'-GGATGGTGTGTTGGTAGCTAGCACACGCAGTGAGATGGTTTCCCG-3' (SEQ ID NO:61)

A 659bp PCR product was amplified from mouse lymph node cDNA and encodes the amino terminal 206 amino acid residues of the extracellular domain of GP42. The PCR product was digested with EcoR1 and Nhe1 and ligated into

30

pIK1.1Hu- CD4IgG2 expression vector digested with EcoR1 and Nhe1 to create pIKMu-GP42 IgG2.

Stable CHO Cell line Engineering

5

The EcoR1/Bgl2 fragments from pIKHu-CD147IgG2 and pIKMu-GP42IgG2 were cloned into the expression vector pWBFNP DHFR digested with EcoR1/Bgl2. PWBFNP DHFR is a derivative of pWBFNP into which a DHFR cDNA under the transcriptional control of SV40 promoter/enhancer and SV40 poly A is cloned at the Not1 site. The resulting constructs, Hu-CD147IgG2 DHFR and Mu-GP42IgG2 DHFR were introduced into DHFR deficient CHO cell lines by CaPo₄ mediated transfection. Stable lines were selected for their ability to grow in the absence of exogenous thymidine, glycine and purines. Clones secreting elevated levels of fusion proteins as judged by SDS-PAGE were suspension adapted to spinner flasks in serum-free media. Mu-GP42IgG2 and Hu-CD147IgG2 fusion proteins were purified from culture media by protein A chromatography.

Following generation of the fusion proteins, rats were immunized using conventional techniques and hybridomas generated also using conventional techniques. Antibodies secreted by such hybridomas could then be utilized as surrogate antibodies in certain animal models, particularly, murine models.

INCORPORATION BY REFERENCE

All references cited herein, including patents, patent applications, papers, text books, and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated herein by reference in their entirety.

EQUIVALENTS

The foregoing description, Figures, and Examples detail certain preferred embodiments of the invention and describes the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the invention may be practiced in many ways and the invention

should be construed in accordance with the appended claims and any equivalents thereof.

CLAIMSWHAT WE CLAIM IS:

1. An isolated monoclonal antibody having an isotype that fixes
5 complement and a variable region that binds to the epitope on CD147 bound by the
IgM monoclonal antibody ABX-CBL, with the proviso that the antibody is not CBL1.
2. The antibody of Claim 1, wherein the antibody in the presence of
complement acts to selectively kill cells selected from the group consisting of
activated T-cells, activated B-cells, and monocytes but is substantially non-toxic to
10 resting T-cells and resting B-cells.
3. The antibody of Claim 1, wherein the antibody is a human antibody.
4. The antibody of Claim 1, wherein the isotype is selected from the
group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human
IgM, human IgG1, and human IgG3.
- 15 5. The antibody of Claim 2, wherein the antibody is a human antibody.
6. The antibody of Claim 2, wherein the isotype is selected from the
group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human
IgM, human IgG1, and human IgG3.
7. An isolated monoclonal antibody having an isotype that fixes
20 complement and a variable region that binds to CD147 on populations of activated T-
cells, activated B-cells, and resting or activated monocytes, that, in the presence of
complement, selectively depletes such populations through complement mediated
killing while being substantially nontoxic to other cells, with the proviso that the
antibody is not CBL1.
- 25 8. The antibody of Claim 7, wherein the antibody is a human antibody.
9. The antibody of Claim 7, wherein the isotype is selected from the
group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human
IgM, human IgG1, and human IgG3.
10. An isolated monoclonal antibody having the following characteristics:
30 (a) binds to CD147;
(b) shows a binding against CEM cell lysates on Western blot
similar to that provided in Figure 1;

- (c) an isotype selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3;
- (d) competes with ABX-CBL for binding to CD147;
- 5 (e) cross reacts with hn-RNP-k protein;
- (f) binds to a consensus sequence on CD147 comprising RVRS;
- (g) selectively kills activated T-cells, activated B-cells, and monocytes in a MLR assay only in the presence of complement; and
- 10 (h) is substantially non-toxic to cells expressing CD55 and CD59, with and without the presence of complement,

with the proviso that the antibody is not CBL1.

11. A method to select an anti-CD147 antibodies for the treatment of disease, comprising:

- 15 generating antibodies that bind to CD147 and that are capable of binding complement;

assaying the antibodies for one or more of the following properties:

- (a) competition with ABX-CBL for binding to CD147;
- (b) capability to selectively kill activated T-cells, activated B-cells, and monocytes in a MLR assay only in the presence of complement; and
- 20 (c) being substantially non-toxic to cells expressing CD55 and CD59, with and without the presence of complement,
- with the proviso that the antibody is not CBL1.

- 25 12. The method of Claim 11, further comprising the following property:

(d) binding to CEM cell lysates on Western blot in a manner similar to that provided in Figure 1.

13. The method of Claim 11, further comprising the following property:

(e) binding to a consensus sequence in a peptide of RXRS.

- 30 14. The method of Claim 11, further comprising the following property:

(f) cross reacts with hn-RNP-k protein.

15. The method of Claim 11, further comprising the following property:

(g) binding to a form of CD147 expressed by COS cells and *E. coli* cells.

16. A method to treat disease, comprising providing an antibody that has an isotype that fixes complement and a variable region that binds to CD147 on populations of activated T-cells, activated B-cells, and resting or activated monocytes, that, in the presence of complement, selectively depletes such populations through complement mediated killing while being substantially nontoxic to other cells, with the proviso that the antibody is not CBL1.

17. The method of Claim 16, wherein the antibody is a human antibody.

18. The method of Claim 16, wherein the isotype is selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

19. A method to treat GVHD, comprising providing an antibody that has an isotype that fixes complement and a variable region that binds to CD147 on populations of activated T-cells, activated B-cells, and resting or activated monocytes, that, in the presence of complement, selectively depletes such populations through complement mediated killing while being substantially nontoxic to other cells, with the proviso that the antibody is not CBL1.

20. The method of Claim 19, wherein the antibody is a human antibody.

21. The method of Claim 19, wherein the isotype is selected from the group consisting of murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3.

22. A monoclonal antibody that binds to an epitope on CD147 comprising the consensus sequence RVRSH, wherein the antibody is not CBL1.

23. The antibody of Claim 22, wherein the antibody is a human antibody.

24. An isolated peptide comprising the sequence selected from the group consisting of RXRS, RXRSH, RVRS, and RVRSH.

25. Use of the peptide of Claim 24 for the generation of antibodies.

26. A human monoclonal antibody that binds to CD147.

27. A kit for the treatment of diseases having an etiology characterized by a harmful presence of activated T cells, B cells, or monocytes, comprising:

(a) a liquid preparation comprising an amount of an anti-CD147 antibody in a pharmaceutically acceptable carrier and

(b) instructions on administering said preparation to a patient suffering from a disease having the etiology characterized by a harmful presence of activated T cells, B cells, or monocytes to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody.

28. The kit of Claim 27, wherein the antibody comprises ABX-CBL.

29. The kit of Claim 27, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

30. The kit of Claim 27, wherein the disease comprises GVHD.

31. An article of manufacture for use in the treatment of diseases having an etiology characterized by a harmful presence of activated T cells, B cells, or monocytes, comprising:

(a) a sterile vial;

(b) an anti-CD147 monoclonal antibody in a pharmaceutically acceptable carrier contained within the vial; and

(c) instructions for administration of the antibody to a patient suffering from such a disease in a manner to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

32. The article of Claim 31, wherein the antibody comprises ABX-CBL.

33. The article of Claim 31, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

34. The kit of Claim 31, wherein the disease comprises GVHD.

35. A kit for the treatment of diseases having an etiology characterized by
5 a harmful presence of activated T cells, B cells, or monocytes, comprising:
(a) a liquid preparation comprising an amount of an anti-CD147
antibody designated ABX-CBL in a pharmaceutically acceptable carrier and
(b) instructions on administering said preparation to a patient suffering
from a disease having the etiology characterized by a harmful presence of
10 activated T cells, B cells, or monocytes in a series of administrations to
provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of
the antibody in each administration.

36. The kit of Claim 35, wherein the instructions further include
15 instructions for the administration of the antibody in a series of administrations to
provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the
antibody in each administration.

37. The kit of Claim 35, wherein the disease comprises GVHD.
20

38. An article of manufacture for use in the treatment of diseases having an
etiology characterized by a harmful presence of activated T cells, B cells, or
monocytes, comprising:
(a) a sterile vial;
25 (b) an anti-CD147 monoclonal antibody designated ABX-CBL in a
pharmaceutically acceptable carrier contained within the vial; and
(c) instructions for administration of the antibody to a patient suffering
from such a disease in a manner to provide a dosage in the range of from about
0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

39. The article of Claim 38, wherein the instructions further include
30 instructions for the administration of the antibody in a series of administrations to

provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

40. The article of Claim 38, wherein the disease comprises GVHD.

41. A kit for the treatment GVHD, comprising:

(a) a liquid preparation comprising an amount of an anti-CD147 antibody in a pharmaceutically acceptable carrier and

(b) instructions on administering said preparation to a patient suffering from GVHD in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

42. The kit of Claim 41, wherein the antibody comprises ABX-CBL.

43. The kit of Claim 41, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

44. An article of manufacture for use in the treatment of GVHD, comprising:

(a) a sterile vial;

(b) an anti-CD147 monoclonal antibody in a pharmaceutically acceptable carrier contained within the vial; and

(c) instructions for administration of the antibody to a patient suffering from GVHD in a manner to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

45. The article of Claim 44, wherein the antibody comprises ABX-CBL.

46. The article of Claim 44, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

5

47. A kit for the treatment of GVHD, comprising:

(a) a liquid preparation comprising an amount of an anti-CD147 antibody designated ABX-CBL in a pharmaceutically acceptable carrier and

10 (b) instructions on administering said preparation to a patient suffering from GVHD in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

48. The kit of Claim 47, wherein the instructions further include
15 instructions for the administration of the antibody in a series of administrations to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

49. An article of manufacture for use in the treatment of GVHD,
20 comprising:

(a) a sterile vial;

(b) an anti-CD147 monoclonal antibody designated ABX-CBL in a pharmaceutically acceptable carrier contained within the vial; and

25 (c) instructions for administration of the antibody to a patient suffering from GVHD in a manner to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

50. The article of Claim 49, wherein the instructions further include instructions for the administration of the antibody in a series of administrations to
30 provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

51. A pharmaceutical composition, comprising an anti-CD147 monoclonal antibody designated ABX-CBL in a pharmaceutically acceptable diluent, buffer, or excipient.

5 52. The pharmaceutical composition of Claim 51, wherein the antibody is provided in a dosage from about 0.1 mg/kg and about 0.2 mg/kg.

53. A method for the treatment of diseases having an etiology characterized by a harmful presence of activated T cells, B cells, or monocytes,
10 comprising administering a liquid preparation comprising an amount of an anti-CD147 antibody in a pharmaceutically acceptable carrier to a patient suffering from such disease.

54. The method of Claim 53, wherein the antibody comprises ABX-CBL.
15

55. The method of Claim 53, wherein the administration is conducted to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.

20 56. The method of Claim 53, wherein the disease comprises GVHD.

57. A method for the treatment of GVHD comprising administering a liquid preparation comprising an amount of an anti-CD147 antibody in a pharmaceutically acceptable carrier to a patient suffering from GVHD.
25

58. The method of Claim 57, wherein the antibody comprises ABX-CBL.

59. The method of Claim 57, wherein the administration is conducted to provide a dosage in the range of from about 0.1 mg/kg to about 0.3 mg/kg of the antibody in each administration.
30

60. The human antibody according to Claim 26, wherein the heavy chain has an amino acid sequence selected from the group consisting of : SEQ ID NO: 23; SEQ ID NO: 25; SEQ ID NO: 27; SEQ ID NO: 29; SEQ ID NO: 31; SEQ ID NO:33; SEQ ID NO: 35; SEQ ID NO:37; SEQ ID NO: 39; SEQ ID NO: 40; and SEQ ID NO.

5

61. The human antibody according to claim 26, wherein the light chain has an amino acid sequence selected from the group consisting of: SEQ ID NO: 24; SEQ ID NO: 26; SEQ ID NO: 28; SEQ ID NO: 30; SEQ ID NO: 32; SEQ ID NO: 34; SEQ ID NO:36; SEQ ID NO: 38; and SEQ ID NO: 41.

10

15

1/52




FIG.1

2/52




FIG. 2A




FIG. 2B




FIG.3

4/52




FIG.4

5/52




FIG. 5

6/52




FIG. 6B








FIG. 6A

7/52



8/52





FIG. 8C

FIG. 8B

FIG. 8A



9/52




FIG. 9B




FIG. 9D




FIG. 9A










FIG. 9C



10/52






FIG. 11E

FIG. 11C

FIG. 11A




FIG. 11F




FIG. 11D




FIG. 11B

12/52

CELL TYPE	SURFACE MARKERS	CDC DEPLETION
RESTING T CELLS ACTIVATED T CELLS	CD3 ⁺ CD25 ⁻ CD3 ⁺ (CD4 ⁺ /CD8 ⁺)CD25 ⁺	NO YES
RESTING B CELLS ACTIVATED B CELLS	CD20 ⁺ CD25 ⁻ CD20 ⁺ CD25 ⁺	NO YES
RESTING MONOCYTES ACTIVATED MONOCYTES	CD14 ⁺ CD25 ⁻ CD14 ⁺ CD25 ⁺	YES YES

FIG.12

CELL	CELL TYPE	CBL Ag EXPRESSION	CBL CDC
CEM	T CELL	++	+
JURKAT	T CELL	++	-
U937	MONOCYTE	++	+
A431	EPIDERMAL	++	-
SW948	COLON	+++	-
MDA468	BREAST	+	-

FIG.13

13/52

CELL	CELL TYPE	CBL EXPRESSION	CBL CDC	CD55	CD59
CEM	T CELL	++	+	-	+
JURKAT	T CELL	++	-	+	+
U937	MONOCYTE	++	+	+	-
A431	EPIDERMAL	++	-	+	+
SW948	COLON	+++	-	+	+
MDA468	BREAST	+	-	+	+

FIG.14

14/52




FIG. 15A




FIG. 15B




FIG. 15C

15/52




FIG. 16A




FIG. 16B




FIG. 16C

16/52




FIG. 17

17/52





ABX - CBL CONCENTRATION ($\mu\text{g/ml}$)

FIG. 18

18/52

**FIG. 19A****FIG. 19B****FIG. 19C**

19/52




FIG. 20A




FIG. 20B




FIG. 20C

20/52




FIG.21

21/52




FIG.22

22/52




FIG.23A

BEST AVAILABLE COPY

23/52




FIG.23B

BEST AVAILABLE COPY

IgM Antibody Sequences

24/52

CEM 10.1 C3 Heavy cDNA

GGACTGTTGA	AGCCTTCGGA	GACCCTGTCC	CTCACCTGCG	CTGTCTATGG	50
TGGGTCCTTC	AGTGGTTACT	ACTGGAGCTG	GATCCGCCAG	CCCCAGGGA	100
AGGGGCTGGA	GTGGATTGGG	GAAATCAATC	ATAGTGGAAG	CACCAACTAC	150
AACCCGTCCC	TCAAGAGTCG	AGTCACCATA	TCAGTAGACA	CGTCCAAGAA	200
CCAGTTCTCC	CTGAAGCTGA	GCTCTGTGAC	CGCNGCGGAC	ACGGCTGTGT	250
ATTACTGTGC	GAGAGGCACT	ACGGAATATT	ACTACTACTA	CTACGGTATG	300
GACGTCTGGG	GCCAAGGGAC	CACGGTCACC	GTCTCCTCAG	GGAGTGCATC	350
CGCCCCAACC	CTTTTCCCCC	TCGTCTCCTG	TGAGAATTCC	CCGTCGGATA	400
CGAGCAGCGT	GGCCGTTGGC	TGCCTCGCAC	AGGACTTCCT	TCCCGACTYC	450
ATCACTTTCT	CCTGGAAATA	CAAGAACAAC	TCTGACATCA	GCAGCACCCG	500
GGGCTTCCCA	TCAGTCCTGA	GAGGGGGCAA	GTACGCAGCC	ACCTCACAGG	550
TGCTGCTGCC	TTCCAAGGAC	GTCATGCAGG	GCACAGACGA	ACACGTGGTG	600
ACGGGATCCA	AAGAGTA				617

(SEQ ID NO:62)

CEM 10.1 C3 Heavy Protein

GLLKPSETLS	LTCVYGGSF	SGYYWSWIRQ	PPGKLEWIG	EINHSGSTNY	50
NPSLKSRTVI	SVDTSKNQFS	LKLSSVTAAD	TAVYYCARGT	TEYYYYYYGM	100
DVWGQGTIVT	VSSGSASAPT	LFPLVSCENS	PSDTSSVAVG	CLAQDFLPDX	150
ITFSWKYKNN	SDISSTRGFP	SVLRGGKYAA	TSQVLLPSKD	VMQGTDEHVV	200
TGSKE					205

(SEQ ID NO:23)

CEM 10.1 C3 Kappa cDNA

CTCTCCCTGC	CCGTCACCCC	TGGAGAGCCG	GCCTCCATCT	CCTGCAGGTC	50
TAGTCAGAGC	CTCCTGCATA	GTAATGGATA	CAACTATTTG	GATTGGTACC	100
TGCAGAAGCC	AGGGCAGTCT	CCACAGCTCC	TGATCTATTT	GGGTTCTAAT	150
CGGGCCTCCG	GGGTCCCTGA	CAGGTTCACT	GGCAGTGGAT	CAGGCACAGA	200
TTTTACACTG	AAAATCAGCA	GAGTGGAGGC	TGAGGATGTT	GGGATTTATT	250
ACTGCATGCA	GACTCGACAA	ACTCCTCGGA	CGTTCGGCCA	AGGGACCAAG	300
GTGGAAATCA	AACGAACTGT	GGCTGCACCA	TCTGTCTTCA	TCTTCCCGCC	350
ATCTGATGAG	CAGTTGAAAT	CTGGAAGTGC	CTCTGTTGTG	TGCCTGCTGA	400
ATAACTTCTA	TCCCAGAGAG	GCCAAAGAGC	ATCAAAAGAG	TCCA	444

(SEQ ID NO:63)

CEM 10.1 C3 Kappa Protein

LSLPVTPGEP	ASISCRSSQS	LLHSNGYNYL	DWYLQKPGQS	PQLLIYLGSN	50
RASGVPDFRS	GSMSGTDFTL	KISRVEAEDV	GIYYCMQTRQ	TPRTFGQGTK	100
VEIKRTVAAP	SVFIFPPSDE	QLKSGTASVV	CLLNNFYPRE	AKEHQKSP	148

(SEQ ID NO:24)

FIG. 24

IgM Antibody Sequences

25/52

CEM 10.1 G10 Heavy cDNA

CTGGTGAAGC	CTTCGGAGAC	CCTGTCCCTC	ACCTGCACTG	TCTCTGGTGG	50
CTCCATCAGT	AGTTACTACT	GGAAGTGGAT	CCGGCAGCCC	CCAGGGAAGG	100
GACTGGAGTG	GATTGGGTAT	ATCTATTACA	GTGGGAGCAC	CAACTACAAC	150
CCCTCCCTCA	AGAGTCGAGT	CACCATATCA	GTAGACACGT	CCAAGAACCA	200
GTTCTCCCTG	AAGCTGAGCT	CTGTGACCGC	TGCGGACACG	GCCGTGTATT	250
ACTGTGCGAG	AGATAGGGGA	GTGGGAGCTA	CTGGTTTTGA	CTACTGGGGC	300
CAGGGAACCC	TGGTCACCGT	CTCCTCAGGG	AGTGCATCCG	CCCCAACCCCT	350
TTTCCCCCTC	GTCTCCTGTG	AGAATTCCCC	GTCGGATACG	AGCAGCGTGG	400
CCGTTGGCTG	CCTCGCACAG	GACTTCCTTC	CCGACTCCAT	CACTTTCTCC	450
TGGAAATACA	AGAACAACCTC	TGACATCAGC	AGCACCCGGG	GCTTCCCATC	500
AGTCCTGAGA	GGGGGCAAGT	ACGCAGCCAC	CTCACAGGTG	CTGCTGCCTT	550
CCAAGGACGT	CATGCAGGGC	ACAGACGAAC	ACAAGGTGTG	CGA	593

(SEQ ID NO:64)

CEM 10.1 G10 Heavy Protein

LVKPSETLSL	TCTVSGGSIS	SYYNWIRQP	PGKGLEWIGY	IYYSGSTNYN	50
PSLKSRTVIS	VDTSKNQFSL	KLSSVTAADT	AVYYCARDRG	VGATGFDYWG	100
QGTLVTVSSG	SASPTLFPL	VSCENSPSDT	SSVAVGCLAQ	DFLPDSITFS	150
WKYKNSDIS	STRGFPSVLR	GGKYAATSQV	LLPSKDVMQG	TDEHKVC	197

(SEQ ID NO:25)

CEM 10.1 G10 Kappa cDNA

AGCCAGTCTC	CATCCTCCCT	GTCTGCATCT	GTAGGAGAGA	GAGTCACCAT	50
CACTTGCCGG	GCAAGTCAGG	GCATTAGAGA	TGAATTAGGC	TGGTATCAGC	100
AGAAACCAGG	GAAAGCCCCT	AAGCGCCTGA	TCTATGTTGC	ATCCAGTTTG	150
CAAAGTGGGG	TCCCATCAAG	GTTCAGCGGC	AGTGGATCTG	GGACAGAATT	200
CACTCTCACA	ATCAGCAGCC	TGCAGCCTGA	AGATTTTGCA	ACTTATTACT	250
GTCTACAGCA	TAATGGTTAC	CCTCGGACGT	TCGGCCAAGG	GACCAAGGTG	300
GAAATCAAAC	GAAGTGTGGC	TGCACCATCT	GTCTTCATCT	TCCCGCCATC	350
TGATGAGCAG	TTGAAATCTG	GAAGTGCCTC	TGTTGTGTGC	CTGCTGAATA	400
ACTTCTATCC	CAGAGAGGCC	AAAGAGCATC	AAAAGAGTCC	A	441

(SEQ ID NO:65)

CEM 10.1 G10 Kappa Protein

SQSPSSLSAS	VGERVTITCR	ASQGIRDELG	WYQQKPGKAP	KRLIYVASSL	50
QSGVPSRFSG	SGSGTEFTLT	ISSLPEDFA	TYQCLOHNGY	PRTFGQGTKV	100
EIKRTVAAPS	VFIFPPSDEQ	LKSGTASVVC	LLNNFYPREA	KEHQKSP	147

(SEQ ID NO:26)

FIG. 25

IgM Antibody Sequences

26/52

CEM 10.12 F3 Heavy cDNA

AAGAAGCCTG	GGGCCTCAGT	GAAGGTCTCC	TGCAAGGCTT	CTGGATACAC	50
CTTCACCAGT	TATGATATCA	ACTGGGTGCG	ACAGGCCACT	GGACAAGGGC	100
TTGAGTGGAT	GGGATGGATG	AACCCTAACA	GTGGTAACAC	AGGCTATGCA	150
CAGAAGTTCC	AGGGCAGAGT	CACCATGAAC	AGGAACACCT	CCATAAGCAC	200
AGCCTACATG	GAGCTGAGCA	GCCTGAGATC	TGAGGACACG	GCCGTGTATT	250
ACTGTGCGAG	AGGGGGTCAT	GGTGGGAGCT	ACTTCTACTC	CTAYTACGGT	300
ATGGACGTCT	GGGGCCAGGG	GACCACGGTC	ACCGTCTCCT	CAGGGAGTGC	350
ATCCGCCCCA	ACCCTTTTCC	CCCTCGTCTC	CTGTGAGAAT	TCCCCGTCGG	400
ATACGAGCAG	CGTGGCCGTT	GGCTGCCTCG	CACAGGACTT	CCTTCCCGAC	450
TCCATCACTT	TCTCCTGGAA	ATACAAGAAC	AACTCTGACA	TCAGCAGCAC	500
CCGGGGCTTC	CCATCAGTCC	TGAGAGGGGG	CAAGTACGCA	GCCACCTCAC	550
AGGTGCTGCT	GCCTTCCAAG	GACGTCATGC	AGGGCACAGA	CGAACACGTG	600
GTGTGCAAAC					610

(SEQ ID NO:66)

CEM 10.12 F3 Heavy Protein

KKPGASVKVS	CKASGYTFTS	YDINWVRQAT	GQGLEWMGWM	NPNSGNTGYA	50
QKFQGRVTMN	RNTSISTAYM	ELSSLRSED	AVYYCARGGH	GGSYFYFYYG	100
MDVWGQGTTV	TVSSGSASAP	TLFPLVSCEN	SPSDTSSVAV	GCLAQDFLPD	150
SITFSWKYKN	NSDISSTRGF	PSVLRGGKYA	ATSQVLLPSK	DVMQGTDEHV	200
VCK					203

(SEQ ID NO:27)

CEM 10.12 F3 Kappa cDNA

CACTCCCTGG	CTGTGTCTCT	GGGCGAGAGG	GCCACCATCA	ACTGCAAGTC	50
CAGCCAGAGT	GTTTTATACA	GTTTAAACAA	TAAGAACTAC	TTAGCTTGGT	100
ACCAGCAGAA	ACCAGGACAG	CCTCCTAAGC	TGCTCATTTA	CTGGGCATCT	150
ACCCGGGAAT	CCGGGGTCCC	TGACCGATTC	GGTGGCAGCG	GGTCTGGGAC	200
AGATTTCACT	CTCACCATCA	GCAGCCTGCA	GGCTGAAGAT	GTGGCAGTTT	250
ATTACTGTCA	GCAATATTAT	AGTACTCCTM	GGACGTTCGG	CCAAGGGACC	300
AAGGTGGAAA	TCAAACGAAC	TGTGGCTGCA	CCATCTGTCT	TCATCTTCCC	350
GCCATCTGAT	GAGCAGTTGA	AATCTGGAAC	TGCCTCTGTT	GTGTGCCTGC	400
TGAATAACTT	CTATCCCAGA	GAGGCCAAAG	AGCATCAAAA	GAGTCCA	447

(SEQ ID NO:67)

CEM 10.12 F3 Kappa Protein

HSLAVSLGER	ATINCKSSQS	VLYSFNNKNY	LAWYQOKPGQ	PPKLLIYWAS	50
TRESGVPDRF	GGSGSGTDFT	LTISSLQAED	VAVYYCQQYY	STPRTFGQGT	100
KVEIKRTVAA	PSVFIFPPSD	EQLKSGTASV	VCLLNNFYPR	EAKEHQKSP	149

(SEQ ID NO:28)

FIG. 26

SUBSTITUTE SHEET (PAGE 3)

IgM Antibody Sequences

27/52

CEM 10.12 G5 Heavy

GAGGTGAAGA	AGCCTGGGGC	CTCAGTGAAG	GTCTCCTGCA	AGGCTTCTGG	50
ATACACCTTC	ACCAGTTATG	ATATCAACTG	GGTGCGACAG	GCCACTGGAC	100
AAGGGCTTGA	GTGGATGGGA	TGGATGAACC	CTAACAGTGG	TAACACAGGC	150
TATGCACAGA	AGTTCCAGGG	CAGAGTCACC	ATGACCAGGA	ACACCTCCAT	200
AAGCACAGCC	TACATGGAGC	TGAGCAGCCT	GAGATCTGAG	GACACGGCCG	250
TGTATTACTG	TGCGAGAGAG	GAGTGGCTGG	TACGTTACTA	CGGTATGGAC	300
GTCTGGGGCC	AAGGGACCAC	GGTCACCGTC	TCCTCAGGGA	GTGCATCCGC	350
CCCAACCTTT	TTCCCCCTCG	TCTCCTGTGA	GAATTCCCCG	TCGGATACGA	400
GCAGCGTGGC	CGTTGGCTGC	CTCGCACAGG	ACTTCCTTCC	CGACTCCATC	450
ACTTTCTCCT	GGAAATACAA	GAACAACTCT	GACATCAGCA	GCACCCGGGG	500
CTTCCCATCA	GTCCTGAGAG	GGGGCAAGTA	CGCAGCCACC	TCACAGGTGC	550
TGCTGCCTTC	CAAGGACGTC	ATGCAGGGCA	CAGACGAACA	CAAGGTGTG	599

(SEQ ID NO:68)

CEM 10.12 G5 Heavy Protein

EVKKPGASVK	VSCKASGYTF	TSYDINWVRQ	ATGQGLEWMG	WMNPNSGNTG	50
YAQKFQGRVT	MTRNTSISTA	YMELSSLRSE	DTAVYYCARE	EWLVRYYGMD	100
VWGQGTITVTV	SSGSASAPTL	FPLVSCENSP	SDTSSVAVGC	LAQDFLPDSI	150
TFSWKYKNNS	DISSTRGFPS	VLRGGKYAAT	SQVLLPSKDV	MQGTDEHKV	199

(SEQ ID NO:29)

CEM 10.12 G5 Kappa cDna

GGCCAGTCTC	CATCCTCCCT	GTCTGCATCT	GTAGGAGACA	GAGTCACCAT	50
CACTTGCCGG	GCAAGTCAGG	ACATTAGAGA	TAATTTAGGC	TGGTATCAGC	100
AGAAACCAGG	GAAAGCCCCCT	AAGCGCCTGA	TCTATGCTGC	ATCCAATTG	150
CAAAGTGGGG	TCCCATCAAG	GTTTCAGCGGC	AGTGGATCTG	GGACAGAATT	200
CACTCTCACA	ATCAGCAGCC	TGCAGCCTGA	AGATTTTGCA	ACTTATTACT	250
GTCTACAGTA	TAAAACTTAC	CCGTGGACGT	TCGGCCAAGG	GACCAAGGTG	300
GAAATCAAAC	GAAGTGTGGC	TGCACCATCT	GTCTTCATCT	TCCCGCCATC	350
TGATGAGCAG	TTGAAATCTG	GAAGTGCCTC	TGTTGTGTGC	CTGCTGAATA	400
ACTTCTATCC	CAGAGAGGMC	AAAGAGCATC	AAAAGAGTCC	A	441

(SEQ ID NO:69)

CEM 10.12 G5 Kappa Protein

GQSPSSLSAS	VGDRVITICR	ASQDIRDNLG	WYQQKPGKAP	KRLIYAASNL	50
QSGVPSRFSG	SGSGTEFTLT	ISSLQPEDFA	TYCYLQYKTY	PWTFGQGTKV	100
EIKRTVAAPS	VFIFPPSDEQ	LKSGTASVVC	LLNFFYPREX	KEHQKSP	147

(SEQ ID NO:30)

FIG. 27

IgM Antibody Sequences

28/52

CEM 13.12 Heavy cDNA

AAGCTTCCGG	AGACCCTGTC	CCTCACCTGC	GCTGTCTATG	GTGGGTCCTT	50
CAGTGGTTAC	TACTGGAGCT	GGATCCGCCA	GCCCCCAGGG	AAGGGGCTGG	100
AGTGGATTGG	GGAAATCAAT	CATAGTGGAA	GCACCAACTA	CAACCCGTCC	150
CTCAAGAGTC	GAGTCACCAT	ATCAGTAGAC	ACGTCCAAGA	ACCAGTTCTC	200
CCTGAAGCTG	AGCTCTGTGA	CCGCCGCGGA	CACGGCTGTG	TATTACTGTG	250
CGAGAGGGGC	AGCTGAATAT	TACTACTACT	ACTACGGTAT	GGACGTCTGG	300
GGCCAAGGGA	CCACGGTCAC	CGTCTCCTCA	GGGAGTGCAT	CCGCCCCAAC	350
CCTTTTCCCC	CTCGTCTCCT	GTGAGAATTC	CCCCTCGGAT	ACGAGCAGCG	400
TGGCCGTTGG	CTGCCTCGCA	CAGGACTTCC	TTCCCGACTY	CATCACTTTC	450
TYCTGGAAT	ACAAGAACAA	CTCTGACATC	AGCAGCACCC	GGGGCTTCCC	500
ATCAGTCCTG	AGAGGGGGCA	AGTACGCAGC	CACCTCACAG	GTGCTGCTGC	550
CTTCCAAGGA	CGTCATGCAG	GGCACAGACG	AACACGTGGT	GACGGGATCC	600
AAAGAGT					607

(SEQ ID NO:70)

CEM 13.12 Heavy Protein

KLPETLSLTC	AVYGGSFSGY	YWSWIRQPPG	KGLEWIGEIN	HSGSTNYNPS	50
LKSRVTISVD	TSKNQFSLKL	SSVTAADTAV	YYCARGAAEY	YYYYYGMDVW	100
GQGTTVTVSS	GSASAPTLFP	LVSCENSPSD	TSSVAVGCLA	QDFLPDXITF	150
XWKYKNNSDI	SSTRGFPSVL	RGGKYAATSQ	VLLPSKDVMQ	GTDEHVVTGS	200
KE					202

(SEQ ID NO:31)

CEM 13.12 Kappa cDNA

ATGCCCCGTCA	CCCCTGGAGA	GCCGGCCTCC	ATCTCCTGCA	GGTCTAGTCA	50
GAGCCTCCTG	CATAGTAATG	GATACAACTA	TTTGGACTGG	TACCTGCAGA	100
AGCCAGGGCA	GTCTCCACAG	CTCCTGATCT	ATTTGGGTTC	TAATCGGGCC	150
TCCGGGGTCC	CTGACAGGTT	CAGTGGCAGT	GGATCAGGCA	CAGATTTTAC	200
ACTGAAAATC	AGCAGAGTGG	AGGCTGAGGA	TGTTGGGATT	TATTACTGCA	250
TGCAAAGTCT	ACAAATTCCC	CGGCTTTTCG	GCCCTGGGAC	CAAAGTGGAT	300
ATCAAACGAA	CTGTGGCTGC	ACCATCTGTC	TTCATCTTCC	CGCCATCTGA	350
TGAGCAGTTG	AAATCTGGAA	CTGCCTCTGT	TGTGTGCCTG	CTGAGTAACT	400
TCTATCCCAG	AGAGGCCAAA	GTACAGTGGA	A		431

(SEQ ID NO:71)

CEM 13.12 Kappa Protein

MPVTPGEPAS	ISCRSSQSLL	HSNGYNYLDW	YLQKPGQSPQ	LLIYLGSNRA	50
SGVPDRFSGS	SGGTDFTLKI	SRVEAEDVGI	YYCMQSLQIP	RLFGPGTKVD	100
IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LSNFYPREAK	VQW	143

(SEQ ID NO:32)

FIG. 28

SUBSTITUTE SHEET (RULE 29)

IgM Antibody Sequences

29/52

CEM 13.5 Heavy cDNA

TCGGAGACCC	TGTCCCTCAC	CTGCGCTGTC	TATGGTGGGT	CCTTCAGTGG	50
TTACTACTGG	AGCTGGATCC	GCCAGCCCCC	AGGGAAGGGG	CTGGAGTGGA	100
TTGGGGAAAT	CAATCATAGT	GGAAGCACCA	ACTACAACCC	GTCCCTCAAG	150
AGTCGAGTCA	CCATATCAGT	AGACACGTCC	AAGAACCAGT	TCTCCCTGAA	200
GCTGAGTTCT	GTGACCGCCG	CGGACACGGC	TGTGTATTAC	TGTGCGAGAG	250
GCGGGACTAC	AGTAACTTTT	GATGCTTTTG	ATATCTGGGG	CCAAGGGACA	300
ATGGTCACCG	TCTCTTCAGG	GAGTGCATCC	GCCCCAACCC	TTTTCCCCCT	350
CGTCTCCTGT	GAGAATTCCC	CGTCGGATAC	GAGCAGCGTG	GCCGTTGGCT	400
GCCTCGCACA	GGACTTCCTT	CCCGACTCCA	TCACTTTCTC	CTGGAAATAC	450
AAGAACAAC	CTGACATCAG	CAGCACCCGG	GGCTTCCCAT	CAGTCCTGAG	500
AGGGGGCAAG	TACGCAGCCA	CCTCACAGGT	GCTGCTGCCT	TCCAAGGACG	550
TCATGCAGGG	CACAGACGAA				570

(SEQ ID NO:72)

CEM 13.5 Heavy Protein

SETLSLTCAV	YGGSFSGYYW	SWIRQPPGKG	LEWIGEINHS	GSTNYPNPSLK	50
SRVTISVDTS	KNQFSLKLSS	VTAADTAVYY	CARGGTTVTF	DAFDIWQOGT	100
MVTVSSGSAS	APTLFPLVSC	ENSPSDTSSV	AVGCLAQDFL	PDSITFSWKY	150
KNNSDISSTR	GFPSVLRGGK	YAATSQVLLP	SKDVMQGTDE		190

(SEQ ID NO:33)

CEM [15.5] Kappa cDNA

CTGGCTGTGT	CTCTGGGCGA	GAGGGCCACC	ATCAACTGCA	AGTCCAGCCA	50
GAGTGTTTTA	TACAGTTTTA	ACAATAAGAA	CTACTTAGCT	TGGTACCAGC	100
AGAAACCAGG	ACAGCCTCCT	AAGCTGCTCA	TTTACTGGGC	ATCTACCCGG	150
GAATCCGGGG	TCCCTGACCG	ATTCAGTGGC	AGCGGGTCTG	GGACAGATTT	200
CACTCTCACC	ATCAGCAGCC	TGCAGGCTGA	AGATGTGGCA	GTTTATTACT	250
GTCAGCAATA	TTATAGTACT	CCTCGGACGT	TCGGCCAAGG	GACCAAGGTG	300
GAAATCAAAC	GAAGTGTGGC	TGCACCATCT	GTCTTCATCT	TCCCGCCATC	350
TGATGAGCAG	TTGAAATCTG	GAAGTGCCTC	TGTTGTGTGC	CTGCTGAATA	400
ACTTCTATCC	CAGAGAGGCC	AAAGTACAGT	GGAAGGTGAT	C	441

(SEQ ID NO:73)

CEM 13.5 Kappa Protein

LAVSLGERAT	INCKSSQSVL	YSFNNKNYLA	WYQQKPGQPP	KLLIYWASTR	50
ESGVPDRFSG	SGSGTDFTLT	ISSLQAEDVA	VYYCQQYYST	PRTFGQGTKV	100
EIKRTVAAPS	VFIFPPSDEQ	LKSGTASVVC	LLNNFYPREA	KVQWKVI	147

(SEQ ID NO:34)

FIG. 29

30/52

IgG Antibody Sequences2.4.4 Heavy cDNA

AACCCACAGA	CGACCCTCAC	GCTGACCTGC	ACCTTCTCTG	GGTTCTCACT	50
CATTACCCGT	GGAGTGGGTG	TGGATTGGAT	CCGTCAGCCC	CCAGGAAAGG	100
CCCTGCAGTG	GCTCGCACTC	ATTTATTGGA	ATGATGATAA	GCGCTACAGT	150
CCATCTCTGA	AGAGCAGGCT	CACCATCACC	AAGGACACCT	CCAAAAACCA	200
GGTGGTCCTC	ACAATGACCA	ACATGGACCC	TGTGGACACA	GCCACATATT	250
ACTGTGCACA	CCATTTCTTT	GATAGTAGTG	GTTATTACCC	TTTTGACTCC	300
TGGGGCCAGG	GAACCCTGGT	CTCCGTCTCC	TCAGCCTCCA	CCAAGGGCCC	350
ATCGGTCTTC	CCCCTGGCGC	CCTGCTCCAG	GAGCACCTCC	GAGAGCACAG	400
CGGCCCTGGG	CTGCCTGGTC	AAGGACTACT	TCCCCGAACC	GGTGACG	447

(SEQ ID NO:74)

2.4.4 Heavy Protein

NPQTTLTLC	TFSGFSLITR	GVGVDWIRQP	PGKALQWLAL	IYWNDDKRY	50
PSLKSRLTIT	KDTSKNQVVL	TMTNMDPVD	ATYYCAHHFF	DSSGYYPFDS	100
WGQGTLVSVS	SASTKGPSVF	PLAPCSRSTS	ESTAALGCLV	KDYFPEPVT	149

(SEQ ID NO:35)

2.4.4 Kappa cDNA

GTGACTCAGT	CTCCACTCTC	TCTGTCCGTC	ACCCCTGGAC	AGCCGGCCTC	50
CATCTCCTGC	AAGTCTAGTC	AGAGCCTCCT	GCATAGTGAT	GGAAAGACCT	100
ATTTGTATTG	GTACCTGCAG	AAGCCAGGCC	AGCCTCCACA	GCTCCTGATC	150
TATGAAGCTT	TCAACCGGTT	CTCTGGAGTG	CCAGATAGGT	TCAGTGGCAG	200
CGGGTCAGGG	ACAGATTTC	CACTGAAAT	CAGCCGGGTG	GAGGCTGAGG	250
ATGTTGGACT	TTATTATTGC	ATGCAAAGTA	TAGAGCTTCC	GTTCACTTTC	300
GGCGGAGGGA	CCAAGGTGGA	GATCAAACGA	ACTGTGGCTG	CACCATCTGT	350
CTTCATCTTC	CCGCCATCTG	ATGAGCAGTT	GAAATCTGGA	ACTGCCTCTG	400
TTGTGTGCCT	GCTGAATAAC	TTCTATCCCA	GAAAAGAAAG	AGTCR	445

(SEQ ID NO:75)

2.4.4 Kappa Protein

VTQSPLSLSV	TPGQPASISC	KSSQSLLHSD	GKTYLYWYLQ	KPGQPPQLLI	50
YEAFNRFSGV	PDRFSGSGSG	TDFTLKISRV	EAEDVGLYYC	MQSIELPFTF	100
GGGTVKVEIKR	TVAAPSVFIF	PPSDEQLKSG	TASVVCLLNN	FYPRKERV	148

(SEQ ID NO:36)

FIG. 30

31/52

IgG Antibody Sequences2.1.1 Heavy cDNA

GGGGAAGGCC	TGGTCAAGCC	TGGGGGGTCC	CTGAGACTCT	CCTGTGCAGC	50
CTCTGGATTC	ACCTTCAGTA	GCTATAGCAT	GAAGTGGGTC	CGCCAGGCTC	100
CAGGGAAGGG	GCTGGAGTGG	GTCTCATCCA	TTAGTAGTAG	TAGTAGTTAC	150
ATATACTACG	CAGACTCAGT	GAAGGGCCGA	TTCACCATCT	CCAGAGACAA	200
CGCCAAGAAC	TCACTGTATC	TGCAAAATGAA	CAGCCTGAGA	GCCGAGGACA	250
CGGCTGTGTA	TTACTGTGCG	AGGGATAGCA	GTGGCTGGTA	TGAGGACTAC	300
TTTGACTACT	GGGGCCAGGG	AACCCTGGTC	ACCGTCTCCT	CAGCCTCCAC	350
CAAGGGCCCA	TCGGTCTTCC	CCCTGGCGCC	CTGCTCCAGG	AGCACCTCCG	400
AGAGCACAGC	GGCCCTGGGC	TGCCTGGTCA	AGGACTACTT	CCCCGAACCG	450
GTGACGGTGT	CGTGGAAGTC	AGGCGCTCTG	ACCAGCGGCG	TGCACACCTT	500
CCCAGCTGTC	CTACAGTCA				519

(SEQ ID NO:76)

2.1.1 Heavy Protein

GEGLVKPGGS	LRLSCAASGF	TFSSYSMNWV	RQAPGKGLEW	VSSISSSSSS	50
IYYADSVKGR	FTISRDNKN	SLYLQMNSLR	AEDTAVYYCA	RDSSGWYEDY	100
FDYWGGQTLV	TVSSASTKGP	SVFPLAPCSR	STSESTAALG	CLVKDYFPEP	150
VTVSWNSGAL	TSGVHTFPAV	LQS			173

(SEQ ID NO:37)

2.1.1 Kappa cDNA

CTTGACATCC	AGCTGACCCA	GTCTCCGTCC	TCACTGTCTG	CATCTGTAGG	50
AGACAGAGTC	ACCATCACTT	GTCGGGCGAG	TCAGGACATT	AGCATTTATT	100
TAGCCTGGTT	TCAGCAGAGA	CCAGGGAAAG	CCCCTAAGTC	CCTGATCTAT	150
GCTGCATCCA	GTTTGCAAAG	TGGGGTCCCA	TCAAAGTTCA	GCGGCAGTGG	200
ATCTGGGACA	GATTTCACTC	TCACCATCAG	CAGCCTGCAG	CCTGAAGATT	250
TTGCAACTTA	TTACTGCCAA	CAATATAATA	GTTATCCATT	CACTTTCGGG	300
CCC					303

(SEQ ID NO:77)

2.1.1 Kappa Protein

LDIQLTQSPS	SLSASVGDRV	TITCRASQDI	SIYLAWFQQR	PGKAPKSLIY	50
AASSLQSGVP	SKFSGSGSGT	DFTLTISLQ	PEDFATYYCQ	QYNSYPFTFG	100
P					101

(SEQ ID NO:38)

FIG. 31

32/52

IgG Antibody Sequences2.3.2 Heavy cDNA

CTGACCTGCA	CCTTCTCTGG	GTTCTCACTC	ATTACCCGTG	GAGTGGGTGT	50
GGATTGGATC	CGTCAGCCCC	CAGGAAAGGC	CCTGCAGTGG	CTCGCACTCA	100
TTTATTGGAA	TGATGATAAG	CGCTACAGTC	CATCTCTGAA	GAGCAGGCTC	150
ACCATCACCA	AGGACACCTC	CAAAAACCAG	GTGGTCCTCA	CAATGACCAA	200
CATGGACCCT	GTGGACACAG	CCACATATTA	CTGTGCACAC	CATTTCTTTG	250
ATAGTAGTGG	TTATTACCCT	TTTGACTCCT	GGGGCCAGGG	AACCCTGGTC	300
TCCGTCTCCT	CAGCCTCCAC	CAAGGGCCCA	TCGGTCTTCC	CCCTGGCGCC	350
CTGCTCCAGG	AGCACCTCCG	AGAGCACAGC	GGCCCTGGGC	TGCCTGGTCA	400
AGGACTACTT	CCCCGAACCG	GTGACGGTGT	CGTGGAATC	AGGCGCTCTG	450
ACCAGCGGCG	TGCACACCTT	CCAGCTG			477

(SEQ ID NO:78)

2.3.2 Heavy Protein

LTCTFSGFSL	ITRGVGVDWI	RQPPGKALQW	LALIYWDDK	RYSPSLKSRL	50
TITKDTSKNQ	VVLTMTNMDP	VDTATYYCAH	HFFDSSGYYP	FDSWGQGTLV	100
SVSSASTKGP	SVFPLAPCSR	STSESTAALG	CLVKDYFPEP	VTVSWNSGAL	150
TSGVHTFQL					159

(SEQ ID NO:39)

FIG. 32

IgG Antibody Sequences

33/52

2.6.1 Heavy cDNA

GGGGGAGGCT	TGGTACAGCC	TGGGGGGTCC	CTGAGACTCT	CCTGTGCAGC	50
CTCTGGATTC	ACTTTTAGCA	GCTATGCCAT	GAGCTGGGTC	CGCCAGGCTC	100
CAGGGAAGGG	GCTGGAGTGG	GTCTCAACTA	TTAGTGTTAG	TGGTATTACC	150
ACATACTACG	TAGACTCCGT	GAAGGGCCGG	TTCACCATCT	CCAGAGACAA	200
TTCCAAGAAC	ATTCTGTATC	TGCAAATGAA	CAGCCTGAGA	GCCGAGGACA	250
CGGCCGTATA	TTACTGTGCG	AAACGGATTT	TTGGAGTGGT	CTGGGGCCAG	300
GGAACCCTGG	TCACCGTCTC	CTCAGCCTCC	ACCAAGGGCC	CATCGGTCTT	350
CCCCCTGGCG	CCCTGCTCCA	GGAGCACCTC	CGAGAGCACA	GCGGCCCTGG	400
GCTGCCTGGT	CAAGGACTAC	TTCCCCGAAC	CGGTGACGGT	GTCGTGGAAC	450
TTAGGCGCTC	TGACCAGCGG	CGTGCACACC	TTCCCAGCTG	TCCTACAGTC	500
CTA					503

(SEQ ID NO:79)

2.6.1 Heavy Protein

GGGLVQPGGS	LRLSCAASGF	TFSSYAMSWV	RQAPGKGLEW	VSTISVSGIT	50
TYIVDSVKGR	FTISRDN SKN	ILYLQMNSLR	AEDTAVYYCA	KRIFGVVWGQ	100
GTLVTVSSAS	TKGPSVFPLA	PCSRSTSEST	AALGCLVKDY	FPEPVTVSWN	150
LGALTSGVHT	FPAVLQS				167

(SEQ ID NO:40)

2.6.1 Kappa cDNA

GGAATTCGGC	TTGATATTCA	GCTGACTCAG	TCTCCATCCT	CACTGTCTGC	50
ATCTGTAGGA	GACAGAGTCA	CCATCACTTG	TCGGGCGAGT	CAGGGCATT A	100
GCATTTATTT	AGCCTGGTTT	CAGCAGAGAC	CAGGGAAAGC	CCCTAAGTCC	150
CTGATCTATG	CTGCATCCAG	TTTGCAAAGT	GGGGTCCCAT	CAAAGTTCAG	200
CGGCAGTGGA	TCTGGGACAG	ATTTCACTCT	CACCATCAGC	AGCCTGCAGC	250
CTGAAGATTT	TGCAACTTAT	TACTGCCAAC	AATATAATAG	TTACCCATTTC	300
ACTTTCGGCC	CTGGGACCAA	AGTGGATATC	AAACGAACTG	TGGCTGCACC	350
ATCTGTCTTC	ATCTTCCCGC	CATCTGATGA	GCAGTTGAAA	TCTGGAACTG	400
CCTCTGTTGT	GTGCCTGCTG	AATAACTTCT	ATCCAGAGA	GGCCAAAGTA	450
CAGTGGAAGG	TGATAACGC	CCTCCAATCG	GGTAAGCCGA	ATTC	494

(SEQ ID NO:80)

2.6.1 Kappa Protein

GIRLDIQLTQ	SPSSLSASVG	DRVITITCRAS	QGISIYLAWF	QQRPGKAPKS	50
LIYAASSLQS	GVPSKFSGSG	SGTDFTLTIS	SLQPEDFATY	YCQQYNSYFP	100
TFGPGTKVDI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPPREAKV	150
QWKVDNALQS	GKPN				164

(SEQ ID NO:41)

FIG. 33

SUBSTITUTE SHEET (PAGE 20)

CEM 10.1 C3 Heavy Protein

GLLKPSETLSLTCAVYGGSESGYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFS
 CDR1 CDR2
 LKLSVTAADTAVYVCARGTTEYYYYYGMVWGQGTTVTVSSGSAAPTLPFLVSCENSPDTSVAVG
 CDR3
 CLAQDELDPDXITFSWKYKYNSDISSTRGFPVLRGGKYAATSQVLLPSKDVMQGTDEHVVTGSKE

CEM 10.1 C3 Kappa Protein

AKEHQKSP
LSLPVTPGEPASISCRSSQSLHNSGYNLDWYLQKPGQSPQLLIYLGSNRASGVDPDRFSGSGSGTDFTL
KISRVEAEDVGIYYCMQTRTPRTFGQGTQVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCCLLNNEYPRE
CDR1 CDR2 CDR3

FIG. 34

CEM 10.1 G10 Heavy Protein

LVKPSETLSLTCTVSGGSISSYYWNWIRQPPGGKLEWIGYIYSGSTNYPNLKSRTVISVDTSKNQFSL
CDR1 CDR2

KLSSVTAADTAVYYCARDRGVGATGFEDYWQGTLVTVSSGSASAPTFPLVSCENSPSDTSSVAVGCLAQ
CDR3

DFLPDSITFSWKYKNNNSDISSTRGFEPSSLRGGKYAATSQVLLPSKDVMQGTDEHKVC

CEM 10.1 G10 Kappa Protein

SQSPSSLSASVGERVTITCRASQGI^{CDR1}DELGWYQKPGKAPKRLIYVASSLQSGVPSRFSGSGSGTEFTLT
 ISSLPEDFATYYCLQHNGYPTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA
 KEHQKSP^{CDR3}

FIG. 35

CEM 10.12 F3 Heavy Protein

KKPGASVKVCKASGYTFTSYDINWVRQATGGLEWMGWNIPNSGNTGYAQKFGQGRVTMPNRTSISITAYM
 ELSSLRSED^{CDR1}AVVYCARGGGGSFY^{CDR2}SYYGMDVWGQGTITVTVSSGSASAPTLFPLVSCENSPSDTSSVAV
 GCLAQDELPSDITFSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDV^{CDR3}MQGTDEHVVCK

CEM 10.12 F3 Kappa Protein

HSLAVSLGERATINCKSSQSVLYSFNNKNYLAWYQQKPGQPCDR1KLIIYWASTRESGVCDR2PDREFGGSGSGTDFT
 LTIISSLQAEADVAYYCQQYYSTPRTFGQGTKVEIKRTVAAPSVFIFFPSDEQLKSGTASVVCLLNNEYPRCDR3
 EAKEHQKSP

FIG. 36

CEM 10.12 G5 Heavy Protein

EVKKPGASVKVSCKASGYTFTSYDINWVRQATGGGLEWGMWNPNSGNTGYAQKFQGRVTMTNTSISTA
CDR1
CDR2
YMEISSLRSEDTAVYYCAREEWLVRYYGMDVWGQGTTVTVSSGSASAPTLFPLVSCENSPDTSVAVGC
CDR3
LAQDFLPDSITFSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEHKV

CEM 10.12 G5 Kappa Protein

KEHQKSP
CDR3
ISSLQPEDEATYYCLQYKTYPWTFEGQGTKVEIKRTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREX
CDR1
GQSPSSLASVGDRTVITCRASQDIRDNLGWYQQKPGKAPKRLIYAASNLSQSGVPFRFSGSGSGTEFTLT
CDR2

FIG. 37

CEM 13.12 Heavy Protein

KLPETLSLTCAVYGGSEFSGYVWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKL
 CDR1 CDR2
 SSVTAADTAVVYCARGAAEYYYYYYGMDVWGQTTVTVSSGSASAPTLFPLVSCENSPSDTSSVAVGCLA
 CDR3
 QDFLPDXITFXWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEHVVTGSKE

CEM 13.12 Kappa Protein

MPVTPGEPASISCRSSQSLLSHSGNYLDWYLQKPGQSPQLLIYLGSNRASGVDPDRFSGSGGTFTLKI
 CDR1 CDR2
 SRVEAEDVGIYYCMQSLQIPRLFPGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLSNFYPREAK
 CDR3
 VQW

FIG. 38

CEM 13.5 Heavy Protein

SETLSLTCAVYGGSFSGYYSWIRQPPGKGLEWIGEINHSGSTNYPNPSLKSRVTISVDTSKNQFSLKLSS
CDR1 CDR2
VTAADTAVYCYARGGTTVTFAEDIWGQGTMTVSSGSASAPTLFPLVSCENS?SDTSSVAVGCLAQDFL
CDR3
PDSITESWKYKKNNSDISSTRGFPSVLRGKKYAATSQVLLPSPKDVMQGTDE

CEM 13.5 Kappa Protein

LAVSLGERATINCKSSQSVLYSENNKNYLAWYQQKPGQPCDR1PKLLIYWASTRESGVDPDRFSGSGGTDFTLT
 ISSLQAEDVAVYQCQYYSTPRTFGQGTKVEIKRTVAAPSVFIEPPSDEQLKSGTASVVCLLNNFYPREACDR2
 KRVQWKVICDR3

FIG. 39

2.4.4 Heavy Protein

NPQTTLTCTFSGESLITRGVGVDWIRQPPGKALQLALIYWNDCKRYPSPSLKSRLTITTKDTSKNQVVL
CDR1 CDR2
TMTNMDPVDATYYCAHHEFDSSGGYYPEDSWGQGTLSVSASSASTKGPSVFPLAPCSRSTSESTAALGLCV
CDR3
KDYFEPEPVT

2.4.4 Kappa Protein

VTQSP¹LSLSVTPGQPASISCKSSQSL²LHSDGKTYLYWY³LQKPGQPQLLIYEAFN⁴RFSGV⁵PD⁶RFSGSGSG
 CDR1 CDR2
 TDETLKISRVEAEDVGLYCMQSI¹ELPFTFGG²GKVEIKRTVAAPSVFIFPPSDEQLKSGTASV³VCLLN
 CDR3
 FYPRKERV

FIG. 40

IgG Antibody Sequences

2.1.1 Heavy Protein

GEGLVKPGGSLRLSCAASGFTESFSSYMNVRQAPGKGLEWVSSISSSSYIYYADSVKGRFTISRDNAKN
 CDR1 CDR2
 SLYLQMNISLRAEDTAVYYCARDSSGWYEDYFDYWGQGLTVTVSSASTKGPVFPLAPCSRSTSESTAALG
 CDR3
 CLVKDYFPEPVTISWNISGALTSGVHTFPAVLQ

2.1.1 Kappa Protein

LDIQLTQSPSSLSASVGDRVITITCRASQDISIYLAWFQQRPFGKAPKSLIYAASSLQSGVPSKFGSGSGT
CDR1
DFTLTISLQPEDEATYYCQQYNSYPETFGP
CDR3

FIG. 41

42/52

IgG Antibody Sequences2.3.2 Heavy Protein

LTCTFSGESLITRGVGVDWIRQPPGKALQWLALIYWND DKRYSPSLKSRITITKDTSKNQVVLTMNMDP
CDR1

CDR2

VDTATYYCAHHEEDSSGYYPEDSWGQGLVSVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEP
CDR3

VTVSWNSGALTSGVHTFQL

2.3.2 Kappa Protein

FIG. 42

2.6.1 Heavy Protein

GGGLVQPGGSLRLSCAASGFTESSYAMSWVRQAPGKGLEWVSTISVSGITTYVDSVKGRFTISRDNSKN
 CDR1
 ILYLQMNSLRAEDTAVYCAKRIFGVNWGGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDY
 CDR2
 FPEPVTVSWNLGALTSGVHTFPAVLQ
 CDR3

2.6.1 Kappa Protein

GIRLDIQLTQSPSSLSASVGDRVITTCRASQGISIYLAWFQRRPGKAPKSLIYAASSLQSGVPSKESGSG
 CDR1 CDR2
 SGTDFTLTISSLQPEDFATYYCQQYNSYPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
 CDR3
 NNEYYPREAKVQWKVDNALQSGKPN

FIG. 43

44/52




FIG. 44A




FIG. 44B




FIG.45A




FIG.45B




FIG. 45C




FIG. 46

47/52




FIG. 47

48/52




FIG.48

49/52




FIG.49

50/52




FIG.50A

51/52




FIG. 50B




FIG. 50C




FIG. 50D




FIG.50E




FIG.50F

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: ABGENIX, INC.

DAVIS, C. Geoffrey
BLACHER, Russell Wayne
CORVALAN, Jose Ramon
CULWELL, Alan Rhodes
GREEN, Larry
HAVRILLA, Nancy
HALES, Joanna
IVANOV, Vladimir E.
LIPANI, John A.
LIU, Qiang
WEBER, Richard F.
YANG, Xiao-dong

(ii) TITLE OF THE INVENTION: CD147 BINDING MOLECULES AS
THERAPEUTICS

(iii) NUMBER OF SEQUENCES: 81

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Fish & Neave
(B) STREET: 1251 Avenue of the Americas
(C) CITY: New York
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 10020

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 1.5

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: N/A
(B) FILING DATE: 03-MAR-1999
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 09/034,607

(B) FILING DATE: 03-MAR-1998

(A) APPLICATION NUMBER: 09/244,253

(B) FILING DATE: 03-FEB-1999

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Haley, James F., Jr., Esq.

(B) REGISTRATION NUMBER: 27,794

(C) REFERENCE/DOCKET NUMBER: ABX-CBLCD147

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212-596-9000

(B) TELEFAX: 212-596-9090

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ile Thr Leu Arg Val Arg Ser His

1 5

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

3

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Glu Glu Arg Leu Arg Ser Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Tyr Glu Arg Val Arg Trp Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Glu Glu Arg Leu Arg Ser Tyr
1 5

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ala Glu Arg Ile Arg Ser Ile

1 5

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Glu Glu Arg Leu Arg Ser Tyr

1 5

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

5

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Thr Val His Gly Asp Leu Arg Leu Arg Ser Leu Pro
1 5 10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Thr Asn Asp Ile Gly Leu Arg Gln Arg Ser His Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ser Pro Leu Leu Asp Gly Gln Arg Glu Arg Ser Tyr
1 5 10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Tyr Asp Leu Pro Met Arg Ser Arg Ser Tyr Pro Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Arg Xaa Arg Ser
1

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Lys Gly Ser Asp Gln Ala Ile Ile Thr Leu Arg Val Arg Ser His
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Arg Xaa Arg Ser His
1 5

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 269 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Ala Ala Ala Leu Phe Val Leu Leu Gly Phe Ala Leu Leu Gly Thr
1 5 10 15
His Gly Ala Ser Gly Ala Ala Gly Thr Val Phe Thr Thr Val Glu Asp
20 25 30

Leu Gly Ser Lys Ile Leu Leu Thr Cys Ser Leu Asn Asp Ser Ala Thr
 35 40 45
 Glu Val Thr Gly His Arg Trp Leu Lys Gly Gly Val Val Leu Lys Glu
 50 55 60
 Asp Ala Leu Pro Gly Gln Lys Thr Glu Phe Lys Val Asp Ser Asp Asp
 65 70 75 80
 Gln Trp Gly Glu Tyr Ser Cys Val Phe Leu Pro Glu Pro Met Gly Thr
 85 90 95
 Ala Asn Ile Gln Leu His Gly Pro Pro Arg Val Lys Ala Val Lys Ser
 100 105 110
 Ser Glu His Ile Asn Glu Gly Glu Thr Ala Met Leu Val Cys Lys Ser
 115 120 125
 Glu Ser Val Pro Pro Val Thr Asp Trp Ala Trp Tyr Lys Ile Thr Asp
 130 135 140
 Ser Glu Asp Lys Ala Leu Met Asn Gly Ser Glu Ser Arg Phe Phe Val
 145 150 155 160
 Ser Ser Ser Gln Gly Arg Ser Glu Leu His Ile Glu Asn Leu Asn Met
 165 170 175
 Glu Ala Asp Pro Gly Gln Tyr Arg Cys Asn Gly Thr Ser Ser Lys Gly
 180 185 190
 Ser Asp Gln Ala Ile Ile Thr Leu Arg Val Arg Ser His Leu Ala Ala
 195 200 205
 Leu Trp Pro Phe Leu Gly Ile Val Ala Glu Val Leu Val Leu Val Thr
 210 215 220
 Ile Ile Phe Ile Tyr Glu Lys Arg Arg Lys Pro Glu Asp Val Leu Asp
 225 230 235 240
 Asp Asp Asp Ala Gly Ser Ala Pro Leu Lys Ser Ser Gly Gln His Gln
 245 250 255
 Asn Asp Lys Gly Lys Asn Val Arg Gln Arg Asn Ser Ser
 260 265

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Pro Glu Arg Ile Leu Ser Ile

1 5

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Gly Gly Ser Arg Ala Arg Asn Leu Pro

1 5

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 463 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met Glu Thr Glu Gln Pro Glu Glu Thr Phe Pro Asn Thr Glu Thr Asn

1 5 10 15

Gly Glu Phe Gly Lys Arg Pro Ala Glu Asp Met Glu Glu Glu Gln Ala

20 25 30

Phe Lys Arg Ser Arg Asn Thr Asp Glu Met Val Glu Leu Arg Ile Leu

35 40 45

Leu Gln Ser Lys Asn Ala Gly Ala Val Ile Gly Lys Gly Gly Lys Asn

50 55 60

Ile Lys Ala Leu Arg Thr Asp Tyr Asn Ala Ser Val Ser Val Pro Asp

10

65 70 75 80
 Ser Ser Gly Pro Glu Arg Ile Leu Ser Ile Ser Ala Asp Ile Glu Thr
 85 90 95
 Ile Gly Glu Ile Leu Lys Lys Ile Ile Pro Thr Leu Glu Glu Gly Leu
 100 105 110
 Gln Leu Pro Ser Pro Thr Ala Thr Ser Gln Leu Pro Leu Glu Ser Asp
 115 120 125
 Ala Val Glu Cys Leu Asn Tyr Gln His Tyr Lys Gly Ser Asp Phe Asp
 130 135 140
 Cys Glu Leu Arg Leu Leu Ile His Gln Ser Leu Ala Gly Gly Ile Ile
 145 150 155 160
 Gly Val Lys Gly Ala Lys Ile Lys Glu Leu Arg Glu Asn Thr Gln Thr
 165 170 175
 Thr Ile Lys Leu Phe Gln Glu Cys Cys Pro His Ser Thr Asp Arg Val
 180 185 190
 Val Leu Ile Gly Gly Lys Pro Asp Arg Val Val Glu Cys Ile Lys Ile
 195 200 205
 Ile Leu Asp Leu Ile Ser Glu Ser Pro Ile Lys Gly Arg Ala Gln Pro
 210 215 220
 Tyr Asp Pro Asn Phe Tyr Asp Glu Thr Tyr Asp Tyr Gly Gly Phe Thr
 225 230 235 240
 Met Met Phe Asp Asp Arg Arg Gly Arg Pro Val Gly Phe Pro Met Arg
 245 250 255
 Gly Arg Gly Gly Phe Asp Arg Met Pro Pro Gly Arg Gly Gly Arg Pro
 260 265 270
 Met Pro Pro Ser Arg Arg Asp Tyr Asp Asp Met Ser Pro Arg Arg Gly
 275 280 285
 Pro Pro Pro Pro Pro Pro Gly Arg Gly Gly Arg Gly Gly Ser Arg Ala
 290 295 300
 Arg Asn Leu Pro Leu Pro Pro Pro Pro Pro Pro Arg Gly Gly Asp Leu
 305 310 315 320
 Met Ala Tyr Asp Arg Arg Gly Arg Pro Gly Asp Arg Tyr Asp Gly Met
 325 330 335
 Val Gly Phe Ser Ala Asp Glu Thr Trp Asp Ser Ala Ile Asp Thr Trp
 340 345 350
 Ser Pro Ser Glu Trp Gln Met Ala Tyr Glu Pro Gln Gly Gly Ser Gly
 355 360 365
 Tyr Asp Tyr Ser Tyr Ala Gly Gly Arg Gly Ser Tyr Gly Asp Leu Gly
 370 375 380
 Gly Pro Ile Ile Thr Thr Gln Val Thr Ile Pro Lys Asp Leu Ala Gly
 385 390 395 400
 Ser Ile Ile Gly Lys Gly Gly Gln Arg Ile Lys Gln Ile Arg His Glu
 405 410 415
 Ser Gly Ala Ser Ile Lys Ile Asp Glu Pro Leu Glu Gly Ser Glu Asp
 420 425 430
 Arg Ile Ile Thr Ile Thr Gly Thr Gln Asp Gln Ile Gln Asn Ala Gln
 435 440 445

Tyr Leu Leu Gln Asn Ser Val Lys Gln Tyr Ser Gly Lys Phe Phe
 450 455 460

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 570 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr
 20 25 30
 Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Glu Ile Arg Leu Lys Ser Asn Asn Tyr Ala Thr His Tyr Ala Glu
 50 55 60
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
 65 70 75 80
 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr
 85 90 95
 Tyr Cys Thr Asp Tyr Asp Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110
 Val Ser Ala Glu Ser Gln Ser Phe Pro Asn Val Phe Pro Leu Val Ser
 115 120 125
 Cys Glu Ser Pro Leu Ser Asp Lys Asn Leu Val Ala Met Gly Cys Leu
 130 135 140
 Ala Arg Asp Phe Leu Pro Ser Thr Ile Ser Phe Thr Trp Asn Tyr Gln
 145 150 155 160
 Asn Asn Thr Glu Val Ile Gln Gly Ile Arg Thr Phe Pro Thr Leu Arg
 165 170 175
 Thr Gly Gly Lys Tyr Leu Ala Thr Ser Gln Val Leu Leu Ser Pro Lys
 180 185 190
 Ser Ile Leu Glu Gly Ser Asp Glu Tyr Leu Val Cys Lys Ile His Tyr
 195 200 205
 Gly Gly Lys Asn Arg Asp Leu His Val Pro Ile Pro Ala Val Ala Glu
 210 215 220

Met Asn Pro Asn Val Asn Val Phe Val Pro Pro Arg Asp Gly Phe Ser
 225 230 235 240
 Gly Pro Ala Pro Arg Lys Ser Lys Leu Ile Cys Glu Ala Thr Asn Phe
 245 250 255
 Thr Pro Lys Pro Ile Thr Val Ser Trp Leu Lys Asp Gly Lys Leu Val
 260 265 270
 Glu Ser Gly Phe Thr Thr Asp Pro Val Thr Ile Glu Asn Lys Gly Ser
 275 280 285
 Thr Pro Gln Thr Tyr Lys Val Ile Ser Thr Leu Thr Ile Ser Glu Ile
 290 295 300
 Asp Trp Leu Asn Leu Asn Val Tyr Thr Cys Arg Val Asp His Arg Gly
 305 310 315 320
 Leu Thr Phe Leu Lys Asn Val Ser Ser Thr Cys Ala Ala Ser Pro Ser
 325 330 335
 Thr Asp Ile Leu Thr Phe Thr Ile Pro Pro Ser Phe Ala Asp Ile Phe
 340 345 350
 Leu Ser Lys Ser Ala Asn Leu Thr Cys Leu Val Ser Asn Leu Ala Thr
 355 360 365
 Tyr Glu Thr Leu Asn Ile Ser Trp Ala Ser Gln Ser Gly Glu Pro Leu
 370 375 380
 Glu Thr Lys Ile Lys Ile Met Glu Ser His Pro Asn Gly Thr Phe Ser
 385 390 395 400
 Ala Lys Gly Val Ala Ser Val Cys Val Glu Asp Trp Asn Asn Arg Lys
 405 410 415
 Glu Phe Val Cys Thr Val Thr His Arg Asp Leu Pro Ser Pro Gln Lys
 420 425 430
 Lys Phe Ile Ser Lys Pro Asn Glu Val His Lys His Pro Pro Ala Val
 435 440 445
 Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala
 450 455 460
 Thr Val Thr Cys Leu Val Lys Gly Phe Ser Pro Ala Asp Ile Ser Val
 465 470 475 480
 Gln Trp Leu Gln Arg Gly Gln Leu Leu Pro Gln Glu Lys Tyr Val Thr
 485 490 495
 Ser Ala Pro Met Pro Glu Pro Gly Ala Pro Gly Phe Tyr Phe Thr His
 500 505 510
 Ser Ile Leu Thr Val Thr Glu Glu Glu Trp Asn Ser Gly Glu Thr Tyr
 515 520 525
 Thr Cys Val Val Gly His Glu Ala Leu Pro His Leu Val Thr Glu Arg
 530 535 540
 Thr Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu
 545 550 555 560
 Ile Met Ser Asp Thr Gly Gly Thr Cys Tyr
 565 570

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 206 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Lys Phe Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys
 1 5 10 15
 Ala Ser Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro
 20 25 30
 Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr
 35 40 45
 Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr
 50 55 60
 Phe Thr Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys
 65 70 75 80
 Gln Gln Asp Tyr Ser Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu
 85 90 95
 Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro
 100 105 110
 Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu
 115 120 125
 Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly
 130 135 140
 Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser
 145 150 155 160
 Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp
 165 170 175
 Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr
 180 185 190
 Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
 195 200 205

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Ser Leu Ala Pro Leu Trp Tyr Tyr Ser Arg His Gly

1 5 10

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

His Thr Pro Glu Thr Ala Pro Leu Pro Ala Thr Val

1 5 10

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 159 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

15

Met Lys Asn His Leu Leu Phe Trp Gly Val Leu Ala Val Phe Ile Lys
 1 5 10 15
 Ala Val His Val Lys Ala Gln Glu Asp Glu Arg Ile Val Leu Val Asp
 20 25 30
 Asn Lys Cys Lys Cys Ala Arg Ile Thr Ser Arg Ile Ile Arg Ser Ser
 35 40 45
 Glu Asp Pro Asn Glu Asp Ile Val Glu Arg Asn Ile Arg Ile Ile Val
 50 55 60
 Pro Leu Asn Asn Arg Glu Asn Ile Ser Asp Pro Thr Ser Pro Leu Arg
 65 70 75 80
 Thr Arg Phe Val Tyr His Leu Ser Asp Leu Cys Lys Lys Cys Asp Pro
 85 90 95
 Thr Glu Val Glu Leu Asp Asn Gln Ile Val Thr Ala Thr Gln Ser Asn
 100 105 110
 Ile Cys Asp Glu Asp Ser Ala Thr Glu Thr Cys Tyr Thr Tyr Asp Arg
 115 120 125
 Asn Lys Cys Tyr Thr Ala Val Val Pro Leu Val Tyr Gly Gly Glu Thr
 130 135 140
 Lys Met Val Glu Thr Ala Leu Thr Pro Asp Ala Cys Tyr Pro Asp
 145 150 155

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 205 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr
 1 5 10 15
 Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro
 20 25 30
 Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr
 35 40 45
 Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr
 50 55 60
 Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp
 65 70 75 80

16

Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Thr Glu Tyr Tyr Tyr Tyr
 85 90 95
 Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
 100 105 110
 Ser Gly Ser Ala Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu
 115 120 125
 Asn Ser Pro Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln
 130 135 140
 Asp Phe Leu Pro Asp Xaa Ile Thr Phe Ser Trp Lys Tyr Lys Asn Asn
 145 150 155 160
 Ser Asp Ile Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly
 165 170 175
 Lys Tyr Ala Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met
 180 185 190
 Gln Gly Thr Asp Glu His Val Val Thr Gly Ser Lys Glu
 195 200 205

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 148 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg
 1 5 10 15
 Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp
 20 25 30
 Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly
 35 40 45
 Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser
 50 55 60
 Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val
 65 70 75 80
 Gly Ile Tyr Tyr Cys Met Gln Thr Arg Gln Thr Pro Arg Thr Phe Gly
 85 90 95
 Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val
 100 105 110

Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser
 115 120 125
 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Glu His
 130 135 140
 Gln Lys Ser Pro
 145

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 197 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
 1 5 10 15
 Gly Ser Ile Ser Ser Tyr Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly
 20 25 30
 Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn
 35 40 45
 Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser
 50 55 60
 Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr
 65 70 75 80
 Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Val Gly Ala Thr Gly Phe
 85 90 95
 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ser Ala
 100 105 110
 Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu Asn Ser Pro Ser
 115 120 125
 Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln Asp Phe Leu Pro
 130 135 140
 Asp Ser Ile Thr Phe Ser Trp Lys Tyr Lys Asn Asn Ser Asp Ile Ser
 145 150 155 160
 Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly Lys Tyr Ala Ala
 165 170 175
 Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met Gln Gly Thr Asp
 180 185 190

Glu His Lys Val Cys
195

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 147 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Ser Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Glu Arg Val Thr
1 5 10 15
Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asp Glu Leu Gly Trp Tyr
20 25 30
Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Val Ala Ser
35 40 45
Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
50 55 60
Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
65 70 75 80
Thr Tyr Tyr Cys Leu Gln His Asn Gly Tyr Pro Arg Thr Phe Gly Gln
85 90 95
Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
100 105 110
Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
115 120 125
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Glu His Gln
130 135 140
Lys Ser Pro
145

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 203 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

```

Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
 1         5         10        15
Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln
 20        25        30
Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly
 35        40        45
Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Asn Arg Asn Thr Ser
 50        55        60
Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
 65        70        75        80
Ala Val Tyr Tyr Cys Ala Arg Gly Gly His Gly Gly Ser Tyr Phe Tyr
 85        90        95
Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val
100       105       110
Ser Ser Gly Ser Ala Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys
115       120       125
Glu Asn Ser Pro Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala
130       135       140
Gln Asp Phe Leu Pro Asp Ser Ile Thr Phe Ser Trp Lys Tyr Lys Asn
145       150       155       160
Asn Ser Asp Ile Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly
165       170       175
Gly Lys Tyr Ala Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val
180       185       190
Met Gln Gly Thr Asp Glu His Val Val Cys Lys
195       200

```

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 149 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

```

His Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys
 1         5         10        15
Ser Ser Gln Ser Val Leu Tyr Ser Phe Asn Asn Lys Asn Tyr Leu Ala
 20        25        30
Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp
 35        40        45
Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Gly Gly Ser Gly
 50        55        60
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp
 65        70        75        80
Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Arg Thr Phe
 85        90        95
Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser
100       105       110
Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala
115       120       125
Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Glu
130       135       140
His Gln Lys Ser Pro
145

```

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 199 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

```

Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
 1         5         10        15
Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr
 20        25        30
Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn
 35        40        45

```

21

Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn
 50 55 60
 Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
 65 70 75 80
 Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Trp Leu Val Arg Tyr
 85 90 95
 Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 100 105 110
 Gly Ser Ala Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu Asn
 115 120 125
 Ser Pro Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln Asp
 130 135 140
 Phe Leu Pro Asp Ser Ile Thr Phe Ser Trp Lys Tyr Lys Asn Asn Ser
 145 150 155 160
 Asp Ile Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly Lys
 165 170 175
 Tyr Ala Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met Gln
 180 185 190
 Gly Thr Asp Glu His Lys Val
 195

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 147 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Gly Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr
 1 5 10 15
 Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asp Asn Leu Gly Trp Tyr
 20 25 30
 Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Ala Ala Ser
 35 40 45
 Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
 50 55 60
 Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
 65 70 75 80

22

Thr Tyr Tyr Cys Leu Gln Tyr Lys Thr Tyr Pro Trp Thr Phe Gly Gln
 85 90 95
 Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
 100 105 110
 Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
 115 120 125
 Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Xaa Lys Glu His Gln
 130 135 140
 Lys Ser Pro
 145

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 202 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Lys Leu Pro Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser
 1 5 10 15
 Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly
 20 25 30
 Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn
 35 40 45
 Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn
 50 55 60
 Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val
 65 70 75 80
 Tyr Tyr Cys Ala Arg Gly Ala Ala Glu Tyr Tyr Tyr Tyr Tyr Tyr Gly
 85 90 95
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Ser
 100 105 110
 Ala Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu Asn Ser Pro
 115 120 125
 Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln Asp Phe Leu
 130 135 140
 Pro Asp Xaa Ile Thr Phe Xaa Trp Lys Tyr Lys Asn Asn Ser Asp Ile
 145 150 155 160

23

Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly Lys Tyr Ala
 165 170 175
 Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met Gln Gly Thr
 180 185 190
 Asp Glu His Val Val Thr Gly Ser Lys Glu
 195 200

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 143 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Met Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser
 1 5 10 15
 Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu
 20 25 30
 Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn
 35 40 45
 Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
 50 55 60
 Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Ile
 65 70 75 80
 Tyr Tyr Cys Met Gln Ser Leu Gln Ile Pro Arg Leu Phe Gly Pro Gly
 85 90 95
 Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
 100 105 110
 Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
 115 120 125
 Cys Leu Leu Ser Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
 130 135 140

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 190 amino acids
- (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

```

Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser
1      5      10      15
Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
20     25     30
Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser
35     40     45
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
50     55     60
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
65     70     75     80
Cys Ala Arg Gly Gly Thr Thr Val Thr Phe Asp Ala Phe Asp Ile Trp
85     90     95
Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Ser Ala Ser Ala Pro
100    105    110
Thr Leu Phe Pro Leu Val Ser Cys Glu Asn Ser Pro Ser Asp Thr Ser
115    120    125
Ser Val Ala Val Gly Cys Leu Ala Gln Asp Phe Leu Pro Asp Ser Ile
130    135    140
Thr Phe Ser Trp Lys Tyr Lys Asn Asn Ser Asp Ile Ser Ser Thr Arg
145    150    155    160
Gly Phe Pro Ser Val Leu Arg Gly Gly Lys Tyr Ala Ala Thr Ser Gln
165    170    175
Val Leu Leu Pro Ser Lys Asp Val Met Gln Gly Thr Asp Glu
180    185    190

```

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 147 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

25

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

```

Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser
 1      5      10      15
Gln Ser Val Leu Tyr Ser Phe Asn Asn Lys Asn Tyr Leu Ala Trp Tyr
      20      25      30
Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser
      35      40      45
Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly
      50      55      60
Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala
      65      70      75      80
Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Arg Thr Phe Gly Gln
      85      90      95
Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
      100     105     110
Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
      115     120     125
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
      130     135     140
Lys Val Ile
      145

```

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 149 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

```

Asn Pro Gln Thr Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser
 1      5      10      15
Leu Ile Thr Arg Gly Val Gly Val Asp Trp Ile Arg Gln Pro Pro Gly
      20      25      30
Lys Ala Leu Gln Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg

```


26

35 40 45
 Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser
 50 55 60
 Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr
 65 70 75 80
 Ala Thr Tyr Tyr Cys Ala His His Phe Phe Asp Ser Ser Gly Tyr Tyr
 85 90 95
 Pro Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Ser Val Ser Ser Ala
 100 105 110
 Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser
 115 120 125
 Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
 130 135 140
 Pro Glu Pro Val Thr
 145

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 148 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Val Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala
 1 5 10 15
 Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ser Asp Gly Lys
 20 25 30
 Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Pro Pro Gln Leu
 35 40 45
 Leu Ile Tyr Glu Ala Phe Asn Arg Phe Ser Gly Val Pro Asp Arg Phe
 50 55 60
 Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val
 65 70 75 80
 Glu Ala Glu Asp Val Gly Leu Tyr Tyr Cys Met Gln Ser Ile Glu Leu
 85 90 95
 Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
 100 105 110
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys

27

115 120 125
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140
 Lys Glu Arg Val
 145

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 173 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Gly Glu Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
 1 5 10 15
 Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln
 20 25 30
 Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Ser Ser
 35 40 45
 Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
 50 55 60
 Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg
 65 70 75 80
 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ser Gly Trp
 85 90 95
 Tyr Glu Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
 100 105 110
 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys
 115 120 125
 Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys
 130 135 140
 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
 145 150 155 160
 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
 165 170

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

```

Leu Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
 1         5         10        15
Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ile
 20        25        30
Tyr Leu Ala Trp Phe Gln Gln Arg Pro Gly Lys Ala Pro Lys Ser Leu
 35        40        45
Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser
 50        55        60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
 65        70        75        80
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro
 85        90        95
Phe Thr Phe Gly Pro
 100

```

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 159 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

```

Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Arg Gly Val Gly
 1         5         10        15

```

29

Val Asp Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Gln Trp Leu Ala
 20 25 30
 Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser
 35 40 45
 Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr
 50 55 60
 Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His
 65 70 75 80
 His Phe Phe Asp Ser Ser Gly Tyr Tyr Pro Phe Asp Ser Trp Gly Gln
 85 90 95
 Gly Thr Leu Val Ser Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 100 105 110
 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
 115 120 125
 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 130 135 140
 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Gln Leu
 145 150 155

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 167 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
 1 5 10 15
 Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln
 20 25 30
 Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Ser Val Ser Gly
 35 40 45
 Ile Thr Thr Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
 50 55 60
 Arg Asp Asn Ser Lys Asn Ile Leu Tyr Leu Gln Met Asn Ser Leu Arg
 65 70 75 80
 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Arg Ile Phe Gly Val
 85 90 95

30

Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 100 105 110
 Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu
 115 120 125
 Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 130 135 140
 Val Thr Val Ser Trp Asn Leu Gly Ala Leu Thr Ser Gly Val His Thr
 145 150 155 160
 Phe Pro Ala Val Leu Gln Ser
 165

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 164 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Gly Ile Arg Leu Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser
 1 5 10 15
 Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
 20 25 30
 Ile Ser Ile Tyr Leu Ala Trp Phe Gln Gln Arg Pro Gly Lys Ala Pro
 35 40 45
 Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser
 50 55 60
 Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80
 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn
 85 90 95
 Ser Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Lys Pro Asn

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GACTACGAAT TCTTGTAGGA CCGGCGAGGA ATAGG

35

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GACTACGGGC CCGGTGAGAA CTTGGAATCT TGCAAGC

37

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

32

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GCAGTCTCCT AAAGTGCT

18

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

ACCTGCAAGG CCAAGT

15

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

CACTCATTCC TGTTGAAG

18

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 500 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

```
TCAGAAGAAG TGAAGTCAAG ATGAAGAACC ATTTGCTTTT
CTGGGGAGTC CTGGCGGTTT   60
TTATTAAGGC TGTTCAATGTG AAAGCCCAAG AAGATGAAAG
GATTGTTCTT GTTGACAACA   120
AATGTAAGTG TGCCCGGATT ACTTCCAGGA TCATCCGTTC
TTCCGAAGAT CCTAATGAGG   180
ACATTGTGGA GAGAAACATC CGAATTATTG TTCCTCTGAA
CAACAGGGAG AATATCTCTG   240
ATCCACCTC ACCATTGAGA ACCAGATTTG TGTACCATTG GTCTGACCTC
TGTAATAAAT   300
GTGATCCTAC AGAAGTGGAG CTGGATAATC AGATAGTTAC
TGCTACCCAG AGCAATATCT   360
GTGATGAAGA CAGTGCTACA GAGACCTGCT ACACTTATGA
CAGAAACAAG TGCTACACAG   420
CTGTGGTCCC ACTCGTATAT GGTGGTGAGA CCAAAATGGT
GGAAACAGCC TTAACCCAG   480
ATGCCTGCTA TCCTGACTAA           500
```

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

34

GAATTCAGAA GAAGTGAAGT C

21

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GTCGACTATG CAGTCAGCAA TGAC

24

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

TGCAGGAATC AGACCCAGTC

20

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

35

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

GTCAGGCTGG AACTGAGGAG CA

22

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

TCATTTGGTG ATCAGCACT

19

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GCTAGCTGAG GAGACGGTGA CCAGG

25

(2) INFORMATION FOR SEQ ID NO:54:

36

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

TCATTGGTG ATCAGCACT

19

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GGATCCTGAG GAGACGGTGA CG

22

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

37

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

GGATTAGCAT CCGCCCCAAC CCTT

24

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GTCGACGCAC ACACAGAGCG GCCA

24

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

GACTACGAAT TCGGACCGGC GAGGAATAGG AATCATG

37

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

GGATGGTGTT GGTAGCTAGC ACGCGGAGCG TGATGATGGC CTG

43

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

GACTACGAAT TCACGAGGCG ACATGGCGGC GGC

33

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

GGATGGTGTGTT GGTAGCTAGC ACACGCAGTG AGATGGTTTC CCG
43

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 617 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

GGACTGTTGA AGCCTTCGGA GACCCTGTCC CTCACCTGCG
CTGTCTATGG TGGGTCCTTC 60
AGTGGTTACT ACTGGAGCTG GATCCGCCAG CCCCCAGGGA
AGGGGCTGGA GTGGATTGGG 120
GAAATCAATC ATAGTGGAAG CACCAACTAC AACCCGTCCC
TCAAGAGTCG AGTCACCATA 180
TCAGTAGACA CGTCCAAGAA CCAGTTCTCC CTGAAGCTGA
GCTCTGTGAC CGCNGCGGAC 240
ACGGCTGTGT ATTACTGTGC GAGAGGCACT ACGGAATATT
ACTACTACTA CTACGGTATG 300
GACGTCTGGG GCCAAGGGAC CACGGTCACC GTCTCCTCAG
GGAGTGCATC CGCCCCAACC 360
CTTTTCCCCC TCGTCTCCTG TGAGAATTCC CCGTCGGATA
CGAGCAGCGT GGCCGTTGGC 420
TGCCTCGCAC AGGACTTCCT TCCCGACTYC ATCACTTTCT CCTGGAAATA
CAAGAACAAC 480
TCTGACATCA GCAGCACCCG GGGCTTCCCA TCAGTCCTGA
GAGGGGGCAA GTACGCAGCC 540
ACCTCACAGG TGCTGCTGCC TTCCAAGGAC GTCATGCAGG
GCACAGACGA ACACGTGGTG 600
ACGGGATCCA AAGAGTA 617

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 444 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

```
CTCTCCCTGC CCGTCACCCC TGGAGAGCCG GCCTCCATCT
CCTGCAGGTC TAGTCAGAGC   60
CTCCTGCATA GTAATGGATA CAACTATTTG GATTGGTACC
TGCAGAAGCC AGGGCAGTCT   120
CCACAGCTCC TGATCTATTT GGGTTCTAAT CGGGCCTCCG
GGGTCCCTGA CAGGTTTCAGT   180
GGCAGTGGAT CAGGCACAGA TTTTACACTG AAAATCAGCA
GAGTGGAGGC TGAGGATGTT   240
GGGATTTATT ACTGCATGCA GACTCGACAA ACTCCTCGGA
CGTTCGGCCA AGGGACCAAG   300
GTGGAAATCA AACGAACTGT GGCTGCACCA TCTGTCTTCA
TCTTCCCGCC ATCTGATGAG   360
CAGTTGAAAT CTGGAAGTGC CTCTGTTGTG TGCCTGCTGA
ATAACTTCTA TCCCAGAGAG   420
GCCAAAGAGC ATCAAAAGAG TCCA                               444
```

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 593 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

```
CTGGTGAAGC CTTCGGAGAC CCTGTCCCTC ACCTGCACTG
TCTCTGGTGG CTCCATCAGT   60
AGTTACTACT GGAAGTGGAT CCGGCAGCCC CCAGGGAAGG
GACTGGAGTG GATTGGGTAT   120
ATCTATTACA GTGGGAGCAC CAACTACAAC CCCTCCCTCA
```

41

AGAGTCGAGT CACCATATCA 180
GTAGACACGT CCAAGAACCA GTTCTCCCTG AAGCTGAGCT
CTGTGACCGC TGCGGACACG 240
GCCGTGTATT ACTGTGCGAG AGATAGGGGA GTGGGAGCTA
CTGGTTTTGA CTA CTACTGGGGC 300
CAGGGAACCC TGGTCACCGT CTCCTCAGGG AGTGCATCCG
CCCCAACCCCT TTTCCCCCTC 360
GTCTCCTGTG AGAATTCCCC GTCGGATACG AGCAGCGTGG
CCGTTGGCTG CCTCGCACAG 420
GACTTCCTTC CCGACTCCAT CACTTTCTCC TGGAAATACA
AGAACAACCTC TGACATCAGC 480
AGCACCCGGG GCTTCCCATC AGTCCTGAGA GGGGGCAAGT
ACGCAGCCAC CTCACAGGTG 540
CTGCTGCCTT CCAAGGACGT CATGCAGGGC ACAGACGAAC
ACAAGGTGTG CGA 593

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 441 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

AGCCAGTCTC CATCCTCCCT GTCTGCATCT GTAGGAGAGA
GAGTCACCAT CACTTGCCGG 60
GCAAGTCAGG GCATTAGAGA TGAATTAGGC TGGTATCAGC
AGAAACCAGG GAAAGCCCCT 120
AAGCGCCTGA TCTATGTTGC ATCCAGTTTG CAAAGTGGGG
TCCCATCAAG GTTCAGCGGC 180
AGTGGATCTG GGACAGAATT CACTCTCACA ATCAGCAGCC
TGCAGCCTGA AGATTTTGCA 240
ACTTATTACT GTCTACAGCA TAATGGTTAC CCTCGGACGT
TCGGCCAAGG GACCAAGGTG 300
GAAATCAAAC GAACTGTGGC TGCACCATCT GTCTTCATCT
TCCCGCCATC TGATGAGCAG 360
TTGAAATCTG GAACTGCCTC TGTTGTGTGC CTGCTGAATA ACTTCTATCC
CAGAGAGGCC 420
AAAGAGCATC AAAAGAGTCC A 441

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 610 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

```
AAGAAGCCTG GGCCTCAGT GAAGGTCTCC TGCAAGGCTT
CTGGATACAC CTTACCAGT   60
TATGATATCA ACTGGGTGCG ACAGGCCACT GGACAAGGGC
TTGAGTGGAT GGGATGGATG  120
AACCCTAACA GTGGTAACAC AGGCTATGCA CAGAAGTTCC
AGGGCAGAGT CACCATGAAC  180
AGGAACACCT CCATAAGCAC AGCCTACATG GAGCTGAGCA
GCCTGAGATC TGAGGACACG  240
GCCGTGTATT ACTGTGCGAG AGGGGGTCAT GGTGGGAGCT
ACTTCTACTC CTAYTACGGT  300
ATGGACGTCT GGGGCCAGGG GACCACGGTC ACCGTCTCCT
CAGGGAGTGC ATCCGCCCCA  360
ACCCTTTTCC CCCTCGTCTC CTGTGAGAAT TCCCCGTCGG
ATACGAGCAG CGTGGCCGTT  420
GGCTGCCTCG CACAGGACTT CCTTCCCGAC TCCATCACTT
TCTCCTGGAA ATACAAGAAC  480
AACTCTGACA TCAGCAGCAC CCGGGGCTTC CCATCAGTCC
TGAGAGGGGG CAAGTACGCA  540
GCCACCTCAC AGGTGCTGCT GCCTTCCAAG GACGTCATGC
AGGGCACAGA CGAACACGTG  600
GTGTGCAAAC                                     610
```

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 447 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

CACTCCCTGG CTGTGTCTCT GGGCGAGAGG GCCACCATCA
ACTGCAAGTC CAGCCAGAGT 60
GTTTTATACA GTTTTAACAA TAAGAACTAC TTAGCTTGGT
ACCAGCAGAA ACCAGGACAG 120
CCTCCTAAGC TGCTCATTTA CTGGGCATCT ACCCGGGAAT
CCGGGGTCCC TGACCGATTC 180
GGTGGCAGCG GGTCTGGGAC AGATTTCACT CTCACCATCA
GCAGCCTGCA GGCTGAAGAT 240
GTGGCAGTTT ATTACTGTCA GCAATATTAT AGTACTCCTM
GGACGTTTCGG CCAAGGGACC 300
AAGGTGGAAG TCAAACGAAC TGTGGCTGCA CCATCTGTCT
TCATCTTCCC GCCATCTGAT 360
GAGCAGTTGA AATCTGGAAC TGCCTCTGTT GTGTGCCTGC
TGAATAACTT CTATCCCAGA 420
GAGGCCAAAG AGCATCAAAA GAGTCCA

447

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 599 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GAGGTGAAGA AGCCTGGGGC CTCAGTGAAG GTCTCCTGCA
AGGCTTCTGG ATACACCTTC 60
ACCAGTTATG ATATCAACTG GGTGCGACAG GCCACTGGAC
AAGGGCTTGA GTGGATGGGA 120
TGGATGAACC CTAACAGTGG TAACACAGGC TATGCACAGA
AGTTCCAGGG CAGAGTCACC 180
ATGACCAGGA ACACCTCCAT AAGCACAGCC TACATGGAGC
TGAGCAGCCT GAGATCTGAG 240

44

GACACGGCCG TGTATTACTG TGCGAGAGAG GAGTGGCTGG
TACGTTACTA CGGTATGGAC 300
GTCTGGGGCC AAGGGACCAC GGTCACCGTC TCCTCAGGGA
GTGCATCCGC CCAACCCTT 360
TTCCCCCTCG TCTCCTGTGA GAATTCCCCG TCGGATACGA
GCAGCGTGGC CGTTGGCTGC 420
CTCGCACAGG ACTTCCTTCC CGACTCCATC ACTTTCTCCT GGAAATACAA
GAACAACTCT 480
GACATCAGCA GCACCCGGGG CTTCCCATCA GTCCTGAGAG
GGGGCAAGTA CGCAGCCACC 540
TCACAGGTGC TGCTGCCTTC CAAGGACGTC ATGCAGGGCA
CAGACGAACA CAAGGTGTG 599

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 441 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

GGCCAGTCTC CATCCTCCCT GTCTGCATCT GTAGGAGACA
GAGTCACCAT CACTTGCCGG 60
GCAAGTCAGG ACATTAGAGA TAATTTAGGC TGGTATCAGC
AGAAACCAGG GAAAGCCCCT 120
AAGCGCCTGA TCTATGCTGC ATCCAATTTG CAAAGTGGGG
TCCCATCAAG GTTCAGCGGC 180
AGTGGATCTG GGACAGAATT CACTCTCACA ATCAGCAGCC
TGCAGCCTGA AGATTTTGCA 240
ACTTATTACT GTCTACAGTA TAAAACTTAC CCGTGGACGT
TCGGCCAAGG GACCAAGGTG 300
GAAATCAAAC GAACTGTGGC TGCACCATCT GTCTTCATCT
TCCCGCCATC TGATGAGCAG 360
TTGAAATCTG GAACTGCCTC TGTGTGTGC CTGCTGAATA ACTTCTATCC
CAGAGAGGMC 420
AAAGAGCATC AAAAGAGTCC A 441

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 607 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

AAGCTTCCGG AGACCCTGTC CCTCACCTGC GCTGTCTATG
GTGGGTCCTT CAGTGGTTAC 60
TACTGGAGCT GGATCCGCCA GGGGGAGGG AAGGGGCTGG
AGTGGATTGG GGAAATCAAT 120
CATAGTGGAA GCACCAACTA CAACCCGTCC CTCAAGAGTC
GAGTCACCAT ATCAGTAGAC 180
ACGTCCAAGA ACCAGTTCTC CCTGAAGCTG AGCTCTGTGA
CCGCCGCGGA CACGGCTGTG 240
TATTACTGTG CGAGAGGGGC AGCTGAATAT TACTACTACT
ACTACGGTAT GGACGTCTGG 300
GGCCAAGGGA CCACGGTCAC CGTCTCCTCA GGGAGTGCAT
CCGCCCCAAC CCTTTTCCCC 360
CTCGTCTCCT GTGAGAATTC CCCGTCGGAT ACGAGCAGCG
TGGCCGTTGG CTGCCTCGCA 420
CAGGACTTCC TTCCCGACTY CATCACTTTC TYCTGGAAAT
ACAAGAACAA CTCTGACATC 480
AGCAGCACCC GGGGCTTCCC ATCAGTCCTG AGAGGGGGCA
AGTACGCAGC CACCTCACAG 540
GTGCTGCTGC CTTCCAAGGA CGTCATGCAG GGCACAGACG
AACACGTGGT GACGGGATCC 600
AAAGAGT 607

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 431 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

46

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

ATGCCCCGTCA CCCCTGGAGA GCCGGCCTCC ATCTCCTGCA
GGTCTAGTCA GAGCCTCCTG 60
CATAGTAATG GATACAACTA TTTGGACTGG TACCTGCAGA
AGCCAGGGCA GTCTCCACAG 120
CTCCTGATCT ATTTGGGTTC TAATCGGGCC TCCGGGGTCC
CTGACAGGTT CAGTGGCAGT 180
GGATCAGGCA CAGATTTTAC ACTGAAAATC AGCAGAGTGG
AGGCTGAGGA TGTTGGGATT 240
TATTACTGCA TGCAAAGTCT ACAAATTCCT CGGCTTTTCG
GCCCTGGGAC CAAAGTGGAT 300
ATCAAACGAA CTGTGGCTGC ACCATCTGTC TTCATCTTCC
CGCCATCTGA TGAGCAGTTG 360
AAATCTGGAA CTGCCTCTGT TGTGTGCCTG CTGAGTAACT
TCTATCCCAG AGAGGCCAAA 420
GTACAGTGGA A 431

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 570 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

TCGGAGACCC TGTCCTCAC CTGCGCTGTC TATGGTGGGT
CCTTCAGTGG TTACTACTGG 60
AGCTGGATCC GCCAGCCCCC AGGGAAGGGG CTGGAGTGGA
TTGGGGAAAT CAATCATAGT 120
GGAAGCACCA ACTACAACCC GTCCCTCAAG AGTCGAGTCA
CCATATCAGT AGACACGTCC 180
AAGAACCAGT TCTCCCTGAA GCTGAGTTCT GTGACCGCCG
CGGACACGGC TGTGTATTAC 240
TGTGCGAGAG GCGGGACTAC AGTAACTTTT GATGCTTTTG
ATATCTGGGG CCAAGGGACA 300

47

ATGGTCACCG TCTCTTCAGG GAGTGCATCC GCCCCAACCC TTTTCCCCCT
CGTCTCCTGT 360
GAGAATTCCC CGTCGGATAC GAGCAGCGTG GCCGTTGGCT
GCCTCGCACA GGAATTCCTT 420
CCCGACTCCA TCACTTTCTC CTGGAAATAC AAGAACAACCT
CTGACATCAG CAGCACCCGG 480
GGCTTCCCAT CAGTCCTGAG AGGGGGCAAG TACGCAGCCA
CCTCACAGGT GCTGCTGCCT 540
TCCAAGGACG TCATGCAGGG CACAGACGAA 570

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 441 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

CTGGCTGTGT CTCTGGGCGA GAGGGCCACC ATCAACTGCA
AGTCCAGCCA GAGTGTTTTA 60
TACAGTTTTA ACAATAAGAA CTA CTACTTAGCT TGGTACCAGC
AGAAACCAGG ACAGCCTCCT 120
AAGCTGCTCA TTTACTGGGC ATCTACCCGG GAATCCGGGG
TCCCTGACCG ATTCAGTGGC 180
AGCGGGTCTG GGACAGATT CACTCTCACC ATCAGCAGCC
TGCAGGCTGA AGATGTGGCA 240
GTTTATTACT GTCAGCAATA TTATAGTACT CCTCGGACGT
TCGGCCAAGG GACCAAGGTG 300
GAAATCAAAC GAACTGTGGC TGCACCATCT GTCTTCATCT
TCCCGCCATC TGATGAGCAG 360
TTGAAATCTG GAACTGCCTC TGTTGTGTGC CTGCTGAATA ACTTCTATCC
CAGAGAGGCC 420
AAAGTACAGT GGAAGGTGAT C 441

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 447 base pairs
- (B) TYPE: nucleic acid

48

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

AACCCACAGA CGACCCTCAC GCTGACCTGC ACCTTCTCTG
GGTTCTCACT CATTACCCGT 60
GGAGTGGGTG TGGATTGGAT CCGTCAGCCC CCAGGAAAGG
CCCTGCAGTG GCTCGCACTC 120
ATTTATTGGA ATGATGATAA GCGCTACAGT CCATCTCTGA
AGAGCAGGCT CACCATCACC 180
AAGGACACCT CAAAAACCA GGTGGTCCTC ACAATGACCA
ACATGGACCC TGTGGACACA 240
GCCACATATT ACTGTGCACA CCATTCTTT GATAGTAGTG GTTATTACCC
TTTTGACTCC 300
TGGGGCCAGG GAACCCTGGT CTCCGTCTCC TCAGCCTCCA
CCAAGGGCCC ATCGGTCTTC 360
CCCCTGGCGC CCTGCTCCAG GAGCACCTCC GAGAGCACAG
CGGCCCTGGG CTGCCTGGTC 420
AAGGACTACT TCCCCGAACC GGTGACG 447

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 445 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

GTGACTCAGT CTCCACTCTC TCTGTCCGTC ACCCCTGGAC
AGCCGGCCTC CATCTCCTGC 60
AAGTCTAGTC AGAGCCTCCT GCATAGTGAT GGAAAGACCT
ATTTGTATTG GTACCTGCAG 120

49

AAGCCAGGCC AGCCTCCACA GCTCCTGATC TATGAAGCTT
TCAACCGGTT CTCTGGAGTG 180
CCAGATAGGT TCAGTGGCAG CGGGTCAGGG ACAGATTTC
CACTGAAAAT CAGCCGGGTG 240
GAGGCTGAGG ATGTTGGACT TTATTATTGC ATGCAAAGTA
TAGAGCTTCC GTTCACTTTC 300
GGCGGAGGGA CCAAGGTGGA GATCAAACGA ACTGTGGCTG
CACCATCTGT CTTTCATCTTC 360
CCGCCATCTG ATGAGCAGTT GAAATCTGGA ACTGCCTCTG
TTGTGTGCCT GCTGAATAAC 420
TTCTATCCCA GAAAAGAAAG AGTCR 445

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 519 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

GGGGAAGGCC TGGTCAAGCC TGGGGGGTCC CTGAGACTCT
CCTGTGCAGC CTCTGGATTG 60
ACCTTCAGTA GCTATAGCAT GAACTGGGTC CGCCAGGCTC
CAGGGAAGGG GCTGGAGTGG 120
GTCTCATCCA TTAGTAGTAG TAGTAGTTAC ATATACTACG
CAGACTCAGT GAAGGGCCGA 180
TTCACCATCT CCAGAGACAA CGCCAAGAAC TCACTGTATC
TGCAAATGAA CAGCCTGAGA 240
GCCGAGGACA CGGCTGTGTA TTACTGTGCG AGGGATAGCA
GTGGCTGGTA TGAGGACTAC 300
TTTGACTACT GGGGCCAGGG AACCCTGGTC ACCGTCTCCT
CAGCCTCCAC CAAGGGCCCA 360
TCGGTCTTCC CCCTGGCGCC CTGCTCCAGG AGCACCTCCG
AGAGCACAGC GGCCCTGGGC 420
TGCCCTGGTCA AGGACTACTT CCCCGAACCG GTGACGGTGT
CGTGGAAGTC AGGCGCTCTG 480
ACCAGCGGCG TGCACACCTT CCCAGCTGTC CTACAGTCA
519

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 303 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

```
CTTGACATCC AGCTGACCCA GTCTCCGTCC TCACTGTCTG
CATCTGTAGG AGACAGAGTC   60
ACCATCACTT GTCGGGCGAG TCAGGACATT AGCATTTATT
TAGCCTGGTT TCAGCAGAGA  120
CCAGGGAAAG CCCCTAAGTC CCTGATCTAT GCTGCATCCA
GTTTGCAAAG TGGGGTCCCA  180
TCAAAGTTCA GCGGCAGTGG ATCTGGGACA GATTTCACTC
TCACCATCAG CAGCCTGCAG  240
CCTGAAGATT TTGCAACTTA TTAGTGCCAA CAATATAATA GTTATCCATT
CACTTTCGGG  300
CCC                                     303
```

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 477 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

```
CTGACCTGCA CTTTCTCTGG GTTCTCACTC ATTACCCGTG
GAGTGGGTGT GGATTGGATC   60
CGTCAGCCCC CAGGAAAGGC CCTGCAGTGG CTCGCACTCA
```

TTTATTGGAA TGATGATAAG 120
CGCTACAGTC CATCTCTGAA GAGCAGGCTC ACCATCACCA
AGGACACCTC CAAAAACCAG 180
GTGGTCCTCA CAATGACCAA CATGGACCCT GTGGACACAG
CCACATATTA CTGTGCACAC 240
CATTTCTTTG ATAGTAGTGG TTATTACCCT TTTGACTCCT
GGGGCCAGGG AACCTGGTC 300
TCCGTCTCCT CAGCCTCCAC CAAGGGCCCA TCGGTCTTCC
CCCTGGCGCC CTGCTCCAGG 360
AGCACCTCCG AGAGCACAGC GGCCCTGGGC TGCCTGGTCA
AGGACTACTT CCCC GAACCG 420
GTGACGGTGT CGTGGAATC AGGCGCTCTG ACCAGCGGCG
TGCACACCTT CCAGCTG 477

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 503 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

GGGGGAGGCT TGGTACAGCC TGGGGGGTCC CTGAGACTCT
CCTGTGCAGC CTCTGGATT 60
ACTTTTAGCA GCTATGCCAT GAGCTGGGTC CGCCAGGCTC
CAGGGAAGGG GCTGGAGTGG 120
GTCTCAACTA TTAGTGTTAG TGGTATTACC ACATACTACG
TAGACTCCGT GAAGGGCCGG 180
TTCACCATCT CCAGAGACAA TTCCAAGAAC ATTCTGTATC
TGCAAATGAA CAGCCTGAGA 240
GCCGAGGACA CGGCCGTATA TTAGTGTGCG AAACGGATTT
TTGGAGTGGT CTGGGGCCAG 300
GGAACCCTGG TCACCGTCTC CTCAGCCTCC ACCAAGGGCC
CATCGGTCTT CCCCCTGGCG 360
CCCTGCTCCA GGAGCACCTC CGAGAGCACA GCGGCCCTGG
GCTGCCTGGT CAAGGACTAC 420
TTCCCCGAAC CGGTGACGGT GTCGTGGAAC TTAGGCGCTC
TGACCAGCGG CGTGACACAC 480
TTCCCAGCTG TCCTACAGTC CTA 503

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 494 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GGAATTCGGC TTGATATTCA GCTGACTCAG TCTCCATCCT CACTGTCTGC
ATCTGTAGGA 60
GACAGAGTCA CCATCACTTG TCGGGCGAGT CAGGGCATT
GCATTTATTT AGCCTGGTTT 120
CAGCAGAGAC CAGGGAAAGC CCCTAAGTCC CTGATCTATG
CTGCATCCAG TTTGCAAAGT 180
GGGGTCCCAT CAAAGTTCAG CGGCAGTGGA TCTGGGACAG
ATTTCACTCT CACCATCAGC 240
AGCCTGCAGC CTGAAGATTT TGCAACTTAT TACTGCCAAC
AATATAATAG TTACCCATTC 300
ACTTTCGGCC CTGGGACCAA AGTGGATATC AAACGAACTG
TGGCTGCACC ATCTGTCTTC 360
ATCTTCCCGC CATCTGATGA GCAGTTGAAA TCTGGAACTG
CCTCTGTTGT GTGCCTGCTG 420
AATAACTTCT ATCCCAGAGA GGCCAAAGTA CAGTGGAAGG
TGGATAACGC CCTCCAATCG 480
GGTAAGCCGA ATTC 494

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1774 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

ATGTA CT TGG GACTGA ACTA TGTATTCATA GTTTTTCTCT TAAATGGTGT
CCAGAGTGAA 60
GTGAAGCTTG AGGAGTCTGG AGGAGGCTTG GTGCAACCTG
GAGGATCCAT GAAACTCTCC 120
TGTGTTGCCT CTGGATTCAC TTTCAGTAAC TACTGGATGA
ACTGGGTCCG CCAGTCTCCA 180
GAGAAGGGGC TTGAGTGGGT TGCTGAAATT AGATTGAAAT
CTAATAATTA TGCAACACAT 240
TATGCGGAGT CTGTGAAAGG GAGGTTCCACC ATCTCAAGAG
ATGATTCCAA AAGTAGTGTC 300
TACCTGCAA TGAACA ACTT AAGAGCTGAA GAACTGGCA
TTTATTACTG TACGGATTAC 360
GATGCTTACT GGGGCCAAGG GACTCTGGTC ACTGTCTCTG
CAGAGAGTCA GTCCTTCCCA 420
AATGTCTTCC CCCTCGTCTC CTGCGAGAGC CCCCTGTCTG
ATAAGAATCT GGTGGCCATG 480
GGCTGCCTGG CCCGGGACTT CCTGCCCAGC ACCATTTCCT
TCACCTGGAA CTACCAGAAC 540
AACACTGAAG TCATCCAGGG TATCAGAACC TTCCCAACAC
TGAGGACAGG GGGCAAGTAC 600
CTAGCCACCT CGCAGGTGTT GCTGTCTCCC AAGAGCATCC
TTGAAGGTT AGATGAATAC 660
CTGGTATGCA AAATCCACTA CGGAGGCAAA AACAGAGATC
TGCATGTGCC CATTCCAGCT 720
GTCGCAGAGA TGAACCCCAA TGTAATGTG TTCGTCCCAC
CACGGGATGG CTTCTCTGGC 780
CCTGCACCAC GCAAGTCTAA ACTCATCTGC GAGGCCACGA
ACTTCACTCC AAAACCGATC 840
ACAGTATCCT GGCTAAAGGA TGGAAGCTC GTGGAATCTG
GCTTACCAC AGATCCGGTG 900
ACCATCGAGA ACAAAGGATC CACACCCCAA ACCTACAAGG
TCATAAGCAC ACTTACCATC 960
TCTGAAATCG ACTGGCTGAA CCTGAATGTG TACACCTGCC
GTGTGGATCA CAGGGGTCTC 1020
ACCTTCTTGA AGAACGTGTC CTCCACATGT GCTGCCAGTC
CCTCCACAGA CATCCTAACC 1080
TTCACCATCC CCCCTCCTT TGCCGACATC TTCCTCAGCA AGTCCGCTAA
CCTGACCTGT 1140
CTGGTCTCAA ACCTGGCAAC CTATGAAACC CTGAATATCT
CCTGGGCTTC TCAAAGTGGT 1200
GAACCACTGG AAACCAAAAT TAAATCATG GAAAGCCATC
CCAATGGCAC CTTAGTGCT 1260
AAGGGTGTGG CTAGTGTTG TGTGGAAGAC TGGAATAACA
GGAAGGAATT TGTGTGTA CT 1320
GTGACTCACA GGGATCTGCC TTCACCACAG AAGAAATTCA

TCTCAAAACC CAATGAGGTG 1380
CACAAACATC CACCTGCTGT GTACCTGCTG CCACCAGCTC
GTGAGCAACT GAACCTGAGG 1440
GAGTCAGCCA CAGTCACCTG CCTGGTGAAG GGCTTCTCTC
CTGCAGACAT CAGTGTGCAG 1500
TGGCTTCAGA GAGGGCAACT CTTGCCCAA GAGAAGTATG
TGACCAGTGC CCCGATGCCA 1560
GAGCCTGGGG CCCCAGGCTT CTACTTTACC CACAGCATCC
TGACTGTGAC AGAGGAGGAA 1620
TGGA ACTCCG GAGAGACCTA TACCTGTGTT GTAGGCCACG
AGGCCCTGCC ACACCTGGTG 1680
ACCGAGAGGA CCGTGGACAA GTCCACTGGT AAACCCACAC
TGTACAATGT CTCCCTGATC 1740
ATGTCTGACA CAGGCGGCAC CTGCTATTGA CCAT

1774